,date,information,related
0,2020-07-30,"Headline: 10 Biggest Biotechnology Companies, source:Yahoo, summary: With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.",MRNA
1,2022-09-22,"Headline: Just 4.4 million Americans have gotten omicron-targeted boosters so far, source:Yahoo, summary: Health experts said it is too early to predict whether demand would match up with the 171 million doses of the new boosters the U.S. ordered for the fall., Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. FDX, COST, FRPT, BA, GM, FUBO, ALLY, SPRO, GSK, APO, EVR, MC, HNHPF, MRNA, AMZN, AAPL, PEP, BX, CANO, HUM, MDGS, CS, APA, HAL, MRO, YETI, IBEX, APEI, FLUX, AIR, DSKE",MRNA
2,2022-09-23,"Headline: Moderna COVID-19 booster shortage causes canceled appointments, WSJ reports, source:Thefly.com, summary: Some US pharmacies and ot... MRNA, PFE, BNTX, Headline: Over 4 million Americans administered updated COVID boosters, says CDC, source:Finnhub, summary: The U.S. Centers for Disease Control and Prevention reported on Thursday that 4.4 million people had received updated COVID-19 booster shots, a few weeks into the government's new vaccination... | September 23, 2022, Headline: Moderna Covid-19 Booster Shortage Leads to Fewer Appointments at Pharmacies, source:Yahoo, summary: A manufacturing-quality problem has led to some vaccine providers only offering the Pfizer-BioNTech booster shot., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. FDX, COST, FRPT, SCHL, BA, FUBO, ALLY, SPRO, GSK, EVR, MC, APO, HNHPF, MRNA, AMZN, META, AAPL, PEP, DSKE, IBEX, APEI, FLUX, AIR, CANO, HUMA, CS, APA, TELL, MDGS, Headline: Moderna says requests for EUAs for Omicron booster for kids submitted to FDA, source:Thefly.com, summary: Moderna tweeted: ""We... MRNA, Headline: U.S. rollout of new COVID boosters off to slow start, source:Finnhub, summary: Updated COVID-19 boosters have goneinto 4.4 million arms in the United States since a newrevaccination campaign began three weeks ago, government datashows, a slower pace for the shots targeting... | September 23, 2022, Headline: Moderna asks FDA to authorize omicron Covid boosters for children as young as 6 years old, source:CNBC, summary: Moderna has asked the FDA to authorize omicron boosters for adolescents ages 12 to 17-years-old and for kids ages 6 to 11-years-old., Headline: Why Novavax (NVAX) Stock Was Down 13% on Thursday, source:Yahoo, summary: Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100., Headline: UPDATE 1-U.S. rollout of new COVID boosters off to slow start, source:Yahoo, summary: Updated COVID-19 boosters have gone into 4.4 million arms in the United States since a new revaccination campaign began three weeks ago, government data shows, a slower pace for the shots targeting the Omicron variant of the coronavirus than the rollout of the first boosters last year.  Last year, when the United States initially authorized COVID boosters just for older and immunocompromised people, nearly 10 million received their third shot in the first three weeks.  The latest data, released late on Thursday by the U.S. Centers for Disease Control and Prevention (CDC), did show increased interest in the Omicron shots over demand for the older boosters during the previous three weeks., Headline: Moderna Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. dropped 0.55% to $123.64 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Moderna : Statement of Changes in Beneficial Ownership - Form 4, source:Finnhub, summary: Ownership Submission FORM 4 Check this box if no longer... | September 23, 2022, Headline: Stocks moving in after hours: Ford, FedEx, Moderna, source:Yahoo, summary: Yahoo Finance Live anchor Seana Smith highlights stocks moving in after-hours trading, including Ford, FedEx, and Moderna., Headline: Moderna's COVID booster faces supply limitations after manufacturing issues, source:Yahoo, summary: Health reporter Anjalee Khemlani examines the shortages Moderna is experiencing in its latest COVID-19 booster shot, while also discussing vaccination options ahead of this year's flu season, Headline: Moderna seeks FDA nod for Omicron-targeted COVID shot for adolescents, younger kids, source:Reuters, summary: Moderna Inc said on Friday it has requested U.S. authorization for use of its Omicron-targeting COVID vaccine in adolescents and children.",MRNA
3,2022-09-24,"Headline: Better Growth Stock: Moderna vs. Teladoc, source:Yahoo, summary: It may be a bit early to establish Moderna's (NASDAQ: MRNA) and Teladoc Health's (NYSE: TDOC) lasting growth stock status by looking at the past couple of years.  Moderna launched the coronavirus vaccine as its first product in 2020 -- and vaccinated a good share of the population.  Teladoc saw revenue and virtual medical visits soar in the triple digits as people opted to stick close to home., Headline: UPDATE 1-Pfizer CEO tests positive for COVID for a second time, source:Yahoo, summary: Pfizer Inc Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19.  ""I’m feeling well and symptom free,"" Bourla said in a statement.  Bourla, 60, back in August had contacted COVID and had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid.",MRNA
4,2022-09-25,"Headline: New minimum tax could hit Berkshire Hathaway and Amazon hardest, study shows, source:CNBC, summary: The 15% minimum tax would impact around 78 companies, according to 2021 financial data, with Berkshire and Amazon paying the most.",MRNA
5,2022-09-26,"Headline: Pfizer/BioNTech seek FDA nod for new COVID boosters for children, source:Finnhub, summary: Pfizer Inc and its Germanpartner BioNTech on Monday sought the U.S. Food andDrug Administration's authorization for an Omicron-tailoredCOVID-19 vaccine booster for children aged 5 through 11... | September 26, 2022, Headline: Pfizer seeks to expand omicron booster to 5- to 11-year-olds, source:Associated Press, The, summary: No summary, Headline: Down 85%, Is There Any Hope for This Struggling Vaccine Stock?, source:Yahoo, summary: In the early days of the pandemic, if there was one coronavirus vaccine stock investors were betting on, it was Novavax (NASDAQ: NVAX).  The biotech stock soared more than 2,700% in 2020 as it developed its vaccine candidate.  In the same timeframe, Pfizer shares hardly budged., Headline: Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna, source:Yahoo, summary: Switzerland would have to discard 10.3 million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine, the health ministry said Saturday. The ministry said it had no choice but to eliminate the shots after the doses expired. It told the news agency that 2.5 million doses were being stored at a Swiss army logistics base and 7.8 million were in an external storage depot in Belgium. The ministry confirmed an initial report, which estimated that the destroyed doses would be worth around CHF280 milli, Headline: Pfizer asks FDA to authorize omicron Covid booster shots for kids ages 5 to 11, source:CNBC, summary: Pfizer's application to the FDA comes before clinical trial results of the omicron BA.5 booster shots have been published. , Headline: Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11, source:MarketWatch, summary: Pfizer and German partner BioNTech said Monday they're seeking Food and Drug Administration authorization for their omicron-targeting bivalent vaccine for..., Headline: Moderna Seeks FDA Approval For Updated COVID-19 Shot For Kids, But Scrambles Supply Challenges, source:Yahoo, summary: Last week, Moderna Inc (NASDAQ: MRNA) said it asked the FDA to authorize the use of its updated booster shot in children ages 6 to 17. The company expects to complete a request for the use of the booster in children six months through 5 years later this year. But federal officials have advised state officials that there is a limited supply of updated booster shots for Moderna. Vaccine sites have either canceled or stopped scheduling new appointments for people seeking a Moderna booster shot. Hen, Headline: Pfizer CEO Contracts COVID-19 Infection For Second Time, source:Yahoo, summary: Pfizer Inc's (NYSE: PFE) CEO Albert Bourla said he had tested positive for COVID-19. ""I'm feeling well and symptom-free,"" 60-year-old Bourla said in a statement. In August, he contacted COVID and received one course of paxlovid, Pfizer's oral COVID-19 antiviral treatment. Bourla has received four doses of the COVID vaccine developed by Pfizer and BioNTech SE (NASDAQ: BNTX). Bourla said he has not yet taken the new bivalent booster. Developed by Moderna Inc (NASDAQ: MRNA) and Pfizer/BioNTech, the, Headline: EMA's CHMP Starts Evaluating Application For Authorisation Of Additional Adapted Version Of Spikevax, source:Finnhub, summary: EMA: * EMA: EMA'S CHMP STARTED EVALUATING AN APPLICATION FOR THE AUTHORISATION OFANADDITIONAL ADAPTED VERSION OF SPIKEVAX: 26/09/2022Further company coverage: ... | September 26, 2022, Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 3.19% to $119.69 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite..., Headline: New corporate tax would have raised $30 billion from 'under a dozen companies' in 2021: Expert, source:Yahoo, summary: University of North Carolina Kenan-Flagler Business School Associate Professor Jeffrey Hoopes joins Yahoo Finance Live to explain why the new 15% minimum corporate tax rate would hit companies like Amazon and Berkshire Hathaway the hardest., Headline: U.S. FDA clears additional lots of Moderna's Covid booster amid shortage, source:Reuters, summary: The U.S. Food and Drug Administration said on Monday it has authorized an additional five batches of Moderna Inc's updated Covid booster shots made at a Catalent facility in Indiana, after it deemed them safe for use.",MRNA
6,2022-09-27,"Headline: The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market, source:InvestorPlace, summary: Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market., Headline: As Moderna Grapples With Supply Shortage, FDA Gives Nod To Additional Lots of COVID-19 Booster, source:Yahoo, summary: The FDA authorized an additional five batches of Moderna Inc's (NASDAQ: MRNA) updated Covid booster shots made at Catalent Inc's (NYSE: CTLT) Indiana facility after it deemed them safe for use. Last week, the agency allowed the use of ten batches of Moderna's updated booster shots made at the Bloomington facility, owned by a unit of Catalent, which is currently not a part of emergency use authorization. Reuters reported that the FDA had earlier said Moderna had requested authorization for additi, Headline: Pfizer or Moderna: Which new omicron-specific Covid booster should you get?, source:CNBC, summary: Americans have two options for getting a new omicron-specific Covid booster shot: Pfizer or Moderna. Which one should you get? Here's what experts say., Headline: Canada to scrap mask mandate on planes, joining Japan, Hong Kong and U.A.E. in lifting COVID restrictions, source:MarketWatch, summary: The Canadian government announced Monday it will no longer require people to wear masks on airplanes to guard against COVID-19, the Associated Press reported., Headline: Stocks making the biggest moves midday: Hertz, Ford, Keurig Dr Pepper and more , source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rallied 2.12% to $122.23 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Why Moderna Stock Crushed the Market Today, source:Yahoo, summary: The coronavirus pandemic might, just might, be easing, but top COVID-19 vaccine maker Moderna (NASDAQ: MRNA) was ascendant on Tuesday.  Shortly before market close on Monday, the Food and Drug Administration (FDA) announced it had authorized a set of Moderna's latest Spikevax COVID booster vaccine for use.  Strictly speaking, that company isn't covered under Moderna's emergency use authorization (EUA) for the booster.",MRNA
7,2022-09-28,"Headline: Who will pay for the next Covid vaccines?, source:Yahoo, summary: Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic, Headline: Indonesia approves first home-grown COVID vaccine for emergency use - media, source:Finnhub, summary: Indonesia has approved its first domestically-produced COVID-19 vaccine for emergency use for people over 18, the chief of the country's food and drugs agency was quoted by news media as saying... | September 28, 2022, Headline: European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency (EMA) has accepted a variation for the evaluation of a 50 µg booster dose of the Omicron-containing bivalent COVID booster candidate, mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) in adults 12 years and older., Headline: 7 Growth Stocks to Buy Before the Bull Market Returns, source:Yahoo, summary: In this market slowdown there appear to be fewer growth stocks to buy, but patience will be rewarded. It’s been a forgettable year, to say the least, for equity investors. The Fed continues to raise interest rates, spooking investors in the process. However, as our very own maverick stock analyst Luke Lango puts it, there’s always a bull market somewhere. Moreover, November, December, and January are typically strong months for the stock market that should encourage you to look for growth stocks, Headline: Covid vaccination linked to slight increase in menstrual cycle, NIH study confirms, source:CNBC, summary: A change in menstrual cycle length of eight days or less is considered within the normal range of variation, according to NIH., Headline: Biogen stock explodes higher after potential 'mega blockbuster' Alzheimer's drug study, source:Yahoo, summary: Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying., Headline: Europe's Health Agency Accepts Moderna's Filing For Its Updated Omicron-Targeted COVID-19 Vaccine, source:Yahoo, summary: The European Medicines Agency (EMA) has accepted a variation for evaluating Moderna Inc's (NASDAQ: MRNA) 50 µg booster dose of the Omicron-containing bivalent COVID booster candidate for individuals 12 years and older. Spikevax bivalent original/omicron BA.4-5 is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.4/BA.5). Related: As Moderna Grapples With Supply Shortage, FDA Gives Nod To Ad, Headline: COVID-19: Young, healthy people may not need bivalent boosters, vaccine expert says, source:Yahoo, summary: Data is still scarce on latest COVID-19 boosters, Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. sank 0.07% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Why Moderna Stock Lagged the Market Today, source:Yahoo, summary: This was the case with high-profile biotech Moderna (NASDAQ: MRNA) on Wednesday.  Moderna's positive news came from across the Atlantic Ocean, where the European Medicines Agency (EMA) accepted a conditional marketing authorization (CMA) application for the company's bivalent coronavirus booster vaccine.  Moderna didn't hesitate to point out that the new booster has already been given the green light by the U.S. Food and Drug Administration (FDA) and a host of other jurisdictions, including Australia, Taiwan, and the U.K., Headline: Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed at $122.15 in the latest trading session, marking a -0.07% move from the prior day.",MRNA
8,2022-09-29,"Headline: Moderna appoints Juan Andres to new role, hires Jerh Collins to succeed, source:Thefly.com, summary: Moderna announced that th... MRNA, Headline: Moderna names Andres president, strategic partnerships, enterprise expansion, source:Thefly.com, summary: Moderna (MRNA) announced ... MRNA, NVS, Headline: MODERNA, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K), source:Finnhub, summary: Item 5.02 Departure of Directors or Certain Officers; Election of Directors;Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 29, 2022, Moderna, Inc. ... | September 29, 2022, Headline: Moderna Adds New Role Ahead of Product Launches, source:Finnhub, summary: By Will Feuer Moderna Inc. is creating a new role on its executive committee as it prepares for the launch of multiple new products after the success of its Covid-19 vaccine. The... | September 29, 2022, Headline: These 2 Growth Stocks Have Fallen Out of Grace. Are They Buys?, source:Yahoo, summary: In the past two years, biotech companies Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) rose to fame thanks to their successful attempts to develop vaccines for COVID-19 and help us end the outbreak.  The pandemic isn't over yet, but Moderna and Novavax have given up substantial chunks of their value in the past year.  Where does that leave Moderna and Novavax?, Headline: Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids, source:Yahoo, summary: Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults., Headline: EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster, source:Yahoo, summary: The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants., Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 3.34% to $118.07 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Around 3.2 million Americans administered updated COVID boosters last week -CDC, source:Finnhub, summary: Around 3.2 million people in the United States were administered updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.... | September 29, 2022, Headline: Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2022 Update, source:SeekingAlpha, summary: Stanley Druckenmillerâs 13F portfolio value decreased from $2.65B to $1.63B this quarter. Click to read the Q2 2022 update on the portfolio., Headline: UPDATE 1-Around 3.2 mln Americans received updated COVID boosters last week -CDC, source:Yahoo, summary: Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.  The 7.6 million figure represents only 3.5% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series.  The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people., Headline: Why Moderna Was a Sickly Stock Today, source:Yahoo, summary: A shuffle at the top of the executive ranks, combined with the continued decline of the coronavirus, rattles some investors.",MRNA
9,2022-09-30,"Headline: Moderna Creates New Executive Committee Role Ahead of New Product Launches, source:Finnhub, summary: CAMBRIDGE, MA - Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines announced that the Company has expanded the Executive Committee to prepare for multiple... | September 30, 2022, Headline: Two thirds of U.S. adults don't plan on getting COVID boosters soon -poll, source:Finnhub, summary: Around two-thirds ofadults in the United States do not plan to get updated COVID-19booster shots soon, according to a survey conducted by theKaiser Family Foundation , a health policy... | September 30, 2022, Headline: 1 in 5 of Americans don't know about new omicron-targeting COVID boosters, survey finds, source:MarketWatch, summary: A Kaiser Family Foundation survey found that about half of Americans have heard little or nothing about new COVID bivalent boosters targeting omicron variants., Headline: 10 Best COVID Stocks To Buy Now, source:Yahoo, summary: In this article, we discuss 10 best COVID stocks to buy now. If you want to see more stocks in this selection, check out 5 Best COVID Stocks To Buy Now. In 2020, the COVID-19 pandemic was the primary driver of global uncertainty, making headlines around the world. The virus took a backseat only recently, […], Headline: Moderna Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.15% higher to $118.25 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...",MRNA
10,2022-10-01,"Headline: How to perfectly time your new omicron-specific Covid booster, source:CNBC, summary: When should you get your new omicron-specific Covid booster? It depends on your age, health status and how recently you've been vaccinated or infected by Covid., Headline: Here's Why the Post-Pandemic World May Be Even Better for This Vaccine Maker, source:Yahoo, summary: Moderna (NASDAQ: MRNA) is the name behind one of last year's top-selling pharmaceutical products.  Does that mean Moderna's sales will plunge?  In fact, Moderna's best days may not be in the past -- but in the future., Headline: Moderna refused China request to reveal vaccine technology, source:Yahoo, summary: Moderna has refused to hand over to China the core intellectual property behind the development of its breakthrough Covid-19 vaccine, leading to a collapse in negotiations on its sale there, according to multiple people familiar with the matter.  The Massachusetts-based pharmaceutical company turned down Beijing’s request to hand over the recipe for its messenger RNA vaccine because of commercial and safety concerns, said two people involved in negotiations that took place between 2020 and 2021.  The vaccine maker says it is still “eager” to sell the product to China., Headline: Moderna refused China request to reveal vaccine technology - FT, source:Yahoo, summary: Moderna Inc has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.  The Cambridge, Massachusetts-based pharmaceutical company turned down China’s request to hand over the recipe for its mRNA vaccine because of commercial and safety concerns, the newspaper said, citing people involved in negotiations that took place between 2020 and 2021, adding that the vaccine maker is still “eager” to sell the product to China.  The company had “given up” on its previous efforts to access the Chinese market because of China’s demand that it hand over the technology as a prerequisite for selling in the country, the report said.",MRNA
11,2022-10-02,"Headline: 7 S&P 500 Stocks to Sell Before They Die, source:Yahoo, summary: There’s a saying in investing, attributed to Warren Buffett, that you don’t see who’s swimming naked until the tide goes out. Essentially, this means that poorly run and troubled companies are most exposed during market downturns. This is certainly proving to be the case this year. With all the major U.S. indices now in bear markets, many stocks that were flying high during the pandemic are getting crushed under the weight of poor financial results, bad management and flawed strategies. Since U., Headline: Moderna refuses request to hand over Covid-19 vaccine tech to China, source:Finnhub, summary: MODERNA has reportedly refused a request from China to share the tech behind its Covid-19 vaccine.Moderna's rejection prompted negotiations for the sale of its vaccine in China to fall apart, the... | October 3, 2022, Headline: Notable Monday Option Activity: MRNA, MET, SPLK, source:Stock Options Channel, summary: Staff article entitled Notable Monday Option Activity: MRNA, MET, SPLK, about stock options, from Stock Options Channel., Headline: 7 S&P 500 Stocks to Sell Before They Die, source:InvestorPlace, summary: Investors should unload these S&P 500 stocks to sell and recognize that their fortunes have taken a dramatic turn for the worse., Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. TSLA, GM, STLA, VWAGY, VSAT, LHX, HOOD, DIS, DISH, WFC, C, DOCU, BOX, RBLX, ENFN, NKE, FRPT, AAPL, UAL, QCOM, TCEHY, MRNA, MYOV, VRT, RIG, LTHM, APLS, IDCC, DUOT, APRN, VERO, ILMN",MRNA
12,2022-10-03,"Headline: 2 Growth Stocks That Could Jump 64.1% to 86.1% Higher, According to Wall Street, source:Yahoo, summary: Investment bank analysts think both of these stocks have what they need to deliver big gains in the foreseeable future., Headline: Moderna: A Great Diversification Into Large Cap, source:SeekingAlpha, summary: Moderna continues to generate increasing sales for its COVID vaccine while other pipeline molecules advance. Read here for a full investment analysis of MRNA stock., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. TSLA, VSAT, LHX, HOOD, DIS, DISH, MRNA, FRPT, AAPL, QCOM, UAL, TCEHY, SONY, MYOV, VRT, RIG, LTHM, APLS, IDCC, DUOT, APRN, VRTV, VERO, WFC, C, DOCU, BOX, RBLX, ENFN, NKE, Headline: Moderna Says No To China's Request To Handover COVID-19 Vaccine Technology: Report, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) refused to hand over to China the core intellectual property related to the development of its famed COVID-19 vaccine. Earlier this month, Moderna's CEO Stephane Bancel said the company has talked with the Chinese government about supplying COVID-19 vaccines. Moderna refused to transfer the technology for its COVID-19 vaccine because of commercial and safety concerns, Financial Times reported citing two people involved in negotiations between 2020 and 2021. The company, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rallied 2.32% to $120.99 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Tracking Philippe Laffont's Coatue Management Portfolio - Q2 2022 Update, source:SeekingAlpha, summary: Philippe Laffont's 13F portfolio value decreased from $13.67B to $8.26B this quarter. Read more about Coatue Management's holdings and trades for Q2 2022.",MRNA
13,2022-10-04,"Headline: Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?, source:Yahoo, summary: Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects., Headline: Moderna Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.87% to $125.67 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Moderna asks Japan health ministry to approve BA.5-tailored vaccine, source:Finnhub, summary: The Japan unit of Moderna Inc. said Wednesday it has asked the country's health ministry to approve its updated coronavirus vaccine tailored to the now-prevalent BA.5 subvariant.								The U.S.... | October 5, 2022",MRNA
14,2022-10-05,"Headline: COVID-19: Is The IP Truce Over?, source:Finnhub, summary: The COVID-19 pandemic brought with it something of an IP truce, with major pharmaceutical companies seemingly happy to co-exist. However, it now seems that a battle is about to commence with three of... | October 5, 2022, Headline: Pfizer COVID vaccine clears Japan panel for use with young children, source:Yahoo, summary: A Japanese health ministry panel on Wednesday recommended approving Pfizer Inc's COVID-19 vaccine for children as young as six months old.  Japan in January expanded use of the vaccine to those as young as 5 years old.  Last month, health authorities started to dispensing Pfizer and Moderna Inc booster shots that target the Omicron variant of the virus., Headline: UPDATE 1-Pfizer COVID vaccine clears Japan panel for use with young children, source:Yahoo, summary: A Japanese health ministry panel on Wednesday recommended approving Pfizer Inc's COVID-19 vaccine for children as young as six months old.  Japan in January expanded use of the vaccine to those as young as five years old.  Last month, health authorities started to dispensing Pfizer and Moderna Inc booster shots that target the Omicron variant of the virus., Headline: Moderna Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. dropped 0.04% to $125.62 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Stock Moves -0.04%: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $125.62, marking a -0.04% move from the previous day.",MRNA
15,2022-10-06,"Headline: The Petri Dish: Moderna nabs Novartis exec as new CTO, Ginkgo acquires two companies, source:Yahoo, summary: Biogen's patent battles over Tecfidera are over after SCOTUS decision; Ginkgo Bioworks delves into the RNA therapeutics; and Peter Thiel invests in Waltham startup creating ""humanized"" mice., Headline: Top 20 Drug Companies in the World in 2022, source:Yahoo, summary: In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […], Headline: Moderna Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Moderna Inc. slipped 0.37% to $125.15 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: UPDATE 1-Nearly 4 mln Americans received updated COVID boosters last week - CDC, source:Yahoo, summary: Around 3.9 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.  The 11.5-million figure represents only 5.3% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series.  The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people., Headline: Why Moderna Stock Couldn't Shake the Thursday Blues, source:Yahoo, summary: The CDC's latest report on COVID-19 vaccinations didn't provide enough fuel for shareholder optimism.",MRNA
16,2022-10-07,"Headline: Get Ready for the Next Bull Market: 3 Stocks to Buy Right Now, source:Yahoo, summary: With the three major indexes falling into a bear market, you may not be thinking about the next bull market.  Bear markets often offer us the chance to pick up solid stocks for a bargain -- and then reap the rewards when market conditions improve.  Let's check out three top names that have declined -- but may soar in a bull market, thanks to their strong businesses., Headline: UPDATE 2-Canada authorises Pfizer's Omicron retooled booster, source:Yahoo, summary: Canada on Friday authorised updated COVID-19 booster shots from Pfizer Inc and its partner BioNTech SE that target the Omicron BA.4 and BA.5 subvariants, according to the government's website.  Pfizer and BioNTech said in a joint statement the companies will make ""significant volumes of the vaccine available in the coming days"".  The booster shot, which has been authorised for people 12 years and older, is the second to get clearance from Health Canada after Moderna Inc's modified booster last month., Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 4.66% to $119.32 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...",MRNA
17,2022-10-08,"Headline: Moderna: A Look At The Monster ROIC, source:SeekingAlpha, summary: Moderna is a bet that they will produce product diversification that will carry it beyond just production of COVID vaccine. See why MRNA stock is a hold for me.",MRNA
18,2022-10-09,"Headline: Week In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong Exchange, source:SeekingAlpha, summary: AIM Vaccine conducted a very small IPO on the Hong Kong exchange, raising US$20 million, which netted the company only US$10 million. The IPO saw less than 1% of the company's shares sold., Headline: 7 Stocks to Buy on the Dip for Brave Contrarians, source:InvestorPlace, summary: If you have nerves of steel, these higher-risk opportunities can potentially bolster your portfolio over the long run., Headline: Dear NVAX Stock Fans, Mark Your Calendars for Oct. 11, source:InvestorPlace, summary: Shares of NVAX stock are climbing ahead of the World Vaccine Congress Europe 2022, where Novavax will share new vaccine data.",MRNA
19,2022-10-10,"Headline: Early notable gainers among liquid option names on October 10th, source:Thefly.com, summary: Notable gainers among liq... MRK, KHC, MRNA, WBA, BA, Headline: Better Buy: Moderna vs. Axsome Therapeutics, source:Yahoo, summary: At the same time, fellow biotech company Axsome Therapeutics (NASDAQ: AXSM) is getting its moment in the spotlight.  Moderna shares have dropped 50% so far this year.  Sure, Moderna is generating billions of dollars from its coronavirus vaccine now.",MRNA
20,2022-10-11,"Headline: Noteworthy Wednesday Option Activity: MRNA, CDW, LRCX, source:Stock Options Channel, summary: Staff article entitled Noteworthy Wednesday Option Activity: MRNA, CDW, LRCX, about stock options, from Stock Options Channel., Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. PEP, MRK, MRNA, KNBE, PHG, SPX, SPY, $ECON, NCLH, CNK, LYFT, AIG, SWK, MGPI, EVA, VTRS, INTC, AAPL, CANG, FTCH, CCJ, BEP, RKLB, OMI, SIEN, TTOO, SDPI, WIT, PFE, BNTX",MRNA
21,2022-10-12,"Headline: U.S. stock futures trim gains after higher-than-expected inflation data, source:DowJones, summary: U.S. stock-index futures trim gains on Wednesday after hotter-than-expected inflation data reinforced fears that the Federal Reserve may continue its..., Headline: Moderna exercises option to license Autolus Therapeutics' targeting technology, source:Thefly.com, summary: Moderna (MRNA) has exerci... AUTL, MRNA, Headline: Merck exercises option for joint development, commercialization of PCV, source:Thefly.com, summary: Moderna (MRNA) and Merck ... MRNA, MRK, Headline: Moderna exercises option to license proprietary targeting technology from Autolus, source:GlobeNewswire, summary: No summary, Headline: What's going to break next? Look for leverage and artificial constraints, says this fund manager, source:MarketWatch, summary: One fund sees a rough fourth quarter both for U.S. stocks and commodities, anticipating consumer spending will finally turn and earnings growth expectations..., Headline: Merck Exercises Option on Personalized Cancer Vaccine With Moderna, source:MarketWatch, summary: By Colin Kellaher Moderna Inc. and Merck &amp; Co. on Wednesday said Merck has exercised its option to jointly develop and commercialize mRNA-4157/V940, a..., Headline: Merck, Moderna to develop personalized cancer vaccine, source:MarketWatch, summary: Merck & Co. Inc. and Moderna Inc. said Wednesday that they plan to jointly develop and commercialize a personalized cancer vaccine. The investigational..., Headline: Moderna (MRNA) Gets a Buy from Brookline Capital Markets, source:TipRanks, summary: In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Moderna (MRNA &#8211; Research Report), with a price target of $5..., Headline: Merck move positive signal for Moderna, says Piper Sandler, source:Thefly.com, summary: Piper Sandler analyst Edw... MRNA, MRK, Headline: nan, source:TipRanks, summary: nan, Headline: Unusually active option classes on open October 12th, source:Thefly.com, summary: Unusual total active opti... KNBE, PEP, MRNA, IPOF, MLCO, KHC, TELL, ENVX, CHPT, KO, Headline: Home - The Fly, source:Thefly.com, summary: The Fly is a leading digital publisher of real-time financial news. The Fly team scours all sources of company news and delivers short-form stories consisting of only market moving content., Headline: Early notable gainers among liquid option names on October 12th, source:Thefly.com, summary: Notable gainers among liq... MRNA, PEP, NCLH, CME, EW, Headline: FDA authorizes new Moderna, Pfizer boosters for younger age groups, source:Thefly.com, summary: The Food and Drug Adminis... PFE, BNTX, MRNA, Headline: Merck pays USD250 million to Moderna on cancer vaccine collaboration, source:Alliance News, summary: No summary, Headline: Moderna receives FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine, source:Thefly.com, summary: Moderna announced that it... MRNA, Headline: FDA authorizes Covid omicron booster shots for kids as young as 5 years old, source:CNBC, summary: The Centers for Disease Control and Prevention still has to issue its recommendations before pharmacies can administer the new shots to kids. , Headline: FDA clears updated COVID boosters for kids as young as 5, source:Associated Press, The, summary: No summary, Headline: Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients, source:CNBC, summary: Moderna's vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form skin cancer. , Headline: Merck partners with Moderna to develop a cancer vaccine, source:CNBC, summary: CNBC's Jim Cramer and the 'Squawk on the Street' team discuss Merck's decision to develop a cancer vaccine with mRNA developer Moderna., Headline: Why Is Moderna (MRNA) Stock Up 10% Today?, source:InvestorPlace, summary: The medical community is witnessing a potential watershed moment in vaccine development. And MRNA stock traders are in a buying mood., Headline: Pfizer, BioNTech stocks surge after FDA grants emergency use of BA.4, BA.5 adapted booster shots in children, source:MarketWatch, summary: Shares of Pfizer Inc. climbed 2.2% and BioNTech SE hiked up 5.5% in morning trading Wednesday, after the companies said the U.S. Food and Drug Administration..., Headline: Why Is Cameco (CCJ) Stock Down 15% Today?, source:InvestorPlace, summary: Cameco (CCJ) stock is slipping on Wednesday after the company announced its intent to acquire Westinghouse Electric Company., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. PEP, MRK, MRNA, KNBE, INTC, PHG, NCLH, CNK, LYFT, AIG, SWK, MGPI, EVA, NFLX, BBBY, VTRS, GRIN, CANG, FTCH, CCJ, RKLB, OMI, SIEN, TTOO, SDPI, WIT, Headline: Merck opts to jointly develop cancer vaccine with Moderna , source:Reuters, summary: Moderna Inc said on Wednesday that Merck & Co Inc had exercised an option to jointly develop and potentially sell a mRNA-based cancer vaccine., Headline: Stocks Post Midday Gains As Inflation Data Rolls In , source:TalkMarkets, summary: Wall Street is cautiously higher this afternoon, as investors digest this morning's producer price index (PPI) reading and look ahead to Thursday's consumer price index (CPI) report. , Headline: Why Is Hempacco (HPCO) Stock Up 35% Today?, source:InvestorPlace, summary: Hempacco (HPCO) stock is taking off on Wednesday after announcing results for its first half of 2022 and strong revenue growth., Headline: Most Active Equity Options For Midday - Wed., Oct. 12, source:TalkMarkets, summary: Here are the most active equity options for midday., Headline: FDA approves Pfizer, Moderna Omicron boosters for children, source:United Press International, summary: No summary, Headline: Autolus Therapeutics Shares Rise 16% After Moderna Exercises Licensing Option, source:MarketWatch, summary: By Chris Wack Autolus Therapeutics Plc shares were up 16% to $3.44 after the company said Moderna Inc. has exercised its option to license Autolus'..., Headline: Stocks making the biggest moves midday: Moderna, Pepsi, Lyft and more, source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Merck opts to develop, sell cancer vaccine with Moderna, source:Reuters, summary: Merck & Co Inc opted to jointly develop and potentially sell a personalized mRNA vaccine with Moderna Inc for a $250 million upfront payment on Wednesday, sending the vaccine maker's shares up over 8%., Headline: U.S. FDA authorizes updated COVID booster for children aged 5-11, source:Reuters, summary: The U.S. Food and Drug Administration on Wednesday authorized Omicron-tailored COVID-19 booster shots from Moderna Inc as well as Pfizer Inc and its partner BioNTech SE for children, a move that will boost the government's fall vaccination campaign. (Reporting by Jyoti Narayan..., Headline: U.S. FDA authorizes updated COVID booster shots for children as young as 5, source:Reuters, summary: The U.S. Food and Drug Administration on Wednesday authorized Omicron-tailored COVID-19 booster shots from Moderna Inc and Pfizer Inc for children, a move that will expand the government's fall vaccination campaign., Headline: FDA said children between 6 and 17 can get Moderna’s new COVID-19 booster, source:Yahoo, summary: Shares of Moderna Inc.  (MRNA)  soared 9.4% in trading on Wednesday after the Food and Drug Administration said children between the ages of 6 and 17 years old can now get the bivalent COVID-19 booster developed by the company.  The regulator also said that children between the ages of 5 and 11 years old can get the updated BioNTech SE  (BNTX)  /Pfizer Inc.  (PFE)  shot., Headline: Why Moderna Stock Is Bolting Higher Today, source:Yahoo, summary: A cancer vaccine deal with pharma heavyweight Merck is lighting a fire underneath the biotech's shares today., Headline: Moderna Jumps as Merck Extends Partnership on Cancer Vaccine, source:Yahoo, summary: (Bloomberg) -- Covid-19 vaccine maker Moderna Inc. rose the most in two months after Merck & Co. said it would exercise an option to maintain its partnership with the biotech company on a messenger RNA cancer vaccine.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketIntel Is Planning Thousands of Job Cuts in Face of PC SlumpA First Look at the Ritz-Carlton Superyacht: PhotosHome Flippers Get Burned by US Housing Market’s Sudden SlumpUS Core Inflation Seen Returning, Headline: Moderna In-Licenses Autolus' Technology For mRNA-Based Cancer Therapeutics, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) has exercised its option to license Autolus Therapeutics plc's (NASDAQ: AUTL) proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics. This follows an original agreement with Moderna announced in August 2021, granting Moderna an exclusive option to license Autolus' proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics. Related: Moderna Shares Are, Headline: U.S. clears Omicron COVID boosters for kids as young as 5, source:Yahoo, summary: The FDA cleared the COVID-19 booster tweaks without requiring human test results, just like it approves yearly changes to flu vaccines., Headline: Pfizer and Moderna Stocks Jump After FDA Grants Emergency Use of Boosters for Children, source:Yahoo, summary: The regulator granted emergency-use authorization for children as young as five to receive the Covid-19 vaccines. Stock in Pfizer and Moderna gained., Headline: PepsiCo, Moderna rise; Cameco, Owens & Minor fall, source:Associated Press, The, summary: No summary, Headline: Stock Market Inching Higher; Fed Minutes On Tap; Education Stock Breaks Out, source:Yahoo, summary: The stock market flashed a mild shade of green at noon on Wednesday. Investors now await the 2pm Fed Minutes., Headline: NEW YORK MARKET CLOSE: Stocks tread water ahead of US CPI, source:Alliance News, summary: No summary, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 8.28% to $130.72 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: U.S. authorizes updated COVID booster shots for children as young as 5, source:Reuters, summary: U.S. health regulators authorized the use of Omicron-tailored COVID-19 booster shots from Moderna Inc and Pfizer Inc in children as young as 5, a move that will expand the government's fall vaccination campaign., Headline: Omicron-Targeting Covid-19 Boosters Recommended for Kids as Young as 5, source:Yahoo, summary: The FDA’s decision broadens a campaign by health officials to bolster protection against the Omicron strains of the coronavirus., Headline: CDC officially recommends new boosters for young children, source:Yahoo, summary: MARKET PULSE The Centers for Disease Control and Prevention officially signed off on allowing children as young as 5 years old to get an updated COVID-19 booster shot. CDC Director Rochelle Walensky signed the decision memo on Wednesday afternoon, the same day that the Food and Drug Administration expanded the authorizations for Moderna Inc., Headline: Moderna and Merck enter joint venture to develop cancer vaccine, source:Yahoo, summary: Pharmaceutical manufacturers Moderna and Merck are partnering together to develop a cancer vaccine., Headline: Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment, source:Yahoo, summary: Merck opted Wednesday to help Moderna develop a personalized cancer vaccine based on messenger RNA technology, and MRNA stock rocketed., Headline: Moderna Stock Takes Off on Cancer Vaccine News, source:Yahoo, summary: Merck will pay Moderna $250 million to exercise an option for the development and future commercialization of the cancer vaccine., Headline: 7 Stocks That Could Sink Your Portfolio if You Don’t Sell Now, source:Yahoo, summary: This market downturn has not hit all stocks equally. While the major indices are down between 20% and 35% on the year, many stocks are down 70% or more in 2022. Although it might make sense to hold onto some tried-and-true stocks through the current downturn, there are some securities that investors would be better off selling before their losses compound and meaningfully worsen. Many stocks are down not only because of macroeconomic conditions and a decline in sentiment, but also because their, Headline: These 2 Stocks Gave Investors a Nice Surprise Wednesday, source:Yahoo, summary: Investors have been scared of high inflation for a long time, and traders apparently didn't want to have a lot of exposure to the stock market heading into Thursday morning's release of the September Consumer Price Index.  After having spent most of the day in positive territory, the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) once again set fresh closing lows for the year, and the Dow Jones Industrial Average (DJINDICES: ^DJI) moved modestly lower as well.  Amid the turbulent market, though, there were a couple of stocks that gave investors positive surprises.",MRNA
22,2022-10-13,"Headline: Old Port Advisors Buys 3, Sell - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Morgan Stanley says Merck opt-in suggests confidence in Moderna PCV data, source:Thefly.com, summary: After Merck (MRK) announc... MRNA, MRK, Headline: Moderna Now Priced Attractively For Long-Term Investors, source:SeekingAlpha, summary: Moderna's revenue is declining as public resists boosting. Read why accumulating MRNA stock at the current price will be likely to look very smart by 2030., Headline: Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?, source:Yahoo, summary: Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term., Headline: Fresh data supports updated boosters targeting omicron subvariants, raising hopes more Americans will get the shot, source:DowJones, summary: A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support for the new bivalent boosters that target the most..., Headline: CPI Thursday, Fed Minutes, Treasury Auction, Inside Days, Moderna's Shocking Run, source:Yahoo, summary: This time, the macroeconomic data-point that is currently ""the most focused upon piece of information ever"" that traders, investors, economists and the general public are geared up for, will be this morning's BLS (Bureau of Labor Statistics) September release of CPI (Consumer Price Index) data.  Headline September CPI is expected to print up 0.1% from August.  From a month-over-month perspective, headline CPI would appear to be slowing., Headline: Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m., Headline: 7 Stocks That Could Sink Your Portfolio if You Don't Sell Now, source:InvestorPlace, summary: Investors should take note. These seven stocks to sell could sink your portfolio if you don't unload them now., Headline: Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab, source:Yahoo, summary: FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine., Headline: Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab, source:Yahoo, summary: Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies., Headline: Moderna Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rallied 3.06% to $134.72 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Merck And Moderna Move Forward With Melanoma Vaccine - There's A Case For Backing Both, source:SeekingAlpha, summary: Merck will take up an option to partner with Moderna on development of a cancer vaccine used as an adjuvant alongside Keytruda. Read why the move is good for investors in both companies., Headline: Did Moderna Stock Mark a Bottom? Here's the Chart., source:Yahoo, summary: Moderna stock is sharply off its highs, but the charts are showing constructive action and investors wonder whether the stock has bottomed.",MRNA
23,2022-10-14,"Headline: FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids, source:Yahoo, summary: Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years., Headline: Dolly Parton donation strategy: 'I just give from my heart', source:Associated Press, The, summary: No summary, Headline: Carnegie Medal of Philanthropy celebrates 20th anniversary, source:Associated Press, The, summary: No summary, Headline: 1 Critical Thing About Moderna That the Market Is Ignoring, source:Yahoo, summary: Top coronavirus vaccine maker Moderna (NASDAQ: MRNA) used to be one of the stock market's stars.  Sure, Moderna continues to bring in billions of dollars in vaccine revenue.  First, let's take a step back and look at what Moderna's done so far., Headline: The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK, source:Yahoo, summary: Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog., Headline: This market is incredibly oversold, says Piper Sandler's Craig Johnson, source:CNBC, summary: Craig Johnson, chief market technician at Piper Sandler, joins 'Power Lunch' to discuss three stocks that have been especially volatile this past week: MRNA, WBA, and LRCX., Headline: Moderna becomes S&P 500 top performer amid Merck deal, source:Yahoo, summary: Yahoo Finance anchors discuss Moderna's performance this week and Kwasi Kwarteng ousted as UK finance minister., Headline: Pfizer (PFE) Posts Positive Data on Bivalent BA.4/5 COVID Jab, source:Yahoo, summary: Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration., Headline: Moderna Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Moderna Inc. slumped 0.53% to $134.00 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study, source:Yahoo, summary: Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine., Headline: 3 Under-the-Radar Fintech Stocks With 200% Upside Potential, source:Yahoo, summary: Sometimes, when it comes to investing, under-the-radar stocks are a much better option than very well-known names. For example, few people heard of Moderna (NASDAQ:MRNA) before the coronavirus pandemic or even in the pandemic’s early days. However, MRNA stock turned out to be a wonderful investment for those who bought it in the first half of 2020. In fact, the investors who bought the company’s shares then made much more money than thosewho bought the best-known pharmaceutical stocks. According, Headline: Moderna (MRNA) Stock Moves -0.53%: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $134, moving -0.53% from the previous trading session., Headline: The Importance Of Government Contracting For Pfizer And Moderna, source:SeekingAlpha, summary: Pfizer's sales is likely to show less erosion owing to its diversified vaccine/treatment mix, as opposed to Moderna's vaccine only exposure. Read here for more.",MRNA
24,2022-10-15,"Headline: 3 Beaten-Down Stocks to Buy and Hold, source:Yahoo, summary: With this in mind, we asked three Motley Fool contributors to pick beaten-down stocks to buy and hold.  Here's why they chose Abbott Laboratories (NYSE: ABT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE).  Keith Speights (Abbott Laboratories): Shares of Abbott Laboratories have fallen close to 30% year to date., Headline: GNOM: ETF Review And Healthcare Dashboard For October, source:SeekingAlpha, summary: Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued. Focus on a biotech ETF: GNOM (and why I donât like it).",MRNA
25,2022-10-16,"Headline: Vaccine makers face revenue slump as demand falls for Covid-19 jabs, source:Yahoo, summary: Airfinity, a health data analytics group, said Pfizer, BioNTech and Moderna had begun raising vaccine prices but this would not fully compensate for the drop in demand for Covid inoculations in 2023.  The average price per dose next year will rise to $37, which is double the amount charged for Covid jabs in 2021.  Vaccine makers are expected to update investors on Covid sales during third-quarter results next month, but analysts have begun cutting revenue forecasts, citing weaker than expected jab sales.",MRNA
26,2022-10-17,"Headline: Moderna, Gavi agree to cancel remaining COVID-19 vaccine pending orders, source:Thefly.com, summary: Moderna and Gavi, the Vac... MRNA, Headline: nan, source:TipRanks, summary: nan, Headline: Brookline Capital Markets Sticks to Its Buy Rating for Moderna (MRNA), source:TipRanks, summary: Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna (MRNA &#8211; Research Report) today and set a price target of $506.00. The compan..., Headline: Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Gavi, the Vaccine Alliance, have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022., Headline: 10 questions for business leaders amid the current tone: Morning Brief, source:Yahoo, summary: Yahoo Finance's biggest conference of the year kicks off, with major questions for leaders swirling. More on that, and what else to watch in markets Monday, October 17, 2022., Headline: Moderna signs new deal on variant-adapted COVID-19 shots for world's poorest, source:Reuters, summary: Moderna Inc (MRNA.O) has agreed to provide its new variant-adapted COVID-19 vaccine to the global scheme aiming to deliver shots to the world's poorest people., Headline: Moderna, Gavi cancel COVID-19 vaccine orders for rest of 2022 due to 'sufficient supply', source:Yahoo, summary: Moderna Inc. said it and GAVI, the Vaccine Alliance supplying vaccines to low- and middle-income countries, have agreed to cancel remaining orders under their 2022 COVID-19 vaccine agreement given ""sufficient supply."" The biotechnology company has supplied Gavi with nearly 70 million doses of COVID-19 vaccines, in addition to facilitating the donation of more than 100 million doses. Moderna and Gavi said they will create a new framework that enables Gavi to buy up to 100 million COVID-19 vaccine, Headline: UPDATE 1-Moderna signs deal on variant-adapted COVID shots for world's poorest, source:Yahoo, summary: Moderna Inc (MRNA.O) has agreed to provide its new variant-adapted COVID-19 vaccine to the global scheme aiming to deliver shots to the world's poorest people.  The biotech company and vaccine alliance GAVI will cancel their existing supply deal for vaccines based on the original coronavirus strain.  Instead, Moderna will supply up to 100 million doses of its new, variant-adapted vaccines at its lowest available price from 2023., Headline: Moderna CEO: Merck deal ‘could be a game changer’ for cancer treatment, source:Yahoo, summary: Moderna CEO Stéphane Bancel spoke with Anjalee Khemlani at Yahoo Finance's All Markets Summit about the company's deal with Merck to develop a cancer vaccine., Headline: Moderna CEO: COVID-19 accelerated manufacturing network by 5 years, source:Yahoo, summary: Moderna CEO Stephane Bancel spoke with Anjalee Khemlani at Yahoo Finance's All Markets Summit about Moderna's manufacturing network and how it plays into what the company can now do., Headline: Moderna CEO on developing a vaccine ‘franchise’ for COVID, flu, HIV, source:Yahoo, summary: Moderna CEO Stephane Bancel spoke with Yahoo Finance's Anjalee Khemlani on medicines currently in development., Headline: Moderna CEO talks competition with J&J, Novavax, AstraZeneca, source:Yahoo, summary: Moderna CEO Stephane Bancel on competing with traditional players in the drug and vaccine space., Headline: Moderna CEO Stephane Bancel talks business, vaccine demand, and medical advances, source:Yahoo, summary: Moderna CEO Stephane Bancel spoke with Yahoo Finance's Anjalee Khemlani at the 2022 Yahoo Finance All Markets Summit., Headline: Moderna CEO on COVID vaccines: Not everyone will need an annual COVID-19 booster, source:Yahoo, summary: Moderna CEO Stephane Bancel speaks with Anjalee Khemlani at Yahoo Finance's All Markets Summit about the COVID vaccine and why boosters will be necessary each year., Headline: Moderna Inks Deal For Updated COVID Shots For Low Income Countries, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) and Gavi, the Vaccine Alliance, agreed to cancel the remaining pending orders under the current COVID-19 vaccine supply agreement for 2022 based on the original coronavirus strain. Instead, Moderna will supply up to 100 million doses of its new, variant-adapted vaccines at its lowest price from 2023. Moderna's agreement with Gavi has led to the supply of nearly 70 million doses of COVID-19 vaccines to the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-in, Headline: CDC identifies new COVID variants that accounted for 11.4% of new cases in week ending Oct. 15, source:Yahoo, summary: The Centers for Disease Control and Prevention said a new COVID variant dubbed BQ.1 and a descendant called BQ.1.1 have gained traction in the U.S., accounting for 11.4% of new cases across the nation in the week ending Oct. 15., Headline: Moderna CEO: Not everyone will need an annual COVID booster, source:Yahoo, summary: Moderna CEO says not everyone will need an annual COVID booster., Headline: Moderna Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rallied 3.92% to $139.25 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Does my child need the bivalent COVID booster? One expert says it’s critical to helping prevent long COVID in kids, source:Yahoo, summary: The FDA authorized emergency use of the bivalent booster for Moderna and Pfizer for younger kids last week., Headline: Moderna signs deal on variant-adapted COVID shots for world's poorest, source:Reuters, summary: Moderna Inc (MRNA.O) has agreed to provide its new variant-adapted COVID-19 vaccine to the global scheme aiming to deliver shots to the world's poorest people., Headline: Covid Companies Are Losing Steam. Not This One., source:MarketWatch, summary: As the virus spread, hundreds of labs ordered Hologic’s molecular diagnostic machines. Now the company is out to prove it can keep those devices humming with..., Headline: Tuesday Sector Laggards: Healthcare, Energy, source:Market News Video, summary: Looking at the sectors faring worst as of midday Tuesday, shares of Healthcare companies are underperforming other sectors, higher by 1.1% - Within that group, Moderna Inc (MRNA) and DexCom Inc (DXCM) are two of the day's laggards, showing a loss of 4.3% and 2.7%, respectively. - MRNA,DXCM,XLV,COP,APA.",MRNA
27,2022-10-18,"Headline: Moderna price target lowered to $175 from $197 at Morgan Stanley, source:Thefly.com, summary: Morgan Stanley analyst Ma... MRNA, Headline: 3 Growth Stocks That Could Soar 62.6% to 66.3%, According to Wall Street, source:Yahoo, summary: Record-breaking inflation levels, rising interest rates, and fear of a recession on the horizon are all weighing down stock prices right now.  Investment bank analysts on Wall Street who follow these three stocks think they've been beaten down way too far.  In fact, consensus price targets on these stocks suggest they could climb between 62.6% to 66.3% once the rest of the market sees their underlying businesses in the same light as Wall Street does., Headline: What the Smartest Investors Know About Moderna Stock, source:Yahoo, summary: It's important to understand Moderna's near-term challenges and its long-term opportunities., Headline: Video: Nasdaq 100 Movers: MRNA, OKTA, source:Market News Video, summary: In early trading on Tuesday, shares of Okta topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.8% - Year to date, Okta has lost about 75.5% of its value - MRNA,OKTA,REGN,PDD., Headline: 10 Best Low Price Pharma Stocks To Buy Now, source:Yahoo, summary: In this article, we discuss 10 best low price pharma stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Low Price Pharma Stocks To Buy Now. The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a […], Headline: Will This News Send Moderna's Stock Soaring?, source:Yahoo, summary: A big challenge with Moderna (NASDAQ: MRNA) right now is that many investors see it as a COVID-19 stock and not much else.  The company is developing more types of COVID vaccines, and its revenue for the foreseeable future will come primarily from Spikevax.  Although the COVID vaccine has been a huge success story for Moderna, for forward-looking investors, the business remains full of question marks and uncertainty., Headline: Here’s Why Moderna (MRNA) Underperformed in the Third Quarter, source:Yahoo, summary: Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor […], Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 3.71% to $134.09 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Why Moderna Stock Tripped and Fell on Tuesday, source:Yahoo, summary: The latest news about the coronavirus is encouraging, so the company's one commercialized product might not be such a popular item.",MRNA
28,2022-10-19,"Headline: Moderna's Omicron booster has superior antibody response v. spikevax prototype, source:Thefly.com, summary: Moderna announced new cli... MRNA, Headline: Moderna announces clinical data on mRNA-1273.214 bivalent booster, source:Thefly.com, summary: Moderna announced new cli... MRNA, Headline: Moderna put volume heavy and directionally bearish, source:Thefly.com, summary: Bearish flow noted in Mod... MRNA, Headline: EMA recommends approval of Comirnaty, Spikevax for children over 6 months, source:Thefly.com, summary: EMA's human medicine... PFE, BNTX, MRNA, Headline: EMA recommends approval of second adapted Spikevax vaccine, source:Thefly.com, summary: EMA's human medicine... MRNA, Headline: CDC recommends Novavax's Covid shots as mix-and-match first booster to Pfizer or Moderna, source:CNBC, summary: Novavax's Covid shots rely on protein technology used in other vaccines for decades, rather than the messenger RNA used in the Pfizer and Moderna vaccines. , Headline: Moderna announces CHMP issues positive opinion on variation to Spikevax CMA, source:Thefly.com, summary: Moderna announced that th... MRNA, Headline: 90-Day Analysis Shows Moderna’s Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster, source:Yahoo, summary: Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214., Headline: Moderna announces CHMP issues positive opinion on bivalent vaccine, source:Thefly.com, summary: Moderna announced that th... MRNA, Headline: Moderna says Omicron booster response stays high through 3 months, source:Reuters, summary: Moderna Inc said on Wednesday its COVID-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months., Headline: Moderna's Covid-19 Vaccine Recommended for Children Under 6 Years in EU, source:MarketWatch, summary: By Sabela Ojea Moderna Inc. on Wednesday said that its Covid-19 vaccine has been recommended for marketing authorization in the European Union to include..., Headline: 15 Best Drug Stocks to Buy Now, source:Yahoo, summary: In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […], Headline: Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option Play, source:Yahoo, summary: Traders who think Moderna stock will not reclaim the 50-day line could look at a bear call spread at 145-150., Headline: Swiss to destroy 9 million expired Moderna COVID-19 jabs, source:Reuters, summary: Switzerland will destroy 9 million doses of Moderna COVID-19 vaccine that have reached their expiry date, with another 5.1 million vaccine jabs set to meet the same fate by February, the government said on Wednesday., Headline: EMA recommends Moderna's new Omicron-tailored vaccine, source:Reuters, summary: The European Medical Agency on Wednesday recommended authorization of Moderna Inc's COVID-19 vaccine tailored towards targeting the Omicron sub-variants BA.4 and BA.5 for 12 and above ages., Headline: UPDATE 1-EMA recommends Moderna's updated Omicron-tailored vaccine, source:Yahoo, summary: The European Medical Agency on Wednesday recommended authorization of Moderna Inc's COVID-19 vaccine-tailored booster shots for 12 and above ages to further vaccination campaigns in the region.  The agency also authorized Pfizer-BioNTech's and Moderna's vaccines for children as young six months.  The updated bivalent booster shots from Moderna will target the original version as well as the BA.4 and the currently dominant BA.5 sub-variants of Omicron., Headline: EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a variation to the conditional marketing authorization (CMA) to include a 25 µg two-dose series of Spikevax (mRNA-1273) for active immunization to prevent coronavirus disease 2019 (COVID-19), Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 7.88% to $123.52 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Moderna's Omicron-Adapted Booster Maintains Response Through Three Months, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) COVID-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant. Ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 (updated vaccine) elicited a superior neutralizing antibody response against Omicron BA.1 when compared to a 50 µg booster dose of mRNA-1273 in all participants regardless of prior infection. Related: Mo, Headline: FDA Authorizes Novavax Covid-19 Shot as Booster for Adults, source:Yahoo, summary: The Food and Drug Administration granted emergency authorization to  Novavax  Covid-19 shot as a booster for adults.  The shot targets the original strain of the virus, whereas the updated booster shots from  Moderna  and  Pfizer  and its partner  BioNTech SE  authorized in August by the FDA, target both the original strain and newer Omicron strains.  The Novavax shot also uses a protein platform, whereas the other two companies’ boosters use messenger RNA, a newer technology., Headline: EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization for mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2, Headline: EMA recommends Moderna's updated Omicron-tailored vaccine, source:Reuters, summary: The European Medical Agency on Wednesday recommended authorization of Moderna Inc's COVID-19 vaccine-tailored booster shots for 12 and above ages to further vaccination campaigns in the region., Headline: European Regulatory Authority Backs Approval For Moderna's New Omicron Targeted COVID-19 Booster, source:Yahoo, summary: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has backed conditional approval for Moderna Inc's (NASDAQ: MRNA) updated omicron BA.4-5 COVID-19 vaccine booster for 12 years and above. This vaccine now joins Moderna's other updated booster vaccine, mRNA 1273.214, that targets the BA.1 variant for use in individuals 12 years and older. Related: Moderna's Omicron-Adapted Booster Maintains Response Through Three Months. The updated vaccine is a next-generation, Headline: FDA greenlights Novavax's original COVID-19 vaccine as booster, source:Yahoo, summary: Novavax gets FDA nod for original formula as its booster differs from mRNA boosters., Headline: Why Moderna Stock Dropped Today, source:Yahoo, summary: What happened Shares of Moderna (NASDAQ: MRNA) fell 7.9% on Wednesday after health regulators authorized Novavax's (NASDAQ: NVAX) COVID-19 vaccine, Adjuvanted, as a booster for adults.  So what The Centers for Disease Control and Prevention (CDC) will allow Novavax's vaccine to be used as a first booster shot for people aged 18 and older who would rather take it than initial boosters offered by Moderna and Pfizer (NYSE: PFE)., Headline: CDC panel says COVID shots to be added to regular vaccinations, WSJ says, source:Thefly.com, summary: The Advisory Committee on... PFE, BNTX, JNJ, MRNA, NVAX",MRNA
29,2022-10-20,"Headline: HQH: A Dividend Paymaster That Fails To Register Price Growth, source:SeekingAlpha, summary: Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy., Headline: Moderna price target lowered to $145 from $165 at Cowen, source:Thefly.com, summary: Cowen analyst Tyler Van B... MRNA, Headline: 3 Things the Smartest Investors Know About This Beaten-Down Stock, source:Yahoo, summary: Most people consider Moderna (NASDAQ: MRNA) a coronavirus vaccine stock. And for good reason. The vaccine is the company's only product right now. And it's generated billions of dollars in revenue and profit for this biotech player., Headline: Analysis-Falling demand for COVID boosters puts price hikes on the table, source:Yahoo, summary: With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations.  With fewer shots needed, vaccine makers including Pfizer Inc, partner BioNTech SE, rival Moderna Inc and Novavax Inc could have to hike prices as much as three times current levels if they hope to meet Wall Street revenue forecasts for the shots for 2023 and beyond, several analysts said.  Last year, many on Wall Street were estimating the number of  COVID-19 shots would be in line with the annual flu vaccine, which is the vaccine market leader with more than 160 million shots per year in the United States and 600 million shots globally., Headline: The Petri Dish: MIT launches 'brain-machine interface' startup, source:Yahoo, summary: A Boston-based startup that spun out of MIT in 2021 launched this week aiming to develop a system of nanoelectronic implants., Headline: 3 Potentially Explosive Stocks You'll Want in Your Portfolio Before the Next Bull Market (and They're Dirt Cheap Now), source:Yahoo, summary: Amazon (NASDAQ: AMZN) has disappointed investors over the past few quarters.  As for the past, Amazon has a solid track record of revenue and profit growth.  The company also has grown important metrics, such as return on invested capital and free cash flow (until recently)., Headline: EASTERN BANK Buys 1, Sells 4 i - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Vaccine Wastage: Switzerland Throws Away Some 9M Expired Moderna COVID-19 Vaccines, source:Yahoo, summary: Switzerland will need to discard around 9 million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine that have reached their expiry date. The wastage reflects the Swiss strategy of ordering more vaccines than needed to ensure its population of around 8.7 million would get sufficient supplies despite supply bottlenecks or quality issues. Related: Moderna's Omicron-Adapted Booster Maintains Response Through Three Months. ""With this deliberately chosen strategy, it was accepted that too much va, Headline: WHO says another omicron subvariant, which may be more resistant to antibodies,  spread to 26 countries in latest week, source:Yahoo, summary: The WHO found that omicron subvariant XBB, which may be even more resistant to antibodies than other variants, spread to more countries in the week ending Oct. 16 from the previous week., Headline: Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More, source:Yahoo, summary: Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week., Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 4.16% to $118.38 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab, source:Yahoo, summary: Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen., Headline: Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab, source:Yahoo, summary: The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older., Headline: Covid-19 Vaccines Should be Added to Regular Immunizations, CDC Advisers Say, source:Yahoo, summary: Vaccine experts advising the Centers for Disease Control and Prevention recommended the agency add Covid-19 vaccines to lists including measles, tetanus and other inoculations recommended for adults and children., Headline: Press Release Service & Global Newswire | ACCESSWIRE, source:Accesswire, summary: ACCESSWIRE is an effective, cost efficient global newswire and press release distribution service. Tell your story with unlimited media and a large investor network., Headline: Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?, source:InvestorPlace, summary: Vaccine stocks are flying higher on Friday on word that Pfizer will quadruple the price of its Covid-19 vaccine. Will others follow suit?",MRNA
30,2022-10-21,"Headline: Moderna upgraded to Market Perform from Underperform at SVB Securities, source:Thefly.com, summary: SVB Securities analyst Ma... MRNA, Headline: Premarket Movers: Snap, SVB Financial Group, CSX, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (CSX) was up 4.8% in pre-market trading, and (ALV) was up 4.5%. (COTY), (EXEL), and (MRNA) were all posting..., Headline: Pfizer’s Covid Vaccine Is Going to Cost a Lot More. That’s Good News for Moderna., source:MarketWatch, summary: Pfizer and other pharma companies are under pressure to raise prices to meet revenue targets after government supplies of Covid vaccines runs out., Headline: Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie?, source:Yahoo, summary: Take the case of AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA).  AbbVie spun off from Abbott Laboratories in 2013 to shield the parent company from an impending loss-of-exclusivity disaster.  International sales of AbbVie's lead drug, an anti-inflammation injection called Humira, tanked a few years ago when biosimilar competition became available in the EU., Headline: Does This 1 Number Mean Trouble for Moderna?, source:Yahoo, summary: Today, most of the people who wanted the primary vaccine series have gotten it.  Of course, all of this is unlikely to lead to a huge jump this year in the numbers of people opting for strain-specific boosters., Headline: CDC shoots down false claims it will mandate COVID-19 vaccines for schoolchildren, saying states make that decision, source:MarketWatch, summary: The Centers for Disease Control and Prevention has refuted claims that it will add COVID-19 vaccine to immunization schedules for schoolchildren, noting..., Headline: Pfizer sets new prices for its COVID-19 vaccines. The cost? $110 to $130 per dose, source:Yahoo, summary: The company plans to sell the COVID-19 shot it developed with BioNTech for $110 to $130 per dose once the U.S. market for COVID-19 shots becomes commercial., Headline: UPDATE 1-Pfizer COVID vaccine price hike seen giving revenue boost for years, source:Yahoo, summary: Pfizer's plan to as much as quadruple current U.S. prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said.  The drugmaker, which developed and sells the vaccine with Germany's BioNTech said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the United States moves to a commercial market next year.  Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 8.40% to $128.32 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Pfizer Quadruples Its Covid Shot Price — And Other Vaccine Stocks Rocket, source:Yahoo, summary: Moderna snagged an upgrade Friday on the likelihood it will hike the price of its Covid vaccine in 2023 — and MRNA stock jumped., Headline: Pfizer’s Price Hike Shot in the Arm for  Vaccine Makers, source:Yahoo, summary: Company’s decision to price its Covid-19 vaccine at $110-$130 per dose seeks to make up for the lower demand for boosters., Headline: Why Moderna Stock Rallied Today, source:Yahoo, summary: Shares of Moderna (NASDAQ: MRNA) jumped 8.4% on Friday after rival drugmaker Pfizer (NYSE: PFE) said it intends to drastically increase the price of its COVID-19 vaccine next year.  Pfizer is seeking to charge as much as $130 per dose, up from the $30.50 per shot it currently receives from the U.S. government.  The pharmaceutical giant is currently in talks with health insurers to determine the final price of the drug, according to The Wall Street Journal.",MRNA
31,2022-10-23,"Headline: Which Stocks Are Most Likely to Thrive in a Recession? Here's What History Shows, source:Yahoo, summary: Recession-proof stocks must offer something that makes investors want to buy them even when the economy is tanking.",MRNA
32,2022-10-24,"Headline: Moderna price target lowered to $122 from $165 at JPMorgan, source:Thefly.com, summary: JPMorgan analyst Jessica ... MRNA, Headline: 10 Most Undervalued Value Stocks To Buy Now, source:Yahoo, summary: In this article, we will look at the 10 most undervalued value stocks to buy now. If you want to explore similar stocks, you can also take a look at 5 Most Undervalued Value Stocks To Buy Now. 2022 has been an unfavorable year for stocks so far due to rampant inflation and high interest […], Headline: Pfizer just announced plans to sell its COVID-19 vaccine for at least $110 a dose in 2023 ⁠— that's a markup of about 10,000%, source:Yahoo, summary: The move will fuel revenue for years., Headline: Study suggests bivalent boosters didn't induce superior antibody responses, source:Thefly.com, summary: A preprint study posted O... MRNA, PFE, BNTX",MRNA
33,2022-10-25,"Headline: GLOBAL BROKER RATINGS: Morgan Stanley cuts Adidas to 'underweight', source:Alliance News, summary: No summary, Headline: Could This News from Pfizer Equal Billions for Moderna?, source:Yahoo, summary: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) both have generated billions of dollars of revenue from their coronavirus vaccines.  While Pfizer has a vast portfolio of products across therapeutic areas, Moderna still depends on its coronavirus vaccine and booster for all of its revenue.  Moderna's share performance reflects these concerns: The stock has dropped about 50% so far this year., Headline: Buy Novavax At $20 And Hold On For The Wild Ride Up, source:SeekingAlpha, summary: Novavax is sitting on a mountain of cash and its vaccine is a blockbuster. Read why I think NVAX will emerge as a highly profitable vaccine biotech over time.",MRNA
34,2022-10-26,"Headline: Are Pfizer and Moderna Stocks Buys With a Potential COVID Surge Coming?, source:Yahoo, summary: COVID-19 hasn't gone away. But a quick look at the charts of Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) stocks will tell you that the coronavirus isn't as big of a concern as it used to be. The situation could change in the near future, though., Headline: Moderna close to U.S. pact to develop Ebola vaccine, Bloomberg says, source:Thefly.com, summary: Moderna is near an agreem... MRNA, Headline: Moderna close to U.S. deal to make vaccines for Ebola, biological threats - Bloomberg News, source:Yahoo, summary: Moderna Inc is nearing a deal with the U.S. government to develop vaccines against a range of biological threats including Ebola, Bloomberg News reported on Wednesday, citing people familiar with the matter.  The potential deal with the U.S. Department of Defense (DoD) would see Moderna's mRNA technology being used to develop a vaccine targeting the Ebola strain responsible for the disease's outbreak in Uganda, the report said.  Uganda declared the Ebola outbreak in September, and the disease has claimed 30 lives so far with the number of confirmed cases rising to 109., Headline: UPDATE 1-Moderna close to U.S. deal to make vaccines for Ebola, biological threats - Bloomberg News, source:Yahoo, summary: Moderna Inc is nearing a deal with the U.S. government to develop vaccines against a range of biological threats including Ebola, Bloomberg News reported on Wednesday, citing people familiar with the matter.  The potential deal with the U.S. Department of Defense (DoD) would see Moderna's mRNA technology being used to develop a vaccine targeting the Ebola strain responsible for the disease's outbreak in Uganda, the report said.",MRNA
35,2022-10-27,"Headline: TOP NEWS: Merck & Co 3rd-quarter sales up; profit slips as costs rise, source:Alliance News, summary: No summary, Headline: Merck Stock Jumps As Keytruda Sales Power Q3 Earnings Beat, Profit Forecast Boost, source:Yahoo, summary: ""We continue to execute on our strategy, invest in leading-edge science and drive innovation,"" said CEO Robert Davis., Headline: Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know, source:Yahoo, summary: No summary, Headline: Company News for Oct 27, 2022, source:Yahoo, summary: Companies in The News Are: MRNA, V, CNI, BA, Headline: Could This Bullish News Make Novavax a Hot Buy?, source:Yahoo, summary: Novavax (NASDAQ: NVAX) is a beaten-down COVID stock that has seen its shares plummet 85% since the start of the year.  For people who prefer a more traditional shot or who had bad side effects from the mRNA vaccines, Novavax could be a welcome alternative for their boosters., Headline: Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for, source:Yahoo, summary: Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View, source:Yahoo, summary: Merck (MRK) beats Q3 estimates for earnings and sales. The company continues to see robust growth in Keytruda and Gardasil sales., Headline: Moderna Named a Top Employer by Science for Eighth Consecutive Year, source:Yahoo, summary: Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it was ranked one of the top employers in the global biopharmaceutical industry by Science and Science Careers' 2022 Top Employers Survey for the eighth consecutive year. Moderna was ranked no., Headline: Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its first virtual ESG Day for analysts and investors at 9:00 a.m.",MRNA
36,2022-10-28,"Headline: Moderna Breaks Above 200-Day Moving Average - Bullish for MRNA, source:Market News Video, summary: In trading on Friday, shares of Moderna Inc (MRNA) crossed above their 200 day moving average of $149.51, changing hands as high as $151.19 per share - Moderna Inc shares are currently trading up about 4.8% on the day. - MRNA., Headline: Three buys and a bail: AbbVie, Eli Lilly, Humana and Moderna, source:CNBC, summary: Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three stocks Sanchez is interested in buying and one the strategist is bailing on., Headline: FDA says two studies showing omicron boosters weren't much better than old Covid shots were too small to come to any conclusions, source:CNBC, summary: The FDA pushed back against two independent studies that found the new boosters don't trigger a better immune response than the old shots., Headline: Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?, source:Yahoo, summary: Investors will likely focus on the progress of Moderna's (MRNA) late-stage pipeline candidates during the third-quarter earnings call, which can lower its dependence on COVID vaccine sales., Headline: 10 Best Vaccine Stocks To Buy Now, source:Yahoo, summary: In this article, we will discuss the 10 best vaccine stocks to buy now. If you want to explore similar stocks, you can also take a look at 5 Best Vaccine Stocks To Buy Now. One of the most defensive areas of the market is healthcare, and in 2022 when the markets are falling to […]",MRNA
37,2022-10-29,"Headline: This Fallen Growth Stock Is Still a Wall Street Favorite: Here's Why, source:Yahoo, summary: The stock may be down by 60% over the past 12 months, but Maravai LifeSciences Holdings (NASDAQ: MRVI) is still in Wall Street's good graces, with all 10 of the big-time financial analysts who cover the stock rating it as either a buy or a strong buy.  Let's take a minute to see why Wall Street hasn't given up on this stock yet and to understand whether it might be a smart way to build more growth in your portfolio now.  Maravai's business model is to sell pure and ready-to-use nucleic acids to biopharma companies making molecular diagnostics and DNA- or RNA-based medicines.",MRNA
38,2022-10-30,"Headline: Under-the-radar trend shows tech investors remain loyal despite major losses this year, source:CNBC, summary: The widely held ARK Innovation ETF and the Technology Select Sector SPDR Fund aren't showing meaningful outflows so far this year., Headline: South Africa health minister hopes for more pharma investment, source:Yahoo, summary: The global inequity in vaccine distribution throughout the pandemic triggered calls for more decentralized manufacturing and distribution solutions, especially for low- and middle-income countries., Headline: Why Moderna Stock Soared Last Week, source:Yahoo, summary: Shares of Moderna (NASDAQ: MRNA) popped 18% last week, according to data provided by S&P Global Market Intelligence.  Investors were encouraged by news of several potential catalysts that could boost the pharmaceutical company's sales and profits.  Moderna came into the week with some positive momentum after fellow drugmaker Pfizer (NYSE: PFE) announced plans to raise the price of its COVID-19 vaccine next year to as much as $130 per shot.",MRNA
39,2022-10-31,"Headline: Eaton Vance Worldwide Health S - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Discussion of markets, performance and holdings, Headline: Tracking Baillie Gifford's 13F Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: Baillie Giffordâs 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. Click here to find out the Q3 2022 portfolio update., Headline: Top 5 3rd Quarter Trades of ST - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: 3 Beaten-Down Growth Stocks That Could Crush the Market, source:Yahoo, summary: Especially when it comes to growth stocks.  Let's look at three beaten-down growth stocks that actually could crush the market in the years to come.  Teladoc Health (NYSE: TDOC) shares have dropped more than 65% so far this year., Headline: New omicron subvariants accounted for 42.5% of cases in New York region in latest week, CDC data shows, source:DowJones, summary: The omicron sublineages BQ.1 and BQ.1.1 continued to spread in the U.S. in the week through Oct. 29, accounting for 27.1% of new cases nationwide, according..., Headline: Biogen: Super-Strong Momentum In A Defensive Sector, source:SeekingAlpha, summary: Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. See why I would reenter a position in BIIB stock.",MRNA
40,2022-11-01,"Headline: Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222 (Spikevax Bivalent Original/Omicron BA.4-5) in adults 18 years and older., Headline: Dentsply Sirona completes internal probe of accounting; to restate Q3 and full-year 2021 earnings and book up to $1.3 billion goodwill charge, source:MarketWatch, summary: Dentsply Sirona Inc. undefined, a maker of dental products and technology, said Tuesday it has completed an internal probe of financial reporting involving..., Headline: Moderna (MRNA) Gets a Buy from Brookline Capital Markets, source:TipRanks, summary: In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Moderna (MRNA &#8211; Research Report), with a price target of $5..., Headline: Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release, source:Yahoo, summary: Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 2.85% to $154.62 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Why Moderna Stock Rose Today, source:Yahoo, summary: Shares of Moderna (NASDAQ: MRNA) climbed 2.9% on Tuesday after fellow COVID-19 vaccine maker Pfizer (NYSE: PFE) boosted its full-year sales and profit forecast.  Pfizer raised the low end of its revenue guidance range to $99.5 billion from $98 billion.  Most encouraging to Moderna's shareholders was Pfizer's increased sales forecast for its COVID-19 vaccine, Comirnaty., Headline: REIK & CO., LLC Buys 4, Sells  - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",MRNA
41,2022-11-02,"Headline: Notable companies reporting before tomorrow's open, source:Thefly.com, summary: Notable companies reporti... COP, CI, REGN, ZTS, MRNA, MAR, FIS, DDOG, K, RCL, PENN, TPX, W, UAA, UA, PTON, COMM, PZZA, SPR, NKLA, Headline: Global company events calendar - next 7 days, source:Alliance News, summary: No summary, Headline: Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More, source:Yahoo, summary: Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release., Headline: NEW YORK MARKET CLOSE: Stocks crash back down to earth on hawkish Fed, source:Alliance News, summary: No summary, Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 3.88% to $148.62 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Moderna Sales Could Drop on Weakening COVID-19 Vaccine Demand, source:Yahoo, summary: Moderna (MRNA) reports third-quarter earnings before the market opens on Nov. 3. Profit is expected to decline by two-thirds as revenue drops for the first time in 11 quarters., Headline: GLOBAL BRIEFING: BoE to unveil biggest interest rate rise since 1980s, source:Alliance News, summary: No summary",MRNA
42,2022-11-03,"Headline: U.S. stocks book 4-day losing streak ahead of jobs data as investors continue to weigh Powell remarks, source:MarketWatch, summary: U.S. stocks ended lower on Thursday as investors absorb Federal Reserve Chairman Jerome Powell's comments from a day earlier., Headline: Moderna reports Q3 EPS $2.53, consensus $3.29, source:Thefly.com, summary: Reports Q3 revenue $3.4B,... MRNA, Headline: Moderna sees revenue from APAs for product sales $18B-$19B in 2022, source:Thefly.com, summary: Advance Purchase Agreemen... MRNA, Headline: Moderna Crashes As Q3 Results Disappoint, source:TipRanks, summary: nan, Headline: Moderna: Q3 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Moderna shares fall after Covid vaccine maker lowers 2022 sales outlook, source:CNBC, summary: Moderna also missed revenue and earnings expectations for the quarter., Headline: Moderna Stock Tumbles on Earnings Miss, Guidance Cut. Blame Covid-19 Vaccine Sales., source:MarketWatch, summary: The Covid-19 vaccine maker reported earnings early Thursday that missed Wall Street estimates, while cutting its estimate of total vaccine sales this year by..., Headline: Stocks making the biggest moves premarket: Restaurant Brands, Under Armour, Peloton and more, source:CNBC, summary: These are the stocks posting the largest moves before the bell., Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: Peloton plummets following Q1 earnings COP, CI, TPX, DDOG, UA, NKLA, BKNG, ZTS, FIS, MRNA, K, PTON, PZZA, QCOM, ROKU, UAA, QRVO, Headline: Moderna misses on 3Q, shaves 2022 vaccine expectations, source:Associated Press, The, summary: No summary, Headline: Why Is Moderna (MRNA) Stock Down 5% Today?, source:InvestorPlace, summary: Moderna (MRNA) stock is falling on Thursday following the release of the vaccine company's earnings report for the third quarter of 2022., Headline: Peloton (PTON) Stock Slumps on Gloomy Holiday Forecast, source:InvestorPlace, summary: Peloton (PTON) stock is falling on Thursday after the exercise equipment company provided an outlook update for the holidays., Headline: VAXED-out: The Demise of Vaccine Makers Continues, source:TipRanks, summary: After two years of a raging pandemic, the manufacturers of COVID-19 vaccines seem to be all &#8220;vaxed-out&#8221;. Shares of COVID-19 vaccine makers including Mod..., Headline: Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the third quarter of fiscal year 2022., Headline: Moderna cuts annual sales forecast for COVID vaccine , source:Reuters, summary: Moderna Inc on Thursday cut the sales forecast for its COVID-19 vaccine to between $18 billion and $19 billion from $21 billion, citing short-term supply constraints. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur), Headline: Moderna cuts COVID vaccine sales forecast on supply woes, shares tumble, source:Yahoo, summary: Moderna's forecast cut comes just two days after rival Pfizer Inc's quarterly sales of its COVID-19 vaccine exceeded market expectations and the drugmaker raised the full-year sales forecast for its shots.  The vaccine maker reported sales of $3.36 billion in the third quarter, missing Wall Street estimates of $3.53 billion., Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Chimerix (CMRX) and Moderna (MRNA), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Chimerix (<a hr..., Headline: Moderna stock slides 14% premarket after profit and revenue fall short of estimates and biotech offers soft guidance, source:Yahoo, summary: Moderna Inc. shares slid 14% in premarket trade Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and said short-term supply constraints would impact 2022 advance purchase agreements. The Cambridge, Mass.-based biotech posted net income of $1.043 billion, or $2.53 a share, for the quarter, down from $3.333 billion, or $7.70 a share, in the year-earlier period. Revenue fell to $3.364 billion from $4.969 billion a year ago. Both numbers were below the F, Headline: Moderna Cuts Outlook Amid Supply Constraints, source:Yahoo, summary: The pharmaceutical company said third-quarter revenue fell by nearly a third and cut its outlook as supply constraints sap up to $3 billion in sales this year., Headline: Moderna Stock Tumbles on Earnings Miss, Guidance Cut, source:Yahoo, summary: The Covid-19 vaccine maker reported earnings early Thursday that missed Wall Street estimates, while cutting its estimate of total vaccine sales this year by between $2 and $3 billion., Headline: Moderna, Inc. (MRNA) Q3 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Lavina Talukdar â Head-Investor Relations StÃ©phane Bancel â Chief..., Headline: Moderna Stock Tumbles On Softer Covid Vaccine Sales Forecast, Weakening Q3 Profits, source:Yahoo, summary: Moderna cautioned Thursday that $2 billion to $3 billion of its vaccine sales could be pushed into next year amid broader supply chain challenges., Headline: Moderna Shares Deep Dive After Lower COVID-19 Vaccine Sales Weigh On Q3 Sales, Profits, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) reports a Q3 EPS of $2.53, compared to the $7.70 posted a year ago, missing the consensus of $3.29. Revenue was $3.36 billion compared to $4.96 million a year ago, missing the consensus of $3.53 billion, mainly due to a decline in COVID-19 vaccine sales. Product sales were $3.1 billion, a decrease of 35% Y/Y, primarily driven by lower sales volume due to the timing of market authorizations for COVID-19 bivalent boosters and the related manufacturing ramp-up. Operating, Headline: Moderna, Inc. 2022 Q3 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Moderna, Inc., Headline: Moderna Profit and Revenue Down on Lower COVID Vaccine Sales, source:Yahoo, summary: Source: Visible AlphaModerna (MRNA) Financial Results: AnalysisModerna, Inc. (MRNA), maker of the second-most-popular COVID-19 vaccine in the U.S., dropped 11% in pre-market trading after profit and revenue missed estimates amid falling sales of its COVID-19 vaccine., Headline: Moderna misses on earnings as supply constraints hinder COVID vaccine deliveries, source:Yahoo, summary: Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss third-quarter earnings for Moderna., Headline: Midday Movers: Peloton Interactive, Etsy, Moderna and More, source:Yahoo, summary: By Liz Moyer, Headline: Moderna stock falls after earnings miss by a wide margin and company cuts sales outlook by up to $3 billion, source:Yahoo, summary: Moderna Inc. shares moved lower Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and lowered full-year sales guidance by up to $3 billion., Headline: Moderna says it could have an RSV vaccine as soon as next year, source:Yahoo, summary: Moderna Inc. said on Thursday morning that its vaccine for respiratory syncytial virus, better known as RSV, could be ready for commercialization as soon as next year., Headline: Pfizer: Q3 Earnings Review - Planning For Life After COVID, source:SeekingAlpha, summary: Pfizer released its Q3 2022 earnings on 1st November. PFE had another blockbuster quarter, generating $22.6B revenues & $8.6B net income. Read more here., Headline: Pfizer-BioNTech to test combined Covid and flu vaccine, source:Alliance News, summary: No summary, Headline: Moderna cuts Covid vaccine sales forecast on supply chain ‘pain points’, source:Yahoo, summary: Moderna cut its forecast for Covid-19 vaccine sales this year, citing delays in deliveries linked to supply chain constraints.  The US biotech company on Thursday said it expected vaccine sales to generate revenues of $18bn-$19bn in 2022, down from a forecast in August of $21bn.  This reflects deferrals of orders worth between $2bn-$3bn into 2023, according to the company., Headline: Weekly tally of COVID cases and deaths continues to fall; Moderna lowers vaccine-sales outlook by as much as $3 billion, source:Yahoo, summary: The global tally of COVID cases fell 17% in the week through Oct. 30 from the previous week, while the death toll fell 5%, the World Health Organization said in its weekly update on the virus., Headline: Moderna: What Do the Charts Suggest?, source:Yahoo, summary: In this daily bar chart of MRNA, below, we can see that prices spiked up into late November and then quickly tumbled lower into early March.  MRNA bounced but the rally failed and prices sank to new lows in May and June.  Prices are struggling Thursday and have dipped back below the declining 200-day moving average line., Headline: Moderna cuts 2022 sales projections, but offers little guidance for 2023, source:Yahoo, summary: Moderna's outlook for 2023 involves several unknowns, including what the company's relationship with the U.S. government might look like and how it chooses to price its Covid vaccines for a commercial market., Headline: Moderna Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Moderna Inc. shed 0.75% to $147.50 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Moderna Q3 earnings miss blamed on slow global demand, manufacturing constraints, source:Yahoo, summary: Moderna sees slow quarter as production capacity tested by differing government strategies., Headline: Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook, source:Yahoo, summary: Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales., Headline: Moderna COVID vaccine sales forecasts fall short for 2022, 2023, source:Reuters, summary: Moderna Inc on Thursday cut its 2022 COVID-19 vaccine sales forecast, citing regulatory and production delays, and issued a 2023 outlook for the shots well below Wall Street estimates, sending its shares down as much as 9%., Headline: Moderna Inc. (MRNA) Q3 2022 Earnings Call Transcript, source:Yahoo, summary: My name is Kevin, and welcome to Moderna's third quarter 2022 earnings call.  At this time, I'd like to turn the call over to Lavina Talukdar, head of investor relations at Moderna.  Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's third quarter 2022 financial results and business updates., Headline: Moderna Sinks On Slashed Outlook, But Rivals Recovering From Setback, source:Yahoo, summary: Moderna stock dropped Thursday after the company slashed its 2022 outlook, noting supply issues have delayed some of its deliveries., Headline: BioNTech Shares Up On Hope For Combined Flu, Covid Shot, source:Yahoo, summary: Pfizer and BioNTech started testing a combined flu and Covid vaccine on Thursday, helping BNTX stock pare earlier Moderna-inspired losses.",MRNA
43,2022-11-04,"Headline: Moderna receives Health Canada Authorization for COVID-19 booster vaccine, source:Thefly.com, summary: Moderna announced Health ... MRNA, Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Merus (MRUS), Moderna (MRNA) and Agilon Health (AGL), source:TipRanks, summary: Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Merus (<span class='tr-stock-ticker' style='color:blue; font-weig..., Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Veracyte (VCYT) and Moderna (MRNA), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (<a hre..., Headline: Moderna's Earnings Collapsed. Time to Sell?, source:Yahoo, summary: This drugmaker's bottom line fell down a deep hole in the third quarter and investors want to know if it's time to run for the hills., Headline: BioNTech's COVID-19 Vaccine Becomes First Foreign Shot To Be Available In Chinese Market, source:Yahoo, summary: German Chancellor Olaf Scholz agreed to allow expatriates in China to use BioNTech SE (NASDAQ: BNTX) made COVID-19 vaccine. BioNTech would be the first non-Chinese coronavirus vaccine in China, as Beijing has insisted on administering domestically produced vaccines. BioNTech partners on COVID vaccines with Pfizer Inc (NYSE: PFE) in regions outside Greater China. Also Read: Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity. In October, Moderna Inc', Headline: This Key Piece Of News Could Spark BioNTech, Moderna — And Could Stoke Demand For Covid Boosters, source:Yahoo, summary: Covid vaccine stocks surged Friday after a new study suggested an added benefit of the updated omicron-targeting boosters., Headline: Moderna Says Health Canada Authorizes Second Omicron-Targeting Bivalent Booster, source:MarketWatch, summary: By Stephen Nakrosis Moderna Inc. on Friday said Health Canada has approved its BA.4/BA.5 Omicron-targeting bivalent Covid-19 booster vaccine, mRNA-1273.222...., Headline: 7 Cash-Rich Stocks to Buy for Peace of Mind, source:Yahoo, summary: Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way. However, when investing, it’s not enough to look for businesses with cash. They should also have limited debt and strong cash flow generation in good times and bad. So, who are these companies? For this article, I selected four large-cap and three mid-cap cash-rich stocks to buy. Cash-rich, Headline: Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has authorized the use of its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, as a booster dose for active immunization against COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older., Headline: Did Vaccine Stocks Just Get Their Last Boost?, source:Yahoo, summary: Some positive news sent their share prices higher, but biotech companies will need to find other ways to make money.",MRNA
44,2022-11-05,"Headline: 3 Things You Need to Know About Moderna's Post-Pandemic Revenue, source:Yahoo, summary: During the pandemic, Moderna's (NASDAQ: MRNA) billion-dollar revenue has been pretty much a sure thing.  As a result, Moderna's shares have climbed more than 140% since the launch of its vaccine program.  Today, though, Moderna has offered us a few clues that should remove at least some of that uncertainty.",MRNA
45,2022-11-06,"Headline: Moderna (MRNA) Receives a Hold from SVB Securities, source:TipRanks, summary: In a report released on November 3, Mani Foroohar from SVB Securities reiterated a Hold rating on Moderna (MRNA &#8211; Research Report), with a price target of $10..., Headline: Is Moderna a Bad-News Buy?, source:Yahoo, summary: The coronavirus vaccine maker posted a 35% drop in third-quarter product sales.  The company also recorded a charge for inventory write-downs, linked to coronavirus vaccines that went unused.  Does this news mean that demand is falling and it may be time to walk away from Moderna?",MRNA
46,2022-11-07,"Headline: Moderna price target lowered to $186 from $188 at Chardan, source:Thefly.com, summary: Chardan analyst Geulah Li... MRNA, Headline: BioNTech earnings drop but forecast for vaccine income grows, source:Associated Press, The, summary: No summary, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 3.55% to $164.04 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: 7 Cheap Penny Stocks To Buy For Under $1 Right Now, source:PennyStocks, summary: Penny stocks under $1: Are they worth the risk to buy right now?, Headline: Why Moderna Stock Jumped on Monday, source:Yahoo, summary: Durable coronavirus stock Moderna (NASDAQ: MRNA) rose by over 3.5% in price on Monday, nearly quadrupling the percentage gain of the S&P 500 index on the day.  The move followed news that the company racked up yet another approval from a healthcare authority for a new booster version of its Spikevax coronavirus vaccine.  Late Friday after market hours, Moderna announced that the second of its two bivalent booster vaccines targeting the coronavirus had been authorized for use in Canada.",MRNA
47,2022-11-08,"Headline: Patent wars: Moderna’s battle for the spoils of Covid vaccines, source:Yahoo, summary: In autumn 2020, as drugmakers raced to get vaccines to market in the face of the biggest public health crisis in a generation, Moderna made a bold pledge: it would not enforce its patents against rivals developing Covid-19 jabs.  This year, however, almost two years after Pfizer and BioNTech beat it to the first approved mRNA jab, Moderna fired back with a lawsuit over patents for a technology that could open the door to many more vaccines.  If Moderna wins, it could gain a slice of billions of dollars in revenues from the BioNTech/Pfizer Covid jab., Headline: Moderna Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.35% higher to $164.61 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...",MRNA
48,2022-11-09,"Headline: The 7 Best Pharma Stocks to Buy Now, source:InvestorPlace, summary: Investors searching for gains in the current market storm should consider taking a position in some of the best pharma stocks., Headline: Why Moderna Stock Could Still Be More Than 50% Overvalued, source:Yahoo, summary: Moderna (NASDAQ: MRNA) took the world by storm in 2020.  The company quickly became a leader in the race to develop COVID-19 vaccines.  Since the middle of last year, though, Moderna has been through storms of its own., Headline: Moderna to Present at the Jefferies 2022 London Healthcare Conference, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, Nov. 16th at 8:30 a.m., Headline: Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook, source:Yahoo, summary: Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022., Headline: Moderna Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Moderna Inc. slid 0.85% to $163.21 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update, source:Yahoo, summary: Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week., Headline: Noteworthy Thursday Option Activity: MRNA, CYRX, CRWD, source:Stock Options Channel, summary: Staff article entitled Noteworthy Thursday Option Activity: MRNA, CYRX, CRWD, about stock options, from Stock Options Channel., Headline: Analysts Are Bullish on These Healthcare Stocks: Benitec Biopharma (BNTC), Moderna (MRNA), source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Benitec Biopharma (<span class='tr-stock-ticker' style='color:b...",MRNA
49,2022-11-10,"Headline: Moderna to hold a virtual event, source:Thefly.com, summary: Management holds first Vi... MRNA, Headline: Moderna shares ESG highlights at first ESG Day, source:Thefly.com, summary: Moderna highlighted progr... MRNA, Headline: 2 Nasdaq 100 Stocks That Could Plunge as Much as 88%, According to Wall Street, source:Yahoo, summary: Although it's been a challenging year for new and tenured investors, Wall Street has historically remained optimistic about the equity markets.  This is particularly visible in the price targets Wall Street analysts and pundits assign for publicly traded companies.  For example, the vast majority of the innovation-driven companies that comprise the Nasdaq 100 -- an index of the 100 largest nonfinancial companies listed on the Nasdaq exchange -- have a higher average price target set by Wall Street analysts and pundits than their current share price., Headline: 5 Companies Buying Back Their Stock Aggressively in This Bear Market, source:Yahoo, summary: On the other hand, some companies have just started buying back stock in 2022 in response to the recent market declines.  Investors are generally pessimistic about consumer spending, and this has caused Simon Property Group (NYSE: SPG) to plunge by about 32% from its 52-week high, despite excellent results from the business.  Simon approved a $2 billion stock-buyback plan (about 5% of the current market cap) and has repurchased nearly 2 million shares in the past two quarters alone., Headline: Ready to Sell Moderna? Check Out This Chart First, source:Yahoo, summary: Moderna (NASDAQ: MRNA) was a winning investment during the early days of the pandemic.  The coronavirus vaccine leader climbed more than 400% in 2020.  This year, Moderna shares are heading for a 35% decline., Headline: Mawer Investment Management Lt - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Moderna Shares Environmental, Social and Governance Highlights at First ESG Day, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted progress on its environmental, social and governance (ESG) strategy presented at the Company's first ESG Day., Headline: Moderna Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.28% to $168.56 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Harbour BioMed Enters into a License and Collaboration Agreement with Moderna, source:PR Newswire, summary: No summary, Headline: TOP NEWS: Scottish Mortgage net asset value falls; cuts China exposure, source:Alliance News, summary: No summary",MRNA
50,2022-11-11,"Headline: LONDON MARKET MIDDAY: FTSE 100 trails peers on strong pound, source:Alliance News, summary: No summary, Headline: Moderna (NASDAQ:MRNA) Joins Hands With Harbour BioMed for Cancer Treatment, source:TipRanks, summary: Moderna (NASDAQ:MRNA) has entered into an agreement with a subsidiary of Hong Kong-based biopharmaceutical company, Harbour BioMed, to discover and develop nucleic ..., Headline: Moderna Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rose 1.57% to $171.20 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite...",MRNA
51,2022-11-12,"Headline: 3 Beaten-Down Stocks to Buy Right Now, source:Yahoo, summary: Here's why they chose Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE), and Zoetis (NYSE: ZTS).  Prosper Junior Bakiny (Moderna): The market is forward-looking.  Right now, it sees trouble ahead for companies that rely partly or exclusively on their coronavirus vaccines or medicines to generate revenue.",MRNA
52,2022-11-13,"Headline: Moderna: Too Little Clarity To Sustain Its Recovery, source:SeekingAlpha, summary: Moderna's forward guidance at its Q3 earnings highlighted its immense challenges. Read why investors should be patient with MRNA stock., Headline: Vertex: High Growth For Years Ahead, source:SeekingAlpha, summary: Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3., Headline: Late slide leaves stocks lower after a wobbly day of trading, source:Associated Press, The, summary: No summary, Headline: Week In Review: Insilico Signs Six-Drug AI Discovery Deal With Sanofi Worth Up To $1.2 Billion, source:SeekingAlpha, summary: Insilico Medicine signed a six-drug research collaboration with Sanofi. Wuhan Neurophth announced a $140 mn agreement to use Cyagenâs AI platform to discover novel AAV vectors., Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. RHHBY, BIIB, LLY, DIS, AAPL, MRNA, AMD, HAS, NIO, BAC, GPN, AMZN, TSLA, GOOG, GOOGL, META, DSKE, FREY, CAN, AMC, RIDE, GOEV, BBBY, TSN, MNDY, TSEM, OTLY, PIII",MRNA
53,2022-11-14,"Headline: Dow closes lower after stock-market gains evaporate, investors re-evaluate peak-inflation narrative, source:MarketWatch, summary: U.S. stocks end lower Monday after failing to hold earlier gains, as investors evaluate a mixed batch of views from Federal Reserve officials., Headline: Why biotech could be a place to hide in a U.S. recession - MarketWatch, source:MarketWatch, summary: After taking a beating, biotech stocks could be due for growth in the next few years, even if the Federal Reserve weakens the economy and the jobs market. Jordan Stuart Vice President, Client Portfolio Manager at Federated Hermes explains why investors should keep an eye out for biotech stocks., Headline: Moderna says new Covid booster better against omicron BA.5, triggers immune response against BQ.1.1, source:CNBC, summary: Moderna found that the new booster triggered five times more antibodies against omicron BA.5 than the old vaccines in people with prior Covid infections. , Headline: Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Genmab (GMAB) and Adaptimmune Therapeutics (ADAP), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (<a hre..., Headline: As new omicron strains overtake BA.5 in the U.S., Biden administration's public-health emergency may extend into spring, source:MarketWatch, summary: The BQ.1 and BQ.1.1 omicron sublineages jointly accounted for more coronavirus cases in the U.S. in the week through Nov. 12 than the BA.5 omicron variant,..., Headline: Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial, source:Yahoo, summary: Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that both of Moderna's bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger a superior antibody response compared to a booster dose of mRNA-1273, the Company's prototype vaccine, against Omicron (BA.4/BA.5) in Phase 2/3 clinical trials., Headline: Moderna’s New Covid-19 Booster Produced Strong Immune Response in Study, source:Yahoo, summary: Moderna  new updated Covid-19 booster shot for the U.S. generated strong immune responses in people against Omicron subvariants, according to the first data from a company-sponsored study testing the new doses in volunteers.  Moderna said Monday that people receiving the updated booster shot had more than five times the neutralizing antibodies against Omicron subvariants BA.4 and BA.5 than people who received Moderna’s original booster shot, which targeted an earlier strain of the coronavirus.  “That really bodes well for the vaccine and public health,” Moderna President  Stephen Hoge  said in an interview., Headline: Moderna's Omicron shots shows better immune response than original COVID vaccine, source:Reuters, summary: Moderna Inc said on Monday its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot., Headline: Moderna says its new COVID-19 boosters work against BA.5, BQ.1.1, source:Yahoo, summary: Moderna Inc. said in a news release on Monday that both of its new COVID-19 boosters produced a better antibody response against the BA.4 and BA.5 variants in a Phase 2/3 clinical than the company's original booster. Moderna has two bivalent boosters, one of which is authorized for use in the U.S. That shot, mRNA-1273.222, produced a ""superior neutralizing antibody response"" against BA.4 and BA.5 in about 500 clinical-trial participants who had already been vaccinated and boosted. Moderna also s, Headline: Stocks making the biggest moves midday: Oatly, Amazon, Hasbro and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Moderna: Updated COVID-19 booster effective against Omicron subvariants, source:United Press International, summary: No summary, Headline: Final Trades: Nucor, Moderna, Palto Alto & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: As new omicron strains overtake BA.5 in the U.S., Biden administration’s public-health emergency may extend into spring, source:Yahoo, summary: The BQ.1 and BQ.1.1 omicron sublineages jointly accounted for more coronavirus cases in the U.S. in the week through Nov. 12 than the BA.5 omicron variant, according to data from the Centers for Disease Control and Prevention., Headline: Moderna, Biogen rise; Oatly, Dentsply fall, source:Associated Press, The, summary: No summary, Headline: NEW YORK MARKET CLOSE: Stocks slip as post-US CPI rally subsides, source:Alliance News, summary: No summary, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 4.57% to $179.03 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Moderna Says Omicron Tailored COVID-19 Shots Shows Better Immune Response Than Original Vaccine, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) said that data shows its omicron-tailored vaccines, mRNA-1273.214 and mRNA-1273.222, produced a higher antibody response against BA.4/5 subvariants than its original shot in vaccinated and boosted adults. Moderna, however, said that in an exploratory analysis of approximately 40 participants, both bivalent vaccines demonstrated robust neutralizing activity against BQ.1.1, despite an approximately 5-fold drop in titers compared to BA.4/BA.5. Related: Moderna Shares Deep, Headline: Moderna Stock Climbs. Its New Covid Booster Works Against Variants., source:Yahoo, summary: Moderna  was rising sharply Monday after the vaccine maker said its updated Covid-19 boosters work against the BA.4 and BA.5 variants better than its previous shot.  Moderna  (ticker: MRNA) announced Monday that in a trial of more than 500 adults the company’s updated Covid-19 boosters “induced significantly higher neutralizing antibody titers” against BA.4/BA.5 compared with a booster dose of mRNA-1273, the company’s original booster.  “We are pleased to see that both of our bivalent booster vaccine candidates offer superior protection against Omicron BA.4/BA.5 variants compared to our original booster, which is encouraging given Covid-19 remains a leading cause of hospitalization and death globally,” Chief Executive Stéphane Bancel said in a news release., Headline: Moderna reports its new COVID-19 booster offers enhanced protection from Omicron, source:Yahoo, summary: Yahoo Finance Live examines data from Moderna indicating the heightened efficacy of its latest booster vaccine against the Omicron variant., Headline: Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride, source:Yahoo, summary: Moderna stock popped Monday after the company said its bivalent Covid booster led to a 15-fold jump in omicron-blocking antibodies., Headline: Stanley Druckenmiller's Firm Buys The Dip in Amazon, Meta, source:Fintel, summary: nan, Headline: Why Moderna Stock Popped Today, source:Yahoo, summary: Shares of Moderna (NASDAQ: MRNA) rose 4.6% on Monday after the drugmaker released encouraging clinical trial results for its new COVID-19 booster.  Moderna has worked to develop variant-specific vaccines to better protect against emerging coronavirus strains.  An analysis of a phase 2/3 study of the company's Omicron-targeting booster candidates showed that they elicited a superior antibody response against Omicron variants BA.4 and BA.5, compared to a booster dose of Moderna's original COVID vaccine.",MRNA
54,2022-11-15,"Headline: AQR CAPITAL MANAGEMENT LLC Buy - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Moderna Stock Is In An Upswing On New Omicron Booster Data — But Is It A Buy?, source:Yahoo, summary: Is Moderna stock a buy after unveiling new test results for its omicron-blocking booster shot? Is MRNA stock a buy right now?, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.60% to $185.47 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Moderna's (MRNA) Omicron BA.4/5 Booster Jab Study Meets Goal, source:Yahoo, summary: Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.",MRNA
55,2022-11-16,"Headline: Moderna, Inc. (MRNA) 13th Annual Jefferies London Healthcare Conference 2022 - (Transcript), source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) 13th Annual Jefferies London Healthcare Conference 2022 Call November 15, 2022 10:50 A.M., Headline: IDNA: Healthcare Dashboard For November, source:SeekingAlpha, summary: The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Read how this ties into the IDNA healthcare ETF., Headline: 20 Growth Stocks Are Now Actually Cheaper Than Value Stocks, source:Yahoo, summary: Talk about the bear market turning the S&P 500 upside down. More than a few growth stocks are now actually cheaper than value., Headline: Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More, source:Yahoo, summary: Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week., Headline: Moderna Stock Shows Rising Relative Strength, Hitting 90+, source:Yahoo, summary: Moderna had its Relative Strength (RS) Rating upgraded from 88 to 91 Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database., Headline: Moderna Tops BioSpace's Best Places to Work Ranking for Second Consecutive Year, source:Yahoo, summary: Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it was ranked the number one large employer in BioSpace's 2023 Best Places to Work in Biopharma report., Headline: Letter: Ending the Covid patent truce should worry us all, source:Yahoo, summary: It brings to mind the work of Nobel laureate Sir John Sulston who led the campaign to stop the patenting of the human genome so that this monumental discovery would always be in the public domain and available to scientists throughout the world.  This prevented a US scientific enterprise from patenting the knowledge.",MRNA
56,2022-11-17,"Headline: The Petri Dish: Moderna touts new booster; MGH spins out diagnostics startup, source:Yahoo, summary: The Joung Lab at Massachusetts General Hospital and Harvard Medical School has given birth to a new diagnostics startup. It's called SeQure Dx, and it aims to use tests to evaluate the potential that a patient might be vulnerable to off-target editing., Headline: The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen, source:Yahoo, summary: Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog., Headline: David Jiménez Joins Moderna As U.S. General Manager, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of David Jiménez as General Manager, United States, effective November 21, 2022., Headline: 2 Concerning Trends That Make Moderna a Risky Buy, source:Yahoo, summary: Next year is going to be challenging for COVID-19 vaccine maker Moderna (NASDAQ: MRNA).  In the U.S., Moderna projects the COVID vaccine market could be worth between $5.2 billion and $12.9 billion, depending on the price that it obtains per shot., Headline: Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There?, source:Yahoo, summary: Pfizer and BioNTech said Thursday they've started testing a next-generation Covid shot, but the vaccine stocks tumbled.",MRNA
57,2022-11-18,"Headline: Pfizer says omicron booster is better against new subvariants like BQ.1.1 than old shots, source:CNBC, summary: Pfizer said the booster triggered more antibodies against omicron BQ.1.1, BA.4.6, BA.2.75.2 and XBB.1 in adults older than 55 compared to the original vaccines., Headline: Vaccinating the unvaxxed is key to end pandemic: Former FDA official, source:Yahoo, summary: Hundreds of Americans die each day from COVID — and the unvaccinated make up a majority of those dead and hospitalized.",MRNA
58,2022-11-19,"Headline: These Wildly Undervalued Stocks Could Go Parabolic, source:Yahoo, summary: Let's take a look at three wildly undervalued stocks that could go parabolic.  Etsy (NASDAQ: ETSY) made big gains during the earlier days of the pandemic: The e-commerce platform for handmade goods saw gross merchandise sales (GMS) soar by percentages in the triple digits.  Today, macroeconomic factors like higher inflation are weighing on Etsy.",MRNA
59,2022-11-20,"Headline: Got $500? 3 Growth Stocks to Buy That Could Double Your Money, source:Yahoo, summary: With that amount you could buy one of the following growth stocks -- or invest in all three.  Teladoc Health (NYSE: TDOC) is a leader in the growing market of telemedicine.  Moderna (NASDAQ: MRNA) is on its way to becoming more than a coronavirus vaccine stock.",MRNA
60,2022-11-21,"Headline: Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters, source:Yahoo, summary: Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages., Headline: Moderna Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 2.67% to $176.75 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite...",MRNA
61,2022-11-22,"Headline: Confused about COVID boosters? Here’s what the science and the experts say about the new generation of shots., source:Yahoo, summary: Less than 11% of Americans have opted to get the bivalent COVID-19 booster shot ahead of another pandemic winter and holiday season., Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Moderna Inc. rose 1.61% to $179.59 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Moderna Stock Is Yo-Yoing On New Omicron Booster Data — Is It A Buy?, source:Yahoo, summary: Is Moderna stock a buy after unveiling new test results for its omicron-blocking booster shot? Is MRNA stock a buy right now?, Headline: The Petri Dish: J&J vet joins Moderna as U.S. GM; Invivyd partners with investment firm, source:Yahoo, summary: David Jiménez, a multidecade veteran of Johnson & Johnson who was most recently president of the Janssen immunology division, has joined Moderna to oversee U.S. commercial operations.",MRNA
62,2022-11-23,"Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.55% to $176.81 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: 7 Stocks on the Perfect 10 List, source:Yahoo, summary: A stock that scores a perfect 10 should be on every investor’s list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I’d considering a perfect 10. For this article, I’m using StockRover’s stock screening tool, which screens for such qualities among a very large basket of companies. Despite many of these stocks to buy scoring so highly on one particular attribute, the market has heavily discounted most of these companies. Thus, it appears a tug-of-war",MRNA
63,2022-11-24,"Headline: Novavax Stock: Buy, Sell, or Hold in 2023?, source:Yahoo, summary: In the early days of the pandemic, investors bet Novavax (NASDAQ: NVAX) would be a coronavirus vaccine winner.  When the biotech's vaccine candidate fell behind, though, investors lost faith.  With its shares down almost 90% this year, you may be wondering if Novavax presents a great buying opportunity.",MRNA
64,2022-11-25,"Headline: 10 Best Biotech Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this article, we discuss 10 best biotech stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy According To Hedge Funds. In 2023, digitalization will increase in the biotech industry as the possibility of online and remote assessment, diagnosis, […]",MRNA
65,2022-11-26,"Headline: The Worst Mistake Moderna Investors Can Make in 2023, source:Yahoo, summary: Moderna (NASDAQ: MRNA) investors didn't need to have too much patience in the early days of the pandemic.  The company brought its coronavirus vaccine candidate from drawing board to market in about nine months.  Next year, though, Moderna investors may need to rely on their patience.",MRNA
66,2022-11-28,"Headline: China’s zero-COVID strategy makes no sense and its homegrown vaccines are not ‘particularly effective,’ says  Fauci, source:DowJones, summary: Widespread protests across China over the government's zero-COVID policy dominated headlines on the pandemic on Monday., Headline: Moderna Inc. stock falls Monday, still outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 0.58% to $175.38 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite..., Headline: Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why, source:Yahoo, summary: Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.",MRNA
67,2022-11-29,"Headline: IMF head joins chorus calling on China to adapt COVID strategy as officials pledge to boost vaccinations among elderly, source:DowJones, summary: The head of the International Monetary Fund on Tuesday joined the chorus of people urging China to adopt a more targeted approach to the coronavirus pandemic., Headline: Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, Dec. 1st at 9:00 a.m., Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.27% to $173.15 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",MRNA
68,2022-11-30,"Headline: Britain is little better prepared for future pandemics - Former UK vaccine chief, source:Yahoo, summary: Britain is only marginally better prepared for another pandemic than it was for COVID-19, the former head of Britain's vaccine taskforce said on Wednesday, criticising how some structures that helped it emerge from the pandemic had been dismantled.  Britain has one of the highest coronavirus death tolls in the world with more than 177,000 deaths, although its rapid procurement and deployment of vaccines helped the government lift lockdown restrictions sooner than some others.  Kate Bingham, who procured Britain's COVID vaccines in 2020, said there was now no leadership on preparing for possible new variants and some manufacturing capacity had been mothballed., Headline: Top Healthcare Stocks, source:Yahoo, summary: The top healthcare stocks include Azenta Inc. for best value, McKesson Corp. for fastest growth, and Signify Health Inc. for most momentum., Headline: Mirati Therapeutics: Is There A Big Pharma Buyout In Play And What's The Price Tag?, source:SeekingAlpha, summary: Mirati Therapeutics will find out in December if the FDA will approve its lead drug candidate Adagrasib in NSCLC. Read why the company also is part of acquisition speculation., Headline: REUTERS NEXT-Moderna exec says COVID trials improved diversity recruiting, source:Yahoo, summary: Moderna Inc's top scientist said on Tuesday that the vaccine maker has learned how to better recruit from diverse populations for its clinical trials from running its COVID-19 vaccine studies.  Moderna Chief Medical Officer Paul Burton, speaking at the Reuters NEXT conference in New York, said that in 2020 the company needed to slow enrollment in its initial COVID-19 vaccine clinical trial in order to include more people in communities of color.  ""We recognized that to get good uptake to get real acceptance, you need to have representation of all sorts of people from different communities,"" Burton said, noting that the company was eventually able to enroll 37% of its 35,000-person trial from communities of color., Headline: Moderna exec says COVID trials improved diversity recruiting, source:Reuters, summary: Moderna Inc's top scientist said on Tuesday that the vaccine maker has learned how to better recruit from diverse populations for its clinical trials from running its COVID-19 vaccine studies.",MRNA
69,2022-12-01,"Headline: Moderna Stock: Buy, Sell, or Hold in 2023?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) shares delivered top returns to investors in the earlier days of the pandemic.  This year, though, the stock is heading for a 30% loss, even though Moderna's coronavirus vaccine generates billions in revenue and profit.  Looking ahead to 2023, you might be wondering whether Moderna's best days are in the past -- or if this vaccine maker still presents an opportunity.",MRNA
70,2022-12-02,"Headline: 44%of this Moderna, Inc. (NASDAQ:MRNA) insider's holdings were sold in the last year, source:Yahoo, summary: Looking at Moderna, Inc.'s ( NASDAQ:MRNA ) insider transactions over the last year, we can see that insiders were net..., Headline: BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns, source:SeekingAlpha, summary: BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more.",MRNA
71,2022-12-05,"Headline: Ocugen: Still Struggling, source:SeekingAlpha, summary: Ocugen introduces its mucosal COVID vaccine, but can it compete with the mRNA vaccine technology of Moderna and BioNTech/Pfizer? Read more here., Headline: Covid Cases Are Rising. L.A. Could Bring Back Masks., source:MarketWatch, summary: Covid-19 cases are surging, few people are getting updated boosters, and there's even talk of mask mandates in California., Headline: Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents , source:Reuters, summary: Pfizer Inc and its German partner BioNTech SE fired back on Monday at a patent lawsuit filed by Moderna Inc in Boston federal court over their rival COVID-19 vaccines, seeking a dismissal of the lawsuit and a court order that they did not infringe Moderna's patents. (Reporting..., Headline: Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents, source:Yahoo, summary: (Reuters) -Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed.  Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic.  Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany., Headline: UPDATE 2-Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents, source:Yahoo, summary: Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed.  Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic.  Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany., Headline: SPX: The Trend Has Not Been Your Friend, So What's Next? (Technical Analysis), source:SeekingAlpha, summary: With the S&P still down >15% YTD, the classic trend motto for investors hasn't worked in 2022. Read more as I compare 2 expert views about what to expect next., Headline: Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents, source:Reuters, summary: Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed., Headline: Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?, source:Yahoo, summary: Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.",MRNA
72,2022-12-06,"Headline: Investors Desperately Want to See the Market Bottom Out. It’s Not Happening Yet., source:MarketWatch, summary: Delta offers pilots raises as airlines grapple with labor issues, AT&T settles with the SEC in its disclosure case, restaurants oppose California’s fast-food..., Headline: Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history, source:CNBC, summary: Pfizer asked a federal court in Boston on Monday to dismiss Moderna's lawsuit seeking monetary damages for alleged patent violations related to the Covid vaccine., Headline: Moderna (NASDAQ:MRNA) shareholders have earned a 111% CAGR over the last three years, source:Yahoo, summary: Investing can be hard but the potential fo an individual stock to pay off big time inspires us. You won't get it right..., Headline: Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims, source:Yahoo, summary: Pfizer Inc (NYSE: PFE) and its partner, BioNTech SE (NASDAQ: BNTX), said that they developed their vaccine independently, refuting Moderna Inc's (NASDAQ: MRNA) patent claims. In August, Moderna filed patent infringement lawsuits saying Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology critical in creating Moderna's mRNA COVID-19 vaccine. Pfizer called Moderna's lawsuit ""revisionist history"" and argued its patents ""far exceed it, Headline: Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants, source:Yahoo, summary: Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years., Headline: Pfizer accuses Moderna of rewriting history in Covid vaccine patent battle, source:Yahoo, summary: In its response to a lawsuit brought by Covid-19 vaccine competitor Moderna Inc., Pfizer Inc. does not mince words: Pfizer did not copy Moderna's patented technology, it says, and Moderna is rewriting history by claiming otherwise.",MRNA
73,2022-12-07,"Headline: Moderna, Zillow and 28 More Companies That Made the Fortune 500 in 2022, source:Yahoo, summary: The Fortune 500 is a much-lauded list of the America's biggest companies. Qualification is solely based on a company's revenues. The 2022 edition is the 68th in its history. Holiday Spending: Get Top..., Headline: Brad Miller Joins Moderna as Chief Information Officer, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Brad Miller as Chief Information Officer effective January 3. Mr. Miller will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel., Headline: Bucking the Trend: 3 Stocks Showing Stellar Relative Strength this Week, source:Yahoo, summary: Market pullbacks can offer a treasure trove of ideas in the form of relative strength.",MRNA
74,2022-12-08,"Headline: FDA authorizes Covid omicron vaccines for children as young as 6 months old, source:CNBC, summary: The FDA's decision to authorize the shots for the youngest kids comes as Covid infections and hospitalizations are increasing nationally. , Headline: These Top Stocks Are Rebounding: Should You Buy Before 2023?, source:Yahoo, summary: Moderna has declined about 30% year to date.  The general market downturn surely hurt Moderna shares.  It's possible Moderna's recent communications about this potential market has assuaged some of investors' fears., Headline: Foxconn, which makes iPhones, reportedly urged Chinese government to loosen COVID restrictions, source:MarketWatch, summary: A roundup of the day’s need-to-know COVID news., Headline: Company News for Dec 8, 2022, source:Yahoo, summary: Companies in The News Are: UAL, BKNG, MRNA, CVNA, Headline: UPDATE 3-U.S. FDA authorizes bivalent COVID shots for kids as young as 6 months old, source:Yahoo, summary: The U.S. health regulator has authorized COVID-19 shots from Moderna and Pfizer and its partner BioNTech that target both the original coronavirus and Omicron sub-variants for use in children as young as 6 months of age.  The amended authorization on Thursday from the Food and Drug Administration allows use of Moderna's bivalent shot as a booster in children 6 months through 5 years of age, two months after their initial vaccination.  Pfizer/BioNTech's updated shot can now be given as a third dose to those aged 6 months through 4 years, who have not completed their primary vaccination series or are yet to receive the third dose., Headline: FDA to allow bivalent COVID boosters for some infants and young children, source:Yahoo, summary: The Food and Drug Administration on Thursday authorized the bivalent COVID-19 boosters made by Moderna Inc. and BioNTech SE /Pfizer Inc. for children as young as 6 months old. The regulator said children between the ages of 6 months and 6 years old who first received Moderna's two-dose vaccine can now get Moderna's updated booster shot. The authorization for BioNTech and Pfizer's vaccine is slightly different. Children who are 6 months through 4 years can now get the companies' bivalent booster, Headline: Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children 6 months through 5 years of age., Headline: Moderna gets emergency authorization for updated Covid booster in kids under 5, source:Yahoo, summary: Kids as young as 6 months old can now get the updated Covid-19 booster made by Moderna Inc. — if they received their first two shots from Moderna., Headline: FDA Just Authorized Moderna, Pfizer Bivalent Vaccines for Kids Under 5. The Pandemic Is Not Yet Over., source:Yahoo, summary: Rising Covid-19 cases in the U.S. have sparked worries that a new wave of infections could arrive this winter., Headline: U.S. FDA authorizes bivalent COVID shots for kids as young as 6 months old, source:Reuters, summary: The U.S. health regulator has authorized COVID-19 shots from Moderna and Pfizer and its partner BioNTech that target both the original coronavirus and Omicron sub-variants for use in children as young as 6 months of age., Headline: FDA Authorizes Updated Covid-19 Vaccines for Children as Young as 6 Months, source:Yahoo, summary: Under the decision, certain children 6 months through 5 years can get the updated boosters, which target two Omicron offshoots as well as the original strain of the coronavirus., Headline: FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old, source:Yahoo, summary: The FDA has authorized COVID-19 shots from Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)/ BioNTech SE (NASDAQ: BNTX) targeting the original coronavirus and Omicron sub-variants for use in children as young as six months of age. The amended authorization allows the use of Moderna's bivalent shot as a booster in children six months through 5 years of age, two months after their initial vaccination. Pfizer/BioNTech's updated shot can now be given as a third dose to those aged six months thr, Headline: 10 Stocks With Unusual Options Activity: MRNA, UAL, NKE and Others, source:Fintel, summary: nan",MRNA
75,2022-12-09,"Headline: 5 Best Bargain Stocks to Buy Before 2023, source:Yahoo, summary: Carnival (NYSE: CCL) (NYSE: CUK) had a difficult time during the early days of the pandemic.  Carnival faces the impact of higher interest rates on its variable-rate borrowings, which could lead to higher costs.  Demand for cruising is back, and Carnival is progressing toward its earnings goals., Headline: Company News for Dec 9, 2022, source:Yahoo, summary: Companies in The News Are: COP, NVDA, MRNA, RENT, Headline: FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids, source:Yahoo, summary: Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months., Headline: CDC Backs New Covid-19 Boosters for Youngest Kids, source:Yahoo, summary: The agency’s move is the last step before children as young as 6 months could get the shots, which were modified to target offshoots of the Omicron variant and the original strain of the virus., Headline: U.S. CDC expands use of bivalent COVID vaccines for kids as young as 6 months, source:Yahoo, summary: The U.S. Centers for Disease Control and Prevention (CDC) on Friday expanded the use of COVID-19 vaccines that target both the original coronavirus and Omicron sub-variants to include children aged 6 months through 5 years.  The development comes a day after the U.S. Food and Drug Administration authorized the updated shots from Moderna as well as Pfizer and its partner BioNTech for use in children as young as 6 months.  Children aged 6 months through 5 years will now be eligible to get a Moderna bivalent booster 2 months after their final primary vaccination dose for COVID-19., Headline: 'Almost every health care company will be in the in cloud' in the next 10 years: AWS exec, source:Yahoo, summary: Cloud computing is not a new frontier in health care, but it is finally starting to bear some fruit, AWS exec Dr. Taha Kass-Hout, told Yahoo Finance., Headline: 'Almost every health care company will be in the cloud' in the next 10 years: AWS exec, source:Yahoo, summary: Cloud computing is not a new frontier in health care, but it is finally starting to bear some fruit, AWS exec Dr. Taha Kass-Hout, told Yahoo Finance.",MRNA
76,2022-12-10,"Headline: 3 Surefire Stocks to End 2022 on a Good Note, source:Yahoo, summary: This year hasn't been the easiest for investors. The three major indexes headed into bear territory. Many of even the strongest stocks suffered. And as a result, investors' portfolios suffered, too. But there's reason to be positive as we exit this year and enter a new one., Headline: A Moderna, Inc. (NASDAQ:MRNA) insider lowered their holding by 44% earlier this year, source:Yahoo, summary: Viewing insider transactions for Moderna, Inc.'s ( NASDAQ:MRNA ) over the last year, we see that insiders were net...",MRNA
77,2022-12-12,"Headline: 3 Medical Stocks With Solid Growth Drivers to Keep Track Of, source:Yahoo, summary: Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years., Headline: Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag, source:Yahoo, summary: The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19., Headline: Moderna Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 6.89% to $165.13 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: 10 Best Performing Healthcare ETFs in 2022, source:Yahoo, summary: In this article, we will discuss the 10 best performing healthcare ETFs in 2022. If you want to explore similar ETFs, you can take a look at 5 Best Performing Healthcare ETFs in 2022. 2022 has been riddled with volatility, inflation, interest rates, and panicky investors. Investors’ focus has shifted from cyclical and growth sectors […], Headline: Stocks Moving the Most Today: Moderna, Pinterest, Trimble, and More, source:MarketWatch, summary: Adding Moderna's experimental messenger RNA-based cancer vaccine to a standard regimen of Merck's Keytruda in high-risk melanoma patients meaningfully...",MRNA
78,2022-12-13,"Headline: Premarket Movers: Moderna, New Fortress Energy, Trimble, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (MRNA) was up 7.3% in pre-market trading, and (NFE) was up 6.2%. (HES), (EXAS), and (LH) were all posting..., Headline: Stocks making the biggest moves in the premarket: Oracle, Boeing, Moderna and more, source:CNBC, summary: The stocks making the biggest moves in premarket trading include Oracle, Boeing, Moderna, and more., Headline: Moderna CEO Stéphane Bancel on promising new data for mRNA cancer vaccine, source:CNBC, summary: Moderna CEO Stéphane Bancel joins CNBC's 'Squawk Box' to discuss promising new data surrounding its experimental cancer vaccine in development with Merck., Headline: Moderna Shares Up on Clinical Trial Cancer Treatment Results, source:MarketWatch, summary: By Denny Jacob Moderna Inc. shares rose 20% to $198.20 in early trading after the company said results from a mid-stage clinical trial of a cancer vaccine..., Headline: Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful, Headline: Moderna, Merck vaccine combo cut melanoma recurrence by 44% - study, source:Reuters, summary: An experimental personalized melanoma vaccine developed by Moderna Inc given with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of the skin cancer's recurrence or death by 44% compared with Keytruda alone in a midstage trial., Headline: Why Merck's $250 Million Investment In Moderna May Have Just Paid Off, source:Yahoo, summary: Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results could spark downtrodden Moderna stock., Headline: Merck, Moderna say mRNA vaccine and Keytruda lowers the risk of death in melanoma patients, source:Yahoo, summary: Merck & Co. Inc. and Moderna Inc. said Tuesday that their experimental mRNA-based cancer vaccine reduced the risk of recurrence or death when used with Merck's Keytruda in patients with late-stage melanoma. Merck's stock was up 1.9% in premarket trading, while Moderna shares rallied 5.6%. The Phase 2b study compared the combination treatment with Keytruda. The companies said they now plan to move forward with a Phase 3 clinical trial testing the combination treatment in 2023, and they also plan, Headline: Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary Study, source:Yahoo, summary: The shot combined with a Merck immunotherapy reduced the risk of relapse in people with skin cancer in a study, Moderna said., Headline: Moderna-Merck Partnered Cancer Vaccine Meets Primary Efficacy Endpoint, Stock Jumps, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 combined with Keytruda met its primary endpoint. Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial. In October, Merck exercised its option to develop and commercialize mRNA-4157/V940 jointly with Moderna and share costs and profits equally under the worldwide collaboration. The investigational, Headline: Stocks making the biggest moves midday: Moderna, First Solar, Pinterest, Norwegian Cruise Line and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Moderna’s Cancer Vaccine Reduces Deaths in Melanoma Patients. The Stock Is Gaining., source:Yahoo, summary: Adding Moderna's experimental messenger RNA-based cancer vaccine to Merck's Keytruda in high-risk melanoma patients reduced the risk of death or recurrence of cancer in a trial., Headline: CPI Report Live: Consumer Price Inflation Report Is Out, Here’s What It Shows, source:PennyStocks, summary: What the latest November CPI inflation data signals for inflation & the stock market today, Headline: Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%, source:Reuters, summary: A combination of Moderna Inc's experimental melanoma vaccine and Merck & Co's blockbuster immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial., Headline: Moderna's Merck News Will Give a Shot to Its Stock, source:Yahoo, summary: Word is out that a Moderna experimental melanoma vaccine combined with Merck's Keytruda reduced the risk of relapse in people with skin cancer in a trail., Headline: 2 Nasdaq Stocks Taking Big Strides Forward, source:Yahoo, summary: As markets soar following a healthy inflation report, investors are watching these two companies closely., Headline: Moderna and Merck’s cancer vaccine trial shows promising initial results, source:Yahoo, summary: Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss initial cancer vaccine trial results for Moderna and Merck., Headline: Is Moderna Stock A Buy On A Bullish Update For Its Cancer Vaccine?, source:Yahoo, summary: Is Moderna stock a buy after the company offered a promising update for its cancer vaccine? Is MRNA stock a buy right now?, Headline: 2 Pandemic Stocks That Could Make You Richer in 2023 and Beyond, source:Yahoo, summary: Two examples are Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  Pfizer has been one of the most successful companies in the coronavirus vaccine market with Comirnaty.  Pfizer has beefed up its pipeline recently, partly thanks to acquisitions., Headline: Moderna shares soar on trial data from melanoma vaccine, source:Yahoo, summary: Cambridge drugmaker Moderna Inc. gained billions in market cap Tuesday morning after it announced that a trial of 157 patients with melanoma showed its experimental drug helped reduce the risk of recurrence or death by 44%., Headline: Why Moderna Stock Is Skyrocketing Today, source:Yahoo, summary: Shares of Moderna (NASDAQ: MRNA) were skyrocketing 24.3% higher as of 10:21 a.m. ET on Tuesday.  The huge gain came after the company, along with its partner Merck (NYSE: MRK), announced positive results from a phase 2 clinical study evaluating experimental personalized messenger RNA (mRNA) cancer vaccine mRNA-4157/V940 in combination with immunotherapy Keytruda as an adjuvant treatment for stage III/IV melanoma.  You know clinical results have to be spectacular for a vaccine stock with a market cap of greater than $60 billion to jump more than 20%., Headline: Moderna and Merck team-up to fight melanoma, source:Yahoo, summary: Vaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer, Headline: Moderna will apply ‘same intensity’ for cancer vaccine as it did for COVID, CEO says, source:Yahoo, summary: Moderna CEO Stéphane Bancel speaks with Yahoo Finance's Anjalee Khemlani about the company's MRNA skin cancer vaccine trial with Merck and the pipeline for producing cancer vaccines., Headline: Melanoma vaccine data should make investors more positive on Moderna, says Jefferies' Michael Yee, source:CNBC, summary: Michael Yee, Jefferies, joins 'Closing Bell' to discuss Moderna popping on strong Melanoma vaccine data., Headline: Moderna Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. surged 19.63% to $197.54 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Moderna Stock Breaks As Cancer Vaccine Shows Promise In Keytruda Tie-Up, source:Yahoo, summary: Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results sent Moderna shares soaring., Headline: Positive Moderna, Merck cancer vaccine data advances mRNA promise, shares rise, source:Reuters, summary: An experimental cancer vaccine from Moderna Inc based on the messenger RNA (MRNA) technology used in successful COVID-19 vaccines has been shown to work against melanoma, sending Moderna shares more than 20% higher and driving up of other biotechs working on similar treatments..., Headline: Personalized cancer vaccine results are a 'home run': Moderna CEO, source:Yahoo, summary: Moderna and Merck released preliminary results of a personalized cancer vaccine for late-stage melanoma patients., Headline: Moderna's Data From Personalized Cancer Vaccine Provides Relief To Investors, Analyst Says, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc's (NYSE: MRK) investigational personalized mRNA cancer vaccine + Keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival versus Keytruda. SVB Leerink has raised the price target on Moderna from $101 to $102. The analyst says it has fielded a steady stream of inbounds from investors nervous about elevated expectations for personalized cancer vaccine (PCV) data and expects shares to trade up o, Headline: Why Moderna Stock Is Popping Over 20% Today, source:Yahoo, summary: Moderna Stock is ripping higher today after a cancer treatment breakthrough. Is Moderna stock a buy now?, Headline: Encouraging Trial Data Sends Moderna Stock Soaring, source:Yahoo, summary: The security earlier broke through a technical ceiling, Headline: Skin cancer vaccine trial shows promising results, source:Yahoo, summary: Moderna and Merck team up in new study., Headline: Moderna, Merck stocks boosted amid joint cancer vaccine trials, source:Yahoo, summary: Yahoo Finance health correspondent Anjalee Khemlani joins the Live show to review Moderna and Merck shares following positive results seen in their joint cancer vaccine trial., Headline: Moderna Stock Breaks Out As Cancer Vaccine Shows Promise In Keytruda Tie-Up, source:Yahoo, summary: Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results sent Moderna shares soaring., Headline: Dow Jones Gains; Elon Musk Loses This Title As Tesla Tumbles; Bitcoin Up Amid Sam Bankman-Fried Arrest, source:Yahoo, summary: The Dow Jones rallied. Tesla CEO Elon Musk lost a famous title. Bitcoin rose after the Sam Bankman-Fried arrest. Moderna stock jumped., Headline: Dow Jones Rallies; Elon Musk Loses This Title As Tesla Tumbles; Bitcoin Up Amid Sam Bankman-Fried Arrest, source:Yahoo, summary: The Dow Jones moved higher. Tesla CEO Elon Musk lost a famous title. Bitcoin rose after the Sam Bankman-Fried arrest. Moderna stock jumped., Headline: A.I., digitization could ‘usher in completely new way’ of treating chronic illnesses: Montai CEO, source:Yahoo, summary: Flagship Pioneering and Montai Health CEO Margo Georgiadis sits down with Yahoo Finance’s Anjalee Khemlani to discuss the future of health care and how artificial intelligence can play a role in treating chronic diseases., Headline: Preliminary Study Shows Promise for Moderna's Skin Cancer Vaccine, source:Yahoo, summary: When eggheads claimed the best part of the COVID vaccines was the developments in mRNA science, they weren't lying. It might even cure skin...",MRNA
79,2022-12-14,"Headline: Wall Street Breakfast: Shifting Gears, source:SeekingAlpha, summary: Fed Day has finally arrived. Investors and economists will be watching updated interest rate and economic projections, which will largely define trading behavior into 2023. Read more here., Headline: Stocks making the biggest moves premarket: Delta, Tesla, Moderna and others, source:CNBC, summary: These are the stocks posting the largest moves before the bell., Headline: Stocks Moving the Most Today: Moderna, Tesla, Lennar, and More, source:Yahoo, summary: FEATURE  Stock futures were slipping slightly Wednesday with investors expecting the Federal Reserve to boost interest rates by 50 basis points, a step down from the last four consecutive rate hikes of 0., Headline: Recent uptick might appease Moderna, Inc. (NASDAQ:MRNA) institutional owners after losing 30% over the past year, source:Yahoo, summary: A look at the shareholders of Moderna, Inc. ( NASDAQ:MRNA ) can tell us which group is most powerful. And the group..., Headline: Stocks making the biggest moves midday: SoFi Technologies, Charter Communications, Delta and more, source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Is Moderna Stock a Buy After Its Impressive Cancer Vaccine Results?, source:Yahoo, summary: Moderna could have a winner with its personalized cancer vaccine. But the company also faces big questions., Headline: Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study, source:Yahoo, summary: Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 5.78% to $208.95 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Moderna Stock Soared on Good News About Cancer Vaccine. Why One Analyst Downgraded the Stock., source:Yahoo, summary: Chardan Capital Markets analyst Geulah Livshits now rates the biotech company at Neutral, down from Buy., Headline: 7 Stocks to Buy on the Dip as the S&P 500 Falters, source:Yahoo, summary: While the ongoing market churn can be stressful, it also presents a fantastic opportunity for investors to pick up solid stocks to buy on the dip. Even some of the best investors in the world, including Warren Buffett, have been on a buying spree throughout 2022 as share prices slumped. In fact, Buffett has done more buying of stocks over the past year than at anytime since the Great Recession, spending almost $66 billion on stocks in the first nine months of the year. Following on the Oracle of, Headline: Moderna Stock Shows Surprising Strength; Key Rating Upgraded, source:Yahoo, summary: Moderna stock surged as much as 8% Wednesday before settling to a 5.8% gain after it reported promising results for a melanoma cancer treatment the day before.  The Wednesday price jump followed a nearly 20% surge in its stock price Tuesday.  Also on Wednesday, the Relative Strength (RS) Rating for Moderna stock shot up to 96, from 87 a day earlier., Headline: 10-year Treasury yield falls as economic recession fears grow, source:CNBC, summary: Markets digested the Federal Reserve's 50 basis point rate hike, and a disappointing November retail sales report. ",MRNA
80,2022-12-15,"Headline: Is Moderna a Good Stock to Buy Right Now?, source:Yahoo, summary: Recent results suggest the company's cancer vaccine candidate can succeed where others have failed., Headline: Company News for Dec 15, 2022, source:Yahoo, summary: Companies in The News Are:BRZE,DAL,MRNA,MRK,SOFI, Headline: Covid-19 Hospitalizations Keep Climbing as New Variants Take Over, source:Yahoo, summary: The latest Covid-19 surge comes as newer Omicron subvariants nudge out BA.5 as the dominant variant in the U.S., Headline: Moderna Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. sank 0.81% to $207.25 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Pfizer and Moderna Shares Break Out. Here's the Trade., source:Yahoo, summary: Pfizer and Moderna stocks are breaking out to the upside. Here's how to trade both names now, even as the market swoons., Headline: BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline, source:Yahoo, summary: Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines that are currently in various stages of development.  Analysts led by Tazeen Ahmad reiterated their $239 price target on the stock  (BNTX)  which is 28.5% above its current price, and said the German company’s roughly 16 billion euros in cash is a positive.  Positive data this week from Moderna Inc.  (MRNA)  and Merck  (MRK)  in a trial of Merck’s Keytruda and a Moderna mRNA vaccine in treating patients with late-stage melanoma are positives for BioNTech’s NeST platform, which also aims to treat melanoma and other solid tumors, said the note., Headline: Moderna`s Next $20B Franchise - Learning From Merck`s Keytruda, source:Seeking Alpha, summary: No summary, Headline: Tracking Stanley Druckenmiller`s Duquesne Family Office Portfolio - Q3 2022 Update, source:Seeking Alpha, summary: No summary, Headline: Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: Stanley Druckenmillerâs 13F portfolio value increased from $1.38B to $1.76B this quarter. Read more to know Druckenmillerâs Q3 2022 portfolio update.",MRNA
81,2022-12-16,"Headline: EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna`s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union, source:Accesswire, summary: No summary, Headline: Moderna receives positive CHMP opinion for bivalent COVID-19 booster in children, source:Thefly.com, summary: No summary, Headline: Moderna price target raised to $209 from $170 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Moderna announces CHMP recommendation for Spikevax MA, source:Thefly.com, summary: No summary, Headline: Moderna wins EU backing for use of BA.1 targeting Omicron booster in children, source:Seeking Alpha, summary: No summary, Headline: Video: Nasdaq 100 Movers: MRNA, ADBE, source:Market News Video, summary: No summary, Headline: 2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague, source:Yahoo, summary: Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint., Headline: Why Is Novavax (NVAX) Stock Down 10% Today?, source:InvestorPlace, summary: No summary, Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Moderna (MRNA) and Kymera Therapeutics (KYMR), source:TipRanks, summary: No summary, Headline: EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union, source:Yahoo, summary: Moderna, Inc.(Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the marketing authorization (MA) to include a booster dose of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), at the dose level for children (6-11 years) of 12.5mcg/12.5mcg, Headline: Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More, source:Yahoo, summary: Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study., Headline: Moderna Comes Alive On Good Performance From Pipeline, Please Try Again, source:SeekingAlpha, summary: Moderna lauded results from a clinical study readout. The large magnitude of positive trend in a deadly cancer is an encouraging sign. Read more on MRNA here., Headline: Moderna And Merck Celebrate Win With Melanoma Cancer Vaccine - The Hype Is (Just About) Justified, source:SeekingAlpha, summary: Moderna and Merck have been working on an adjuvant personalised cancer vaccine that works alongside Keytruda in melanoma. Read more on the stocks here., Headline: U.S. FDA advisers to weigh on updating initial COVID vaccine doses, source:Reuters, summary: The U.S. Food and Drug Administration (FDA) said on Friday it planned to hold a meeting of outside experts next month to discuss whether initial doses of COVID-19 vaccines need to be updated to combat circulating variants., Headline: Moderna’s Cancer Data Offer Glimpse of Stock’s Path Beyond Covid, source:Yahoo, summary: (Bloomberg) -- Moderna Inc. investors may finally be ready to look beyond Covid, as promising data on a personalized cancer vaccine sparked hope for the biotechnology company’s broader pipeline amid the fading pandemic. Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesCovid Unleashed in Beijing Shows Rest of China What’s NextWorld’s Largest Hotel Aquarium Bursts Spilling 1,500 FishIs Putin Finally Getting Smart About His Ukraine Disaster?After reaching a, Headline: Moderna's Next $20B Franchise - Learning From Merck's Keytruda, source:SeekingAlpha, summary: Keytruda has proved to be MRK's leading sales driver, projected to contribute 35.38% of FY2022 revenues at $20.9B. See a comparison of MRK and MRNA stocks., Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 6.74% to $193.29 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite..., Headline: Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review, source:Yahoo, summary: The market rally came under pressure on a higher Fed rate outlook. Moderna spiked on a cancer vaccine while Tesla continued to dive., Headline: Coinbase, Moderna, Tesla: Stocks That Defined the Week, source:Yahoo, summary: In less than 24 hours, the founder of the crypto exchange was arrested, charged with eight counts of fraud, and sued by regulators for allegedly stealing billions of dollars from FTX customers while misleading investors and lenders.  Shares of a rival crypto exchange, Coinbase, dropped 9.2% Tuesday, while shares of  Silvergate Capital  —a bank tied to crypto—sagged 12%.  A customized Moderna vaccine helped ward off the recurrence of melanoma in a mid-stage trial, marking an important step in the biotech’s ascent.",MRNA
82,2022-12-17,"Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify., Headline: 3 Beaten-Down Stocks That Could Explode Higher in 2023, source:Yahoo, summary: Three Motley Fool contributors were asked to pick beaten-down stocks that they think could explode higher in 2023.  Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Moderna (NASDAQ: MRNA), and Zoetis (NYSE: ZTS).  David Jagielski (CRISPR Therapeutics): CRISPR Therapeutics' shares have underperformed in the current bear market, with the gene-editing stock down almost 40% year to date., Headline: On This Day: House impeaches President Trump, source:United Press International, summary: No summary",MRNA
83,2022-12-18,"Headline: IBBQ: Healthcare Dashboard For December, source:SeekingAlpha, summary: The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF., Headline: 5 No-Brainer Stocks to Buy Before 2023, source:Yahoo, summary: Amazon (NASDAQ: AMZN) didn't deliver its usual top earnings and share price performance this year.  The company is a leader in e-commerce and cloud computing.  Amazon should benefit from this in the coming years., Headline: mRNA-based cancer vaccines have limits, pioneer of the technology says, source:Seeking Alpha, summary: No summary, Headline: Earnings Working Against Moderna, Inc.'s (NASDAQ:MRNA) Share Price, source:Yahoo, summary: Moderna, Inc.'s ( NASDAQ:MRNA ) price-to-earnings (or ""P/E"") ratio of 6.3x might make it look like a strong buy right..., Headline: Are These Multibillion-Dollar Vaccine Stocks Still a Buy?, source:Yahoo, summary: Pharmaceutical companies Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) saw their shares rise 19.6% and 1.7%, respectively, on Tuesday after they announced impressive early results from their mRNA cancer vaccine to prevent melanoma, the deadliest form of skin cancer.  This would be a vaccine against cancer, not just against a virus that could cause cancer (like the human papillomavirus and hepatitis B virus vaccines).  It's also different from two other ""cancer vaccines,"" Sipuleucel-T and Talimogene laherparepvec, which are used on advanced prostate and melanoma patients, respectively, because this vaccine would be a preventative used on  patients who have had prior melanomas excised by surgery and have not yet seen any signs of recurrence., Headline: WSJ Opinion: Hits and Misses of the Week, source:Yahoo, summary: Journal Editorial Report: The week's best and worst from Kim Strassel, Collin Levy, Allysia Finley and Dan Henninger. Image: Agence France-Presse/Getty Images, Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary, Headline: Moderna upgraded to Buy from Hold at Jefferies, source:Thefly.com, summary: No summary",MRNA
84,2022-12-19,"Headline: Wall Street Breakfast: Elon Gone?, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify., Headline: Premarket Movers: TechnipFMC, Moderna, ICL Group, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (FTI) was up 4.4% in pre-market trading, and (MRNA) was up 3.9%. (ICL), (APTV), and (TSLA) were all posting..., Headline: Stocks making the biggest moves premarket: Aerojet Rocketdyne, Tesla, Mesa Air and others, source:CNBC, summary: These are the stocks posting the largest moves before the bell., Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Tesla, Moderna, Mesa Air rise premarket; Meta Platforms lower, source:Yahoo, summary: By Peter Nurse, Headline: Unusually active option classes on open December 19th, source:Thefly.com, summary: No summary, Headline: Moderna call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: My Top 2023 Stock Pick: Truist Financial, source:SeekingAlpha, summary: Truist trades for 7.9x 2023 earnings estimates, sports a 5%+ dividend yield, and flies under the radar compared to bigger peers. Read our buy thesis for TFC here., Headline: Moderna stock rises after analyst upgrade, price target raise, source:Yahoo, summary: Yahoo Finance Live anchors discuss a Jefferies analyst’s decision to upgrade Moderna stock to Buy., Headline: Moderna Stock Is Upgraded on Growth Opportunities Not Related to Covid, source:Yahoo, summary: Jefferies analyst Michael Yee upgrades shares of Moderna to Buy from Hold, and boosts the price target to $275., Headline: Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids, source:Yahoo, summary: The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years., Headline: Moderna shifts focus to developing cancer vaccinations, source:CNBC, summary: Michael Yee of Jefferies joins 'Closing Bell' to discuss Moderna's shift away from Covid-focused pharmaceuticals toward PCV cancer vaccination, the market size for personalized cancer vaccines and the Moderna-Merck partnership., Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.76% to $189.89 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Stock Market Feels Winter Chill; Disney No Longer Happiest Place On Earth; Musk Monday Madness, source:Yahoo, summary: The stock market added to its losses Monday and was down in the last hour, near the lows of the day.  Investors are not showing up for a year-end Santa Claus Claus rally, at least yet.  The S&P 500 sold off 0.5% while the Nasdaq fell 1.2%., Headline: Jefferies upgrades Moderna stock, raises price target, source:Yahoo, summary: Yahoo Finance Live breaks down the action surrounding Moderna after Jefferies analysts upgraded its stock and price target., Headline: Treasury yields rise as Japan unexpectedly loosens its bond yield cap, source:CNBC, summary: U.S. Treasury yields rose after Japan unexpectedly raised its cap on 10-year government bond yields, sparking a sell-off in global long-duration bond markets., Headline: Moderna price target raised to $217 from $214 at Piper Sandler, source:Thefly.com, summary: No summary",MRNA
85,2022-12-20,"Headline: Chantal Friebertsh��user Joins Moderna as Senior Vice President, Commercial, source:Accesswire, summary: No summary, Headline: Moderna appoints Chantal Friebertshauser as SVP, commercial, source:Thefly.com, summary: No summary, Headline: Early notable gainers among liquid option names on December 20th, source:Thefly.com, summary: No summary, Headline: Merck: Why The Company Is Still Undervalued, source:SeekingAlpha, summary: Thanks to its leading positions in various therapeutic areas, Merck's revenue was $14,959 million in Q3 2022, an increase of 13.7%. Click here to read my analysis., Headline: Stocks making the biggest moves midday: Gilead Sciences, Moderna, Tesla and more, source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Chantal Friebertshäuser as Senior Vice President, Commercial, Europe, Middle East and Canada effective January 1, 2023., Headline: Midday movers: Tesla, General Mills, Wells Fargo and more, source:Yahoo, summary: By Liz Moyer, Headline: Moderna builds out upper management with new commercial SVP, source:Yahoo, summary: Moderna Inc. has added a new senior vice president to its upper ranks: Chantal Friebertshäuser, who will oversee commercial operations in Europe, the Middle East and Canada starting next month., Headline: COVID: Bivalent booster shots were ‘tremendous’ in lowering hospitalization rates, doctor says, source:Yahoo, summary: Despite the uptick in COVID cases, one NYC-based physician is optimistic about how the U.S. will fare throughout the winter, thanks to the development of boosters., Headline: US offers Covid vaccines to China to stem outbreak, source:Alliance News, summary: No summary, Headline: Treasury yields muted as calm returns to bond markets after sell-off, source:CNBC, summary: U.S. Treasury yields were muted as global bond markets stabilized after the previous session's sell-off on the back of Bank of Japan's surprise policy shift., Headline: 7 Perfect Presents to Gift Your 2023 Stock Portfolio��, source:InvestorPlace, summary: No summary",MRNA
86,2022-12-21,"Headline: Moderna Finalizes Strategic Partnership with UK Government, source:Accesswire, summary: No summary, Headline: Moderna finalizes strategic partnership with U.K. government, source:Thefly.com, summary: No summary, Headline: Covid Cases Are Surging. Cities Advise Masks., source:MarketWatch, summary: As rates of Covid-19 and influenza continue to climb across the U.S., local officials are recommending, but not requiring, masking in some cities, Headline: Could This Opportunity Make Moderna a Hot Buy Again?, source:Yahoo, summary: Merck and Moderna recently announced positive results from a trial involving their personalized cancer vaccine., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rallied 4.41% to $210.04 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Delta and Moderna Share Good News, source:Yahoo, summary: In this episode of the Motley Fool Money podcast, Motley Fool senior analyst Bill Mann discusses:  Why Delta Airlines is projecting financial optimism about 2023. Why Moderna shares popped by 20% after it reported promising results from a skin cancer treatment trial it performed in combination with a Merck drug., Headline: Moderna's vaccine facility in Britain to create over 150 new jobs, source:Reuters, summary: U.S. biotech Moderna's planned vaccine manufacturing centre in Britain will create more than 150 new jobs in the country, the UK government said on Thursday., Headline: Moderna finalizes strategic partnership with UK Government, source:Seeking Alpha, summary: No summary, Headline: Biotech ETFs rally in Q4 fueled by 70%+ surge in Moderna, source:Seeking Alpha, summary: No summary, Headline: Treasury yields fall as investors return to bond market, source:CNBC, summary: U.S. Treasury yields fell on Thursday as the sell-off seen earlier in the week abated., Headline: IN BRIEF: Moderna partners with UK government for mRNA manufacturing, source:Alliance News, summary: No summary",MRNA
87,2022-12-22,"Headline: Covid-19 Showed Investors the Power of Vaccines. They Could Be Even Bigger in 2023., source:Yahoo, summary: Until the pandemic hit, Wall Street largely ignored the vaccine market. This year will show there’s more to jabs than fighting Covid-19., Headline: Unusually active option classes on open December 22nd, source:Thefly.com, summary: No summary, Headline: Better Buy: Moderna vs Axsome, source:Yahoo, summary: Moderna (NASDAQ: MRNA) and Axsome Therapeutics (NASDAQ: AXSM) are early in their revenue stories.  Moderna launched its first product -- the COVID-19 vaccine -- in 2020.  Axsome started selling its first two products -- a sleep disorder drug and an antidepressant -- this year., Headline: With 65% institutional ownership, Moderna, Inc. (NASDAQ:MRNA) is a favorite amongst the big guns, source:Yahoo, summary: Every investor in Moderna, Inc. ( NASDAQ:MRNA ) should be aware of the most powerful shareholder groups. And the group..., Headline: Moderna Finalizes 10-Year Agreement With UK Government For mRNA Vaccine Manufacturing Centre, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) has finalized a strategic partnership with the U.K. government to establish an mRNA vaccine research, development, and manufacturing facility in the U.K. This milestone follows the agreement in principle between Moderna and the UK Government, announced in June 2022. The Moderna Innovation and Technology Centre (MITC) is intended to provide access to a UK-made supply of COVID-19 jabs. It also has the potential to develop vaccines for other respiratory diseases, such as, Headline: Moderna Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 0.81% to $208.34 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) November 2022 ESG Day - Slideshow, source:SeekingAlpha, summary: The following slide deck was published by Moderna, Inc., Headline: Buy/Sell: Wall Street`s top 10 stock calls this week, source:Thefly.com, summary: No summary, Headline: Friday Sector Laggards: Healthcare, Technology & Communications, source:Market News Video, summary: No summary",MRNA
88,2022-12-23,"Headline: Video: S&P 500 Movers: MRNA, COP, source:Market News Video, summary: No summary, Headline: Video: Nasdaq 100 Movers: MRNA, PAYX, source:Market News Video, summary: No summary, Headline: Immune-evasive Omicron subvariant XBB rapidly gaining ground in U.S., source:Seeking Alpha, summary: No summary, Headline: Here's Where to Invest $1,000 Right Now, source:Yahoo, summary: The market downturn may not inspire you to invest. But these times actually are among the best to buy stocks. Many top companies are trading for bargain valuations. And in some cases, after a difficult year, certain stocks are starting to rebound., Headline: Most Active Equity Options For Midday - Friday, Dec. 23, source:TalkMarkets, summary: No summary, Headline: BUZZ Investing: Volatility Remains Elevated In Equity Markets, source:Seeking Alpha, summary: No summary, Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 4.44% to $199.08 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Why 2023 Will Be a Huge Year for Vaccines, source:Yahoo, summary: Until the pandemic hit, Wall Street largely ignored the vaccine market. This year will show there’s more to jabs than fighting Covid-19.",MRNA
89,2022-12-24,"Headline: Pfizer, Moderna among vaccine makers to watch in 2023, Barron`s says, source:Thefly.com, summary: No summary, Headline: Three Pharma Stocks to Sell Before They Die, source:Yahoo, summary: As we head into New Year 2023, we wanted to take a look at some of the top pharmaceutical blunders of the last several months. While many pharmaceutical stocks can hold immense profit potential, others can wipe out your accounts in the blink of an eye. That’s because – far too often — investors buy these stocks, which turn out to hold weak or non-existent pipelines. Or, investors will buy on the promise of unachieved growth. In fact, here are three that fit those molds, and should be sold headin",MRNA
90,2022-12-26,"Headline: Fly Intel: Top five weekend stock stories, source:Thefly.com, summary: No summary, Headline: Moderna, Inc.'s (NASDAQ:MRNA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?, source:Yahoo, summary: Moderna (NASDAQ:MRNA) has had a great run on the share market with its stock up by a significant 63% over the last..., Headline: This Stock Just Soared by 20%: Should You Buy Now?, source:Yahoo, summary: Biotech company Moderna (NASDAQ: MRNA) has been southbound for most of the year, but the vaccine maker seems to be ending 2022 on a high note.  As is usually the case with biotechs, Moderna had good news from the clinic to thank for that impressive one-day rally (more on that later).  Are Moderna's shares still worth buying right now?, Headline: Why Are Casino Stocks WYNN, LVS Up Today?, source:InvestorPlace, summary: No summary, Headline: Novavax COVID-19 shot lags in effectiveness in first study of its kind, source:Seeking Alpha, summary: No summary",MRNA
91,2022-12-27,"Headline: 5 Ultra-Popular Stocks I'd Sell Right Now, source:Yahoo, summary: The bond market may end up logging its worst year ever, while the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all entered bear markets at one point or another in 2022.  Although bear markets have historically represented the ideal time for opportunistic investors to do some shopping, it's important to recognize that not every perceived discount will prove to be a bargain.  The first stock I believe investors would be wise to pare down or outright sell right now is electric vehicle (EV) manufacturer Tesla (NASDAQ: TSLA)., Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 9.50% to $180.17 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Dow Jones Rises, But Tesla, Moderna Lead Growth Sell-Off; 5 Stocks Near Buy Points, source:Yahoo, summary: The Dow rose in a split market as many industrial, metal and energy plays thrive. Tesla, Moderna and Nvidia led a growth sell-off.",MRNA
92,2022-12-28,"Headline: 4 stocks to watch on Wednesday: Apple, Pfizer and more, source:Seeking Alpha, summary: No summary, Headline: Vertex: Progress Towards Expanding Cystic Fibrosis Market Continues, source:SeekingAlpha, summary: Vertex Pharmaceuticals is doing very well with respect to sales of its CF franchise. Click here to read why VRTX is a great speculative biotech play., Headline: Unusually active option classes on open December 28th, source:Thefly.com, summary: No summary, Headline: Dow Jones Futures Rise, Tesla Bounces After Leading Growth Sell-Off; 5 Stocks Near Buy Points, source:Yahoo, summary: Tesla bounced early after leading a growth sell-off with Moderna and Nvidia. Many industrial and energy plays are thriving, Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 2.04% to $176.50 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Biotech: 3 Profitable Bios Worth Owning, source:Yahoo, summary: The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects., Headline: 12 Best Performing Biotech Stocks in 2022, source:Yahoo, summary: In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]",MRNA
93,2022-12-29,"Headline: February 2023 Options Now Available For Moderna (MRNA), source:Stock Options Channel, summary: No summary, Headline: Market Briefing For Thursday, Dec. 29, source:TalkMarkets, summary: No summary, Headline: Moderna Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 1.34% to $178.86 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Tracking Philippe Laffont's Coatue Management Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: Philippe Laffontâs 13F portfolio value increased from $8.26B to $8.61B this quarter. Click here to read an update on the portfolio's trades for Q3 2022.",MRNA
94,2022-12-30,"Headline: Unusually active option classes on open December 30th, source:Thefly.com, summary: No summary, Headline: Video: S&P 500 Movers: MRNA, KR, source:Market News Video, summary: No summary, Headline: Are Robust Financials Driving The Recent Rally In Moderna, Inc.'s (NASDAQ:MRNA) Stock?, source:Yahoo, summary: Moderna's (NASDAQ:MRNA) stock is up by a considerable 51% over the past three months. Given the company's impressive..., Headline: Tracking Philippe Laffont`s Coatue Management Portfolio - Q3 2022 Update, source:Seeking Alpha, summary: No summary, Headline: Omicron subvariant XBB becomes dominant COVID strain in U.S., source:Seeking Alpha, summary: No summary, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.42% higher to $179.62 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $179.62, moving +0.42% from the previous trading session.",MRNA
95,2023-01-01,"Headline: Top S&P 500 Stocks: Trading Opportunities For Next Week - Monday, Jan. 2, source:TalkMarkets, summary: No summary, Headline: Brookline Capital Markets Reaffirms Their Buy Rating on Moderna (MRNA), source:TipRanks, summary: No summary",MRNA
96,2023-01-02,"Headline: Merck Is Poised To Outperform In 2023, source:SeekingAlpha, summary: Merck substantially outperformed in 2022 and achieved a series of positive trial outcomes. See why I am maintaining a buy rating on MRK stock., Headline: Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony, source:Yahoo, summary: After riding high for much of the pandemic, mRNA vaccine pioneers came down to earth in 2022.  After five decades of failed attempts, cancer vaccines are set for a breakthrough.  Unlike normal vaccines, these shots will treat, not prevent, the disease.",MRNA
97,2023-01-03,"Headline: Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the 41st annual J.P. Morgan Healthcare Conference on Monday, January 9th at 5:15 p.m., Headline: Moderna, Inc.'s (NASDAQ:MRNA) Business And Shares Still Trailing The Market, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 5.9x Moderna, Inc. ( NASDAQ:MRNA ) may be sending very bullish signals at..., Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 0.35% to $178.99 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab, source:Yahoo, summary: Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years., Headline: Analyzing 13Fs: ARK Investment Management (Cathie Wood`s ETFs), source:Seeking Alpha, summary: No summary, Headline: Analyzing 13Fs: ARK Investment Management (Cathie Wood's ETFs), source:SeekingAlpha, summary: Cathie holds tight to outsized ownership stakes in more than 44 of her holdings. Find out more on the moves based on recently disclosed 13F filing data.",MRNA
98,2023-01-04,"Headline: Moderna to acquire OriCiro Genomics for $85M, source:Thefly.com, summary: No summary, Headline: Moderna strengthens mRNA manufacturing with OriCiro buyout, source:Seeking Alpha, summary: No summary, Headline: IN BRIEF: Moderna buys OriCiro Genomics for USD85 million, source:Alliance News, summary: No summary, Headline: Moderna to Acquire OriCiro Genomics for $85 Million, source:MarketWatch, summary: By Dean Seal Moderna Inc. has signed an agreement to purchase Tokyo-based OriCiro Genomics K.K. for $85 million. The biotechnology company said Wednesday..., Headline: Moderna to Acquire OriCiro Genomics, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million., Headline: Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push , source:Reuters, summary: Moderna Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's mRNA manufacturing capabilities., Headline: UPDATE 1-Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push, source:Yahoo, summary: Moderna Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's messenger RNA (mRNA) manufacturing capabilities.  OriCiro's technologies will support Moderna's portfolio of therapeutics and vaccines, the companies said.  Moderna's mRNA technology has been used in developing COVID-19 vaccines., Headline: Be A Better Bull: IJR And IJH Are Superior To The S&P 500 And Russell 2000, source:SeekingAlpha, summary: IJR and IJH are better options than the Russell 2000 and S&P 500. Find out why and what the implications are for you as an investor., Headline: Are Options Traders Betting on a Big Move in Moderna (MRNA) Stock?, source:Yahoo, summary: Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately., Headline: Moderna Bolsters Its Vaccine Pipeline With $85 Million Deal for Biotech Firm OriCiro, source:Yahoo, summary: The small Tokyo-based company's tools will help the pharma giant's messenger RNA manufacturing process., Headline: Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push, source:Reuters, summary: Moderna Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's messenger RNA (mRNA) manufacturing capabilities., Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slumped 0.91% to $177.36 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Riding on its Covid-19 vaccine success, Moderna makes its first-ever acquisition, source:Yahoo, summary: The Cambridge drugmaker (Nasdaq: MRNA) is using some of the billions of dollars it's been sitting on to acquire a Japanese DNA supplier in a $85 million deal., Headline: CytomX Therapeutics, Moderna announce strategic research collaboration, source:Thefly.com, summary: No summary, Headline: CytomX Therapeutics updates business, announces 2023 relationship with Moderna, source:Thefly.com, summary: No summary, Headline: Morgan Stanley sees Moderna`s phase 3 RSV vaccine data as catalyst-driven idea, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary, Headline: CTMX Surges after Announcing MRNA Collaboration, source:TipRanks, summary: No summary",MRNA
99,2023-01-05,"Headline: Fly Intel: After-Hours Movers, source:Thefly.com, summary: No summary, Headline: The Petri Dish: Fulcrum CEO steps down; Moderna cools on mpox vaccine, source:Yahoo, summary: ModernaCEO Stephane Bancel doesn't see much of a market for the company's mRNA-based vaccine for mpox (formerly called ""monkeypox"") despite ""fantastic"" preclinical data., Headline: Interesting MRNA Put And Call Options For February 24th, source:Stock Options Channel, summary: No summary, Headline: SVB Securities Sticks to Its Hold Rating for Moderna (MRNA), source:TipRanks, summary: No summary, Headline: 2 Top Growth Stocks to Buy Right Now and Hold for the Long Term, source:Yahoo, summary: Growth stocks with major industry tailwinds behind them and leading positions in their respective markets can provide life-changing returns for investors.  Moderna (NASDAQ: MRNA) is a leader in mRNA technology that proved effective against COVID-19 and has a large pipeline of products in the works.  Taiwan Semiconductor (NYSE: TSM) is a leading chip foundry with the technology and business model to dominate for decades., Headline: Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout, source:Yahoo, summary: Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities., Headline: Bearishness in stocks sets in as positive seasonal factors did little to lift the market, source:Yahoo, summary: The stock market tried to get off to a good start this year.  Bulls and bears are awaiting a breakout from 3760 to 3870 points in the index  (SPX)  Overhead, there is still heavy resistance in the 3900-3940 area, with the major downtrend line of the bear market above that (it was last tested at 4100, in early December).  Overall, SPX remains bearish in that it is in a downtrend., Headline: Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody® therapeutic platform., Headline: CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics, source:Yahoo, summary: Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna, Inc., Headline: Moderna, CytomX announce mRNA collaboration , source:Reuters, summary: Moderna Inc on Thursday said it will collaborate with CytomX Therapeutics for the development of certain investigational messenger RNA-based therapies. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath), Headline: CytomX shares surge more than 50% on Moderna partnership, source:Yahoo, summary: MARKET PULSE CytomX Therapeutics Inc. (CTMX) shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. (MRNA) CytomX shares were last up 57% after hours, following a 7., Headline: Moderna signs $35 million deal with cancer drug developer CytomX, source:Reuters, summary: Moderna Inc on Thursday announced a $35 million licensing deal with cancer-focused drug developer CytomX Therapeutics to work on messenger RNA-based therapies for a wide range of diseases., Headline: CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal, source:InvestorPlace, summary: No summary, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",MRNA
100,2023-01-06,"Headline: 5 Top Pharma Stocks of 2022 to Buy for the Long Haul, source:InvestorPlace, summary: No summary, Headline: Today`s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday, source:InvestorPlace, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: BioNTech says it will start cancer vaccine trials in the UK from September, source:CNBC, summary: The company aims to test 10,000 personalized mRNA therapies, including cancer vaccines, between September 2023 to the end of the decade. , Headline: Many Investors Wouldn't Touch This Stock With a 10-Foot Pole Last Year. Here's Why It's a Buy in 2023., source:Yahoo, summary: Moderna (NASDAQ: MRNA) was once a stock market champion.  Shares of the biotech company soared more than 400% back in 2020 as investors bet on its ability to win the coronavirus vaccine race.  Let's check out why Moderna is a buy in the new year., Headline: XBB.1.5, which makes up 28% of new COVID cases in the U.S., fuels worries about a winter wave, source:MarketWatch, summary: No summary, Headline: CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) and CytomX Therapeutics Inc (NASDAQ: CTMX) announced a collaboration and licensing agreement to create mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform. Under the terms of the agreement, CytomX will receive an upfront payment of $35 million, including $5 million of pre-paid research funding. CytomX will continue to receive research funding and is eligible to receive up to approximately $1.2 bil, Headline: Genetics, Alzheimer's And AI — Why 2023 Could Be The Year For Biotech Stocks, source:Yahoo, summary: If there's one biotech area to watch in 2023, it's genetic medicine, like CRISPR. But other trends also point to a big year for biotech stocks., Headline: CytomX (CTMX) Up 55% on Strategic Partnership With Moderna, source:Yahoo, summary: CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.",MRNA
101,2023-01-07,"Headline: Looking for Growth in 2023? Where to Invest $5,000, source:Yahoo, summary: This year, some of the stocks most heavily hit by the market downturn could start to make a comeback.  And they're trading at 28 times forward earnings estimates, which looks cheap considering Etsy's earnings performance in tough times.",MRNA
102,2023-01-09,"Headline: Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response, source:MarketWatch, summary: A flurry of vaccine announcements dominated pandemic headlines on Monday, Headline: Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial, source:Reuters, summary: Ocugen Inc said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States., Headline: Moderna generates $18.4 billion in COVID vaccine sales in 2022, source:Reuters, summary: Moderna Inc said on Monday it generated about $18.4 billion in COVID-19 vaccine sales in 2022., Headline: UPDATE 1-Moderna meets forecast with $18.4 billion in COVID vaccine sales in 2022, source:Reuters, summary: Moderna Inc said on Monday it generated about $18.4 billion in COVID-19 vaccine sales in 2022, meeting its forecast of $18 billion-$19 billion for the year., Headline: Moderna’s COVID shot to generate $5.0 billion in sales in 2023, source:Yahoo, summary: Shares of Moderna Inc.  (MRNA)  were up about 1.0% in premarket trading on Monday after the company reiterated that it expects to have $5.0 billion in sales of its COVID-19 vaccine in 2023.  Moderna also said its vaccine generated $18.4 billion in sales in 2022, and the company plans to boost spending on research and development to $4.5 billion this year, up from $3.3 billion in 2022.  Moderna provided the update in advance of the company’s presentation at the annual J.P. Morgan Healthcare Conference in San Francisco., Headline: Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government’s pandemic response, source:Yahoo, summary: A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.  The company plans to boost spending on research and development to $4.5 billion this year, up from $3.3 billion in 2022.  Separately, CureVac  (CVAC)   said preliminary data from its early stage trial for its COVID and seasonal flu shots had positive results to advance to the next stage of clinical testing., Headline: We are in discussion with the Chinese government over the Covid vaccine, says Moderna CEO, source:CNBC, summary: CNBC’s Meg Tirrell joins ‘Closing Bell’ to talk with Moderna CEO Stephane Bancel about the company’s Covid vaccine sales in 2022 and his projections for 2023., Headline: Moderna Surpasses 2022 Covid-19 Vaccine Sales Estimates. Why Its Stock Didn’t Rally., source:Yahoo, summary: The biotech said Covid-19 sales in 2022 were approximately $18.4 billion, while the consensus call on Wall Street was for $17.8 billion., Headline: Top Stock Reports for Thermo Fisher Scientific, Starbucks & Moderna, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), Starbucks Corporation (SBUX) and Moderna, Inc. (MRNA)., Headline: Moderna Considers Price of $110-$130 for Covid-19 Vaccine, source:Yahoo, summary: The commercial price for the shot is similar to Pfizer’s plans for after government contracting ends., Headline: Moderna considers pricing COVID vaccine at $110-$130 - WSJ , source:Reuters, summary: Moderna Inc is considering pricing its COVID-19 shot at $110 to $130 per dose in the United States when it shifts from government contracting to commercial distribution of the shots, the company's Chief Executive Officer Stephane Bancel told the Wall Street Journal on Monday..., Headline: UPDATE 1-Moderna considers pricing COVID vaccine at $110-$130 - WSJ, source:Yahoo, summary: Moderna Inc is considering pricing its COVID-19 shot at $110 to $130 per dose in the United States when it shifts from government contracting to commercial distribution of the shots, the company's Chief Executive Officer Stephane Bancel told the Wall Street Journal on Monday.  ""I would think this type of pricing is consistent with the value,"" said Bancel, according to the WSJ report, adding the company was in discussions with hospital systems, pharmacies and pharmacy-benefit managers to line up distribution of its vaccine ahead of a potential fall booster shot campaign.  Moderna had previously estimated the commercial price expectations in a range of $64 to $100 a shot., Headline: WSJ: Moderna may charge up to $130 per dose of its COVID shot, source:Yahoo, summary: MARKET PULSE Shares of Moderna Inc. (MRNA) were up 2.5% in trading on Monday afternoon after the Wall Street Journal reported that the company is considering pricing its COVID-19 vaccine at $110 to $130 per dose., Headline: Moderna's Interim Earnings Beat Modestly, Uncertainty Looms Over 2023, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) reported interim FY22 COVID-19 vaccine sales of $18.4 billion against $18-19 billion forecasted in the Q3 earnings release and the consensus of $17.8 billion. The company reiterates 2023 expected minimum COVID-19 vaccine sales of approximately $5 billion, with more contracts coming in 2023. BofA writes there were no surprises from the update, but it continues to be cautious on Moderna’s P&L given that increased expenses could pressure earnings over the next few years (, Headline: Moderna considers pricing COVID vaccine at $110-$130 - WSJ, source:Reuters, summary: Moderna Inc is considering pricing its COVID-19 shot at $110 to $130 per dose in the United States when it shifts from government contracting to commercial distribution of the shots, the company's Chief Executive Officer Stephane Bancel told the Wall Street Journal on Monday..., Headline: Moderna (MRNA) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $183.95, moving +2% from the previous trading session.",MRNA
103,2023-01-10,"Headline: The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology, source:Yahoo, summary: Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology are included in this Analyst Blog., Headline: China takes first steps to punish countries that imposed testing mandates for Chinese travelers, source:MarketWatch, summary: China suspended visas for South Koreans on Tuesday in a tit-for-tat response to that country's COVID testing requirement for Chinese tourists., Headline: Moderna Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.10% to $189.65 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Reports 2023 Business View & Pipeline Updates, source:Yahoo, summary: Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023., Headline: CureVac Stock Has Nearly Doubled in 3 Days, source:Yahoo, summary: Biotech CureVac stock has surged since announcing upbeat preliminary data from ongoing Phase 1 trials of its Covid-19 and flu vaccines on Friday., Headline: The ‘Kraken’ COVID variant taking hold in the U.S. Here’s how many vaccine shots there are—and what experts recommend to protect yourself, source:Yahoo, summary: The highly transmissible 'Kraken' COVID variant is here. Experts say getting boosted is your best protection., Headline: UPDATE 1-Sen. Sanders asks Moderna not to hike COVID vaccine price, source:Yahoo, summary: U.S. Senator Bernie Sanders sent Moderna Inc a letter this week asking the drug company to halt planned U.S. price increases on its COVID-19 vaccine, saying price hikes could make the shot unaffordable for millions of Americans.  Sanders said in his letter that raising prices would be particularly egregious after the U.S. government provided around $1.7 billion to fund development of the vaccine.  The letter was addressed to Moderna Chief Executive Stephane Bancel., Headline: Sen. Sanders asks Moderna not to hike COVID vaccine price, source:Reuters, summary: U.S. Senator Bernie Sanders sent Moderna Inc a letter this week asking the drug company to halt planned U.S. price increases on its COVID-19 vaccine, saying price hikes could make the shot unaffordable for millions of Americans.",MRNA
104,2023-01-11,"Headline: Ranking The 10 Largest Biotechs By Pipeline, source:SeekingAlpha, summary: The pipeline is the heart of all drug discovery companies, leading to all growth in the future. Here we rank biotechs by pipeline, click to see the list., Headline: Moderna considers raising COVID vaccine prices, source:Yahoo, summary: Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss reports that Moderna is considering raising the price of its COVID-19 vaccines, Moderna Chairman Noubar Afeyan’s response to Senator Bernie Sanders on drug pricing, and the top takeaways from the JPMorgan healthcare conference., Headline: Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More, source:Yahoo, summary: Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.59% to $186.64 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: 7 Hot Healthcare Stocks to Watch in 2023, source:Yahoo, summary: While it has not produced the big gains seen among other sectors such as energy, healthcare has been a quiet outperformer over the past year. The S&P 500 Healthcare Index is essentially flat over the past 12 months. While that might not sound great, it is a lot better than the 16% decline of the benchmark S&P 500 index during the same period. The stocks of several pharmaceutical companies have increased more than 30% in the last year, driven higher by a combination of strong sales and a pipeline",MRNA
105,2023-01-12,"Headline: The Stock Market Is Heating Up. Read This Before You Jump In., source:Yahoo, summary: In the absence of a clear market trend, investors would be wise to avoid big bets on the broader market. A better alternative is to trade cash-secured put options in stocks such as Moderna., Headline: IBB: A History Of Outperformance During Recessions, source:SeekingAlpha, summary: iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. See why I'm bullish about IBB ETF now., Headline: The Petri Dish: Moderna looks at new price tag for Covid vaccine, source:Yahoo, summary: Moderna Inc. (Nasdaq: MRNA) is considering hiking the price of its Covid-19 vaccine up by up to 400%., Headline: Elon Musk Amplifies Bernie Sanders's Outrage Against Moderna, source:Yahoo, summary: The pharmaceutical company is mulling a move that has enraged both Musk and one of his ideological opposites., Headline: 'We agree that vaccines should be free': Moderna's Noubar Afeyan, source:Yahoo, summary: Moderna will set the price of its COVID-19 vaccine at the same level as Pfizer when the shots hit the commercial market this year., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.76% higher to $188.06 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: White house: Price hike for Moderna's COVID shots hard to justify, source:Reuters, summary: The price hike for Moderna Inc COVID-19 shots is hard to justify, White House spokesperson Karine Jean-Pierre said on Thursday.",MRNA
106,2023-01-13,"Headline: How Novavax Could Shake Up the Market for Covid-19 Vaccines, source:Yahoo, summary: Moderna and Pfizer have both discussed higher-than-expected commercial prices for their shots. Novavax says its pricing strategy could give it leverage., Headline: 5 Potentially Explosive Stocks to Buy in 2023, source:Yahoo, summary: Sometimes, small, under-the-radar stocks are the ones to deliver explosive gains. That's because they often have a very low market value -- and a bit of good news easily sends them soaring. But these days, even some top stocks hold potential to skyrocket., Headline: New COVID subvariant is now dominant across the U.S., accounting for 43% of all new cases in latest week, CDC says, source:MarketWatch, summary: XBB.1.5 has been dominant in the Northeast for several weeks and is now dominant in the U.S. as a whole., Headline: Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Moderna Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 2.10% to $192.00 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: 2023 Market Preview: Value Should Continue To Lead, source:SeekingAlpha, summary: The market's history after negative years is usually positive. What we expect to work in 2023: Industrials and consumer staples. Click for our market preview.",MRNA
107,2023-01-15,"Headline: Moderna's Platform Is Game Changing, source:SeekingAlpha, summary: Moderna has a strong platform of assets that have the potential to revolutionize the treatment of numerous fields. Click here to see our take on MRNA stock.",MRNA
108,2023-01-16,"Headline: Moderna: Wait For The Turn, source:SeekingAlpha, summary: Moderna recently delivered surprisingly positive results on its personalized cancer vaccine study with Merck's Keytruda. Click here for more on MRNA.",MRNA
109,2023-01-17,"Headline: WHO calls on China to release more information on its COVID case surge to learn more about which variants are circulating, source:DowJones, summary: China said Saturday that 60,000 of its citizens have succumbed to the virus since early December, Headline: Moderna says RSV vaccine is 84% effective at preventing disease in older adults, source:CNBC, summary: RSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC., Headline: Ocugen: FDA Sector Head States Bridging Studies Insufficient, source:SeekingAlpha, summary: Ocugen is developing Covaxin in the US and has completed an immuno-bridging study with positive results. Find out why we are short OCGN stock., Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. dropped 0.68% to $190.69 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Moderna's phase three RSV trial found to be 83.7% effective in older adults, source:CNBC, summary: CNBC's Meg Tirrell joins 'Closing Bell' to discuss Moderna's phase three trial results for its RSV vaccine, the decision to submit the vaccine for regulatory review and the competitive landscape for RSV vaccines., Headline: Moderna Shares Up 4.8% After-Hours on Trial Results for RSV Vaccine, source:MarketWatch, summary: By Kathryn Hardison Shares of Moderna Inc. gained 4.8% to $199.85 in after-hours trading Tuesday after the drugmaker said an experimental vaccine..., Headline: Goldman Sachs' bad quarter is the result of environmental factors, says Steve Weiss, source:CNBC, summary: Steve Weiss, chief investment officer and managing partner of Short Hills Capital Partners LLC, joins 'Closing Bell Overtime' to discuss Goldman Sachs' earnings miss, the environmental factors impacting the company's margins and Moderna's RSV vaccine news., Headline: Moderna says RSV vaccine 84% effective at preventing symptoms in older adults, source:Yahoo, summary: Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.  RSV, which produces symptoms similar to a cold but can be fatal for young children and older adults, causes about 14,000 deaths annually in adults ages 65 and older.  Moderna, Pfizer Inc and GSK Plc are racing to get their RSV vaccines to market first., Headline: Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults, source:Yahoo, summary: mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval CAMBRIDGE, MA, ACCESSWIRE / January 17, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA), Headline: Moderna Reports Success in RSV Vaccine Trial. A Clash With Pfizer and GSK Is Coming., source:Yahoo, summary: A common virus that can cause severe illness in older adults and young children, RSV cases were particularly widespread in the U.S. this fall., Headline: Moderna stock rallies 5% after respiratory virus vaccine trial meets endpoints, source:Yahoo, summary: Moderna Inc.  (MRNA)  shares rallied in the extended session Tuesday after the biotech drug company said results from a late-stage clinical trial for its respiratory virus vaccine met endpoints, and that it will submit for Food and Drug Administration approval by mid-2023.  Moderna shares surged as much as 5% after hours, following a 0.7% decline to close the regular session at $190.69.  The company said data from a Phase 3 clinical trial of its mRNA-1345 vaccine candidate showed an efficacy of 83.7% against respiratory syncytial virus in older adults., Headline: Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up, source:Yahoo, summary: Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective in older adults., Headline: Stocks moving in after hours: United Airlines, Interactive Brokers, Moderna, source:Yahoo, summary: Yahoo Finance Live anchor Seana Smith highlights three tickers making the biggest moves in after-hours trading., Headline: Market Rally Pauses, Tesla Keeps Rebounding; United Airlines, Moderna, Microsoft In Focus, source:Yahoo, summary: The market rally had a quiet day, with Tesla leading. United Airlines and Moderna rose overnight on news. Microsoft job cuts loom., Headline: Stocks moving after hours: United, Interactive Brokers, Moderna, source:Yahoo, summary: Stocks moving after hours on Jan. 17, 2023: United Airlines, Interactive Brokers, Moderna, Headline: UPDATE 1-Moderna says RSV vaccine 84% effective at preventing symptoms in older adults, source:Yahoo, summary: Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.  RSV, which produces symptoms similar to a cold but can be fatal for young children and older adults, causes about 14,000 deaths annually in adults aged 65 and older.  Moderna, Pfizer Inc and GSK Plc are racing to get their RSV vaccines to market first., Headline: Moderna Reports RSV Vaccine Cuts Risk of Respiratory Diseases in Older Adults, source:Yahoo, summary: An experimental vaccine from  Moderna  significantly reduced the risk of a viral respiratory disease among older adults in a large clinical trial, the latest promising sign in drugmakers’ efforts to fight the deadly RSV virus.  Citing the results, the Cambridge, Mass., company said Tuesday it would apply in the coming months for U.S. regulatory approval to sell its vaccine against RSV, which stands for respiratory syncytial virus.  Moderna’s RSV vaccine was 83.7% effective against lower-respiratory diseases caused by RSV in the study, the company said., Headline: Moderna Says Its RSV Vaccine Trial Was a Success. A Clash With Pfizer and GSK Looms., source:Yahoo, summary: A common virus that can cause severe illness in older adults and young children, RSV cases were particularly widespread in the U.S. this fall., Headline: Treasury yields fall as traders assess data, Fed outlook, source:CNBC, summary: U.S. Treasury yields were lower on Wednesday as uncertainty around the outlook for monetary policy and the economy clouded risk sentiment., Headline: Dow Jones Futures Rise On Bank Of Japan Surprise; Tesla Jumps, source:Yahoo, summary: Futures rose and yields fell as the Bank of Japan stayed dovish. The market rally paused while Tesla stock jumped. United Airlines, Moderna rose overnight. Microsoft job cuts loom., Headline: Dow Jones Futures: Bank Of Japan Surprise; Tesla Jumps, source:Yahoo, summary: Futures rose and yields fell as the Bank of Japan stayed dovish. The market rally paused while Tesla stock jumped. United Airlines, Moderna rose overnight. Microsoft job cuts loom., Headline: Dow falls 400 points after weak economic data, hawkish Fed remarks ease inflation cheer, source:MarketWatch, summary: U.S. stock indexes trade sharply lower on Wednesday afternoon, after falling retail sales in the holiday shopping season raised concerns that consumer...",MRNA
110,2023-01-18,"Headline: One of Wall Street's biggest bulls last year says he's learned his lesson and isn't chasing stocks right now, source:MarketWatch, summary: The JPMorgan team that was bullish on equities last year isn't in the mood to chase the rally., Headline: Wall Street Breakfast January 18: Microsoft Reportedly Set to Unveil More Layoffs (Podcast), source:SeekingAlpha, summary: Microsoft may cut engineering jobs. Elon Musk faces another legal showdown over taking Tesla private tweet. Apple plans cheaper mixed-reality headset, postpones AR glasses., Headline: S&P 500 Futures Climb in Premarket Trading; Moderna, Tesla Lead, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (MRNA) was up 7.3% in pre-market trading, and (TSLA) was up 3.6%. (IBKR), (UAL), and (ICL) were all posting..., Headline: Moderna, United Airlines rise premarket; Coinbase, Morgan Stanley fall, source:Yahoo, summary: By Peter Nurse, Headline: Davos 2023: Moderna CEO says he wants to have mRNA factory on every continent, source:Yahoo, summary: Moderna chief executive Stephane Bancel said he would like to have factories making vaccines based on its messenger RNA technology on every continent as the U.S. company prepares to build four facilities., Headline: Moderna CEO: We're preparing our FDA filing for our RSV vaccine, source:CNBC, summary: Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's accomplishments in the last few years, insight into the company's RSV vaccine, and more., Headline: Stocks Waver, Retail Sales, United Airlines, Moderna, Albertsons - Five Things To Know, source:Yahoo, summary: Stock futures waver, bonds rally on Bank of Japan surprise; December retail sales in focus amid gas price retreat; United Airlines shares higher on earnings beat, bullish outlook; Moderna shares leap on positive data from RSV drug trial and Albertsons gets court approval for $4 billion dividend payment., Headline: Moderna, Tesla, Charles Schwab, and More Market Movers, source:Yahoo, summary: Stocks paused Wednesday as investors reacted to a monetary policy decision from the Bank of Japan and looked ahead to a wave of economic data., Headline: Moderna Stock Leaps On Positive Data From Late-Stage RSV Vaccine Trial, source:Yahoo, summary: ""We are committed to developing a portfolio of respiratory mRNA vaccines to target the most significant viruses causing respiratory disease, including COVID-19, influenza, and human metapneumovirus,"" said CEO Stéphane Bancel., Headline: U.S. stocks were falling as investors await Fed's beige book, source:Yahoo, summary: By Liz Moyer, Headline: Japan’s Surprise Decision Matters for Markets. The Dollar’s Set for a Bumpy Ride., source:Yahoo, summary: United Airlines smashes expectations and forecasts revenue jump, Moderna’s latest test vaccine expands potential of mRNA technology, Disney defends CEO Robert Iger against activist Nelson Peltz, and other news to start your day., Headline: UPDATE 1-Davos 2023: Moderna CEO in talks with China to supply COVID vaccines, source:Yahoo, summary: Moderna chief executive Stephane Bancel said on Wednesday the U.S. company was in active discussions to supply COVID-19 vaccines to China.  Speaking to Reuters on the sidelines of the World Economic Forum annual meeting in Davos, he said the talks with Beijing also covered the topic of factories, and other products including cancer treatments., Headline: Inflation, Crude Oil, Big Mac(ro) Attack, Tough Market, Defense Stocks, Pharma, source:Yahoo, summary: Wednesday morning will bring traders, investors, Romans, and countrymen more macroeconomic results than they could ever wanted to peruse at one time., Headline: Stocks fall after data showing a cooling economy, source:Yahoo, summary: By Liz Moyer, Headline: Stocks making the biggest moves midday: Microsoft, Moderna, Mobileye, Chegg and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: VHT: 2 Megatrends In Healthcare, source:SeekingAlpha, summary: An aging population is expected to boost the demand for healthcare over the next few decades. Read more to see why I'm bullish VHT ETF., Headline: Midday movers: Microsoft, JB Hunt Transport, Moderna and more, source:Yahoo, summary: By Liz Moyer, Headline: Moderna's mRNA RSV vaccine propels stock gains, source:CNBC, summary: Michael Yee, managing director at Jefferies, joins 'The Exchange' to discuss what's driving Moderna's stock activity, the unique mRNA technology behind the company's RSV vaccine and portfolio opportunities in the biotech business., Headline: Moderna Gets Good News, but Another Biotech Stock Is Falling Again, source:Yahoo, summary: Just as the Nasdaq Composite (NASDAQINDEX: ^IXIC) led markets lower in 2022, the index is working hard to lead a rebound early in 2023.  After being the only one of the three major U.S. stock market indexes to finish higher on Tuesday, the Nasdaq once again looked good early Wednesday morning, with futures on the index rising nearly half a percent.  One winner leading the Nasdaq higher Wednesday morning was vaccine stock Moderna (NASDAQ: MRNA), which announced positive news that showed investors the company is more than just a one-trick pony., Headline: Moderna Stock Rises After RSV Vaccine Test Results, source:Yahoo, summary: Shares of Moderna jumped in Wednesday trading after the company said [it would apply for U.S. regulatory approva](https://www.wsj.com/articles/modernas-rsv-vaccine-reduces-risk-of-respiratory-diseases-study-finds-11673986424)l to sell a vaccine against the [viral respiratory disease](https://www.wsj.com/articles/gsk-poised-for-pfizer-battle-in-rsv-vaccine-market-11665661061?mod=article_inline) RSV following encouraging results from a large clinical trial. The company's stock was recently up abou, Headline: Moderna stock rises after RSV vaccine shown to be 83% effective in older adults, source:Yahoo, summary: Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the latest on Moderna's RSV vaccine., Headline: Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab, source:Yahoo, summary: Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older., Headline: Three-Stock Lunch: MRNA, SCHW & KHC, source:CNBC, summary: Courtney Garcia, senior wealth advisors at Payne Capital Management, joins 'Power Lunch' to share recommendations for three stocks: Moderna, Schwab and Kraft Heinz., Headline: Moderna Shares Surge on Promising Vaccine Results, source:Yahoo, summary: Shares of biotech firm Moderna were rallying Wednesday on the news that their respiratory syncytial virus vaccine shows 83.7% efficacy. I liked the chart improvement on MRNA on December 13 and recommended buying strength., Headline: Stock market today: Dow losses accelerate, closes down more than 600 points, source:Yahoo, summary: By Liz Moyer, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 3.32% to $197.02 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Moderna, Pfizer's new race: The RSV vaccine FDA approval process, source:CNBC, summary: Moderna and Pfizer produced Covid vaccines in record time, and now the novel RSV vaccine is on a similar trajectory for both drug companies' mRNA platforms., Headline: Moderna Finds Life After Covid-19, source:Yahoo, summary: Even as Covid-19 turned Moderna into a biotech giant, the debate on Wall Street over its prospects has continued to rage., Headline: Moderna is the latest company to produce a promising RSV vaccine, source:Yahoo, summary: The experimental respiratory syncytial virus vaccine prevented most infections in older adults in a Phase 3 clinical trial, Headline: Bluebird Bio, J.B. Hunt, GoDaddy, Moderna, and More Market Movers, source:Yahoo, summary: Stocks turned lower Wednesday, following hawkish comments from Federal Reserve officials and as investors digested the latest economic data.  Retail sales fell 1.1% month over month in December.  The stock market dropped, with the  down 1.2%, the  down 0.9%, and the  down 0.7%., Headline: Chegg, Bluebird Bio, Yeti, J.B. Hunt, and More Market Movers, source:Yahoo, summary: Chegg landed a downgrade from analysts at Needham. Bluebird Bio announced a proposed public offering., Headline: Major market, sector indices maintain losses ahead of the closing bell, source:Yahoo, summary: Yahoo Finance markets reporter Jared Blikre examines market and sector losses, in addition to checking in on the semiconductor space, Moderna shares, and Yeti's stock.",MRNA
111,2023-01-19,"Headline: Moderna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock?, source:Yahoo, summary: Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term., Headline: China slams Western media for criticism of zero-COVID, as U.S. cases continue to decline, source:MarketWatch, summary: China has accused ""some Western media"" of bias and political manipulation in covering China's abrupt dropping of COVID restrictions, Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 3.37% to $190.38 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Pharmaceutical Stocks Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market, source:Yahoo, summary: Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks., Headline: CureVac Can Finally Compete  With Moderna. It’s an ‘Under-the-Radar mRNA Story.’, source:Yahoo, summary: CureVac  is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise.  UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 12-month target for the stocks price to $18 from $8 on Thursday.  Merle listed recent clinical trial data and the biopharmaceutical company’s ability to gain market share as reasons for the upgrade.",MRNA
112,2023-01-20,"Headline: Sinopharm unit cleared to study first mRNA COVID shot in China, source:Seeking Alpha, summary: No summary, Headline: 2 Nasdaq 100 Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague, source:Yahoo, summary: The growth-driven Nasdaq 100 is home to two incredible deals in the new year, as well as one previous highflier that can be actively avoided., Headline: Here's the Worst Mistake Novavax Investors Can Make in 2023, source:Yahoo, summary: Novavax (NASDAQ: NVAX) has taken investors on a wild ride since the start of the pandemic.  The shares skyrocketed more than 2,000% back in 2020 as investors bet on Novavax bringing a vaccine to market.  Before deciding what to do, let's check out the worst mistake Novavax investors can make in 2023., Headline: Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds, source:Yahoo, summary: FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints, Headline: 11 Best Performing S&P 500 Stocks in the Last 10 Years, source:Yahoo, summary: In this article, we discuss 11 best performing S&P 500 stocks in the last 10 years. If you want to see more stocks in this selection, check out 5 Best Performing S&P 500 Stocks in the Last 10 Years. While it is important for investors to have a long-term perspective and not get caught up […], Headline: Moderna Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rallied 1.89% to $193.98 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Stock Moves 1.89%: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $193.98, marking a +1.89% move from the previous day.",MRNA
113,2023-01-21,"Headline: COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock, source:Yahoo, summary: Moderna (NASDAQ: MRNA) is on a roll.  Moderna expects to report sales of $18.4 billion for its COVID-19 vaccine in 2022.  The reality is that COVID-19 will almost certainly wane in importance for Moderna.",MRNA
114,2023-01-23,"Headline: Healthcare Outlook 2023, source:SeekingAlpha, summary: Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. Read more here., Headline: Healthcare Sector Is Lagging As We Enter 2022 Earnings Season, source:TalkMarkets, summary: No summary, Headline: 12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […], Headline: Moderna Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rose 1.53% to $196.94 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite..., Headline: Moderna is hiring 2,000 employees this year. Here's where they'll be., source:Yahoo, summary: Moderna Inc. is planning to add 2,000 employees to its 4,000-person workforce this year — and most of them will be in Massachusetts., Headline: An Annual Covid Booster Could Be Coming. What It Would Mean for Pfizer and Moderna., source:Yahoo, summary: The agency appears to be aiming to make Covid-19 vaccination efforts resemble established influenza vaccination efforts., Headline: CDC chief to add new offices, leadership in organizational revamp ��� Bloomberg, source:Seeking Alpha, summary: No summary, Headline: CDC chief to add new offices, leadership in organizational revamp, source:Seeking Alpha, summary: No summary, Headline: Moderna Moves Up In Market Cap Rank, Passing Target, source:The Online Investor, summary: No summary",MRNA
115,2023-01-24,"Headline: Pharma Industry Could Benefit from Rise in Medicine Spending, source:TipRanks, summary: No summary, Headline: Job Cuts Today, What Tomorrow? Big Tech Faces Some Big Tests., source:MarketWatch, summary: Elon Musk says his ‘funding secured’ take-private tweet wasn’t a joke, a new bull market is called amid Bitcoin’s price recovery, the FDA plans to simplify..., Headline: Moderna (MRNA) Gets a Hold from Morgan Stanley, source:TipRanks, summary: No summary, Headline: Moderna Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. dropped 0.09% to $196.76 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Column: Moderna and Pfizer are jacking up the price of COVID vaccines. The government should stop them, source:Yahoo, summary: Moderna and Pfizer have announced plans to quadruple the price of their COVID vaccines, putting them out of reach for millions. The U.S. should step in., Headline: Thursday Predictions: 3 Hot Stocks for Tomorrow, source:InvestorPlace, summary: No summary",MRNA
116,2023-01-25,"Headline: Baillie Gifford Slashes Meta, Boosts Nvidia, source:GuruFocus, summary: No summary, Headline: Top 5 4th Quarter Trades of ARS Investment Partners, LLC, source:GuruFocus, summary: No summary, Headline: Sens. Warren, Welch urge Moderna to reconsider COVID-19 shot price increase, source:Seeking Alpha, summary: No summary, Headline: Moderna price target raised to $150 from $130 at Cowen, source:Thefly.com, summary: No summary, Headline: Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary, Headline: Could This RSV News Make Moderna a Hot Buy Again?, source:Yahoo, summary: Moderna's (NASDAQ: MRNA) business isn't in as horrible shape as bearish investors may think.  The company, which has made a name for itself for its COVID-19 vaccine, has products in its pipeline that could generate significant revenue in the future beyond just COVID.  One of the most promising is a vaccine candidate for respiratory syncytial virus (RSV)., Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.88% to $193.07 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Updated COVID vaccines prevented illness from latest variants -CDC, source:Reuters, summary: The updated COVID-19 boosters from Pfizer Inc/BioNTech SE and Moderna helped prevent symptomatic infections against the new XBB-related subvariants, offering new evidence of how the vaccines perform against these fast-spreading strains, U.S. officials said on Wednesday., Headline: Moderna Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: No summary",MRNA
117,2023-01-26,"Headline: Brookline Capital Markets Remains a Buy on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: March 10th Options Now Available For Moderna (MRNA), source:Stock Options Channel, summary: No summary, Headline: Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe, source:Yahoo, summary: Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share., Headline: 2 Top Biotech Stocks to Buy for the Long Haul, source:Yahoo, summary: Equity markets are entirely unpredictable in the short run.  The biotech industry is a great place to look for stocks that can survive down markets and be successful over long periods since the drugs these companies develop are so critical to their customers' lives.  Let's look at two biotech stocks to buy today and hold on to for a while: Amgen (NASDAQ: AMGN) and Moderna (NASDAQ: MRNA)., Headline: 15 Most Undervalued Quality Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this article, we discuss 15 most undervalued quality stocks to buy according to hedge funds. If you want to see more stocks in this selection, 5 Most Undervalued Quality Stocks To Buy According To Hedge Funds. Quality stocks usually have little debt, steady earnings, regular growth in assets, and effective leadership. Investors can identify […], Headline: FDA's advisers back plan to simplify COVID-19 vaccinations, source:Associated Press, The, summary: No summary, Headline: Moderna (MRNA) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $193.24, moving +0.09% from the previous trading session., Headline: The 3 Best Biotech Stocks Under $1 to Buy for January, source:Yahoo, summary: While biotech may be the next big thing, making money through it isn’t easy. Indeed, investing in biotech stocks is often more of an art than a science. And considering these companies are solely focused on scientific endeavors, that’s not what many investors want to hear. For every Moderna (NASDAQ:MRNA), which shot to wealth and fame on its MRNA-based COVID vaccine, there’s a CureVac (NASDAQ:CVAC), another MRNA play, down 45% in the last year. Even the biggest biotech stocks, like Eli Lilly (NY, Headline: FDA committee endorses making all Covid-19 shots bivalent, source:Yahoo, summary: Following a daylong meeting of an expert advisory committee to the U.S. Food and Drug Administration, all Covid-19 vaccines and boosters will soon be made to address the most current strains., Headline: Notable Friday Option Activity: MRNA, AMD, EBAY, source:Stock Options Channel, summary: No summary, Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: No summary",MRNA
118,2023-01-27,"Headline: FDA advisors recommend replacing original COVID-19 vaccine, CNBC reports, source:Thefly.com, summary: No summary, Headline: FDA panel backs plan for annual COVID-19 booster, as new omicron subvariant continues to dominate in new cases, source:MarketWatch, summary: An FDA panel endorsed the agency's plan for a once-a-year COVID-19 booster. And CDC data shows that XBB.1.5 continues to lead other variants in the U.S., Headline: FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy, source:Yahoo, summary: An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses., Headline: Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip, source:Yahoo, summary: Novavax plans to update its Covid vaccine for new variants, and NVAX stock outperformed its vaccine stock rivals., Headline: Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised), source:Yahoo, summary: Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.",MRNA
119,2023-01-28,"Headline: Novavax: The Vaccine Battle Continues With Gavi, source:SeekingAlpha, summary: NVAX may remain volatile in the short term due to the $700M Advance Purchase Agreement dispute with GAVI. Click here to read my most recent analysis of NVAX.",MRNA
120,2023-01-29,"Headline: Tracking Baillie Gifford`s 13F Portfolio - Q4 2022 Update, source:Seeking Alpha, summary: No summary, Headline: 2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague, source:Yahoo, summary: Teladoc Health (NYSE: TDOC) sank 74% last year -- and for one particular reason.  The telemedicine giant reported two billion-dollar noncash goodwill impairment charges.  Both were linked to the acquisition of chronic-care specialist Livongo., Headline: Tracking Baillie Gifford's 13F Portfolio - Q4 2022 Update, source:SeekingAlpha, summary: Baillie Giffordâs 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. Click here for a detailed analysis., Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: No summary",MRNA
121,2023-01-30,"Headline: Moderna granted Breakthrough Therapy Designation for mRNA-1345, source:Thefly.com, summary: No summary, Headline: Moderna wins FDA`s breakthrough status for RSV vaccine, source:Seeking Alpha, summary: No summary, Headline: Moderna Gets FDA Breakthrough Designation for RSV Vaccine Candidate >MRNA, source:MarketWatch, summary: By Colin Kellaher Moderna Inc. on Monday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to its mRNA-1345 investigational..., Headline: Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and TELA Bio (TELA), source:TipRanks, summary: No summary, Headline: Moderna put volume heavy and directionally bearish, source:Thefly.com, summary: No summary, Headline: The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax, source:Yahoo, summary: Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog., Headline: Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced mRNA-1345, an investigational mRNA vaccine candidate for respiratory syncytial virus (RSV), has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years or older., Headline: Moderna’s RSV vaccine gets Breakthrough Therapy status, source:Yahoo, summary: MARKET PULSE Moderna Inc. (MRNA) said Monday that the Food and Drug Administration granted the company’s experimental respiratory syncytial virus vaccine a Breakthrough Therapy Designation. Moderna said it plans to apply for approval in the first half of this year., Headline: Fact Check-Vaccine work before SARS-CoV-2 had a name does not prove pandemic was planned, source:Reuters, summary: U.S. biotech company Moderna Inc announced its collaboration with the National Institutes of Health (NIH) to develop an mRNA vaccine against the novel coronavirus in January 2020, before the virus was officially named SARS-CoV-2 in February 2020. Users online are circulating..., Headline: Moderna Scores A Win In RSV — But Its Shares Don't Reflect That, source:Yahoo, summary: The Food and Drug Administration granted Moderna's experimental RSV vaccine an expedited review, but Moderna stock dipped Monday.",MRNA
122,2023-01-31,"Headline: Is Moderna (MRNA) a High Growth Stock?, source:Yahoo, summary: Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P […], Headline: Top 5 4th Quarter Trades of REIK & CO., LLC, source:GuruFocus, summary: No summary, Headline: Moderna`s stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023, source:MarketWatch, summary: No summary, Headline: Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag, source:Yahoo, summary: Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults., Headline: The end of the Covid health emergency won't slow FDA clearance of shots and treatments, source:CNBC, summary: The FDA has used separate emergency powers to authorize the Pfizer, Moderna, Johnson & Johnson and Novavax vaccines., Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 2.66% to $176.06 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Moderna’s stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023, source:Yahoo, summary: Moderna Inc.’s  (MRNA)  shares were down 2.8% in trading on Tuesday.  Pfizer Inc.  (PFE)  which makes a competing COVID-19 vaccine to Moderna’s Spikevax, on Tuesday put out guidance for 2023, saying it expects a total of $13.5 billion in sales of its COVID shot for the year.  Moderna’s COVID vaccine is expected to bring in $18.1 billion in sales for 2022 and $7.3 billion in 2023, according to the FactSet consensus., Headline: This Discount Growth Stock Is a Once-in-a-Decade Buying Opportunity Right Now, source:Yahoo, summary: The bad news is Moderna's vaccine may not be able to replicate these levels in a post-pandemic environment.  The good news is the vaccine still could lead to significant blockbuster revenue -- and that will support the development of Moderna's late-stage pipeline.  As a result, Moderna could launch other potential blockbusters over the next few years., Headline: TOP NEWS: GSK profit grows as aims for first-ever approved RSV vaccine, source:Alliance News, summary: No summary",MRNA
123,2023-02-01,"Headline: Novavax, JNJ dispute pre-payments for cancelled COVID shots sought for world`s poor, source:Seeking Alpha, summary: No summary, Headline: Novavax, JNJ dispute pre-payments for canceled COVID shots sought for world`s poor, source:Seeking Alpha, summary: No summary, Headline: 1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell, source:Yahoo, summary: Novavax (NASDAQ: NVAX) has offered investors just such a ride over the past few years.  Initial gains came as investors bet on Novavax's chances of bringing a coronavirus vaccine to market; declines occurred after the vaccine entered the market later than rival products did.  Now, as we start a new year, you might be wondering what to do about Novavax., Headline: Novavax refuses to refund $700M for COVID shots never delivered, NY Times says, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 1.00% to $174.30 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023, source:Yahoo, summary: Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange’s bias toward technology players (including biotech), wagering in this space carries the advantage of relevance. Even if circumstances look shoddy right now, at some point, these enterprises have a shot at upside eventually. Now, a word of caution is in order following the utterances of the last few words above. With the most underv, Headline: Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $174.30, marking a -1% move from the previous day., Headline: U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates, source:Seeking Alpha, summary: No summary",MRNA
124,2023-02-02,"Headline: MRNA March 24th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m., Headline: Moderna Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rose 1.18% to $176.35 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Pharma earnings: COVID ‘is highly uncertain for this year,’ analyst says, source:Yahoo, summary: Wells Fargo Managing Director Mohit Bansal joins Yahoo Finance Live to discuss pharmaceutical earnings amid COVID uncertainty, the impact of diabetic weight loss drugs on the market, and the outlook for drugmakers., Headline: The 7 Most Undervalued Biotech Stocks to Buy in February 2023, source:Yahoo, summary: You don’t have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science. At the same time, the established players tend to be pricey. By picking up underappreciated names, it’s possible to secure significant upside down the line. However, anytime a discussion about the most undervalued biotech stocks to buy materializes, a question comes up: how doe, Headline: COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst, source:Yahoo, summary: Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies., Headline: Notable Friday Option Activity: MRNA, SPLK, SOND, source:Stock Options Channel, summary: No summary",MRNA
125,2023-02-03,"Headline: Top 5 4th Quarter Trades of Lipe & Dalton, source:GuruFocus, summary: No summary, Headline: Personalis, Moderna announce new agreement to leverage NeXT Platform, source:Thefly.com, summary: No summary, Headline: Regeneron’s Earnings Beat Forecasts, With No Sales of Covid-19 Treatment, source:MarketWatch, summary: The pharmaceuticals company's total revenue dropped by 31% to $3.41 billion but beat the FactSet consensus of $3.13 billion., Headline: Personalis Stock Jumps on Cancer-Vaccine Agreement with Moderna, source:MarketWatch, summary: By Sabela Ojea Personalis Inc. on Friday jumped after it said it signed a new agreement with Moderna Inc. to develop the biotechnology company's cancer..., Headline: Is Moderna Stock a Buy Now?, source:Yahoo, summary: The past three years have been fascinating for Moderna (NASDAQ: MRNA) and its shareholders.  Moderna's shares are up by an impressive 731% since early 2020, although its coronavirus-related sales will start falling this year.  At this point, it's fair to ask if Moderna can march on and continue delivering market-beating returns, or if the company won't be worth an investment in a post-pandemic world., Headline: Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials, source:Yahoo, summary: FREMONT, Calif., February 03, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, kn, Headline: Pfizer: The Covid Reset Makes Sense, source:SeekingAlpha, summary: Assuming an upward rerating, PFE could hit our price target ofÂ $55.79, suggesting 27.40% upside potential from current levels. Click here to read our analysis., Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.76% to $173.25 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: UPDATE 1-China's CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots, source:Yahoo, summary: CanSino Biologics Chief Executive Yu Xuefeng said on Friday he was  confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech.  As the COVID-19 pandemic evolves in China after the country abandoned its zero-COVID policy in December, domestic companies like CanSino are racing to develop mRNA COVID vaccines.  The country - which experienced a wave of infections across its 1.4 billion population after the sudden relaxation of COVID restrictions - has so far declined to use mRNA vaccines from abroad, and has yet to approve a domestic one that uses the technology., Headline: China's CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots, source:Reuters, summary: CanSino Biologics Chief Executive Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech., Headline: Why Personalis Shares Are Trading Higher Today, source:Yahoo, summary: Personalis Inc (NASDAQ: PSNL) and Moderna Inc (NASDAQ: MRNA) have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming clinical studies of mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck & Co Inc (NYSE: MRK). The platform, also utilized in the vaccine candidate's Phase 2b study, will be used to sequence genomic information from a patient's tumor sample to identify the unique genetic mutations that are mos, Headline: 3 No-Brainer Growth Stocks to Buy in 2023, source:Yahoo, summary: In last-year's difficult market, growth stocks were among the first to suffer.  Why should we be confident about growth stocks?  Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years., Headline: Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy., source:MarketWatch, summary: With its packed pipeline, growing R&D spending, and potential deals and share buybacks, there's more to the drugmaker than the market realizes.",MRNA
126,2023-02-04,"Headline: Danaher said to be interested in acquiring contract manufacturer Catalent, source:Seeking Alpha, summary: No summary, Headline: U.S. plans to stop buying Covid shots for the public this fall. Here's what that means for you, source:CNBC, summary: Under the Affordable Care Act, most Americans would still get their Covid shots for free once the vaccine program goes commercial., Headline: Cancer vaccines are already a reality—but your doctor might not tell you about them unless you ask, source:Yahoo, summary: “Patients need to advocate for themselves."", Headline: The Clock Is Ticking For Seres Therapeutics: I`m Not Afraid, source:Seeking Alpha, summary: No summary, Headline: The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid, source:SeekingAlpha, summary: April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. See why MCRB stock is a Buy.",MRNA
127,2023-02-05,"Headline: Personalis extends winning streak as Needham upgrades, source:Seeking Alpha, summary: No summary",MRNA
128,2023-02-06,"Headline: Catalent Stock Surges on Report of Danaher Interest. M&A May Be Back., source:MarketWatch, summary: After two major healthcare and life sciences deals at the end of 2022, M&A in the industry could be about to rebound., Headline: Personalis upgraded to Buy at Needham on cost reductions, biopharma potential, source:Thefly.com, summary: No summary, Headline: Catalent stock rockets 21% premarket on report of takeover interest from Danaher, source:MarketWatch, summary: No summary, Headline: FOCUS-Drug companies face COVID cliff in 2023 as sales set to plummet, source:Yahoo, summary: Pharmaceutical companies that made billions from the pandemic  over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend  their windfalls wisely.  Western drugmakers including Pfizer Inc, BioNTech SE , Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022.  Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most., Headline: Drug companies face COVID cliff in 2023 as sales set to plummet, source:Yahoo, summary: Pharmaceutical companies that made billions from the pandemic  over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend  their windfalls wisely.  Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022.  Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most., Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 1.72% to $170.27 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite..., Headline: Moderna Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: No summary",MRNA
129,2023-02-07,"Headline: Catalent Reports Mixed Q2 Earnings, Expands Manufacturing Contract With Moderna, source:Yahoo, summary: Catalent Inc (NYSE: CTLT) reported Q2 FY23 sales of $1.15 billion, which decreased 6% Y/Y as reported, or 2% in constant currency, slightly beating the consensus of $1.12 billion. Adjusted EPS of $0.67, compared to $0.90 last year, missed the consensus of $0.69. Adjusted EBITDA was $283 million, or a margin of 25%, compared to $310 million a year ago. Biologics segment sales decreased by 7% to $580 million on a constant currency basis. Pharma and Consumer Health segment sales increased by 3% to, Headline: Moderna: Likely To See Continued Downward Pressure (Technical Analysis), source:SeekingAlpha, summary: Moderna specializes in developing innovative medicines and therapies using messenger RNA technology. Click here to read my analysis of MRNA stock., Headline: Moderna (MRNA) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $171.06, moving +0.46% from the previous trading session., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",MRNA
130,2023-02-08,"Headline: Catalent price target raised to $82 from $75 at Baird, source:Thefly.com, summary: No summary, Headline: Model N price target raised to $52 from $45 at Truist, source:Thefly.com, summary: No summary, Headline: Sana Biotechnology: Time And Cash Burn Are The Enemies, source:SeekingAlpha, summary: SANA was launched to pioneer a particular aspect of DNA-based therapies. This is new and revolutionary. Read why the therapy will likely to take time to mature., Headline: Pandemic Profits In Healthcare, source:SeekingAlpha, summary: Pfizer and Moderna profited by developing vaccines at a breakneck pace, but should investors add them to their portfolios in 2023? Check out more here.",MRNA
131,2023-02-09,"Headline: See Which Of The Latest 13F Filers Holds Moderna, source:Preferred Stock Channel, summary: No summary, Headline: Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary, Headline: The Covid emergency in the U.S. ends May 11. HHS officials say here's what to expect, source:CNBC, summary: HHS officials in a call with reporters laid out what the public can expect when the emergency ends. , Headline: Cramer's lightning round: EMCOR Group is my kind of stock, source:CNBC, summary: ""Mad Money"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",MRNA
132,2023-02-10,"Headline: Stocks with earnings at risk from UBS, source:Seeking Alpha, summary: No summary, Headline: UPDATE: Hunt disappointed UK loses new AstraZeneca factory to Ireland, source:Alliance News, summary: No summary, Headline: Medicare mulls rebates in 2025 for drug prices rising faster than inflation, source:Seeking Alpha, summary: No summary, Headline: Betting On Biotech, source:SeekingAlpha, summary: Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow., Headline: Is Novavax Stock a Buy With the New Normal for COVID?, source:Yahoo, summary: My view was that the company had a big opportunity with an alternative to the messenger RNA (mRNA) vaccines from Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  Novavax's shares skyrocketed.  Is Novavax stock a buy in the new circumstances?, Headline: 25 Biggest Massachusetts Companies and Stocks, source:Yahoo, summary: In this article, we will be taking a look at the 25 biggest Massachusetts companies and stocks. To skip our detailed analysis, you can go directly to see the 5 biggest Massachusetts companies and stocks. If all U.S. states were countries, Massachusetts would be 32nd largest economy in the world based on a 2021 GDP […], Headline: Moderna Stock Getting Closer To Key Technical Benchmark, source:Yahoo, summary: A Relative Strength Rating upgrade for Moderna shows improving technical performance. Will it continue?, Headline: Fact Check-Moderna CEO did not say company made 100,000 COVID-19 vaccine doses before the pandemic started, source:Reuters, summary: At Davos 2023, Moderna CEO Stephane Bancel spoke about how quickly the company was able to scale up vaccine production at the start of the COVID-19 pandemic, not that Moderna had made 100,000 COVID vaccine doses before the pandemic began, as some are claiming online., Headline: Why Catalent Stock Was on Fire This Week, source:Yahoo, summary: Healthcare stocks were quite a mixed bag over the past few trading sessions, but one standout rising above the pack was contract drug manufacturer Catalent (NYSE: CTLT).  For its second quarter of fiscal 2023, Catalent's revenue was $1.15 billion, representing a 6% drop from the same period of the previous fiscal year.  The company's non-GAAP (adjusted) net income also fell, sliding to $122 million ($0.67 per share) from the year-ago profit of $163 million.",MRNA
133,2023-02-12,"Headline: Top 5 4th Quarter Trades of Theleme Partners LLP, source:GuruFocus, summary: No summary, Headline: Top 5 4th Quarter Trades of Gruss & Co., LLC, source:GuruFocus, summary: No summary, Headline: 6 Ways To Beat Inflation With `AIR` Factors - 2023 YTD Update, source:Seeking Alpha, summary: No summary",MRNA
134,2023-02-13,"Headline: 6 Ways To Beat Inflation With 'AIR' Factors - 2023 YTD Update, source:SeekingAlpha, summary: Aswath Damodaran is an investing and finance authority on markets & valuation, among many other things., Headline: Moderna Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 1.30% to $171.48 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Stephen Mandel`s Lone Pine exits Meta, PayPal in Q4, takes stakes in AMD, Salesforce, source:Seeking Alpha, summary: No summary",MRNA
135,2023-02-14,"Headline: Lone Pine exited PayPal, initiated AMD position during Q4, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 2.41% to $175.62 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Top 5 4th Quarter Trades of STARR INTERNATIONAL CO INC, source:GuruFocus, summary: No summary, Headline: Moderna CEO to face Senate hearing over pricing for COVID shot, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: No summary, Headline: Autolus: Investment Case Further Entrenched With Latest Interim FELIX Data, source:SeekingAlpha, summary: Autolus Therapeutics is a great speculative biotech play to look into. Read how positive interim results from phase 1b/2 FELIX study could make AUTL a Buy.",MRNA
136,2023-02-15,"Headline: Moderna plans to keep COVID vaccine free for consumers, ABC News says, source:Thefly.com, summary: No summary, Headline: Moderna to offer free COVID shots even after pandemic emergency, source:Seeking Alpha, summary: No summary, Headline: Medicare mulls limiting per month costs for generic drugs at $2, source:Seeking Alpha, summary: No summary, Headline: Sanders calls Moderna chief to testify on vaccine price hike plans, WP says, source:Thefly.com, summary: No summary, Headline: Federal government, not Moderna, should face COVID vaccine patent lawsuit, DoJ says, source:Seeking Alpha, summary: No summary, Headline: Moderna CEO Stéphane Bancel will testify before Senate next month on Covid vaccine price hike, source:CNBC, summary: Sen. Bernie Sanders, in a letter to the CEO, slammed a proposed price hike as ""outrageous"" given that the vaccine was developed using taxpayer money., Headline: Moderna promises to keep COVID vaccine free, source:MarketWatch, summary: Moderna Inc. said Wednesday it will keep its COVID-19 vaccines available and free for all people in the U.S. after the public-health emergency ends. The news..., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.95% higher to $177.28 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit, source:Reuters, summary: The U.S. government should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc, the Department of Justice told a Delaware federal court on Tuesday., Headline: Moderna promises free COVID-19 vaccines after U.S. public health emergency ends, source:United Press International, summary: No summary, Headline: Moderna CEO to testify in senate on proposed vaccine price hike, source:Reuters, summary: Senator Bernie Sanders said on Wednesday Moderna Inc's chief executive officer Stéphane Bancel will testify next month in front of the senate on the drugmaker's plans to raise the price of its coronavirus vaccine., Headline: GSK hails positive phase III trial results for RSV vaccine candidate, source:Alliance News, summary: No summary",MRNA
137,2023-02-16,"Headline: Coronavirus tally: Moderna promises to keep COVID vaccine available and free for all Americans, source:MarketWatch, summary: Moderna Inc. undefined will keep its COVID-19 vaccines available and free for all people in the U.S. after the public-health emergency ends. The news came as..., Headline: Brookline Capital Markets Sticks to Its Buy Rating for Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna’s COVID vaccine will remain free for all Americans in coup for Bernie Sanders, source:MarketWatch, summary: Moderna Inc. will keep its COVID-19 vaccine available and free of charge for all people in the U.S. even after the public-health emergency ends., Headline: Pfizer/ BioNTech, Moderna set for 2024 trial in COVID vaccine patent dispute, source:Seeking Alpha, summary: No summary, Headline: 7 Hot Healthcare Stocks With the Potential to Outperform, source:InvestorPlace, summary: No summary, Headline: Moderna, Pfizer, BioNTech Covid jab patent dispute heads to 2024 trial, source:Alliance News, summary: No summary, Headline: IDNA: Healthcare Dashboard For February, source:SeekingAlpha, summary: Pharmaceuticals and biotechs still look attractive. We focus on iShares Genomics Immunology and Healthcare ETF. IDNA is an ETF in genomics and immunology. Click here for more., Headline: Pfizer/BioNTech, Moderna gear up for 2024 London trial over COVID vaccine patents, source:Reuters, summary: Pfizer Inc and its German partner BioNTech SE are gearing up for a 2024 trial with Moderna Inc at London's High Court in competing patent lawsuits over their rival COVID-19 vaccines., Headline: Moderna stock falls 5% after flu vaccine study results, source:MarketWatch, summary: Moderna Inc. shares dove more than 5% in after-hours trading Thursday, after the company announced that a study into a flu vaccine candidate failed to reach..., Headline: Moderna Shares Fall 5.9% on Mixed Results From Flu Shot Study, source:MarketWatch, summary: By Denny Jacob Moderna Inc. shares edged down 5.9% to $162 in after-hours trading Thursday following mixed results of an experimental Moderna vaccine against..., Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 2.80% to $172.31 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Stocks making the biggest moves after hours: DoorDash, Applied Materials, DraftKings and more, source:CNBC, summary: These are the stocks posting the largest moves in extended trading, Headline: Stocks to Watch: iBio, DoorDash, DraftKings, Moderna, source:MarketWatch, summary: By Sabela Ojea iBio Inc. on Thursday disclosed that the MUC16 protein is the target of its latest immune-oncology program. Shares surged 129% in after-hours..., Headline: Moderna flu vaccine delivers mixed results in trial, source:Yahoo, summary: Moderna Inc on Thursday said its experimental messenger RNA-based influenza vaccine generated a strong immune response against A strains of the flu but was inferior to an approved vaccine versus less prevalent influenza B.  Moderna, whose only marketed product is its COVID-19 shot, has high hopes for its flu vaccine and aims to grab large portions of the respiratory syncytial virus (RSV) and seasonal flu markets with new mRNA vaccines., Headline: Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced interim results from its pivotal Phase 3 safety and immunogenicity trial of (P301), an mRNA-based seasonal influenza (flu) vaccine candidate, in adults. The Phase 3 randomized trial was designed to evaluate the safety and immunogenicity of in adults 18 years and older in the Southern Hemisphere., Headline: UPDATE 1-Moderna flu vaccine delivers mixed results in trial, shares fall, source:Yahoo, summary: Moderna Inc on Thursday said its closely-watched experimental messenger RNA-based influenza vaccine generated a strong immune response against A strains of the flu but failed to show it was at least as effective as an approved vaccine versus less prevalent influenza B.  Moderna, whose only marketed product is its COVID-19 shot, has high hopes for its flu vaccine and aims to grab large portions of the respiratory syncytial virus (RSV) and seasonal flu markets with new mRNA vaccines.  The company said its vaccine, called mRNA-1010, generated a stronger immune response for the A/H3N2 and A/H1N1 strains than the marketed vaccine it was tested against in a trial of 6,102 adults aged 18 and over across Argentina, Australia, Colombia, Panama and the Philippines during flu season there., Headline: Moderna flu vaccine delivers mixed results in trial, shares fall, source:Reuters, summary: Moderna Inc on Thursday said its closely watched experimental messenger RNA-based influenza vaccine generated a strong immune response against A strains of the flu but failed to show it was at least as effective as an approved vaccine versus less prevalent influenza B., Headline: Earnings week ahead: Walmart, Nvidia, Home Depot, Alibaba and more, source:Seeking Alpha, summary: No summary, Headline: Moderna stock falls on mixed results of flu vaccine mRNA-1010 in phase 3 trial, source:Seeking Alpha, summary: No summary",MRNA
138,2023-02-17,"Headline: Goldman Sachs Reaffirms Their Buy Rating on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Jefferies says Moderna flu vaccine data doesn`t change improving pipeline thesis, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Moderna (MRNA) and Bio-Rad Laboratories (BIO), source:TipRanks, summary: No summary, Headline: Moderna, NatWest, Cognex among premarket losers` pack, source:Seeking Alpha, summary: No summary, Headline: 5 stocks to watch on Friday: Deere, DoorDash and more, source:Seeking Alpha, summary: No summary, Headline: Moderna Tanks on Phase 3 Data in Seasonal Influenza, source:TipRanks, summary: No summary, Headline: DoorDash, DraftKings, Deere and AutoNation rise premarket; Moderna falls, source:Yahoo, summary: By Peter Nurse, Headline: 10 Sectors Likely To Generate Good Returns In The Next Decade, source:Seeking Alpha, summary: No summary, Headline: Why Is Moderna (MRNA) Stock Down 5% Today?, source:InvestorPlace, summary: No summary, Headline: Is the Stock Market Open on Presidents` Day 2023?, source:InvestorPlace, summary: No summary, Headline: Moderna (MRNA) Receives a Hold from SVB Securities, source:TipRanks, summary: No summary, Headline: Video: Nasdaq 100 Movers: MRNA, AMGN, source:Market News Video, summary: No summary, Headline: Moderna`s stock hit as flu-vaccine trial fails on one target. Meanwhile, China declares victory over COVID., source:MarketWatch, summary: No summary, Headline: Health Canada Authorizes Moderna`s Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years), source:Accesswire, summary: No summary, Headline: Moderna says non-inferiority not met for either endpoint in Phase 3 trial, source:Thefly.com, summary: No summary, Headline: Health Canada authorizes Moderna`s mRNA-1273.214 in children, adolescents, source:Thefly.com, summary: No summary, Headline: Moderna says non-inferiority endpoint not met for B strains in flu vaccine study, source:Thefly.com, summary: No summary, Headline: BUZZ Investing: 2022`s Hard Hit Stocks Continue To Rebound In 2023, source:Seeking Alpha, summary: No summary, Headline: Moderna Omicron booster cleared in Canada for children and adolescents, source:Seeking Alpha, summary: No summary, Headline: Stocks Extend Slide, Moderna, DraftKings, Deere, Applied Materials In Focus - Five Things To Know, source:Yahoo, summary: Stock futures extend slide as Treasury yields leap; Moderna slumps after mixed data from flu vaccine trial; DraftKings jumps on narrower Q4 loss, solid revenue outlook; Deere earnings on deck with global equipment demand in focus and Applied Materials sees AI chip demand support firmer Q2 sales., Headline: Moderna: Health Canada Authorizes Omicron-Targeting Vaccine in 6-to-17-Year-Olds, source:MarketWatch, summary: By Denny Jacob Moderna Inc. on Friday said Health Canada authorized the use of its Omicron-targeting bivalent Covid-19 booster vaccine in children and..., Headline: Coronavirus tally: Moderna flu vaccine trial falls short on one goal, sending stock down, source:Yahoo, summary: Moderna Inc. stock was down 6.6% premarket Friday, after the COVID vaccine maker said a trial of a flu vaccine candidate failed to meet one of its goals. ""While we did not achieve non-inferiority for the Influenza B strains which are more frequent in younger populations, we have already updated the vaccine that we believe could improve immune responses against Influenza B and will seek to quickly confirm those improvements in an upcoming clinical study thanks to the agility of our mRNA platform,, Headline: Moderna Stock: Looking For The Future In Q4 Earnings, source:Seeking Alpha, summary: No summary, Headline: Moderna Stock Falls as Study of Flu Vaccine Has Mixed Results, source:Yahoo, summary: The shot got a strong immune response, but wasn't shown to be more effective than other vaccines., Headline: Stocks making the biggest moves midday: Deere, Airbnb, AutoNation, Moderna and more, source:CNBC, summary: Deere shares popped on strong earnings. , Headline: Midday movers: AMC Networks, AutoNation, DraftKings and more, source:Yahoo, summary: By Liz Moyer, Headline: IN BRIEF: Moderna gets expanded Canada backing for booster jab, source:Alliance News, summary: No summary, Headline: Three-Stock Lunch: DE, AN and MRNA, source:CNBC, summary: Diamond Hill Capital Management's Heather Brilliant joins CNBC's reporter panel on 'Power Lunch' to discuss Deere, AutoNation, and Moderna, three stocks making moves after earnings results., Headline: Moderna stock declines on mixed flu vaccine trial results, source:Yahoo, summary: Yahoo Finance's Julie Hyman, Brian Sozzi, and Brad Smith discuss why Moderna stock is down on Friday., Headline: Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents, source:Yahoo, summary: A High Court battle between Pfizer Inc (NYSE: PFE), its partner BioNTech SE (NASDAQ: BNTX) locked in a dispute with the rival COVID-19 vaccine maker Moderna Inc (NASDAQ: MRNA) over patents for vaccine technology is set to be heard in London next year. In August, Moderna filed patent infringement lawsuits against Pfizer/BioNTech in the U.S. and Germany. Moderna said that Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology, which i, Headline: Moderna’s stock hit as flu-vaccine trial fails on one target. Meanwhile, China declares victory over COVID., source:Yahoo, summary: Moderna Inc.'s stock slid 5% Friday, after the COVID vaccine maker said a trial of a flu-vaccine candidate failed to meet one of its goals., Headline: Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years), source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron) in children and adolescents 6 to 17 years of age., Headline: NEW YORK MARKET CLOSE: Stocks end mixed as rate worries resurface, source:Alliance News, summary: No summary, Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 3.31% to $166.60 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Investors Fear Stock Markets Will Give Up 2023 Gains, source:Yahoo, summary: The stock market continued to move lower on Friday, extending losses from Thursday as investors grew more concerned about the possibility of tighter monetary policy from the Federal Reserve.  Suddenly, market participants who had thought that the Fed might stop raising interest rates entirely now seem to believe that larger rate hikes could come in the short run, potentially bringing about a deeper recession later in 2023.  A couple of stocks showed the cross-currents running through the stock market on Friday., Headline: It's Time to Reevaluate Moderna's Charts, source:Yahoo, summary: Trading volume spiked up in December with the price action but now prices are back below the lows of December putting all those buyers at a loss.  The On-Balance-Volume (OBV) line shows a zigzag pattern following its December zenith.  The trading volume has been light and thus not really attracting institutional buyers., Headline: US STOCKS-Wall St drops on mounting worries about Fed staying hawkish, source:Yahoo, summary: U.S. stock indexes fell on Friday, weighed down by energy and megacap growth names, as investors worried that inflation and signs of strength in the U.S. economy could put the Federal Reserve on pace for more interest rate hikes.  Wall Street indexes turned volatile this week following a strong start to 2023 as economic data pointed to elevated inflation, a tight job market and resilience in consumer spending, giving the Fed more room for to raise borrowing costs.  Goldman Sachs and Bank of America forecast three more rate hikes this year and by a quarter of a percentage point each, up from their previous estimate of two rate rises., Headline: US STOCKS-Wall Street drops as investors fret about interest rates, source:Yahoo, summary: Wall Street dropped on Friday, weighed down by Microsoft and Nvidia as investors worried that inflation and a strong U.S. economy could put the Federal Reserve on pace for more interest rate hikes.  The main indexes were on track to lose ground for the week as economic data pointed to elevated inflation, a tight job market and resilience in consumer spending, giving the Fed more room for to raise borrowing costs., Headline: Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees, source:Yahoo, summary: Moderna stock toppled Friday on mixed results for its flu shot — a rival to experimental vaccines from BioNTech, CureVac and Sanofi., Headline: AMC Networks, DraftKings, AutoNation, Deere, and More of Today’s Stock Market Movers, source:Yahoo, summary: AMC Networks posts better-than-expected adjusted earnings, DraftKings raises guidance for fiscal 2023, and AutoNation and Deere report quarterly earnings that top analysts' estimates., Headline: US STOCKS-S&P 500 ends down as investors fret about interest rates, source:Yahoo, summary: The S&P 500 ended lower on Friday, weighed down by Microsoft and Nvidia as investors worried that inflation and a strong U.S. economy could put the Federal Reserve on pace for more interest rate hikes.  The see-saw session on Wall Street followed economic data this week that pointed to elevated inflation, a tight job market and resilience in consumer spending, giving the Fed more room for to raise borrowing costs., Headline: COVID vaccine sales to see decline through end of decade as pandemic eases, source:Seeking Alpha, summary: No summary",MRNA
139,2023-02-18,"Headline: 2 Resilient Growth Stocks to Buy and Hold Forever, source:Yahoo, summary: The kind of market volatility we have experienced in the past year can sometimes rattle investors, drawing their focus away from the long-term mindset that is important to earning excellent returns over time.  Biotech company Moderna (NASDAQ: MRNA) and fintech specialist PayPal (NASDAQ: PYPL) are two such stocks.  Are Moderna's growth days over?",MRNA
140,2023-02-19,"Headline: Walmart, Alibaba, Moderna, and More Stocks for Investors to Watch This Week, source:Yahoo, summary: Home Depot, Lucid, TJX, and others also report earnings. Investors will see Fed minutes and economic data on manufacturing, home sales, GDP, and income and spending.",MRNA
141,2023-02-20,"Headline: Moderna favored at Morgan Stanley on U.S. support for Arbutus patent case, source:Seeking Alpha, summary: No summary",MRNA
142,2023-02-21,"Headline: Analysts Offer Insights on Healthcare Companies: Mednax (MD) and Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Notable Tuesday Option Activity: MRNA, FSLR, JPM, source:Stock Options Channel, summary: No summary, Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 3.91% to $160.09 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Where Will Moderna Be in 5 Years?, source:Yahoo, summary: The past few years may seem like the best of times for Moderna (NASDAQ: MRNA).  The company launched its very first product: the coronavirus vaccine.  The vaccine also brought Moderna's messenger RNA technology to the forefront., Headline: Moderna Faces Challenges as Pandemic Eases, source:Yahoo, summary: Moderna, which spearheaded development of the first vaccines for COVID-19, faces a challenging outlook as vaccination rates increase and infection rates fall., Headline: S&P 500 Q4 2022 Earnings Review: Swing And A Miss, source:SeekingAlpha, summary: As we exit the peak period of earnings season, we review the S&P 500 2022 Q4 earnings season in more detail, providing both aggregate and company level insights., Headline: Moderna stock pops after receiving cancer-vaccine candidate gets FDA breakthrough designation, source:MarketWatch, summary: No summary, Headline: MRNA Makes Notable Cross Below Critical Moving Average, source:Market News Video, summary: No summary",MRNA
143,2023-02-22,"Headline: Moderna, Life Edit enter collaboration for in vivo gene editing therapies, source:Thefly.com, summary: No summary, Headline: Moderna, Life Edit team up to develop gene editing therapies for genetic diseases, source:Seeking Alpha, summary: No summary, Headline: Notable companies reporting before tomorrow`s open, source:Thefly.com, summary: No summary, Headline: Notable earnings before Thursday`s open, source:Seeking Alpha, summary: No summary, Headline: Moderna Q4 results, COVID vaccine`s future in focus with pandemic at `transition point`, source:Seeking Alpha, summary: No summary, Headline: Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies., Headline: Moderna to collaborate with Life Edit on gene editing therapies, source:Yahoo, summary: Moderna Inc.  (MRNA)  announced Wednesday a collaboration agreement with privately held Life Edit Therapeutics Inc. to discover and develop in vivo gene editing therapies.  Moderna’s stock edged up 0.4% in premarket trading.  The companies will combine the use of Moderna’s mRNA platform and Life Edit’s gene editing technologies to advance therapies against a select set of therapeutic targets., Headline: UPDATE 1-Moderna enters R&D collaboration for mRNA gene-editing therapies, source:Yahoo, summary: Moderna Inc will collaborate with privately-owned Life Edit Therapeutics Inc under an agreement to discover and develop mRNA gene-editing therapies, the companies said on Wednesday.  The tie-up will apply Life Edit's diverse collection of new technology for gene editing with the Moderna mRNA platform that was behind its COVID-19 vaccine.  Under the agreement, the companies will collaborate on research and preclinical studies funded by Moderna to develop curative therapies for some of the most challenging genetic diseases., Headline: Moderna enters R&D collaboration for mRNA gene-editing therapies, source:Reuters, summary: Moderna Inc will collaborate with privately-owned Life Edit Therapeutics Inc under an agreement to discover and develop mRNA gene-editing therapies, the companies said on Wednesday., Headline: Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More, source:Yahoo, summary: Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release., Headline: GDP reading, Booking Holdings, Moderna: 3 things to watch, source:Yahoo, summary: By Liz Moyer, Headline: Moderna, Merck receives FDA breakthrough status for personalized cancer vaccine, source:CNBC, summary: CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Merck and Moderna receiving FDA breakthrough status for a personalized cancer vaccine., Headline: NEW YORK MARKET CLOSE: US stocks slip as Fed signals more rate rises, source:Alliance News, summary: No summary, Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.20% to $158.17 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Stocks making the biggest moves after hours: Nvidia, Etsy, Lucid, Bumble, Moderna and more, source:CNBC, summary: These are the stocks posting the largest moves in extended hours trading. , Headline: Moderna co-founder talks COVID-19 vaccines, mRNA growth, agriculture portfolio, source:Yahoo, summary: Moderna Co-Founder and Flagship Pioneering CEO Noubar Afeyan joins Yahoo Finance Live to discuss building on mRNA technology, the future of vaccines, keeping COVID-19 vaccines free, and the outlook for Moderna’s Senate testimony., Headline: FOMC Meeting Minutes Live: January Fed Minutes Recap, source:PennyStocks, summary: January 2023 Fed Meeting Minutes. What do the latest FOMC meeting minutes mean for investors in the stock market today?, Headline: 12 Most Profitable Pharmaceutical Stocks Now, source:Yahoo, summary: In this piece, we will take a look at 12 most profitable pharmaceutical stocks now. For more stocks, head on over to 5 Most Profitable Pharmaceutical Stocks Now. The pharmaceutical industry was the center of attention in 2020 and 2021 after the deadly coronavirus pandemic ravaged the globe and disrupted the way of living. As […], Headline: Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy Designation by the U.S., Headline: Moderna stock pops after cancer-vaccine candidate gets FDA breakthrough designation, source:Yahoo, summary: MARKET PULSE Moderna Inc. (MRNA) and Merck Inc. (MRK) shares increased in after-hours trading Wednesday after the pharmaceutical companies announced that a cancer-vaccine candidate received the “breakthrough therapy” designation from the Food and Drug Administration., Headline: REFILE-Moderna's combination skin cancer therapy receives FDA's breakthrough tag, source:Reuters, summary: Moderna Inc said on Wednesday its experimental mRNA skin cancer vaccine in combination with Merck & Co Inc blockbuster drug Keytruda has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA). (Reporting by Khushi Mandowara in Bengaluru..., Headline: UPDATE 1-Moderna's combination skin cancer therapy receives FDA's breakthrough tag, source:Yahoo, summary: Moderna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.  Shares of Moderna rise 2.5% to $164 after the market.  The breakthrough tag is granted by the U.S. Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44% compared with Keytruda alone., Headline: Moderna's combination skin cancer therapy receives FDA's breakthrough tag, source:Reuters, summary: Moderna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients., Headline: Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough Designation, source:Yahoo, summary: Moderna stock jumped late Wednesday after the FDA granted its Merck-partnered cancer vaccine a breakthrough designation., Headline: Stocks climb, breaking a 4-day losing streak for Wall Street, source:Associated Press, The, summary: No summary, Headline: GLOBAL BRIEFING: Minutes show majority of Fed backed 25bp hike, source:Alliance News, summary: No summary, Headline: Hot Stocks: MRNA, TDOC, DPZ drop on earnings; NEO soars, source:Seeking Alpha, summary: No summary, Headline: Moderna price target lowered to $185 from $205 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street On Thursday, source:Thefly.com, summary: No summary",MRNA
144,2023-02-23,"Headline: Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940, source:Thefly.com, summary: No summary, Headline: Moderna reports Q4 GAAP EPS $3.61 vs. $11.29 y/y, source:Thefly.com, summary: No summary, Headline: Moderna sees FY23 CapEx at about $1.0B and R&D expense at about $4.5B, source:Thefly.com, summary: No summary, Headline: Moderna backs forecast of $5B in COVID-19 sales contracted for 2023 delivery, source:Thefly.com, summary: No summary, Headline: Moderna reports Q4 EPS $3.61, consensus $4.67, source:Thefly.com, summary: No summary, Headline: Moderna GAAP EPS of $3.61 misses by $1.14, revenue of $5.1B beats by $80M, source:Seeking Alpha, summary: No summary, Headline: Moderna says $2.8B remaining under latest buyback authorization, source:Thefly.com, summary: No summary, Headline: Moderna Falls as Q4 Results Disappoint, source:TipRanks, summary: No summary, Headline: Moderna (MRNA) Receives a Hold from Bank of America Securities, source:TipRanks, summary: No summary, Headline: Moderna stock dips as Q4 earnings fall; reaffirms COVID vaccine sales outlook of $5B, source:Seeking Alpha, summary: No summary, Headline: Moderna and Merck receive FDA breakthrough status for personalized cancer vaccine, source:CNBC, summary: CNBC's Meg Tirrell reports on news from Moderna and Merck., Headline: Moderna: Q4 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Investors could become cautious in near-term on Moderna, says BofA, source:Thefly.com, summary: No summary, Headline: Moderna’s stock slides as earnings fall short of estimates , source:MarketWatch, summary: With the boost Moderna got from COVID vaccines now fading, analysts are focused on the company's pipeline., Headline: What Makes Moderna (MRNA) an Attractive Investment?, source:Yahoo, summary: ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark, the Russell 3000 Index, in the fourth quarter. On an absolute basis, the strategy gained across nine of the 10 sectors in which it was invested. […], Headline: Alibaba's and Nvidia's stocks rise, Domino's and Dollar General shares fall, and other stocks on the move, source:MarketWatch, summary: Nvidia's stock rallied to pace the S&P 500's gainers, while Domino's Pizza shares led the losers after the companies reported quarterly results., Headline: Sliding vaccine sales, new costs, squeeze Moderna 4Q profit, source:Associated Press, The, summary: No summary, Headline: Stocks making the biggest moves premarket: Lucid, Nvidia, Dollar General, Sunrun and more, source:CNBC, summary: These are the stocks posting the largest moves in early morning trading. , Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Moderna misses on earnings as costs rise from surplus production capacity, lower Covid shot demand, source:CNBC, summary: Moderna reported quarterly earnings of $3.61 per share, a 68% decrease from the same period in 2021 when it booked $11.29 per share., Headline: Unusually active option classes on open February 23rd, source:Thefly.com, summary: No summary, Headline: Moderna falls as waning demand for COVID-19 vaccines hit sales, profit, source:Yahoo, summary: By Geoffrey Smith, Headline: The Petri Dish: Blindness drug approved; Moderna strikes gene-editing deal, source:Yahoo, summary: Apellis' new drug is the only FDA-approved treatment for geographic atrophy, a leading cause of blindness., Headline: Stocks Edge Higher, Nvidia, Moderna, eBay, Wells Fargo In Focus - Five Things To Know, source:Yahoo, summary: Stock futures higher on Fed minutes relief, tech boost; Nvidia shares surge as AI chip demand powers solid sales outlook; Moderna earnings on deck as drugmaker looks past vaccine growth; eBay shares slump as muted outlook offsets Q4 earnings beat and Wells Fargo cutting more mortgage jobs as market extends slump., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Moderna yearly revenue boosted by Covid sales, profit falls, source:Alliance News, summary: No summary, Headline: Top Trades of Steve Mandel`s Lone Pine in the 4th Quarter, source:GuruFocus, summary: No summary, Headline: Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2022., Headline: Stocks making the biggest moves midday: Domino's Pizza, Lucid, Nvidia, Nikola and more , source:CNBC, summary: Nvidia shares spiked, while Domino's Pizza dropped. , Headline: Moderna forecasts 2023 COVID vaccine sales below market expectations, source:Reuters, summary: Moderna Inc on Thursday reiterated its forecast of $5 billion in sales for its COVID-19 vaccines this year, which was below analysts' estimates as the company anticipated lower demand for the products in the fourth year of the pandemic., Headline: Moderna sticks to $5 billion sales view for COVID shot despite strong Q4, source:Yahoo, summary: Sales of the vaccine, Moderna's sole commercial product, were expected to fall sharply this year from $18.4 billion in 2022 as most people globally have received their shots and boosters, while governments and other agencies cut purchases.  The sales forecast implies a ""possible EPS net loss"" this year compared to the huge profit its COVID vaccines drove during its peak, Jefferies analyst Michael Yee said in a note.  However, there is a potential for positive cash flow this year if Moderna is able to get more advanced purchase agreements for its COVID shots, Yee said., Headline: Moderna`s stock slides as earnings fall short of estimates amid steep decline in COVID-vaccine sales, source:MarketWatch, summary: No summary, Headline: Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first half, source:Yahoo, summary: Moderna Inc.  (MRNA)  said Thursday it had net income of $1.465 billion, or $3.61 a share, in the fourth quarter, down from $4.868 billion, or $11.29 a share, in the year-earlier period.  The decline in sales was mostly due to a steep fall in sales of the company’s COVID vaccines.  Product sales fell 30% to $4.9 billion, due to lower sales volume and lower demand vs. the prior year., Headline: Moderna’s Earnings, Revenue Fall on Fewer Vaccine Sales, source:Yahoo, summary: Demand for its Covid-19 vaccine sank from year-earlier highs when the spread of the Omicron variant boosted sales., Headline: Sliding vaccine sales, new costs, shrink Moderna 4Q profit, source:Yahoo, summary: Moderna’s fourth-quarter profit tumbled 70% as COVID-19 vaccine sales fell and the drugmaker caught up on a royalty payment.  Heavy research and development costs also weighed on Moderna as the vaccine developer looks to strengthen an income statement currently dominated by its Spikevax coronavirus preventive shots.  Moderna said Thursday that its cost of sales jumped nearly a billion dollars to $1.9 billion in the final quarter of 2022., Headline: Moderna, Inc. (MRNA) Q4 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsLavina Talukdar - Head, Investor RelationsStephane Bancel - Chief..., Headline: Moderna, Inc. 2022 Q4 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Moderna, Inc., Headline: Moderna (MRNA) Lags Q4 Earnings and Revenue Estimates, source:Yahoo, summary: Moderna (MRNA) delivered earnings and revenue surprises of -22.53% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day, source:Yahoo, summary: Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article., Headline: Moderna Stock Drops on Disappointing Earnings, Falling Covid-19 Vaccine Sales, source:Yahoo, summary: Shares of the biotech company fell early Thursday, wiping out gains from positive news around its cancer vaccine candidate, as fourth-quarter earnings missed expectations., Headline: Moderna's Cancer Vaccine Wins An FDA Boon, But Shares Drop On Mixed Earnings, source:Yahoo, summary: Moderna stock reversed lower Thursday after the FDA granted its Merck-partnered cancer vaccine a breakthrough designation., Headline: Moderna FY22 Earnings: Key Takeaways - Shares Are Now A Contrarian Trade, source:SeekingAlpha, summary: Moderna faces a tough 2023 by most measures. Read why Moderna stock may be a contrarian bet as management can still stun the market with its technology and pipeline assets., Headline: The Covid Downfall Is Here: Moderna's Outlook Misses By More Than $2 Billion, source:Yahoo, summary: Moderna stock toppled Thursday after missing guidance expectations by at least $2 billion as waning Covid shots champ at sales., Headline: Moderna's Q4 Earnings Fall 68% On Sliding COVID-19 Vaccine Revenues, Miss Earnings Expectations, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) reported Thursday, a Q4 FY22 EPS of $3.61, compared to the $11.29 posted a year ago, missing the consensus of $4.68. Revenue was $5.08 billion compared to $7.21 billion a year ago, slightly above the consensus of $5.02, mainly due to a decline in COVID-19 vaccine sales. Product sales for the fourth quarter of 2022 were $4.9 billion, a 30% Y/Y decrease primarily driven by lower sales volume compared to overall higher demand a year ago. Also Read: Pfizer/BioNTech Get Rea, Headline: Falling COVID-19 vaccine sales weigh on Moderna’s Q4 earnings results, source:Yahoo, summary: Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss fourth-quarter earnings for Moderna, the U.S. FDA’s grant for Moderna’s mRNA cancer vaccine, and the outlook for biotech and pharmaceutical companies., Headline: Moderna misses 4th-quarter profit as royalty payment hits, shares fall, source:Reuters, summary: Moderna Inc on Thursday reported fourth-quarter profit that missed Wall Street expectations by almost 23% in part due to a newly-disclosed royalty payment to the U.S. National Institutes of Health (NIH) related to development of the company's COVID-19 vaccine, and higher..., Headline: NEW YORK MARKET CLOSE: Nvidia boosts Nasdaq; eBay and Moderna tumble, source:Alliance News, summary: No summary, Headline: Stocks rise on Wall Street and break a 4-day losing streak, source:Associated Press, The, summary: No summary, Headline: Asia stocks mixed after Wall St breaks losing streak, source:Associated Press, The, summary: No summary, Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 6.70% to $147.57 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y, source:Yahoo, summary: Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023., Headline: Moderna Peers Over a Scary Profit Cliff, source:Yahoo, summary: The vaccine maker’s profits will drop sharply this year as the debate around the stock moves to its pipeline of new vaccines and therapies., Headline: Moderna: Covid vaccine sales will drop 73% this year, source:Yahoo, summary: Moderna Inc. expects sales of its Covid-19 vaccines to drop precipitously this year as global demand for the shots continues to wane.  Meanwhile, unused doses and excess manufacturing capacity are costing Moderna money.  In the fourth quarter, Moderna lost $297 million in expired Covid vaccines, $281 million in cancellation charges on prior purchase commitments, and $376 million in surplus manufacturing capacity — $954 million in total., Headline: Moderna’s stock slides as earnings fall short of estimates amid steep decline in COVID-vaccine sales, source:Yahoo, summary: With the boost Moderna got from COVID vaccines now fading, analysts are focused on the company's pipeline., Headline: Moderna (MRNA) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: My name is Kevin and welcome to Moderna's fourth quarter 2022 earnings call.  At this time, I would like to turn the call over to Lavina Talukdar, head of investor relations at Moderna.  Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's fourth quarter and full year 2022 financial results and business updates., Headline: Moderna forecasts COVID sales decline as costs rise, shares fall, source:Reuters, summary: Moderna Inc on Thursday forecast declining COVID-19 vaccine sales and rising costs for 2023, raising concerns the U.S. biotech company could post a loss this year, and its shares fell 7%., Headline: Is Moderna Stock A Sell After Waning Covid Shots Crush Its 2023 Outlook?, source:Yahoo, summary: Is Moderna stock a sell after massively missing 2023 sales guidance expectations on a mixed quarterly report? Is MRNA stock a sell?, Headline: Treasury yields little changed as investors assess Fed minutes, data, source:CNBC, summary: U.S. Treasury yields fell slightly on Friday morning as investors reacted to the Fed's latest meeting minutes and awaited key inflation and consumer data., Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary",MRNA
145,2023-02-24,"Headline: Moderna downgraded to Underperform from Market Perform at SVB Securities, source:Thefly.com, summary: No summary, Headline: SVB downgrades Moderna to Underperform as COVID boom reverses, source:Thefly.com, summary: No summary, Headline: Barclays Sticks to Its Buy Rating for Moderna (MRNA), source:TipRanks, summary: No summary, Headline: GLOBAL BROKER RATINGS: Jyske cuts BMW; SocGen cuts Burberry, source:Alliance News, summary: No summary, Headline: Moderna downgraded at SVB to underperform on end of COVID pandemic revenue boom, source:Seeking Alpha, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Moderna (MRNA) and Bio-Rad Laboratories (BIO), source:TipRanks, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Pfizer, BioNTech seek FDA full approval for Omicron shot, source:Seeking Alpha, summary: No summary, Headline: Moderna Full Year 2022 Earnings: EPS Misses Expectations, source:Yahoo, summary: Moderna ( NASDAQ:MRNA ) Full Year 2022 Results Key Financial Results Revenue: US$19.3b (up 4.3% from FY 2021). Net..., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: WHO panel is reviewing whether COVID vaccines need to be updated , source:DowJones, summary: Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand., Headline: Stocks making the biggest moves midday: Beyond Meat, Live Nation, Yeti, Boeing and more, source:CNBC, summary: Beyond meat rallied on a smaller-than-expected loss for the previous quarter. Yeti fell on a Goldman Sachs downgrade., Headline: Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo, source:Yahoo, summary: FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates., Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 5.63% to $139.26 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite..., Headline: WHO panel is reviewing whether COVID vaccines need updating, as agency monitors 7 omicron subvariants, source:Yahoo, summary: Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand., Headline: The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks, source:Yahoo, summary: Startling cancer vaccine results from Moderna could drive the company's second act and usher in the next big thing in biotech. Here's what you need to know., Headline: Q4 2022 Personalis Inc Earnings Call, source:Yahoo, summary: Q4 2022 Personalis Inc Earnings Call, Headline: Does This Number Mean It's Time to Sell Moderna Stock?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) investors have gotten used to reports of major growth and billion-dollar-plus quarterly earnings.  The biotech company is a leader in the coronavirus vaccine market -- and its Spikevax product has helped it deliver a whopping $37.8 billion in revenue over the past two years.  The cost of sales for Spikevax totaled 39% of product sales in the fourth quarter -- that's compared to 14% a year ago., Headline: Why Moderna Stock Dropped Today, source:Yahoo, summary: Shares of Moderna (NASDAQ: MRNA) fell 5.6% on Friday, following bearish analyst commentary.  SVB Securities analyst Mani Foroohar placed an underperform rating on Moderna's stock.  Foroohar believes Moderna's recently released fourth-quarter results and guidance for 2023 show that the pandemic-driven surge in the company's sales and profits is ending., Headline: SVB Leerink Downgrades Moderna (MRNA), source:Fintel, summary: nan, Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $7,500.88K, source:Fintel, summary: nan, Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $4,545.00K, source:Fintel, summary: nan, Headline: Domino’s Pizza, Wayfair, Nvidia: Stocks That Defined the Week, source:Yahoo, summary: Domino’s Pizza, Wayfair, Nvidia, Walmart, Bath & Body Works, Moderna and Netflix were seven major stocks that moved on news this past week., Headline: Moderna to make milestone payments to NIH for COVID vaccine, source:Reuters, summary: Moderna Inc will make certain contingent development, commercial and regulatory milestone payments to the U.S. National Institutes of Health (NIH) related to the development of COVID-19 vaccines, the company said in a filing on Friday., Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify., Headline: Pharmas, medtechs dominate list of innovation leaders thanks to patents, source:Seeking Alpha, summary: No summary",MRNA
146,2023-02-25,"Headline: 10 Most Promising Biotech Stocks According to Analysts, source:Yahoo, summary: In this article, we discuss 10 most promising biotech stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Biotech Stocks According to Analysts. Last year was a period of transition for biotech firms. Following significant investment, the availability of cheap capital, and public recognition for […]",MRNA
147,2023-02-26,"Headline: Moderna, Inc. (NASDAQ:MRNA) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Good morning. My name is Kevin and welcome to Moderna’s Fourth Quarter 2022 Earnings Call. Please be advised this call is being recorded. At this time, I’d like to turn the call over to Lavina Talukdar, Head of Investor Relations at Moderna. Please […], Headline: Baron Health Care Fund Q4 2022 Quarterly Letter, source:Seeking Alpha, summary: No summary, Headline: Treasury yields rise slightly to start the week, source:CNBC, summary: U.S. Treasury yields were marginally lower on Monday morning as investors continue to monitor the outlook for inflation and the economy.",MRNA
148,2023-02-27,"Headline: Video: Nasdaq 100 Movers: MRNA, SGEN, source:Market News Video, summary: No summary, Headline: 3 Crucial Things to Know About Moderna Right Now, source:Yahoo, summary: During the earlier days of the pandemic, it was easy to see why Moderna (NASDAQ: MRNA) made for a great investment.  The vaccine has generated billions in earnings for Moderna -- and helped it build up a massive cash level.  The year 2023 isn't likely to be Moderna's biggest when it comes to earnings growth., Headline: Company News for Feb 27, 2023, source:Yahoo, summary: Companies in The News Are: NVDA, BA, ADBE, MRNA, Headline: Moderna Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 0.71% to $138.27 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Start Putting Together Your Shopping List For Beaten-Down Tech Stocks, source:SeekingAlpha, summary: Put together a stock shopping list. You have time to understand the stocks you are investing in., Headline: Treasury prices fall slightly to close out bumper month for yields, source:CNBC, summary: U.S. Treasury prices fell slightly on Tuesday to close out a bumper month for government bond yields., Headline: Noteworthy Tuesday Option Activity: MRNA, CARG, HZNP, source:Stock Options Channel, summary: No summary, Headline: The 20 worst U.S. stocks in February: the biggest loser dropped 35%, source:MarketWatch, summary: No summary",MRNA
149,2023-02-28,"Headline: Moderna’s Covid Boom Is Ending. Why the Outlook Isn’t All Grim., source:Yahoo, summary: Troubles that were put off during the biotech’s pandemic-era boom, notably various intellectual property wrinkles, are now coming home to roost., Headline: Stocks most and least liked by hedge funds and mutual funds -  Goldman, source:Seeking Alpha, summary: No summary, Headline: Moderna to Present at Cowen`s 43rd Annual Health Care Conference, source:Accesswire, summary: No summary, Headline: Moderna, Pfizer: Top mRNA Innovator Stocks are Oversold, source:TipRanks, summary: No summary, Headline: 10 Stocks With Unusual Options Activity: INTC, TSLA, AMD and More, source:Fintel, summary: nan, Headline: Moderna price target lowered to $200 from $225 at Deutsche Bank, source:Thefly.com, summary: No summary, Headline: It’s Crunch Time for RSV Vaccines as FDA Advisers Prepare to Vote, source:MarketWatch, summary: The agency's vaccine-advisory committee is looking at dueling products from Pfizer and GSK. Lots of money is at stake., Headline: Moderna to Present at Cowen's 43rd Annual Health Care Conference, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6th at 9:10 a.m., Headline: Moderna Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.39% higher to $138.81 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: 11 Most Promising Cancer Stocks According to Analysts, source:Yahoo, summary: In this article, we discuss 11 most promising cancer stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Cancer Stocks According to Analysts. The market for community oncology services worldwide is projected to experience substantial growth, with an estimated increase from $47.95 billion in 2022 […], Headline: Novavax Says There Is ‘Substantial Doubt’ Around Its Ability to Continue Operating This Year, source:Yahoo, summary: The Covid-19 vaccine maker will be forced to compete again the far-better-resourced Pfizer and Moderna, casting questions over its 2023 revenues., Headline: Moderna initiated with an Outperform at RBC Capital, source:Thefly.com, summary: No summary, Headline: Moderna initiated at outperform at RBC on potential of cancer vaccine candidates, source:Seeking Alpha, summary: No summary",MRNA
150,2023-03-01,"Headline: Retail Earnings Indicate Unclear Outlook. Why the Fed Needs Consumers to Cut Back., source:MarketWatch, summary: China growth, a U.S. TikTok ban?, Pfizer clears FDA vaccine hurdle, and other news to start your day., Headline: NVAX Stock Alert: Is Novavax Going Bankrupt?, source:InvestorPlace, summary: No summary, Headline: New Investor? Buy These 2 Growth Stocks, source:Yahoo, summary: Amazon (NASDAQ: AMZN) is a leader in two high-growth businesses: e-commerce and cloud computing.  Amazon has already demonstrated it can increase earnings over time thanks to these businesses.  In recent times, a few things have weighed on Amazon, though., Headline: UBS: Moderna's clinical-stage vaccines could drive post-COVID revenues, source:Yahoo, summary: By Scott Kanowsky, Headline: Novavax: The Gig Is Up, source:SeekingAlpha, summary: Novavax has issued dire warnings to shareholders as the company continues to burn substantial amounts of cash. Click here for our take on NVAX stock., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 2.27% to $135.66 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback, source:Yahoo, summary: Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week., Headline: Novavax to pause RSV vaccine trial, assess pipeline, source:Yahoo, summary: Novavax warns of uncertain 2023 outlook as COVID-19 market turns commercial and new CEO calls for pipeline assessment., Headline: Novavax: Covid shots became commodities faster than imagined, source:Yahoo, summary: This is shaping up to be an unpredictable few months for Novavax.  The biotech company’s Covid-19 vaccine finally received US regulatory approval only last summer.  Novavax pitched its protein-based vaccine as an alternative to those offered by Moderna and BioNTech/Pfizer.",MRNA
151,2023-03-02,"Headline: GLOBAL BROKER RATINGS: Numis cuts BT Group to 'sell', source:Alliance News, summary: No summary, Headline: I Asked ChatGPT for 10 Meme Stocks to Buy. Here`s What It Recommended., source:InvestorPlace, summary: No summary, Headline: Interesting MRNA Put And Call Options For April 14th, source:Stock Options Channel, summary: No summary, Headline: The 'Edison Of Medicine' Shows You How To Get More Done, source:Yahoo, summary: Robert Langer isn't impressed with incremental scientific milestones. The rock star scientist, known as the ""Edison of Medicine,"" sets and usually reaches the loftiest of goals., Headline: Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 1.62% to $137.86 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Moderna May Be Just Getting Started in This Big Market, source:Yahoo, summary: Moderna is ready to tackle this market this year -- and revenue should climb once it does.  In fact, Moderna compares the post-pandemic coronavirus vaccine market to that of the flu vaccine.  Worldwide, Moderna has predicted the market could be worth $12 billion to $24 billion -- depending on vaccine price -- if the coronavirus vaccine follows the path of the flu vaccine., Headline: RBC Capital Initiates Coverage of Moderna (MRNA) with Outperform Recommendation, source:Fintel, summary: nan, Headline: Covid Vaccine Maker Novavax’s Flameout Mints Shorts $2.7 Billion, source:Yahoo, summary: (Bloomberg) -- Waning interest in Covid-19 vaccines has left a long-standing drug developer, Novavax Inc., struggling to stay afloat and handed short sellers a windfall.Most Read from BloombergIsrael’s Window to Strike Iran Narrows as Putin Enters EquationTycoon Deripaska Warns Russia May Run Out of Money in 2024Americans Need to Be Richer Than Ever to Buy Their First HomeSorry, Twitter. Elon Found His Next Shiny Object.US Stocks Snap Two Days of Losses; Yields Rise: Markets WrapBets against the",MRNA
152,2023-03-03,"Headline: 7 Over-$100 Stocks That Are Worth Every Penny, source:Yahoo, summary: If searching out over-$100 stocks to buy seems arbitrary, take a step back and consider this. It’s great to have a mix of stocks in your portfolio. There are all sorts of sizes and flavors of stocks from which to choose, including mega-cap stocks and even small-cap stocks. So it’s understandable that when you’re looking for stocks to buy, you may sometimes miss some obvious well-priced choices that are right in front of you. Some of the best names out there fall into the category of over-$100 st, Headline: Is Moderna Stock a Buy Now?, source:Yahoo, summary: The company is looking to transition beyond its COVID-19 vaccine, and that could mean a bumpy ride for investors., Headline: 12 'Dirt Cheap' Stocks Are Due For A Rally, Analysts Say, source:Yahoo, summary: The S&P 500 isn't as cheap as it was — it's up 3.6% this year after all. But analysts still spot relatively bargain-priced stocks due to rally., Headline: 12 Most Profitable Biotech Stocks Today, source:Yahoo, summary: In this article, we will discuss the 12 Most Profitable Biotech Stocks Today. You can skip our industry overview and go directly to the 5 Most Profitable Biotech Stocks Today. The term “biotechnology” refers to the utilization of living organisms or biological systems to create solutions that address various agricultural, industrial, and health-related problems. The most […], Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.87% to $143.20 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising, source:Yahoo, summary: The U.S. government invested at least $31.9 billion to develop, produce, and purchase mRNA COVID-19 vaccines, including sizeable investments in the three decades before the pandemic through March 2022, according to a new BMJ study. That includes at least $337 million was invested pre-pandemic. 34 NIH-funded research grants directly related to mRNA covid-19 vaccines were identified. Estimates of the extent of public investment for covid-19 vaccines vary widely. For example, the Biomedical Advance",MRNA
153,2023-03-04,"Headline: Pharma R&D funding soared to a new record in 2022 as oncology candidates dominate pipelines, source:Seeking Alpha, summary: No summary, Headline: 13 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this article, we will take a look at the 13 most undervalued healthcare stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds. According to a report by T.Rowe Price, healthcare stocks can be generally divided into two […]",MRNA
154,2023-03-05,"Headline: Better Growth Stock: Moderna vs. CRISPR Therapeutics, source:Yahoo, summary: Now is a great time to get in on biotech growth stocks.  Many of them are trading lower than in the past -- yet, at the same time, they're closer than ever to reaching the commercialization of key products.  Two terrific examples of growth stocks to buy today are coronavirus vaccine maker Moderna (NASDAQ: MRNA) and gene editing expert CRISPR Therapeutics (NASDAQ: CRSP)., Headline: Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks of 2023?, source:Yahoo, summary: After declining 19% in 2022, the S&P 500 has risen about 4% this year as investors grew accustomed to inflation, rising interest rates, and other macro headwinds.  Let's see if the four worst-performing S&P 500 components so far in 2023 -- Lumen Technologies (NYSE: LUMN), Moderna (NASDAQ: MRNA), Baxter International (NYSE: BAX) and Pfizer (NYSE: PFE) -- are actually contrarian buys., Headline: 5 Stocks ChatGPT Says Will Make Me Rich in 20 Years, source:InvestorPlace, summary: No summary, Headline: Moderna chooses Harwell Campus as site for UK research facility, source:Seeking Alpha, summary: No summary",MRNA
155,2023-03-06,"Headline: 2 Reasons to Buy Moderna Stock, and 1 Reason to Sell, source:Yahoo, summary: Moderna (NASDAQ: MRNA) became a household name thanks to its quickly produced and approved coronavirus vaccine in 2020.  As it turns out, there are several compelling reasons why this biopharma is a smart long-term play.  Let's examine two big points in favor of Moderna stock and one point against buying., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.58% higher to $144.03 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Moderna Eyes Testing Mpox, Bird Flu Vaccines in Humans This Year, source:Yahoo, summary: (Bloomberg) -- Moderna Inc. is eyeing possible human testing of shots to fight mpox and bird flu this year, as the Covid-19 vaccine maker expands into more public-health immunizations. Most Read from BloombergHolding Cash Will Be a Winning Strategy in 2023, Investors SayTrump’s Threat of a Third-Party Run Is Undercut by ‘Sore Loser’ LawsUS Banks Are Finally Being Forced to Raise Rates on DepositsTesla Slashes Model S and X Prices for the Second Time This YearTesla’s China Price War Sparks $18 Bi, Headline: Moderna eyes human testing of mpox, bird flu vaccines this year: ‘They’re really for public health’, source:Yahoo, summary: A shot against mpox would be valuable in case outbreaks reemerge, and the company sees bird flu as a “clear threat,” the company's president said., Headline: Moderna CEO Defends Pricing Plans for Covid-19 Shot, source:Yahoo, summary: Moderna  Chief Executive  Stéphane Bancel  pushed back against criticism of the company’s pricing plans for its Covid-19 vaccine at Monday’s Wall Street Journal Health Forum.  Bernie Sanders (I., Vt.), Elizabeth Warren (D., Mass.) and Peter Welch (D., Vt.) have questioned the company’s strategy around commercial pricing, which could be unveiled in the coming months.  Moderna received funding from the U.S. government related to development of its Covid-19 vaccine., Headline: Moderna, Inc. (MRNA) Presents at Cowen 43rd Annual Healthcare Conference (Transcript), source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Cowen 43rd Annual Healthcare Conference Call March 6, 2023 9:10 AM ETCompany ParticipantsStephen Hoge - PresidentConference Call ParticipantsTyler Van..., Headline: Healthcare Leaders on the Rise of Vaccine Misinformation, source:Yahoo, summary: At WSJ’s Health Forum, leaders from across the industry talk about the rise in vaccine hesitancy during the Covid-19 pandemic., Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: No summary, Headline: Moderna CEO pushes back on pricing plans for Covid-19 shot, WSJ reports, source:Thefly.com, summary: No summary",MRNA
156,2023-03-07,"Headline: Moderna sees several disease growth opportunities, says TD Cowen, source:Thefly.com, summary: No summary, Headline: Biden to announce plan to keep Medicare solvent beyond 2050, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?, source:Yahoo, summary: An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world., Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 2.07% to $141.05 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...",MRNA
157,2023-03-08,"Headline: Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day, source:Yahoo, summary: Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day., Headline: Moderna Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.73% higher to $142.08 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...",MRNA
158,2023-03-09,"Headline: February`s 7 Worst-Performing S&P 500 Stocks to Buy on the Cheap, source:InvestorPlace, summary: No summary, Headline: 4 Stocks That Moved the Market in February, source:Yahoo, summary: The S&P 500 fell in February, halting momentum in the stock market from earlier this year.  Major indexes eventually slumped due to concerns about high interest rates and slowing economic growth, but there were winners and losers within these overall trends.  Shares of Chevron (NYSE: CVX) fell 6.8% in February, primarily due to declining prices for crude oil and natural gas., Headline: February’s 7 Worst-Performing S&P 500 Stocks to Buy on the Cheap, source:Yahoo, summary: The S&P 500 lost 2.6% in February. However, on the plus side, the index has gained nearly 5% year-to-date through March 7. So while your first instinct might be to focus on S&P 500 stocks to buy that are on a roll, I’m going with some of the index’s worst-performing stocks from February. According to MarketWatch, the seven worst-performing sectors experienced declines ranging from -7.6% (energy) to -2.5% (consumer staples) in February. For this article, I’ll select seven S&P 500 stocks to buy th, Headline: Is It Too Late to Buy Moderna Stock?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) was the star of 2020 and 2021, with its shares skyrocketing as a result of its ambitious work to develop a coronavirus vaccine and get it approved for sale.  Since March 2020, the stock is up 414%.  The near term doesn't look so hot for the biotech as global demand for its only product, a coronavirus jab, seems to be in persistent decline., Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 3.32% to $137.36 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Moderna Stock: Bear vs. Bull, source:Yahoo, summary: Investors have gotten used to Moderna (NASDAQ: MRNA) delivering earnings growth.  Thanks to its coronavirus vaccine, the biotech has reported billions of dollars in revenue and profit over the past two years.  Does this mean we should forget about investing in Moderna?",MRNA
159,2023-03-10,"Headline: Moderna boosted by expansion plans, while SVB fallout continues to pressure banks and financials, source:MarketWatch, summary: Moderna is planning to hire 2,000 people this year and expand beyond its Cambridge, Mass. base., Headline: Moderna expands U.S. presence, plans to hire 2,000 by end of 2023, source:Thefly.com, summary: No summary, Headline: Moderna announces West Coast expansion; to hire 2K employees in 2023, source:Seeking Alpha, summary: No summary, Headline: Wall Street Thinks These 2 Undervalued Stocks Have Exceptional Growth Potential, source:Yahoo, summary: Most investors know about BioNTech (NASDAQ: BNTX) thanks to the coronavirus vaccine it developed in conjunction with Pfizer, but there will be a lot more to talk about in the company's future, and it's selling at a dirt-cheap valuation today.  BioNTech's price-to-earnings (P/E) ratio is a hair over 3, which is dramatically lower than the market's average of 23 or so -- a surefire sign that the market is pessimistic about its near-term ability to grow its earnings.  Paradoxically, given their bearish revenue estimates, Wall Street analysts are estimating that its share price will rise by around 57% this year -- and there could be some good reasons., Headline: Moderna expands US footprint with two new offices on west coast, source:Alliance News, summary: No summary, Headline: Where Will Moderna Be In 5 Years?, source:Yahoo, summary: The biotech company is working on plenty of other potential products in its pipeline that could send its stock higher again -- and it (hopefully) won't need to create a vaccine for an emerging global pandemic this time around.  The Moderna of early 2028 will almost certainly have a few more products on the market than it does today.  Aside from updates to its coronavirus vaccine, it could also be selling jabs for influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), and perhaps even a couple of other infectious diseases too, not to mention combination vaccines that inoculate against multiple common viruses at once., Headline: Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023, source:Yahoo, summary: Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its U.S. presence and establishing a corporate presence on the West Coast with new offices in South San Francisco, California and Seattle, Washington. Moderna's Seattle location will provide technology solutions across the enterprise and Moderna Genomics will expand to South San Francisco., Headline: Moderna to hire around 2,000 employees globally by 2023-end , source:Reuters, summary: Moderna Inc said on Friday it was planning to hire about 2,000 employees globally by the year-end and would expand its U.S. presence to include new offices on the West Coast. (Reporting by Raghav Mahobe in Bengaluru; Editing by Anil D'Silva), Headline: Moderna Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.68% higher to $138.29 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Moderna plans to hire 2,000 workers, open new offices in West Coast, source:Yahoo, summary: Moderna Inc.  (MRNA)  said Friday it is expanding in the U.S., opening new offices in South San Francisco, Calif., and Seattle, and hiring 2,000 workers worldwide by the end of the year.  Seattle will be a technology hub providing support for the whole company, and Moderna’s genomics business will expand to South San Francisco, the company said.  Moderna has U.S. offices in Georgia, Maryland, Massachusetts and New Jersey, with headquarters in Cambridge, Mass. Shares of Moderna have gained 1% in the last 12 months, contrasting with losses of about 8% for the S&P 500 index., Headline: UPDATE 2-Moderna to hire around 2,000 employees amid mRNA development push, source:Yahoo, summary: Moderna Inc said on Friday it was planning to hire about 2,000 employees globally by 2023-end and set up new offices on the U.S. West Coast, as it aims to scale up development of new products amid declining COVID vaccine sales.  The COVID vaccine maker said it will open new offices in California and Seattle, adding that its Genomics unit will expand to south San Francisco.  The latest move comes at a time when Moderna has been working on developing vaccines for skin cancer, flu and respiratory syncytial virus (RSV) using its mRNA technology, which if approved would significantly boost the biotech company that currently relies heavily on its COVID-19 shot., Headline: Moderna to hire around 2,000 employees globally by 2023-end, source:Reuters, summary: Moderna Inc said on Friday it was planning to hire about 2,000 employees globally by the year-end and expand its U.S. presence to include new offices on the West Coast., Headline: Novavax Stock: Bear vs. Bull, source:Yahoo, summary: Novavax (NASDAQ: NVAX) has a track record of major gains and major losses within the past few years.  Novavax shares have dropped a mind-boggling 97% from their peak.  Considering all of this, should you buy Novavax or avoid the stock?, Headline: Moderna to hire around 2,000 employees amid mRNA development push, source:Reuters, summary: Moderna Inc said on Friday it was planning to hire about 2,000 employees globally by 2023-end and set up new offices on the U.S. West Coast, as it aims to scale up development of new products amid declining COVID vaccine sales., Headline: Moderna (MRNA) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed at $138.29 in the latest trading session, marking a +0.68% move from the prior day., Headline: Moderna loses bid to shift liability in COVID-19 vaccine patent case, source:Reuters, summary: Despite the backing of the U.S. government, Moderna Inc on Friday failed to persuade a federal judge it should not have to face a patent lawsuit over its COVID-19 vaccine and that the United States should have been sued instead., Headline: Moderna adding 2,000 new workers this year, source:Yahoo, summary: Moderna will add to its workforce and its U.S. real estate footprint, the biotech company announced in a press release Friday. The employees will be added by the end of the year.",MRNA
160,2023-03-12,"Headline: A Nasdaq Bull Market Is Coming: 2 Revolutionary Stocks to Buy and Hold, source:Yahoo, summary: Last year, the Nasdaq Composite fell into a bear market and lagged behind the other two major U.S. market indexes.  Let's consider two revolutionary companies to invest in before that happens: Moderna (NASDAQ: MRNA) and Exact Sciences (NASDAQ: EXAS).  Moderna became widely known during the pandemic for being one of the leaders in the coronavirus vaccine market., Headline: Moderna Gains on Cowen Remarks, source:TipRanks, summary: No summary, Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary",MRNA
161,2023-03-13,"Headline: Morgan Stanley Reaffirms Their Hold Rating on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna upgraded to Outperform from Market Perform at TD Cowen, source:Thefly.com, summary: No summary, Headline: Early notable gainers among liquid option names on March 13th, source:Thefly.com, summary: No summary, Headline: Why did Moderna stock go up today?, source:Seeking Alpha, summary: No summary, Headline: Moderna gains as Cowen upgrades citing a favorable catalyst path, source:Seeking Alpha, summary: No summary, Headline: Why did Moderna stock go up today? Street upgrade, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: 2 Top Biotech Stocks to Buy In March and Hold Forever, source:Yahoo, summary: Most biotech companies are too risky to even think about holding forever.  Between the big risk of a clinical trial blowing up and the lesser risk of getting one-upped by a competitor's medicine even after successfully moving a drug from the lab to the market, it's incredibly difficult to feel confident in a biotech's long-term future.  Moderna (NASDAQ: MRNA) is a biotech stock that needs no introduction after successfully commercializing its coronavirus vaccine and raking in $18.8 billion in revenue in 2022 as a result., Headline: Stocks making the biggest moves midday: First Republic Bank, Moderna, Newmont, Illumina and more, source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Moderna Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rose 6.95% to $147.90 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite..., Headline: Moderna shares pop 7% after Cowen upgrades stock, saying it 'will be a leader' in RSV vaccines, source:CNBC, summary: Moderna shares closed nearly 7% after TD Cowen upgraded the stock, saying the company will ""be a leader"" in the RSV vaccine market. , Headline: CNBC Daily Open: The bank rout continues. The Fed might still raise rates anyway, source:CNBC, summary: Bank stocks had a very rough Monday in the aftermath of Silicon Valley Bank’s implosion. The 2-year Treasury yield plummeted. , Headline: Why Moderna Stock Zoomed 7% Higher Today, source:Yahoo, summary: Coronavirus stock Moderna (NASDAQ: MRNA) had a Monday reminiscent of some of its more bullish days in the thick of the pandemic.  On Monday morning, TD Cowen prognosticator Tyler Van Buren changed his recommendation on Moderna from market perform (read: hold) to outperform (buy).  Van Buren sees several catalysts that should push Moderna ahead in the coming years., Headline: My Hedge Against The Silicon Valley Bank Crisis, source:TalkMarkets, summary: No summary, Headline: CNBC Daily Open: Banks got hammered by SVB's collapse. But the Fed might still raise rates , source:CNBC, summary: Bank stocks had a very rough Monday in the aftermath of Silicon Valley Bank’s implosion. The 2-year Treasury yield plummeted. ",MRNA
162,2023-03-14,"Headline: Moderna announces two presentations on mRNA-4157/V940 at AACR, source:Thefly.com, summary: No summary, Headline: Moderna to present mid-stage results on personalized cancer vaccine in April, source:Seeking Alpha, summary: No summary, Headline: A Bull Market Is Coming: 5 Top Stocks to Buy Now, source:Yahoo, summary: With stock indexes still in the doldrums, you may not be thinking about the next bull market right now.  Today, many top stocks with amazing growth prospects are cheap, beaten down by today's tough market.  When you think of Moderna (NASDAQ: MRNA), you probably think of the coronavirus vaccine., Headline: Moderna, Inc.'s (NASDAQ:MRNA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?, source:Yahoo, summary: With its stock down 25% over the past three months, it is easy to disregard Moderna (NASDAQ:MRNA). But if you pay close..., Headline: Is It Time to Buy the Nasdaq's 3 Worst-Performing February Stocks?, source:Yahoo, summary: Now that the dust of February has settled, investors can start looking for some stocks that had an abysmal month.  While the Nasdaq-100 fell 2.6% in February, a few stocks had an even worse performance.  The stocks claiming this ""honor"" were JD.com (NASDAQ: JD), SiriusXM (NASDAQ: SIRI), and Moderna (NASDAQ: MRNA)., Headline: FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults, source:CNBC, summary: FDA staff said Pfizer's clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease. , Headline: Moderna Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 2.29% to $151.28 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: FDA authorizes Pfizer's Covid omicron booster as fourth shot for kids under 5, source:CNBC, summary: The FDA authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original shot.  , Headline: TD Cowen Upgrades Moderna (MRNA), source:Fintel, summary: nan, Headline: Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL., Headline: 3 Vaccine Stocks to Watch for Their Post-Pandemic Moves, source:Yahoo, summary: During the Covid-19 pandemic, vaccine stocks shot up on the promise that they could end the lockdowns. Many vaccines were developed, but few were approved. Since the end of 2021, even the approved vaccine developers have seen their stocks slump as part of the biotech price rout. However the winners of the vaccine race are still companies to watch closely for their post-pandemic moves. Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) all have Covid-19 vaccines in the U.S. market",MRNA
163,2023-03-15,"Headline: Why a nasal vaccine could reduce the risk of COVID infections and new variants, source:MarketWatch, summary: No summary, Headline: How a nasal vaccine could reduce the risk of COVID infections — and new variants, source:MarketWatch, summary: Three years into the pandemic, the World Health Organization's Joachim Hombach talked with MarketWatch about the future of vaccines., Headline: 2 Top Biotech Stocks to Buy for the Long Haul, source:Yahoo, summary: First, they give you the opportunity to watch a company develop innovative and often life-saving technologies -- and that pipeline progress can drive their shares higher.  Then, if the company successfully brings products to market, a new phase of growth -- in earnings and share performance -- often begins.  One has shown over the past couple of years that its groundbreaking technology works -- and might be applied across many indications., Headline: Senate Health, Ed, Labor & Pensions Committee to hold a hearing, source:Thefly.com, summary: No summary, Headline: How a nasal vaccine could reduce the risk of COVID infections ��� and new variants, source:MarketWatch, summary: No summary, Headline: Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary, Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.11% to $149.60 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: ChatGPT Says These 7 Stocks Could Be the Next Trillion-Dollar Companies, source:Yahoo, summary: Investors will always be on the hunt for the next trillion-dollar companies. This is a milestone that every company aims for, though very few reach. For investors, this means constantly being on the lookout for innovators with revolutionary products that can take them to market capitalizations above $1 trillion. As InvestorPlace analyst Luke Lango notes, in 2022, the iPhone helped Apple (NASDAQ:AAPL) reach that milestone and become the world’s most valuable company with a market cap above $2 tri, Headline: Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants, source:Yahoo, summary: Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.",MRNA
164,2023-03-16,"Headline: PBE: Healthcare Dashboard For March, source:SeekingAlpha, summary: Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold., Headline: Moderna Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rose 1.46% to $151.78 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: This High-Growth Company Is Expanding. Time to Buy the Stock?, source:Yahoo, summary: Moderna's (NASDAQ: MRNA) reliance on its COVID-19 vaccine has worried some investors.  The vaccine -- Moderna's only commercialized product -- has generated billions of dollars in earnings over the past two years.  Now, though, with vaccine demand on the decline, the biotech company's revenue may look a lot different in the coming quarters., Headline: Moderna (MRNA) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed at $151.78 in the latest trading session, marking a +1.46% move from the prior day.",MRNA
165,2023-03-17,"Headline: Tracking Lone Pine Capital Portfolio - Q4 2022 Update, source:SeekingAlpha, summary: Lone Pine Capitalâs 13F portfolio value decreased marginally from $10.61B to $10.48B this quarter. Click here for a complete analysis of the portfolio., Headline: Is It Time to Buy the S&P 500's 2 Worst-Performing February Stocks?, source:Yahoo, summary: Silicon Valley Bank and Signature Bankhave already failed.  Credit Suisse plunged after it disclosed material weaknesses in its financial reporting, and its biggest investor, the Saudi National Bank, said it wasn't going to come to its rescue.  Let's take a look at the S&P 500's two worst performers from February to see if either of them offers a good buying opportunity., Headline: Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?, source:Yahoo, summary: No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization.  Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it.  One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized., Headline: COVID-19: Moderna price hike to reflect ‘the value of the vaccine,’ company president says, source:Yahoo, summary: Moderna President Stephen Hoge joins Yahoo Finance Live to discuss a post-pandemic market, Sen. Bernie Sanders’ remarks on the COVID-19 vaccine price hike, and the outlook for the biotechnology company., Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.16% to $150.02 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...",MRNA
166,2023-03-18,"Headline: 1 Green Flag and 1 Red Flag for Novavax, source:Yahoo, summary: Novavax (NASDAQ: NVAX) has had more than its share of ups and downs over the past few years -- and investors have been along for the ride.  The stock soared 2,700% in 2020 as the company brought its coronavirus vaccine candidate through late-stage clinical trials.  The biotech company's vaccine reached commercialization later than rivals.",MRNA
167,2023-03-19,"Headline: Shareholders may not want to ignore the US$4.3m worth sales made by Moderna, Inc. (NASDAQ:MRNA) insiders this past year, source:Yahoo, summary: While Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had a good week with the stock up 8.5%, they shouldn't let their..., Headline: Pfizer CEO pockets $33M for 2022 after 36% pay hike, source:Seeking Alpha, summary: No summary, Headline: 3 (Good) Reasons Warren Buffett Doesn't Invest in Biotech Stocks, source:Yahoo, summary: There's a pretty good chance Warren Buffett knows a few things about investing that we don't.  Let's take a look at three of his most likely arguments against buying biotechs.  Biotech stocks are risky, and there isn't really any way of de-risking their line of business, both of which are things that Buffett almost certainly hates about them., Headline: 15 Most Promising Stocks to Buy According to Analysts, source:Yahoo, summary: In this article, we will take a look at the 15 most promising stocks to buy according to analysts. To see more such companies, go directly to 5 Most Promising Stocks to Buy According to Analysts. The international financial system is yet again wavering amid the banking sector problems. Analysts are now processing the possibility […]",MRNA
168,2023-03-20,"Headline: FOCUS-Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies, source:Yahoo, summary: Some of the world's leading makers of flu vaccines say they could make hundreds of millions of bird flu shots for humans within months if a new strain of avian influenza ever jumps across the species divide.  One current outbreak of avian flu known as H5N1 clade 2.3.4.4b has killed record numbers of birds and infected mammals.  Human cases, however, remain very rare, and global health officials have said the risk of transmission between humans is still low., Headline: Very Good News For REIT Investors, source:SeekingAlpha, summary: Future interest rate expectations are now lower and this is very good news for REITs. Check out a few REIT picks that we are accumulating., Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Moderna (MRNA) and Decibel Therapeutics (DBTX), source:TipRanks, summary: No summary, Headline: 2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market, source:Yahoo, summary: Rewards that the next bull market will bring are being built right now by farsighted investors who can find opportunities among today's discounted stocks.  While there's no telling exactly when a bull market will develop, planting the seeds of success by buying some shares of cheap yet high-quality companies out there right now is a good move.  With that in mind, here are two businesses you're probably acquainted with that are priced for a no-brainer purchase -- and have a good shot at flourishing in the next bull market and beyond., Headline: Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case', source:Yahoo, summary: https://cdn.benzinga.com/files/images/story/2023/03/20/bird_flu-_image_by_jeyaratnam_caniceus_from_pixabay-.jpg?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Executives at GSK Plc (NYSE: GSK), Moderna Inc (NASDAQ: MRNA), and CSL Seqirus, owned by CSL Ltd (OTC: CSLLY), said they are developing or about to test sample human vaccines against bird flu as a precautionary measure against a future pandemic. Others, like Sanofi SA (NASDAQ: SNY), said they ""stand ready"" to begin production if needed, w, Headline: Moderna Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rose 3.00% to $154.52 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite..., Headline: UPDATE 1-Moderna expects to price its COVID vaccine at about $130 in the US, source:Yahoo, summary: Moderna Inc expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday.  “There are different customers negotiating different prices right now, which is why it's a little bit complicated,” Hoge said ahead of a Congressional hearing run by Democratic U.S. Senator Bernie Sanders on Moderna’s pricing plans.  Moderna previously said it was considering pricing its COVID vaccine in a range of $110 to $130 per dose in the United States, similar to the range Pfizer Inc said in October it was considering for its rival COVID shots sold in partnership with BioNTech., Headline: Moderna expects to price its COVID vaccine at about $130 in the US, source:Reuters, summary: Moderna Inc expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday.",MRNA
169,2023-03-21,"Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: No summary, Headline: Moderna Mulls COVID-19 Vaccine Price at $130, source:TipRanks, summary: No summary, Headline: FDA moving towards authorizing second omicron booster, WSJ reports, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose, source:Yahoo, summary: From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector. ""There are different customers negotiating different prices right now, which is why it's a little bit complicated,"" the company's president Stephen Hoge said in an interview ahead of a Congressional hearing run by Democratic U.S. Senator Bernie Sanders on Moderna's pricing plans. Moderna previously considered pricing its COVID vaccine in a, Headline: Moderna Wants $130 Per COVID-19 Vaccine Dose, US Health Authorities Warn Of Incurable Deadly Fungal Infection, Elon Musk Wants Interest Rate Cut: Today's Top Stories, source:Yahoo, summary: Reuters Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move to the private sector from the government. ""There are different customers negotiating different prices right now, which is why it's a little bit complicated,"" the company's president Stephen Hoge said in an interview ahead of a Congressional hearing run by Democratic U.S. Senator Bernie Sanders on Moderna's pricing plans. EU Co, Headline: Moderna CEO faces Sen. Sanders in COVID-19 vaccine pricing hearing Wednesday, source:Yahoo, summary: Moderna CEO Stéphane Bancel is set to face Sen. Bernie Sanders to defend the company's fast growth and planned price hike of its COVID-19 vaccine., Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 1.57% to $152.10 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Moderna CEO Will Face Senate Committee About Covid Vaccine Pricing. What to Expect., source:Yahoo, summary: Sen. Bernie Sanders is expected to focus on the company's plans to charge insurers $130 per dose for its Covid-19 vaccine., Headline: If You Invested $5,000 in Moderna in 2020, This Is How Much You Would Have Today, source:Yahoo, summary: Moderna's (NASDAQ: MRNA) success in the coronavirus vaccine race has equaled success for early investors.  Let's take a look at how much you would have today if you'd invested $5,000 in Moderna back in 2020.  Moderna became one of the first to bring a coronavirus vaccine candidate into clinical trials., Headline: Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders, source:Yahoo, summary: Moderna CEO Stephane Bancel will face off with Sen. Bernie Sanders on Wednesday over the Covid shot. The battle could rock Moderna stock., Headline: BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani, source:Business Wire, summary: No summary, Headline: China approves first domestic mRNA vaccine for Covid-19, source:Alliance News, summary: No summary",MRNA
170,2023-03-22,"Headline: China approves emergency use of 1st home-grown mRNA COVID vaccine, source:Seeking Alpha, summary: No summary, Headline: China grants emergency use for first homegrown mRNA COVID vaccine: WSJ, source:MarketWatch, summary: China has granted its first emergency use authorization to a homegrown mRNA COVID vaccine, the Wall Street Journal reported Wednesday. The vaccine, known as..., Headline: Senate Health, Ed, Labor & Pensions Committee to hold a hearing, source:Thefly.com, summary: No summary, Headline: Moderna: Now`s Your Chance (Rating Upgrade), source:Seeking Alpha, summary: No summary, Headline: Watch: Moderna CEO Stephane Bancel testifies before Senate on Covid vaccine price hike, source:CNBC, summary: The Boston biotech company plans to charge $130 per dose once the vaccination program moves to the private market as early as this fall., Headline: Moderna CEO faces Senate panel as price of COVID-19 vaccine set to quadruple, source:United Press International, summary: No summary, Headline: Moderna: Now's Your Chance (Rating Upgrade), source:SeekingAlpha, summary: Moderna stock potential is overshadowed by downcast analysts' projections of three years of operating losses until 2025. Click here for our take on MRNA., Headline: The Bank Turmoil Isn’t Over. What It Means for the Fed Looking Forward., source:Yahoo, summary: Moderna’s CEO is faces a Senate grilling over $130 Covid-19 shot, Google expands public access to its ‘Bard’ chatbot, and other news to start your day., Headline: Sen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearing, source:CNBC, summary: CNBC's Meg Tirrell reports on the Senate hearing on drug prices, which featured an exchange between Sen. Bernie Sanders and Moderna CEO Stéphane Bancel., Headline: Moderna to Price Its Covid-19 Vaccine at $130 a Dose, source:Yahoo, summary: The company is preparing for commercial distribution of the shots as the U.S. winds down its pandemic-emergency purchases., Headline: Moderna CEO Bancel tells senators COVID vaccine price hikes are appropriate, source:Seeking Alpha, summary: No summary, Headline: Moderna CEO Stephane Bancel defends fivefold price hike of Covid vaccine during Senate grilling, source:CNBC, summary: Bernie Sanders pressed Stephane Bancel during the Senate hearing to make a commitment that Moderna will not increase the vaccine's list price to $130. , Headline: Moderna CEO defends price increase for COVID vaccine to Congress, source:MarketWatch, summary: A hearing focused on Moderna’s plan to raise the price of its COVID-19 vaccine raised longstanding questions about how drugs should be priced in the U.S., Headline: Moderna CEO Bancel defends $130 COVID vaccine price in Senate hearing, source:Reuters, summary: Moderna Inc will no longer have the economies of scale it had in government procurement when its COVID-19 vaccine moves into the private market, Chief Executive Officer Stephane Bancel told lawmakers on Wednesday at a Senate committee hearing as he defended the company's..., Headline: Moderna defends COVID-19 vaccine price hike before U.S. Senate, source:Yahoo, summary: Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss Moderna CEO Stephane Bancel’s testimony before the U.S. Senate health committee., Headline: UPDATE 2-Moderna CEO defends $130 US COVID vaccine price in Senate hearing, source:Yahoo, summary: Moderna Inc's chief executive on Wednesday defended the company's plan to quadruple the price of its COVID-19 vaccine, telling a U.S. Senate committee hearing it will no longer have the economies of scale from government procurement when the shots move into the private market.  Moderna CEO Stephane Bancel was called to testify after the company flagged plans to raise the vaccine's price to as much as $130 per dose, drawing the ire of Democratic U.S. Senator Bernie Sanders, who chairs the influential Committee on Health, Education, Labor and Pensions (HELP).  Sanders on Wednesday asked Bancel to reconsider the price hikes, saying they could make it unaffordable for millions of Americans and were unjustified given the government's research contributions and $1.7 billion in assistance in developing the vaccine., Headline: Moderna to charge $130 for COVID vaccines in shift to commercial distribution, source:Yahoo, summary: Pfizer has said it’s considering a similar price for its vaccine., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 2.58% to $148.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Moderna CEO defends $130 US COVID vaccine price in Senate hearing, source:Reuters, summary: Moderna Inc's chief executive on Wednesday defended the company's plan to quadruple the price of its COVID-19 vaccine, telling a U.S. Senate committee hearing it will no longer have the economies of scale from government procurement when the shots move into the private market..., Headline: Moderna CEO Faces Senate Grilling Over Price of Covid-19 Vaccine, source:Yahoo, summary: Sen. Bernie Sanders homed in on the company's plans to charge insurers $130 per dose for its Covid-19 vaccine., Headline: Is Moderna Stock A Sell As Senators Eye 400% Price Hike For Covid Shots?, source:Yahoo, summary: Moderna stock is under pressure as the company contends with a pitfall in Covid shots and plans for a 400% price hike. Is MRNA stock a sell?, Headline: Senators press Moderna CEO on COVID-19 vaccine price hike, source:Yahoo, summary: Moderna’s CEO on Wednesday defended a plan to more than quadruple the company’s COVID-19 vaccine price, but he also said the drugmaker will work to ensure patients continue paying nothing at drugstores or clinics.  Stephane Bancel told the Senate Committee on Health, Education, Labor and Pensions that the drugmaker will charge a list price of around $130 per dose for the vaccine in the U.S.  More than 270 million doses of Moderna’s original COVID-19 vaccine and booster shots have been administered in the U.S., according to the U.S. Centers for Disease Control and Prevention., Headline: It Will Cost More Than $100 to Get a Moderna Covid Vaccine, source:Yahoo, summary: Remember when they used to be free? As the US government winds down its pandemic emergency spending, health giant Moderna is preparing to shift its..., Headline: GLOBAL BRIEFING: Dollar softens after dovish Fed rhetoric, source:Alliance News, summary: No summary, Headline: Moderna rebuked over plan to hike Covid vaccine to USD130, source:Alliance News, summary: No summary",MRNA
171,2023-03-23,"Headline: Moderna CEO defends $130 price of Covid-19 vaccine, Reuters reports, source:Thefly.com, summary: No summary, Headline: PRESS DIGEST- Wall Street Journal - March 23, source:Yahoo, summary: Following are the top stories in the Wall Street Journal.  - Moderna Inc  will price its Covid-19 vaccine at about $130 a dose when it shifts to commercial distribution of the shots later this year, much higher than what the federal government has paid.  - A federal judge found that special counsel Jack Smith's team presented convincing evidence that former U.S. President Donald Trump misled his own lawyers about his retention of classified documents after leaving the White House, according to people familiar with the decision., Headline: Generation Bio, Moderna announce strategic collaboration, source:Thefly.com, summary: No summary, Headline: Moderna, Generation Bio enter collaboration for non-viral genetic medicines, source:Thefly.com, summary: No summary, Headline: Moderna to pay Generation Bio $40M upfront under pact to develop non-viral genetic drugs, source:Seeking Alpha, summary: No summary, Headline: Generation Bio stock surges ~20% on Moderna pact to develop non-viral genetic drugs, source:Seeking Alpha, summary: No summary, Headline: Moderna Is Great Value For Money Right Now, source:SeekingAlpha, summary: Modernaâs investments put it in a strong position to develop new products. Check out why I'm bullish on MRNA stock., Headline: Generation Bio, Moderna Enter Collaboration to Accelerate Non-Viral Genetic-Medicines Pipeline, source:MarketWatch, summary: By Denny Jacob Genetic-medicine company Generation Bio Co. and pharmaceutical company Moderna Inc. on Thursday entered into a strategic collaboration. The..., Headline: Generation Bio Shares Rise 19% on Moderna Strategic Collaboration, source:MarketWatch, summary: By Denny Jacob Genetic medicine company Generation Bio Co. shares rose 19%, to $4.61, in premarket trading Thursday after it and pharmaceutical company..., Headline: Generation Bio, Moderna announce collaboration, source:MarketWatch, summary: Shares of Generation Bio Co. jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. to to develop novel..., Headline: Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Moderna (MRNA) and Pyxis Oncology (PYXS), source:TipRanks, summary: No summary, Headline: GBIO Soars on Teaming Up with Moderna, source:TipRanks, summary: No summary, Headline: Biotech ETF XBI drops to an 8-month low, source:Seeking Alpha, summary: No summary, Headline: Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co., Headline: UPDATE 2-Moderna signs licensing deal with Generation Bio in push beyond COVID, source:Yahoo, summary: Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots.  Generation Bio's shares rose about 13.14% to $4.40 in premarket trading on Thursday.  Moderna will pay $40 million in cash upfront, and make a $36 million equity investment in Cambridge, Massachusetts-based Generation Bio., Headline: Moderna, Generation Bio Collaborate To Develop Non-Viral Genetic Medicines, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) and Generation Bio Co (NASDAQ: GBIO) have collaborated to combine the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines. ""Non-viral DNA therapeutics may offer durable, redosable, titratable genetic medicines to patients suffering from rare and prevalent diseases on a global scale,"" said Phillip Samayoa, Chief Stra, Headline: Penny Stocks To Buy Under $5? 7 To Watch This Week, source:PennyStocks, summary: Penny stocks to watch under $5 this week., Headline: Moderna Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.84% higher to $149.42 Thursday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: Moderna signs licensing deal with Generation Bio in push beyond COVID, source:Reuters, summary: Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots., Headline: A COVID-19 Vaccine Could Cost You Four Times As Much Soon — Here’s Why, source:Yahoo, summary: A leading drugmaker's plan to quadruple the price of its COVID-19 vaccine when the public health emergency ends has not gone over well on Capitol Hill, where lawmakers criticized the company's top..., Headline: 7 Blue-Chip Stocks Sitting in the Sweet Spot, source:Yahoo, summary: Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won’t do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they’re tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts. Further, adding to the sweet nature of these blue-chip stocks, they’re all undervalued based on earnings m, Headline: Moderna's Bancel defends COVID-19 vaccine price at Sanders hearing, source:Yahoo, summary: Moderna's CEO Stéphane Bancel faced off with Sen. Bernie Sanders and others of the Senate HELP committee to defend raising the COVID vaccine price for the commercial market., Headline: Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $149.42, moving +0.84% from the previous trading session.",MRNA
172,2023-03-24,"Headline: With 65% institutional ownership, Moderna, Inc. (NASDAQ:MRNA) is a favorite amongst the big guns, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Moderna's stock price might be vulnerable to their..., Headline: Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m., Headline: Moderna Inc. stock underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.98% higher to $150.88 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio, source:Yahoo, summary: Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.",MRNA
173,2023-03-25,"Headline: 3 Things About Moderna That Smart Investors Know, source:Yahoo, summary: Moderna (NASDAQ: MRNA) helped some investors make a fortune over the past few years.  The stock has climbed more than 400% since March 2020 -- that's when the company's coronavirus vaccine program gained traction.  Recently, though, investors have worried about Moderna's post-pandemic revenue, and that's weighed on share performance.",MRNA
174,2023-03-27,"Headline: Video: S&P 500 Movers: MRNA, FRC, source:Market News Video, summary: No summary, Headline: Could CRISPR Therapeutics Become the Next Moderna?, source:Yahoo, summary: CRISPR Therapeutics (NASDAQ: CRSP) has a couple of things in common with a company that's made the headlines over the past few years: coronavirus vaccine maker Moderna (NASDAQ: MRNA).  Today, CRISPR's market value sits at about $3.4 billion.  Since, Moderna has grown to become a $58 billion company, with a blockbuster product and three more potential ones on the horizon., Headline: As Covid-19 shot sales dwindle, BioNTech doubles down on cancer vaccines, source:Yahoo, summary: BioNTech is over covid. Or looking past it, at least, planning to invest the company’s pandemic windfall into the development of oncology products., Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.68% to $148.35 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",MRNA
175,2023-03-28,"Headline: Gritstone bio draws Buy rating at B. Riley on mRNA potential, source:Seeking Alpha, summary: No summary, Headline: 2 Nasdaq 100 Stocks to Buy Hand Over Fist Right Now, source:Yahoo, summary: When there are bargains on stocks with long-term appeal, astute investors make sure to get a few shares while the getting is good.  In truth, Moderna (NASDAQ: MRNA) is a bit of a contrarian purchase at the moment as nobody expects it to one-up its 2022 top line of nearly $19 billion now that sales of its coronavirus vaccine are expected to fall to as low as $5 billion in 2023., Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. dropped 0.96% to $146.92 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...",MRNA
176,2023-03-29,"Headline: The Ultimate Growth Stock to Buy With $150 Right Now, source:Yahoo, summary: What makes a top growth stock?  It's generated billions of dollars thanks to its coronavirus vaccine -- but the company has other major growth drivers on the way.  Let's find out more about this ultimate growth stock to buy now., Headline: Moderna's CEO Just Gave Investors a Huge Reason to Sell the Stock, source:Yahoo, summary: Recently, Moderna (NASDAQ: MRNA)'s CEO highlighted a big risk for the company: Demand for its COVID-19 vaccine is going to crater.  It's a big enough decline to get investors worried.  Moderna is anticipating a big drop in demand this year as concerns around COVID-19 subside., Headline: J&J backs out of RSV vaccine race with rivals Pfizer and GSK , source:CNBC, summary: J&J lagged behind rival drugmakers Pfizer and GSK, both of which made major strides toward U.S. approval of their RSV vaccines in the last month. , Headline: Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?, source:Yahoo, summary: Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: What WHO’s New Covid-19 Vaccine Guidance Means for Pfizer and Moderna Stock, source:Yahoo, summary: The two companies have said they expect roughly 100 million Covid-19 vaccines doses to be administered in the U.S. this year., Headline: Moderna Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rallied 1.28% to $148.80 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out, source:Yahoo, summary: Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out., Headline: Moderna (MRNA) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed at $148.80 in the latest trading session, marking a +1.28% move from the prior day.",MRNA
177,2023-03-30,"Headline: 11 Stocks: 9 Dividend Payers 2 For Growth, source:TalkMarkets, summary: No summary, Headline: Gandeeva and Moderna Enter into Cryo-EM Research Collaboration to Explore Protein Surface Structure at Atomic Resolution, source:Business Wire, summary: No summary, Headline: Brookline Capital Markets Reaffirms Their Buy Rating on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna, Gandeeva ink pact to research on protein surface structure, source:Seeking Alpha, summary: No summary, Headline: Moderna finalizes agreement with Government of the Republic of Kenya, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Cutera (CUTR), Moderna (MRNA) and BiomX (PHGE), source:TipRanks, summary: No summary, Headline: Moderna to set up mRNA manufacturing site in Kenya, source:Seeking Alpha, summary: No summary, Headline: Moderna to produce up to half a billion mRNA vaccines yearly in Kenya, source:Alliance News, summary: No summary, Headline: Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an mRNA manufacturing facility in the Republic of Kenya., Headline: 1 Growth Stock With 741% Upside, According to Wall Street, source:Yahoo, summary: Shares of biotech Novavax (NASDAQ: NVAX) have plunged 91% in the past year as the company has struggled to make its mark in the coronavirus vaccine market.  Novavax's lack of success in this space is even more troubling, considering global COVID-19 vaccine sales will drop substantially starting this year, so even the leaders in the field have struggled of late.  While it seems highly unlikely that Novavax will soar by that much anytime soon, perhaps the broader question is whether there's a substantial upside ahead for the company., Headline: Mirati (MRTX) Down 16.1% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 0.91% to $147.44 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Top Stock Reports for Walt Disney, Marathon Petroleum & Moderna, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Marathon Petroleum Corporation (MPC), and Moderna, Inc. (MRNA)., Headline: Catalyst watch: Tesla deliveries, Walmart event and jobs report headline big week, source:Seeking Alpha, summary: No summary",MRNA
178,2023-03-31,"Headline: Gritstone initiated with an Outperform at Evercore ISI, source:Thefly.com, summary: No summary, Headline: Early notable gainers among liquid option names on March 31st, source:Thefly.com, summary: No summary, Headline: The Zacks Analyst Blog Highlights Disney, Marathon Petroleum, Moderna, Nucor and CenterPoint Energy, source:Yahoo, summary: Disney, Marathon Petroleum, Moderna, Nucor and CenterPoint Energy are included in this Analyst Blog., Headline: Generation Bio`s Collaboration With Moderna Will Either Be Seismic, Or Disastrous, source:Seeking Alpha, summary: No summary, Headline: Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know, source:Yahoo, summary: No summary, Headline: Generation Bio's Collaboration With Moderna Will Either Be Seismic, Or Disastrous, source:SeekingAlpha, summary: Generation Bio announced a strategic collaboration with Moderna worth $5m upfront plus a $40m equity investment. See what this deal could do for both companies., Headline: Moderna Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rallied 4.16% to $153.58 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...",MRNA
179,2023-04-02,"Headline: Could This Move by Johnson & Johnson Equal Billions for Moderna?, source:Yahoo, summary: What does big pharma Johnson & Johnson (NYSE: JNJ) have in common with biotech Moderna (NASDAQ: MRNA)?  Last week, however, Johnson & Johnson said it would discontinue its adult RSV program.  Could the J&J news eventually translate into billions of dollars for Moderna?",MRNA
180,2023-04-03,"Headline: MRNA Makes Bullish Cross Above Critical Moving Average, source:Market News Video, summary: No summary, Headline: FDA poised to authorize second Omicron COVID boosters for some - WaPo, source:Seeking Alpha, summary: No summary, Headline: Moderna Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.84% to $159.48 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Treasury yields fractionally lower as slowdown fears persist, source:CNBC, summary: U.S. Treasury yields were slightly lower on Tuesday as concerns over economic growth persisted into the second quarter.",MRNA
181,2023-04-04,"Headline: 2 Top Biotech Stocks to Buy in April, source:Yahoo, summary: Biotech stocks make a great addition to your portfolio at any time.  Axsome Therapeutics (NASDAQ: AXSM) beat the bear market last year.  Each drug could reach peak sales of more than $1 billion, according to analyst and company forecasts., Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 1.86% to $156.52 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite..., Headline: Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots, source:Yahoo, summary: Arbutus Biopharma Corporation (NASDAQ: ABUS) and its licensee Genevant Sciences have sued Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) in the U.S. District Court for the District of New Jersey, seeking damages for infringement of five U.S. patents. Arbutus and Genevant Sciences seek compensation for the unlicensed use of patented lipid nanoparticle (LNP) delivery technologies in Pfizer/BioNTech's famed COVID-19 vaccine. The lawsuit by Arbutus and Genevant says Pfizer/BioNTec, Headline: 7 Sorry Blue-Chip Stocks to Sell in April Before It’s Too Late, source:Yahoo, summary: Stock markets have been rising this year, but the gains have not been equal. While many stocks are in the process of recovering, others continue to fall or trade sideways. Somewhat surprisingly, many blue-chip stocks that have been consistent outperformers over the past decade are now lagging the market. These are companies that are household names and familiar to people in their daily lives. For a variety of internal and external reasons, many once much-loved stocks have now fallen out of favor, Headline: Treasury yields rise as investors weigh potential for higher Fed rates, source:CNBC, summary: U.S. Treasury yields rose Tuesday as traders assessed the likelihood of higher Federal Reserve rates in the future.",MRNA
182,2023-04-05,"Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 1.22% to $154.61 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Moderna (MRNA) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed at $154.61 in the latest trading session, marking a -1.22% move from the prior day., Headline: WHO chief expects COVID emergency to end this year, source:Seeking Alpha, summary: No summary, Headline: Treasury yields slightly higher as investors track key economic data, source:CNBC, summary: U.S. Treasury yields were slightly higher as investors assessed recent labor market data in order to gauge the possibility of a recession.",MRNA
183,2023-04-06,"Headline: Moderna, Merck say mRNA cancer vaccine-KEYTRUDA combo granted PRIME designation, source:Thefly.com, summary: No summary, Headline: Morgan Stanley Sticks to Their Hold Rating for Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna (MRNA) Receives a Buy from Brookline Capital Markets, source:TipRanks, summary: No summary, Headline: 5 Top Growth Stocks to Buy Before the Next Bull Market, source:Yahoo, summary: It's never too early to start planning for the next bull market. Those days of market gains and optimism will be back. History tells us so -- bull markets always have followed bear markets. So, how should you prepare? By taking advantage of the low prices a down market offers us and buying quality companies that could win over time., Headline: Moderna Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rose 2.37% to $158.27 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Moderna, Merck Combined Treatment Gets EMA Designation for Melanoma, source:MarketWatch, summary: By Denny Jacob Pharmaceutical company Moderna Inc. on Thursday said its mRNA-4157/V940 in combination with drugmaker Merck &amp; Co.'s Keytruda was granted..., Headline: MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant, Headline: Catalyst Watch: Eyes on inflation data, big bank earnings, source:Seeking Alpha, summary: No summary",MRNA
184,2023-04-09,"Headline: Premier cancer research event, AACR is starting this week; Here is what to expect, source:Seeking Alpha, summary: No summary, Headline: Cantor biopharma/biotech analysts to hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Catalent upgraded at Deutsche Bank on potential upside to forecasts, source:Seeking Alpha, summary: No summary",MRNA
185,2023-04-10,"Headline: Moderna, Merck win priority designation for personalized cancer vaccine in EU, source:Seeking Alpha, summary: No summary, Headline: U.S. launches $5B program to speed up development of next-gen COVID vaccines, source:Seeking Alpha, summary: No summary, Headline: Pfizer CEO signs open letter calling for reversal of Texas abortion pill ruling, source:CNBC, summary: Pfizer's CEO was among the more than 200 pharmaceutical company executives who signed the letter after a federal judge's controversial ruling on mifepristone., Headline: Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag, source:Yahoo, summary: The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma., Headline: Moderna says it hopes to offer new vaccines for cancer, heart disease, and other conditions by 2030, source:CNBC, summary: Moderna's chief medical officer said advancements in mRNA technology since the outset of the Covid pandemic have ushered in a golden age for new vaccines. , Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rallied 1.19% to $160.15 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: S&P 500 futures are little changed as March inflation report looms ahead: Live updates, source:CNBC, summary: Two key economic data points weigh on the minds of investors this week: the latest consumer price index and the producer price index readings., Headline: Moderna Stock Yo-Yoes Winning A Key Battle For Its Cancer Vaccine, source:Yahoo, summary: Moderna stock rose Monday after European regulators granted its Merck-partnered personalized cancer vaccine a key designation., Headline: Moderna wins appeal court ruling in Arbutus COVID vaccine patent dispute, source:Seeking Alpha, summary: No summary, Headline: Moderna wins appeals court ruling in Arbutus COVID vaccine patent dispute, source:Seeking Alpha, summary: No summary, Headline: Wall Street drifts ahead of inflation, earnings reports, source:Associated Press, The, summary: No summary, Headline: Asian shares moderately higher with focus on inflation data, source:Associated Press, The, summary: No summary, Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: No summary",MRNA
186,2023-04-11,"Headline: Tracking Philippe Laffont`s Coatue Management Portfolio - Q4 2022 Update, source:Seeking Alpha, summary: No summary, Headline: These Stocks Are Moving the Most Today: CarMax, Coinbase, Moderna, WW International, and More, source:MarketWatch, summary: CarMax jumps after posting better-than-expected fiscal fourth-quarter earnings, Coinbase surges after Bitcoin tops $30,000 for the first time in 10 months,..., Headline: Tracking Philippe Laffont's Coatue Management Portfolio - Q4 2022 Update, source:SeekingAlpha, summary: Philippe Laffontâs 13F portfolio value increased from $8.61B to $8.92B this quarter. Read more to see the portfolio's full Q4 2022 update., Headline: 3 Overvalued Blue-Chip Stocks Not Worth Your Green, source:InvestorPlace, summary: No summary, Headline: Moderna Announces Clinical and Program Updates at 4th Vaccines Day, source:Accesswire, summary: No summary, Headline: Moderna announces clinical, program updates at 4th Vaccines Day, source:Thefly.com, summary: No summary, Headline: Moderna announces development of candidates for norovirus, lyme disease, source:Thefly.com, summary: No summary, Headline: Moderna says DSMB recommends continuation of efficacy followup for mRNA-1010, source:Thefly.com, summary: No summary, Headline: Moderna expects six major vaccine product launches in next few years, source:Thefly.com, summary: No summary, Headline: Moderna sees 2027 respiratory product sales $8B-$15B, source:Thefly.com, summary: No summary, Headline: Bank of America Securities Keeps Their Hold Rating on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna is developing a vaccine candidate against Lyme disease that would be its first bacterial vaccine, source:MarketWatch, summary: No summary, Headline: Moderna's MRNA cancer vaccine receives EU Prime designation, source:Alliance News, summary: No summary, Headline: Moderna to hold a virtual event, source:Thefly.com, summary: No summary, Headline: Moderna stock dips after flu shot fails to meet early success threshold, trial continues, source:Seeking Alpha, summary: No summary, Headline: Moderna is developing a Lyme disease vaccine in a first for the company , source:DowJones, summary: Moderna Inc. said Tuesday that it's working to develop its first bacterial vaccine to protect against Lyme disease., Headline: Brookline Capital Markets Remains a Buy on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna Expects 6 Major Vaccine Launches In Next Few Years, source:MarketWatch, summary: By Dean Seal Moderna Inc. expects to launch six major vaccine products in the next few years. The vaccine maker said Tuesday that it is expanding and..., Headline: Stocks making the biggest moves premarket: Moderna, CarMax, Whirlpool and more, source:CNBC, summary: CarMax soared on the back of better-than-expected quarterly earnings., Headline: Moderna says it expects up to $15 billion in sales of Covid, RSV, flu vaccines in 2027, source:CNBC, summary: Moderna said it sees a corresponding operating profit from its Covid, RSV, and flu vaccines in the range of $4 billion to $9 billion in 2027. , Headline: Video: S&P 500 Movers: MRNA, KMX, source:Market News Video, summary: No summary, Headline: Moderna is developing a vaccine against the tick-borne Lyme disease, in a first for the company, source:MarketWatch, summary: No summary, Headline: Video: Nasdaq 100 Movers: MRNA, LCID, source:Market News Video, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Moderna sees up to $15 bln in respiratory vaccine sales in 2027, source:Reuters, summary: Moderna Inc said on Tuesday it expects sales from its respiratory vaccines to be between $8 billion and $15 billion in 2027., Headline: Moderna says there are not enough cases to declare early success for its mRNA flu vaccine, source:CNBC, summary: CNBC's Meg Tirrell reports on news from Moderna that it will delay results from its flu vaccine trials., Headline: Moderna says flu vaccine candidate requires additional study, source:United Press International, summary: No summary, Headline: Stocks making the biggest moves midday: WW International, CarMax, Mohawk, Moderna and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Moderna says potential flu vaccine needs more study, source:Yahoo, summary: Moderna shares slipped Tuesday morning after the COVID-19 vaccine developer said its potential flu vaccine needs more study in a late-stage clinical trial.  The company said an independent data and safety monitory board found that the potential vaccine “did not meet the statistical threshold necessary to declare early success” in the study.  Moderna is developing the vaccine, labeled mRNA-1010, to guard against seasonal flu., Headline: WeightWatchers, CarMax, Moderna, and other stocks on the move, source:MarketWatch, summary: No summary, Headline: Moderna Slumps as Vaccine Data Improves, source:TipRanks, summary: No summary, Headline: These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar, source:Yahoo, summary: The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now., Headline: Moderna to Push Backup Experimental Flu Shot After Setback, source:Yahoo, summary: (Bloomberg) -- Moderna Inc.’s first experimental flu shot didn’t accumulated enough data to determine efficacy in a final-stage study, and the company said it will advance another candidate.Most Read from BloombergKatie Cotton, Guardian of the Apple Brand for 18 Years, DiesElizabeth Holmes Will Have to Wait Out Her Appeal in PrisonTwitter Company ‘No Longer Exists,’ Is Now Part of Musk’s XTumbling Money Supply Alarms Economists Who Foresaw InflationRich Chinese Splashing Out on Luxury Have Yet t, Headline: Moderna stock slides following experimental flu vaccine setback, source:Yahoo, summary: Yahoo Finance Live anchors Julie Hyman and Brad Smith discuss the decline in stock for Moderna., Headline: Could Moderna Become a Warren Buffett Stock?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) is a growth stock that's had plenty of time in the limelight, but that doesn't mean it'd fit the exacting specifications of Warren Buffett.  Berkshire Hathaway's portfolio isn't known for making speculative bets on biotech companies, and the Oracle of Omaha's penchant for reliable growth seems anathema to the industry as a whole, even when considering quality businesses like Moderna.  There are a few reasons why Warren Buffett would probably not want to invest in Moderna today., Headline: Midday movers: CarMax, Moderna, Coinbase Global, source:Yahoo, summary: By Liz Moyer, Headline: Moderna's Vaccine Day: Influenza Vaccine Candidate Testing To Continue As It Misses 'Early Success' Threshold, source:Yahoo, summary: Moderna Inc's (NASDAQ: MRNA) first vaccine candidate against influenza is mRNA-1010, which is being developed in adults. The independent Data and Safety Monitoring Board (DSMB) has completed the first interim efficacy analysis for the second Phase 3 trial (P302) conducted in the Northern Hemisphere to evaluate the safety and non-inferior efficacy compared to a licensed flu vaccine. The DSMB said mRNA-1010 did not meet the statistical threshold necessary to declare early success. The safety board, Headline: S&P 500 Q1 2023 Earnings Preview: Entering An Earnings Recession, source:SeekingAlpha, summary: Q1 is expected to mark the second consecutive quarter of negative y/y earnings growth, which meets the criteria of an earnings recession., Headline: 12 Best Covid Treatment Stocks to Buy Today, source:Yahoo, summary: In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there’s one thing that can be said for sure, it’s that the coronavirus pandemic has changed the world. The deadly disease, […], Headline: Twitter Inc Is Officially Defunct, Alibaba Plans to Integrate ChatGPT Like Chatbot Across Products, Moderna's Flu Shot Study Misses 'Early Success' Criteria: Today's Top Stories, source:Yahoo, summary: Benzinga Twitter Inc Is Officially Defunct As Elon Musk Pursues' Superapp' Goal Twitter Inc, the parent company of the namesake social media platform, has ceased to exist, and it has now been merged into X Corp., court filings show. 'Chief Twit' Elon Musk also appeared to acknowledge the change early on Tuesday by tweeting out ""X."" The development came to light in a court filing of Twitter's corporate disclosure statement in connection with a lawsuit brought about by right-wing activist Laura Lo, Headline: Moderna Stock Slides Despite Positive Vaccines Update. Here’s Why., source:Yahoo, summary: The biotech company is working on new drugs for Lyme disease and Covid-19 as it prepares to roll out six new products with “sizable markets.”, Headline: Antivaccine Groups See Hope in Abortion-Pill Ruling. What It Means for Pharma., source:MarketWatch, summary: A judge's reversal of the FDA's approval of mifepristone has raised concern that it may not have the last word on what drugs may be prescribed in the U.S., Headline: NEW YORK MARKET CLOSE: US stocks wary ahead of key inflation figures, source:Alliance News, summary: No summary, Headline: Moderna, TSR fall; CarMax, Coinbase rise, source:Associated Press, The, summary: No summary, Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 3.06% to $155.25 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: How major US stock indexes fared Tuesday 4/11/2023, source:Associated Press, The, summary: No summary, Headline: Moderna flu shot misses 'early success' bar, shares fall, source:Reuters, summary: Moderna Inc said on Tuesday its experimental flu vaccine did not meet the criteria for ""early success"" in a late-stage trial, and its shares fell 4%., Headline: Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight, source:Reuters, summary: A U.S. appeals court handed Moderna Inc a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp patent related to the companies' legal fight over Moderna's blockbuster COVID-19 vaccines., Headline: Dow Jones Hits 2-Month High; Warren Buffett Targets This Group; Solar Stock Pops, source:Yahoo, summary: The major stock market indexes traded mixed on Tuesday, ahead of Wednesday's inflation report. The Dow Jones and S&P 500 shined, holding near highs of the day. Investors kept their powder dry ahead of the first batch of bank earnings, due on Friday., Headline: Moderna says flu shot misses early success bar, but expects 2024 revenue, source:Reuters, summary: Moderna Inc said on Tuesday its experimental flu vaccine did not meet the criteria for ""early success"" in a late-stage trial, and its shares fell 3%., Headline: UPDATE 1-Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight, source:Yahoo, summary: A U.S. appeals court handed Moderna Inc a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp patent related to the companies' legal fight over Moderna's blockbuster COVID-19 vaccines.  The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal's ruling that the patent for Arbutus' lipid nanoparticle (LNP) technology was invalid based on an earlier Arbutus patent that disclosed the same invention.  Moderna challenged the patent at the PTO's Patent Trial and Appeal Board in 2018, and the board invalidated it in 2019., Headline: Moderna stock drops on mixed data tied to flu vaccine approval, source:Yahoo, summary: The Yahoo Finance Live team takes a look at Moderna shares amid the pharmaceutical company’s outlook on its vaccine products., Headline: Moderna Stock Skids Below Key Line On Unexpected Flu Shot Debacle, source:Yahoo, summary: Moderna stock skidded Tuesday on a mixed update for its mRNA-based flu vaccine. The update could impact the shot's commercial timing.",MRNA
187,2023-04-12,"Headline: Morgan Stanley Sticks to Their Hold Rating for Moderna (MRNA), source:TipRanks, summary: No summary, Headline: BofA says `left with more questions than answers` after Moderna Vaccines Day, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Moderna (MRNA) and REPRO-MED Systems (KRMD), source:TipRanks, summary: No summary, Headline: Why Is Novavax (NVAX) Stock Moving Today?, source:InvestorPlace, summary: No summary, Headline: Why Upcoming Bank Earnings Could Hold the Key to Fed’s Next Rate Rise, source:Yahoo, summary: This time, more than usual, what the banks say will be one of the best forward-looking economic indicators available.  Banks were already tightening lending conditions in January, before the turmoil that brought down Silicon Valley Bank, according to the Federal Reserve’s Senior Loan Officer Opinion Survey.  The question is by how much—is it equivalent to a quarter-point Fed hike, a half-point, or even more?, Headline: Arrowhead adds 11% as SVB upgrades on compelling risk-reward setup, source:Seeking Alpha, summary: No summary, Headline: Moderna`s investments in pipeline leads to P&L uncertainty: Bank of America, source:Seeking Alpha, summary: No summary, Headline: Moderna`s investments in pipeline lead to P&L uncertainty: Bank of America, source:Seeking Alpha, summary: No summary, Headline: Company News for Apr 12, 2023, source:Yahoo, summary: Companies in The News Are: MRNA, COIN, NVDA, DVN, Headline: Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback, source:Yahoo, summary: Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.20% higher to $155.56 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the..., Headline: US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma, source:Yahoo, summary: A U.S. appeals court affirmed a decision to cancel an Arbutus Biopharma Corporation (NASDAQ: ABUS) patent related to a legal fight over Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines. The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal's ruling that the patent for Arbutus' lipid nanoparticle (LNP) technology was invalid based on an earlier Arbutus patent that disclosed the same invention. Moderna challenged the patent at the PTO's Patent Trial and, Headline: JP Morgan Maintains Moderna (MRNA) Neutral Recommendation, source:Fintel, summary: nan, Headline: Moderna (MRNA) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $155.56, marking a +0.2% move from the previous day., Headline: Thursday Sector Leaders: Healthcare, Services, source:Market News Video, summary: No summary, Headline: Carisma Therapeutics initiated with an Outperform at Baird, source:Thefly.com, summary: No summary",MRNA
188,2023-04-13,"Headline: Can Pfizer Beat GSK and Moderna in This $10 Billion Market?, source:Yahoo, summary: Pfizer (NYSE: PFE) and GSK (NYSE: GSK) have competed against each other for years.  Moderna (NASDAQ: MRNA) is a more recent rival, with its COVID-19 vaccine, SpikeVax, going head to head with Pfizer's Comirnaty.  Can Pfizer beat GSK and Moderna in this $10 billion market?, Headline: Buffett Thinks This Is the Most Important Quality an Investor Can Have, source:Yahoo, summary: Warren Buffett is a successful stock picker and his company, Berkshire Hathaway, has regularly outperformed the S&P 500 over multiple decades.  Investors can learn a lot from his strategies, which center around value, competitive advantage, and a reasonable growth.  Buffett usually looks for these attributes while searching for the wonderful businesses he invests in., Headline: MRNA June 2nd Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: Moderna (MRNA) Receives a Sell from SVB Securities, source:TipRanks, summary: No summary, Headline: Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News, source:Yahoo, summary: Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 3.19% to $160.53 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Don`t Count Out Moderna Stock (NASDAQ:MRNA) for the Long Term, source:TipRanks, summary: No summary, Headline: Carisma jumps 14% as Baird starts at Outperform on lead asset, source:Seeking Alpha, summary: No summary",MRNA
189,2023-04-14,"Headline: Ghana 1st in world to approve new malaria vaccine by Oxford, source:Seeking Alpha, summary: No summary, Headline: Drug manufacturer Catalent's stock tumbles 25% after profit warning and CFO departure, source:MarketWatch, summary: Drug manufacturer Catalent said higher-than-expected costs and productivity issues at three plants would have a material adverse impact on fiscal..., Headline: Analysts` Top Healthcare Picks: Thermo Fisher (TMO), Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Drug manufacturer Catalent`s stock tumbles 25% after profit warning and CFO departure, source:MarketWatch, summary: No summary, Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary, Headline: 3 Medical Stocks With Solid Growth Potential to Keep Track Of, source:Yahoo, summary: Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years., Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 2.14% to $157.10 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite..., Headline: Catalent warns of production issues, finishes day as worst S&P 500 performer, source:CNBC, summary: CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Catalent and Moderna.",MRNA
190,2023-04-15,"Headline: Merck, Moderna announce results from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, source:Thefly.com, summary: No summary, Headline: Moderna, Merck, And A Personalized Cancer Vaccine: What Does Their AACR Presentaion Tell Us?, source:TalkMarkets, summary: No summary",MRNA
191,2023-04-16,"Headline: Moderna, Merck combo cancer-vaccine treatment shows ���significant` promise, source:MarketWatch, summary: No summary, Headline: Moderna, Merck, And A Personalized Cancer Vaccine: What Does Their AACR Presentation Tell Us?, source:TalkMarkets, summary: No summary, Headline: Brookline Capital Markets Reaffirms Their Buy Rating on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna, Merck, And A Personalized Cancer Vaccine - Updates from AACR, source:TalkMarkets, summary: No summary, Headline: US executive pay bucked falling stock market in 2022, source:Yahoo, summary: More than a third of S&P 500 executives received pay rises last year despite negative shareholder returns, Headline: Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients, Headline: CORRECTED-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return, source:Yahoo, summary: An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.  The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which revs up the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU Langone Perlmutter Cancer Center, who presented the findings., Headline: Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancer, source:Reuters, summary: An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday., Headline: Moderna, Merck combo cancer-vaccine treatment shows 'significant' promise, source:MarketWatch, summary: A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%., Headline: Moderna, Merck Show Progress Toward Cancer Vaccines, source:Yahoo, summary: Moderna  and  Merck  & Co.’s cancer vaccine helped prevent relapse for melanoma patients, results from a midstage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system.  About 79% of high-risk melanoma patients who got the personalized vaccine and Merck’s immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, researchers said Sunday.  The 157-person trial offers some of the strongest evidence yet that such vaccines could benefit cancer patients., Headline: CORRECTED-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return , source:Reuters, summary: An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday., Headline: UPDATE 1-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return, source:Yahoo, summary: An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.  The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which revs up the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU Langone Perlmutter Cancer Center, who presented the findings., Headline: Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return, source:Reuters, summary: An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday., Headline: Moderna & Merck Are Better Together, source:TipRanks, summary: No summary, Headline: Noteworthy Monday Option Activity: MRNA, ENPH, TRUP, source:Stock Options Channel, summary: No summary",MRNA
192,2023-04-17,"Headline: These Stocks Are Moving the Most Today: State Street, Alphabet, Prometheus, Roblox, Moderna, Enphase, and More, source:MarketWatch, summary: State Street tumbled after a profit miss, Alphabet fell on a report Samsung could switch the default search engine on its smartphones, and Merck agreed to..., Headline: Prometheus soars 70%, Merck dips after ~$11B buyout deal, source:Seeking Alpha, summary: No summary, Headline: Why did Moderna stock drop today? mRNA cancer therapy data, source:Seeking Alpha, summary: No summary, Headline: Piper Sandler Sticks to Its Buy Rating for Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna, Xpeng and Uber rise premarket; State Street falls, source:Yahoo, summary: By Peter Nurse, Headline: IN BRIEF: Merck, Moderna note positive results for Keytruda, mRNA-4157, source:Alliance News, summary: No summary, Headline: Stocks making the biggest moves premarket: Charles Schwab, Dell, Alphabet, HP Inc. & more, source:CNBC, summary: JPMorgan downgraded Dell to neutral from overweight, citing its preference for HP's expected recovery in the PC segment., Headline: Unusually active option classes on open April 17th, source:Thefly.com, summary: No summary, Headline: Moderna (MRNA) Stock Sinks Despite Positive Cancer Vaccine Update, source:InvestorPlace, summary: No summary, Headline: PRST Stock Alert: What to Know About Red-Hot Presto Automation Today, source:InvestorPlace, summary: No summary, Headline: Video: Nasdaq 100 Movers: MRNA, ENPH, source:Market News Video, summary: No summary, Headline: This Prediction May Completely Change Your Opinion of Moderna, source:Yahoo, summary: Moderna (NASDAQ: MRNA) has brought investors great returns -- if you bought the stock in the early days of the pandemic or before that point.  Moderna's reliance on its coronavirus vaccine for revenue has worried some investors.  It may shift your view of Moderna from negative to positive., Headline: These Stocks Are Moving the Most Today: Prometheus, Merck, Moderna, Charles Schwab, XPeng, and More, source:Yahoo, summary: Merck agrees to buy Prometheus Biosciences for about $10.8 billion, and Charles Schwab reports quarterly earnings on Monday, kicking off a busy week for corporate results., Headline: Netflix (NFLX) Stock Slips After Botched ���Love Is Blind` Live Event, source:InvestorPlace, summary: No summary, Headline: Big Bank Earnings Won’t Reveal If the Turmoil Is Over. Here’s What Will., source:Yahoo, summary: The CBOE Volatility Index (VIX), the so-called fear gauge, closed last week at its lowest level since early January 2022.  The MOVE Index, which tracks Treasury market volatility, has also fallen below where it was before Silicon Valley Bank collapsed last month, Deutsche Bank analysts noted., Headline: Enphase Energy (ENPH) Stock Pops After Scoring Another Analyst Upgrade, source:InvestorPlace, summary: No summary, Headline: Wall Street Analysts Are Bullish On Moderna Stock Price: Should You?, source:TalkMarkets, summary: No summary, Headline: Wall Street Analysts Are Bullish On Moderna Stock Price: Should You Be?, source:TalkMarkets, summary: No summary, Headline: Moderna shares fall despite promising data from cancer vaccine trial, source:CNBC, summary: Moderna's mRNA vaccine, when combined with Merck's blockbuster drug Keytruda, showed promise in treating melanoma, a kind of skin cancer., Headline: TD Cowen biotech analysts to hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Moderna Slumps as Vaccine Momentum Wanes, source:GuruFocus, summary: No summary, Headline: 5 Penny Stocks With Explosive 5X Potential, source:InvestorPlace, summary: No summary, Headline: Stocks making the biggest moves midday: Alphabet, Charles Schwab, State Street, Moderna and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Personalis: Revisiting The Investment Thesis, source:SeekingAlpha, summary: nan, Headline: Moderna, Merck's Cancer Vaccines Exhibit Positive Outcomes Under Midstage Trial, source:Yahoo, summary: Moderna, Inc (NASDAQ: MRNA) and Merck & Company, Inc's (NYSE: MRK) cancer vaccine exhibited positive results against relapse for melanoma patients, results from a midstage trial showed. About 79% of high-risk melanoma patients who got the personalized vaccine and Merck's immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, the Wall Street reports citing researchers. Some 157 patients with stage three or four melanom, Headline: Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence, source:Yahoo, summary: Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death., Headline: Stock Market Slides After Mixed Bank Earnings, Meta Downgrade, Google's AI Trauma, source:Yahoo, summary: Stock market indexes slid lower Monday and were near session lows in the last hour. Bank earnings showed mixed results. State Street Bank led the downside, plunging more than 12%. The Dow Jones Industrial Average was relatively unchanged., Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 8.36% to $143.97 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Moderna stock plunges following mixed analyst reviews of cancer vaccine data, source:Yahoo, summary: Moderna stock plunges following mixed analyst reviews of cancer vaccine data, Headline: Wells Fargo's Mohit Bansal on Merck's $10.8B deal to buy Prometheus, source:CNBC, summary: Mohit Bansal, Wells Fargo securities analyst, joins 'Closing Bell: Overtime' to discuss Merck's acquisition of Prometheus and Moderna's positive cancer therapy trial results., Headline: Moderna Cancer-Therapy Sees More Upbeat Data, source:Yahoo, summary: New data bolster the case for Moderna’s experimental cancer treatment, but the path to turning it into a marketable product remains a long one., Headline: Moderna Crumbles As Cancer Vaccine Data Show A 'Longish And Complex' Road, source:Yahoo, summary: Moderna stock crumbled Monday after updated results for its Merck-partnered cancer vaccine show a ""longish and complex path"" toward approval., Headline: Why Moderna Stock Plunged Today, source:Yahoo, summary: Mildly positive results from a phase 2b cancer trial fell short of more hopeful investors' expectations., Headline: S&P 500: Top 5 Performers Today Include Enphase Energy, First Solar, source:Yahoo, summary: The five best S&P 500 performers Monday included Enphase Energy and First Solar. Moderna was a key laggard. Banks were big winners and losers., Headline: These 2 Stocks Were Monday's Big Disappointments, source:Yahoo, summary: The Nasdaq Composite (NASDAQINDEX: ^IXIC), Dow Jones Industrial Average (DJINDICES: ^DJI), and S&P 500 (SNPINDEX: ^GSPC) all finished higher by about a third of a percent.  In particular, Roblox (NYSE: RBLX) and Moderna (NASDAQ: MRNA) saw substantial losses on the day.  Below, you'll learn more about what happened with both companies and why their investors aren't pleased with what they see ahead., Headline: Treasury yields little changed as focus remains on economic outlook, earnings, source:CNBC, summary: U.S. Treasury yields were little changed on Tuesday, as investors continued to assess the outlook for the U.S. economy and digested the latest round of corporate earnings.",MRNA
193,2023-04-18,"Headline: FDA clears second bivalent COVID booster for older individuals, source:Thefly.com, summary: No summary, Headline: Second updated COVID booster dose OKd by FDA for at-risk individuals, source:Seeking Alpha, summary: No summary, Headline: Moderna's Flu Vaccine Struggles: Is Novavax Stock Now a Better Buy?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) knows that it needs new products.  The good news is that Moderna has three vaccine candidates in late-stage testing.  Moderna reported more disappointing results for its experimental flu vaccine last week., Headline: FDA clears extra COVID booster for some high-risk Americans, source:Associated Press, The, summary: No summary, Headline: FDA authorizes additional omicron Covid booster for seniors and people with weak immune systems, source:CNBC, summary: Although the burden of the pandemic has eased substantially, the CDC says Covid continues to kill more than 1,300 people per week., Headline: FDA withdraws authorization for older COVID vaccines by Moderna, Pfizer, source:Reuters, summary: The U.S. Food and Drug Administration on Tuesday withdrew its emergency use authorization for older messenger RNA vaccines by Moderna Inc and Pfizer-BioNTech/ as it now recommends the use of newer Omicron-targeting shots for all doses. (Reporting by Leroy Leo in Bengaluru..., Headline: Extra COVID-19 booster now open to some high-risk Americans, source:Yahoo, summary: Older Americans and people with weak immune systems can get an extra COVID-19 booster dose this spring.  The Centers for Disease Control and Prevention on Wednesday signed off on a more flexible booster schedule for people who remain at the highest risk from COVID-19 — giving them the choice of a second “bivalent” Pfizer or Moderna booster, the most up-to-date formula.  “Many in the population are experiencing vaccine fatigue but there is a subset who are eager to receive additional doses,” CDC’s Dr. Sara Oliver told an agency advisory panel that expressed support for the change., Headline: Top Stocks To Buy Now? 3 Healthcare Stocks To Know, source:StockMarket, summary: Healthcare stocks for your Mid-April 2023 watchlist., Headline: Johnson & Johnson expects no new Covid vaccine revenue, after shots drive earnings beat, source:CNBC, summary: J&J's unpopular Covid vaccine appeared to bear its last fruit during the first quarter, contributing $747 million in sales. , Headline: Moderna Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Moderna Inc. sank 0.93% to $142.63 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Bearish Option Trade For MRNA Stock, source:Yahoo, summary: With low implied volatility right now, a bear put spread on Moderna is a viable strategy to profit on the downside., Headline: FDA Gives Green Signal To Second Omicron-Adapted Booster Shots For People At High Risk From Covid, source:Yahoo, summary: On Tuesday, the FDA amended the emergency use authorizations (EUAs) of Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE), and BioNTech SE's (NASDAQ: BNTX) COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule. This action includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for all doses administered to individuals six months of age and older, including for an additional dose or doses for certain populations. The monovalent Mod, Headline: Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $142.63, moving -0.93% from the previous trading session.",MRNA
194,2023-04-19,"Headline: CDC endorses second updated COVID jab for seniors, immunocompromised, source:Seeking Alpha, summary: No summary, Headline: FDA approves single booster dose of bivalent COVID vaccine for people aged 65 and older or those with immunocompromise, source:MarketWatch, summary: The U.S. Food and Drug Administration has approved an additional single dose of the bivalent COVID vaccines for individuals above the age of 65 and those..., Headline: FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations, source:Yahoo, summary: To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older., Headline: Abbott Labs shares pop as revenue, earnings defy steep drop in Covid test sales, source:CNBC, summary: Abbott Laboratories said Covid-related headwinds may actually be easing. , Headline: Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates, source:Yahoo, summary: Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.13% higher to $142.82 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Moderna Stock: Bear vs. Bull, source:Yahoo, summary: Moderna (NASDAQ: MRNA) has become one of the most talked-about companies on the planet.  Or is Moderna still a hot stock to add to your portfolio?  Moderna's coronavirus vaccine generated more than $17 billion in annual revenue over the past two years., Headline: Top Companies for Financial Strength, source:Yahoo, summary: The Management Top 250 ranking, developed by the Drucker Institute, measures corporate effectiveness by examining performance in five categories: customer satisfaction, employee engagement and development, innovation, social responsibility and financial strength.  Moderna scored 93.2 for financial strength, with Apple at 92.7 and Microsoft at 91.7., Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $9,077.00K, source:Fintel, summary: nan, Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $2,937.00K, source:Fintel, summary: nan, Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $5,397.50K, source:Fintel, summary: nan, Headline: Moderna (MRNA) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $142.82, marking a +0.13% move from the previous day.",MRNA
195,2023-04-20,"Headline: WHO officially launches mRNA vaccine hub in Cape Town, source:Yahoo, summary: The World Health Organization (WHO) on Thursday officially launched its mRNA vaccine technology hub in Cape Town, a facility established during the COVID-19 pandemic to help poorer countries struggling to access life-saving medication.  In 2021, the WHO picked South African biotech firm Afrigen Biologics for a pilot project to give poor and middle-income countries the know-how and licenses to make COVID vaccines, in what South African President Cyril Ramaphosa then called a historic step.  Afrigen Biologics has used the publicly available sequence of Moderna Inc's mRNA COVID vaccine to make its own version of the shot - AfriVac 2121 - at lab scale and is now scaling up production., Headline: Moderna, IBM to explore quantum computing, generative AI for mRNA science, source:Thefly.com, summary: No summary, Headline: Novavax downgraded at TD Cowen citing COVID uncertainty, source:Seeking Alpha, summary: No summary, Headline: Moderna Teams With IBM to Explore AI, Quantum Computing in Vaccine Development, source:MarketWatch, summary: By Dean Seal Moderna Inc. and International Business Machines Corp. have teamed up to explore the use of artificial intelligence and quantum computing in the..., Headline: Is Moderna About to Face the Same Challenge as Other Biotechs?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) has brought in billions thanks to its coronavirus vaccine.  Now, though, the biotech company has to show investors it can excel beyond the coronavirus portfolio.  One of Moderna's programs that have spurred excitement among investors is its personalized cancer vaccine candidate., Headline: Moderna teams up with IBM to put A.I., quantum computing to work on mRNA technology used in vaccines, source:CNBC, summary: Moderna's partnership with IBM comes as the drugmaker navigates its post-pandemic boom driven by its mRNA Covid vaccine. , Headline: Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and IBM (NYSE:IBM) today announced an agreement under which Moderna will explore next generation technologies including quantum computing and artificial intelligence to advance and accelerate mRNA research and science., Headline: Cantor biopharma/biotech analysts to hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: UPDATE 1-WHO launches mRNA vaccine hub in Cape Town, source:Yahoo, summary: The World Health Organization (WHO) on Thursday officially launched its mRNA vaccine technology hub in Cape Town, a facility established during the COVID-19 pandemic to help poorer countries struggling to gain access to life-saving medication.  In 2021, the WHO picked South African biotech firm Afrigen Biologics and local vaccine-maker Biovac for a proof-of-concept pilot project to give poor and middle-income countries the know-how and licences to make COVID vaccines, in what South African President Cyril Ramaphosa then called a historic step.  Afrigen Biologics has used the publicly available sequence of Moderna Inc's mRNA COVID vaccine to make its own version of the shot - AfriVac 2121 - at lab scale and is now scaling up production., Headline: Where Will Moderna Be in 1 Year?, source:Yahoo, summary: A lot can happen in 12 months in the active and volatile biotech industry, especially for a company like Moderna (NASDAQ: MRNA).  The vaccine maker has a pipeline full of promising candidates in addition to its commercialized COVID-19 product which is bringing in solid revenue for now.  Key ongoing developments on both fronts will help shape Moderna's long-term prospects, so investors should stay tuned., Headline: Stocks making the biggest moves midday: Tesla, IBM, American Express, AT&T and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: New Covid-19 Booster Shots: What to Know, source:Yahoo, summary: New booster shots are available to bolster people’s protection against Omicron subvariants BA.4 and BA.5., Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.18% to $141.14 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m., Headline: Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't?, source:Yahoo, summary: Novavax has a solid platform but continues to face a $700 million litigation headwind, an analyst said Thursday as he downgraded NVAX stock., Headline: Treasury yields continue to fall on signs of economic contraction, source:CNBC, summary: U.S. Treasury yields dropped further on Friday morning after a round of data indicated that the economy may be contracting., Headline: Moderna Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",MRNA
196,2023-04-21,"Headline: ClearBridge International Value Strategy Q1 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: nan, Headline: Moderna: Critically Undervalued With a Promising Pipeline, source:GuruFocus, summary: No summary",MRNA
197,2023-04-22,"Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: nan, Headline: Can This AI Deal With IBM Be a Game-Changer for Moderna?, source:Yahoo, summary: You may not automatically think of artificial intelligence (AI) or quantum computing when you think of biotech giant Moderna (NASDAQ: MRNA).  You might think more about coronavirus vaccines and traditional laboratory work.  After all, Moderna is a leading coronavirus vaccine maker today., Headline: Microsoft, Google lead week`s AI action, source:Seeking Alpha, summary: No summary, Headline: Insiders who sold Moderna, Inc.'s (NASDAQ:MRNA) earlier this year didn't have to weather this week's 10% slide, source:Yahoo, summary: Moderna, Inc.'s (NASDAQ:MRNA) value has fallen 10% in the last week, but insiders who sold US$4.3m worth of stock over...",MRNA
198,2023-04-23,"Headline: The Best Stocks to Invest $20,000 in Right Now, source:Yahoo, summary: For instance, one may pay you a top-notch dividend, another may offer you a solid track record of earnings growth, and a third might promise the potential for enormous growth ahead.  If you're a cautious investor, you should favor dividend stocks and companies that have increased their earnings over time.  AbbVie (NYSE: ABBV) is a stock you'll like for its earnings and dividend growth over time., Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: No summary",MRNA
199,2023-04-24,"Headline: Top Biotech Stocks For Q2 2023: First Gem Is BioNTech, source:SeekingAlpha, summary: nan, Headline: Moderna initiated with a Neutral at Guggenheim, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary, Headline: Moderna`s mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19, source:Seeking Alpha, summary: No summary",MRNA
200,2023-04-25,"Headline: Is Moderna Setting Expectations Too High?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) is going to see its revenue nosedive this year, as demand for its COVID vaccine won't be nearly as strong as it was in the past few years.  The company hopes that through its pipeline, however, it will be able to get its business back to generating growth, and that by 2027 its top line could hit up to $15 billion.  In 2022, Moderna reported $19.3 billion in revenue., Headline: Noteworthy Tuesday Option Activity: MRNA, AMZN, OTIS, source:Stock Options Channel, summary: No summary, Headline: 3 Cash-Rich Biotech Stocks to Bet on for the Long Haul, source:Yahoo, summary: The Federal Reserve’s recent interest rate hikes mean banks charge much higher interest rates for loans. The interest on loans can be considered the price of borrowing more money. And since acquiring cash now costs more money, it’s becoming much more complicated for companies to invest. For biotech stocks, the pain is clearly borne by investors, who choose to dive into these capital-intensive businesses. For a cash-strapped company, the rising cost of money can be a death sentence. But cash-rich, Headline: CureVac: Potential Of mRNA Tech Beyond Covid-19 Vaccine Development, source:SeekingAlpha, summary: Clinical candidates being advanced in phase 1 studies from the CureVac pipeline areÂ for rabies andÂ oncology. Click for our CVAC stock review., Headline: How to make sense of the new CDC guidelines on covid vaccine boosters for children, source:Yahoo, summary: Covid vaccines aren’t popular among parents of young American children. As of April 5, just 12% of kids between six months and four years of age had received at least one dose of vaccine, and only about 5% had completed their primary series (three shots)., Headline: Moderna's mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19, source:SeekingAlpha, summary: With a robust pipeline and promising clinical trial results, Moderna is well-positioned to capitalize on various market opportunities. Click here for more on the stock prospects., Headline: Insider selling could be signaling recession and a stock market selloff, source:MarketWatch, summary: No summary, Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",MRNA
201,2023-04-26,"Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: No summary, Headline: EU publishes proposed reforms for pharma industry, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Novavax: Dead Cat Bounce, source:SeekingAlpha, summary: Novavax bounced on hype while the prospects from the business continue to dim with the demand for Covid vaccines. Click here for our take on VNAX stock., Headline: Merck’s First-Quarter Earnings Beat Estimates. The Stock Is Rising., source:MarketWatch, summary: The big pharma company has been getting ready for the loss of patent protection for the cancer immunotherapy Keytruda in 2028. Merck also raised guidance., Headline: Guggenheim Initiates Coverage of Moderna (MRNA) with Neutral Recommendation, source:Fintel, summary: nan, Headline: Better Buy: Pfizer vs. Moderna, source:Yahoo, summary: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have one big thing in common.  Both companies have dominated the coronavirus vaccine market -- and aim to continue generating blockbuster revenue from their vaccines in a post-pandemic world.  Pfizer is a big pharmaceutical player with many blockbusters on the market., Headline: Second judge says US not liable in Moderna COVID-19 vaccine patent case, source:Yahoo, summary: Moderna Inc failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna's COVID-19 vaccine.  Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit., Headline: Moderna’s CEO shares what it was like to leap from pre-revenue startup to household name and Fortune 500 company, source:Yahoo, summary: The COVID-19 vaccine turned Moderna into a household name. What's next for the company?, Headline: Blue-Chip Stocks: 7 Hidden Gems for Long-Term Growth, source:Yahoo, summary: While most financial advisors may direct you to blue-chip stocks to buy now, the problem with this well-meaning concept is that everybody else also has the same idea. Because of their massive footprint, these high-profile companies feature transparent, predictable businesses. However, the other side of this relationship centers on a decided lack of upside potential. Nevertheless, every now and then, some top enterprises slip under the radar. Here, the best blue-chip stocks for 2023 might not alw, Headline: UPDATE 1-Second judge says US not liable in Moderna COVID-19 vaccine patent case, source:Yahoo, summary: Moderna Inc failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna's COVID-19 vaccine.  Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit.",MRNA
202,2023-04-27,"Headline: Merck revenue falls after dramatic drop in sales of Covid antiviral treatment , source:CNBC, summary: Despite the drop in molnupiravir sales, Merck's revenue and adjusted earnings for Q1 2023 beat Wall Street's expectations. , Headline: 3 Stocks That Could Be Worth More Than Berkshire Hathaway by 2030, source:Yahoo, summary: Berkshire Hathaway is an enormous company.  Let's have a look at three companies I think are poised to surpass Berkshire over the next seven years: Tesla (NASDAQ: TSLA), Moderna (NASDAQ: MRNA), and Nvidia (NASDAQ: NVDA)., Headline: 7 Healthcare Stocks With Huge Return Potential for Long-Term Investors, source:Yahoo, summary: Healthcare stocks are one of the best bets out there. The U.S. spends more on healthcare than any other country. In 2021, America spent 17.8% of its gross domestic product on healthcare, nearly twice as much as the average among OECD nations. Health spending per person in the U.S. was $12,914 in 2021, which was about $5,000 more than any other developed country. All told, the U.S. spends more than $4 trillion each year on healthcare, making it one of the leading sectors of the world’s biggest ec, Headline: Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Moderna (MRNA) Expected to Beat Earnings Estimates: Should You Buy?, source:Yahoo, summary: Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $130.07, moving -0.5% from the previous trading session., Headline: CDC relaxes COVID-19 vaccination rules for international travelers, source:United Press International, summary: No summary",MRNA
203,2023-04-28,"Headline: Moderna tries to show it’s not a ‘one trick pony’, source:Yahoo, summary: Moderna’s Covid-19 vaccine saved millions of lives and made the biotech group one of America’s fastest-growing companies.  The US drugmaker is funding an ambitious expansion with the windfall profits generated by its successful Spikevax Covid jab, which is, at present, its only approved product.  “Our base plan is to, hopefully, not lose money but there is a chance we could,” explains Jamey Mock, Moderna’s chief financial officer., Headline: Moderna`s COVID vaccine booster gets EMA nod for use in kids over 6, source:Seeking Alpha, summary: No summary, Headline: Better Healthcare AI Buy: Moderna vs. Medronic, source:Yahoo, summary: Artificial intelligence (AI) could be the next big thing in healthcare. Companies may predict surgical outcomes, select the best drug candidates, improve manufacturing processes -- and these are just a few examples., Headline: Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?, source:Yahoo, summary: Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings., Headline: Earnings Week Ahead: Apple, Ford, Starbucks, Anheuser Busch, and more, source:Seeking Alpha, summary: No summary, Headline: Could The Market Be Wrong About Moderna, Inc. (NASDAQ:MRNA) Given Its Attractive Financial Prospects?, source:Yahoo, summary: With its stock down 31% over the past three months, it is easy to disregard Moderna (NASDAQ:MRNA). However, a closer..., Headline: Moderna Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rallied 2.17% to $132.89 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...",MRNA
204,2023-04-30,"Headline: BioNTech/Pfizer’s mooted EU deal for 70mn Covid shots threatens rivals, source:Yahoo, summary: A proposed deal between BioNTech/Pfizer and the EU for about 70mn Covid-19 shots a year until 2026 threatens to push rivals Moderna, Novavax, and Sanofi out of the market, risking the regional prevention of Covid-19 being left to just one product.  The bloc is negotiating an amended deal with Pfizer despite the European public prosecutor opening a criminal investigation into their original agreement.  Poland and some other central European countries are refusing to sign the amended deal because they do not want to pay for cancelled doses, according to two of the people., Headline: Weekly Preview: Earnings to Watch This Week 4-30-23 (AMD, AAPL, MRNA, SQ), source:Nasdaq, summary: This week, Apple, AMD, Moderna, and Square report earnings., Headline: This Cathie Wood Stock Is Tanking In 2023. Here's Why You Should Be Buying It, source:Yahoo, summary: While demand for its Covid vaccine may be fading, Moderna has other potential products at various stages of clinical trials., Headline: Blockbuster IPOs Are Coming To Push The Rally Higher, source:SeekingAlpha, summary: Kenvue, the consumer health product spinoff from Johnson & Johnson, was going to be the biggest in a year. Learn more about the IPOs and my trades.",MRNA
205,2023-05-01,"Headline: Moderna co-founder calls on US politicians and judges to stop questioning science, source:Yahoo, summary: Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases, Headline: 5 things to know before the stock market opens Monday, source:CNBC, summary: Here are the most important news items that investors need to start their trading day., Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.38% higher to $133.40 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Will Pfizer (PFE) Beat Expectations This Earnings Season?, source:Yahoo, summary: Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q1., Headline: Top Stock Reports for AMD, Cigna & Moderna, source:Yahoo, summary: Today's Research Daily features new research reports on 12 major stocks, including Advanced Micro Devices, Cigna and Moderna., Headline: Why the human genome could be healthcare’s holy grail, source:Yahoo, summary: 23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andME (ME) CEO also says they are looking into building new partnerships with pharmaceutical companies once the company’s partnership with GlaxoSmithKline (GSK) ends in July.  Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe",MRNA
206,2023-05-02,"Headline: Moderna plans to open an enterprise solutions hub in the Philippines, source:Seeking Alpha, summary: No summary, Headline: The 3 Most Talked-About Stocks and Cryptos Right Now, source:InvestorPlace, summary: No summary, Headline: Pfizer earnings and revenue top expectations despite Covid vaccine sales decline, source:CNBC, summary: Pfizer topped analysts' expectations with its first-quarter earnings report, despite a sales decline driven by the lower demand for the company's Covid vaccine., Headline: The Zacks Analyst Blog Highlights Advanced Micro Devices, The Cigna Group, Moderna, Parker-Hannifin and Rollins, source:Yahoo, summary: Advanced Micro Devices, The Cigna Group, Moderna, Parker-Hannifin and Rollins are included in this Analyst Blog., Headline: In the wake of Moderna, Inc.'s (NASDAQ:MRNA) latest US$1.8b market cap drop, institutional owners may be forced to take severe actions, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Moderna implies that they have significant influence over the..., Headline: Moderna to Report First Quarterly Loss Since Debuting Covid-19 Vaccine, source:Yahoo, summary: The mRNA drugmaker will look to excite investors with its product pipeline as Covid earnings falter., Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.50% to $131.40 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite..., Headline: Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets., Headline: Big Pharma Stocks Offer Income and Growth Potential. The Case for Gilead Sciences and Merck., source:MarketWatch, summary: Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy., Headline: You Can Have Dividends and Growth. Here’s How. , source:MarketWatch, summary: Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.",MRNA
207,2023-05-03,"Headline: Moderna Stock: Looking A Little Undervalued Ahead Of Q1 Earnings, source:SeekingAlpha, summary: Moderna is reliant on COVID vaccine revenues only in 2023 - no other new products will be launched this year. Check out why I have a buy rating on MRNA stock., Headline: All eyes on Moderna Q1 earnings with focus on pipeline beyond COVID, source:Seeking Alpha, summary: No summary, Headline: Should You Buy Moderna (MRNA) Ahead of Earnings?, source:Yahoo, summary: Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season., Headline: FDA approves GSK's RSV vaccine for older adults, world's first shot against virus , source:CNBC, summary: The FDA's approval is a victory for GSK in a race against Pfizer and Moderna to bring a shot that targets respiratory syncytial virus to the market. , Headline: Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More, source:Yahoo, summary: Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release., Headline: NEW YORK MARKET CLOSE: Banks drag US stocks lower after rate increase, source:Alliance News, summary: No summary, Headline: Moderna Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Moderna Inc. dropped 0.96% to $130.14 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Moderna to Report Earnings. What Comes After Covid Vaccine Will Be the Focus., source:Yahoo, summary: As the biotech reports first-quarter earnings, the focus will be on Moderna's pipeline of future vaccines and cancer treatments and whether they can fill the hole left by dwindling Covid vaccine sales. ., Headline: Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting, source:Yahoo, summary: Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that an abstract reporting on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA) has been accepted for presentation at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting being held May 16-20, 2023 in Los Angeles, CA., Headline: GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line, source:Yahoo, summary: GSK stock jumped Wednesday after the drugmaker won the first-ever approval for an RSV vaccine, leading rivals Pfizer and Moderna., Headline: GLOBAL BRIEFING: China's manufacturing weakens; Fed enacts 25bp hike, source:Alliance News, summary: No summary, Headline: LONDON BRIEFING: Shell sets USD4 billion buyback; Next backs outlook, source:Alliance News, summary: No summary",MRNA
208,2023-05-04,"Headline: U.S. stock futures see volatile trading on Fed and bank angst; Apple results loom, source:MarketWatch, summary: No summary, Headline: Moderna GAAP EPS of $0.19 beats by $1.94, revenue of $1.9B beats by $730M, source:Seeking Alpha, summary: No summary, Headline: Moderna stock up premarket after posting surprise profit and revenue that crushed estimates, source:MarketWatch, summary: No summary, Headline: Moderna posts Q1 2023 beat amid stronger than expected vaccine demand, source:Seeking Alpha, summary: No summary, Headline: ‘COVID is not going away’: Moderna posts surprise quarterly profit as it looks to fall vaccinations  , source:MarketWatch, summary: Company aims to take a ‘sizable share’ of a $30 billion global respiratory vaccine market, Headline: Moderna: Q1 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Moderna posts surprise quarterly profit despite waning demand for Covid vaccines, source:CNBC, summary: Moderna maintained its full-year guidance of around $5 billion in revenue from its Covid vaccine, its only marketable product. , Headline: Tracking Baillie Gifford`s 13F Portfolio - Q1 2023 Update, source:Seeking Alpha, summary: No summary, Headline: PacWest, First Horizon, Paramount fall premarket; Shopify, Moderna rise, source:Yahoo, summary: Investing.com -- Stocks in focus in premarket trade on Thursday, May 4th. Please refresh for updates., Headline: Two Covid Era Stars, Two Different Long-Term Outlooks, source:Nasdaq, summary: With the benefit of 20/20 hindsight, many of the pandemic related market moves that we saw in 2020 and 2021 were ridiculous, Headline: Moderna CEO St��phane Bancel On Surprise Q1 Profit, Post-Covid Future, source:TalkMarkets, summary: No summary, Headline: These Have Been 3 of the Best-Performing Healthcare Stocks Since 2020, source:Yahoo, summary: The COVID-19 public health emergency is slated to end in the U.S. on May 11.  Three of the best-performing healthcare stocks since then include Moderna (NASDAQ: MRNA), McKesson (NYSE: MCK), and Eli Lilly (NYSE: LLY).  It has multiple products in its approval pipeline, including a vaccine for the respiratory syncytial virus that has been highly effective in late-stage trials., Headline: ���COVID is not going away`: Moderna posts surprise quarterly profit as it looks to fall vaccinations����, source:MarketWatch, summary: No summary, Headline: Moderna beats COVID vaccine sales expectations as deferred revenue rolls in, source:Yahoo, summary: Moderna Inc on Thursday reported stronger-than-expected sales of $1.9 billion for its COVID-19 vaccine in the first quarter, driven by a surge of revenue deferred from 2022, but left its 2023 sales expectations unchanged.  The vaccine maker posted a profit of 19 cents per share, compared with analyst expectations for a loss of $1.77 per share, in part because sales were higher than expected.  Moderna said it continued to expect COVID vaccine sales of $5 billion for the year based on advance purchase agreements., Headline: Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the first quarter of 2023., Headline: UPDATE 4-Moderna reports surprise profit as it books deferred COVID vaccine sales, source:Yahoo, summary: Moderna Inc on Thursday reported a small profit of 19 cents per share instead of an expected loss as it booked more revenue in the first quarter from last year's deferred orders for its COVID-19 vaccine than had been anticipated.  The company did not change its forecast of $5 billion in COVID vaccine sales for the year based on advance purchase agreements.  The company expects to sign commercial contracts for updated COVID vaccine boosters over the next few weeks and into the third quarter, Chief Commercial Officer Arpa Garay said on a conference call to discuss results., Headline: 7 Blue-Chip Stocks That Have Serious Potential for the Long Haul, source:InvestorPlace, summary: No summary, Headline: Moderna (MRNA) Q1 Earnings and Revenues Beat Estimates, source:Yahoo, summary: Moderna (MRNA) delivered earnings and revenue surprises of 110.73% and 60.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Moderna, Novocol Pharma enter long-term fill-finish agreement, source:Thefly.com, summary: No summary, Headline: Moderna up 5% after Q1 results beat estimates, source:Thefly.com, summary: No summary, Headline: Moderna sees Q2 sales $200M-$300M, consensus $982.37M, source:Thefly.com, summary: No summary, Headline: Moderna in fill-finish agreement with Novocol Pharma for mRNA vaccines, source:Seeking Alpha, summary: No summary, Headline: Moderna Posts Earnings Beat. There’s Good News on Covid Vaccines Too., source:Yahoo, summary: The biotech reports first-quarter profit of 19 cents a share, beating estimates of a $1.75 loss. Moderna also reiterates its Covid-19 vaccine sales outlook., Headline: Moderna, Inc. (MRNA) Q1 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Q1 2023 Results Conference Call May 4, 2023 8:00 AM ETCompany ParticipantsLavina Talukdar - Head, Investor RelationsStephane Bancel - Chief Executive..., Headline: Moderna stock rises on Q1 earnings, positive vaccine guidance, source:Yahoo, summary: Yahoo Finance Live’s Rachelle Akuffo and Brad Smith discuss the rise in stock for Moderna following first-quarter earnings., Headline: Moderna tops 1Q forecasts; vaccine sales plunge as expected, source:Yahoo, summary: Sales of Moderna’s COVID-19 vaccine plunged in the first quarter and some expenses soared, but Wall Street expected this and the drugmaker topped expectations.  Moderna said Thursday that revenue from its Spikevax vaccine tumbled to $1.83 billion in the quarter from nearly $6 billion a year ago.  The vaccine makers are shifting to commercial sales this year after selling to the government through huge contracts., Headline: COVID-19 ‘is not leaving the planet,’ Moderna CEO says, source:Yahoo, summary: Moderna Therapeutics CEO Stéphane Bancel joins Yahoo Finance Live to discuss first-quarter earnings, COVID-19 vaccine sales, profit growth, and the outlook for the biotechnology company’s RSV vaccine., Headline: Baron Health Care Fund Q1 2023 Shareholder Letter, source:SeekingAlpha, summary: Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.22% to $134.33 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: MODERNA AND NOVOCOL PHARMA ANNOUNCE FILL-FINISH AGREEMENT FOR CANADIAN-MADE MRNA VACCINES, source:Yahoo, summary: Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a long-term agreement with Ontario-based Novocol Pharma, a leading sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines expected to be produced in Canada. Fill-finish sterile manufacturing is the final step in the production cycle and includes transferring the, Headline: Moderna reports surprise profit as it books deferred COVID vaccine sales, source:Reuters, summary: Moderna Inc on Thursday reported a small profit of 19 cents per share instead of an expected loss as it booked more revenue in the first quarter from last year's deferred orders for its COVID-19 vaccine than had been anticipated.Analysts expected a loss of $1.77 per share..., Headline: Moderna Jumps On Unexpected First-Quarter Profit Amid Plummeting Covid Sales, source:Yahoo, summary: Moderna stock jumped Thursday on an unexpected first-quarter gain even as sales plummeted amid waning demand for Covid vaccines., Headline: Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%, source:Yahoo, summary: Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine, Headline: Moderna (MRNA) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's first quarter 2023 financial results and business updates.  On today's call are Stéphane Bancel, our chief executive officer; Stephen Hoge, our president; Arpa Garay, our chief commercial officer; and Jamie Mock, our chief financial officer., Headline: Tracking Baillie Gifford's 13F Portfolio - Q1 2023 Update, source:SeekingAlpha, summary: Baillie Giffordâs 13F portfolio value increased from ~$96B to ~$111B this quarter. Click here to see an update on the portfolio for Q1 2023.",MRNA
209,2023-05-05,"Headline: Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Moderna (MRNA) and AlloVir (ALVR), source:TipRanks, summary: No summary, Headline: Moderna files automatic mixed securities shelf, source:Thefly.com, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol Myers (BMY), Chimerix (CMRX) and Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Analysts` Top Healthcare Picks: Becton Dickinson (BDX), Argenx Se (ARGX), source:TipRanks, summary: No summary, Headline: Moderna price target lowered to $153 from $185 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: RBC Capital Keeps Their Buy Rating on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: SVB Securities Keeps Their Sell Rating on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Moderna, Inc. (NASDAQ:MRNA) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA) Q1 2023 Earnings Call Transcript May 4, 2023 Operator: Good day and thank you for standing by. Welcome to Moderna’s First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised today’s conference is being […], Headline: Moderna Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 2.02% to $137.04 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Morgan Stanley Maintains Moderna (MRNA) Equal-Weight Recommendation, source:Fintel, summary: nan",MRNA
210,2023-05-06,"Headline: Is Moderna Building a Respiratory Vaccine Empire?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) made a name for itself through its coronavirus vaccine.  The vaccine has generated billions of dollars in earnings over the past two years.  Now, however, demand from that star product is on the decline -- and Moderna faces a serious drop in revenue., Headline: Moderna (NASDAQ:MRNA) climbs 3.1% this week, taking three-year gains to 131%, source:Yahoo, summary: It hasn't been the best quarter for Moderna, Inc. ( NASDAQ:MRNA ) shareholders, since the share price has fallen 21% in...",MRNA
211,2023-05-07,"Headline: Is Moderna a Value Stock to Buy Right Now?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) can be described in several ways.  One description of Moderna you probably won't hear very often, however, is value stock.  There is an argument to be made that Moderna is a value stock.",MRNA
212,2023-05-08,"Headline: Rates Have Risen. Here Are 5 Stocks With Little Debt, source:GuruFocus, summary: No summary, Headline: Video: Nasdaq 100 Movers: MRNA, ZS, source:Market News Video, summary: No summary, Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 3.86% to $131.75 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Goldman Sachs’ Top 15 Stock Picks for 2023, source:Yahoo, summary: In this piece, we will take a look at Goldman Sachs’ Top 15 Stock Picks for 2023. For more top stocks, head on over to Goldman Sachs’ Top 5 Stock Picks for 2023. After a vicious drubbing in 2022 that led to growth and technology stocks sometimes bleeding as much as half of their value […]",MRNA
213,2023-05-09,"Headline: 26. ElevateBio, source:CNBC, summary: With biotech partners including Moderna, ElevateBio brings deep lab expertise to the emerging race for life-saving gene and cell therapies., Headline: Novavax’s stock soars 51% after positive COVID and flu trial data and news of plan to lay off 25% of workforce, source:DowJones, summary: The news helped ease fears raised by the company's ""going-concern"" language earlier this year., Headline: Novavax shares rise after company unveils positive vaccine data, plan to cut 25% of workforce, source:CNBC, summary: Novavax still reported bleak first-quarter earnings and revenue that missed Wall Street's estimates. , Headline: COVID-19 vaccine maker Novavax to chop workforce, expenses, source:Associated Press, The, summary: No summary, Headline: Novavax`s stock soars 51% after positive COVID and flu trial data and news of plan to lay off 25% of workforce, source:MarketWatch, summary: No summary, Headline: S&P 500 2023 Q1 Earnings Review: A Strong Start To The Year, source:Seeking Alpha, summary: No summary, Headline: Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary, Headline: Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market, source:Yahoo, summary: High demand for coronavirus vaccines earlier in the pandemic pushed Moderna's (NASDAQ: MRNA) earnings into the stratosphere.  In fact, Moderna could continue to generate billions in revenues annually from its first -- and so far, only -- approved product.  For example, Moderna sold its vaccine to the U.S. government for about $26 a dose., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 1.53% to $133.77 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: 15 Biggest Immunotherapy Companies in the World, source:Yahoo, summary: In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]",MRNA
214,2023-05-10,"Headline: Parnassus Value Equity Fund`s 1st-Quarter Commentary, source:GuruFocus, summary: No summary, Headline: Novavax`s stock soars after positive COVID and flu trial data and news of plan to lay off 25% of workforce, source:MarketWatch, summary: No summary, Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 2.20% to $130.83 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $21,737.60K, source:Fintel, summary: nan, Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $21,296.60K, source:Fintel, summary: nan",MRNA
215,2023-05-11,"Headline: 25 Best Hospitals for Cancer Treatment in the World, source:Yahoo, summary: In this article, we will discuss the 25 best hospitals for cancer treatment in the world. To skip the detailed analysis and recent updates about the oncology market, go directly to the 5 Best Hospitals for Cancer Treatment in the World. The oncology segment in the healthcare industry is a fast-growing market due to several […], Headline: MRNA June 30th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer, source:Yahoo, summary: Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV).  In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market.  The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies., Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.85% to $128.41 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Pfizer CEO says Medicare will likely face legal action over drug price negotiations, source:CNBC, summary: Pfizer CEO Albert Bourla argued the Biden administration's plan will cut profits and force Big Pharma companies to pull back on developing medicines. , Headline: 3 Healthcare Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: It's always a great idea to buy stocks and hold them for the long term. That means at least five years. This offers you the opportunity to benefit from any dividend payments and/or growth in earnings.",MRNA
216,2023-05-12,"Headline: Here's why Covid vaccines will still be free for uninsured Americans as public health emergency ends, source:CNBC, summary: The Biden administration and drugmakers Pfizer and Moderna have announced programs that aim to help uninsured Americans access Covid shots for free. , Headline: Q1 2023 Gritstone bio Inc Earnings Call, source:Yahoo, summary: Q1 2023 Gritstone bio Inc Earnings Call, Headline: Moderna Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.69% higher to $129.30 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...",MRNA
217,2023-05-13,"Headline: Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too, source:Yahoo, summary: Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race.  To make matters worse, earlier this year, Novavax even questioned its ability to continue operations.  Jacobs revealed details about his strategy to cut costs, manage cash flow, and match Novavax's size to the demand for its only product: the coronavirus vaccine.",MRNA
218,2023-05-14,"Headline: Cash-strapped Novavax urges governments to honour Covid jab deals, source:Yahoo, summary: The new chief executive of Novavax has urged governments to honour Covid-19 vaccine purchase commitments as the once high-flying US biotech battles to stay afloat amid a collapse in demand for jabs.  John Jacobs told the Financial Times there was no guarantee governments would deliver on all their existing commitments with the company, which include $2.1bn in advanced purchase agreements signed with the US biotech group stretching into 2025.  Novavax is one of a handful of vaccine makers, along with BioNTech/Pfizer and Moderna, which are approved to supply Covid jabs in the US, EU and other western countries., Headline: Warning! 3 Stocks That Are Waving Big Red Flags, source:Yahoo, summary: The current recovery in the stock market has been uneven. Tech is booming, financials are lagging and everything in between is a mixed bag. This is frustrating, especially as some once dominant stocks continue to fall to new lows. This has created some stocks with big red flags that could crash. Many strong businesses that are household names are seeing their share prices continue to slump as the market contends with a range of issues that include high interest rates, failing banks and a looming",MRNA
219,2023-05-15,"Headline: Is It Too Late to Buy Moderna Stock?, source:Yahoo, summary: Demand for Moderna's (NASDAQ: MRNA) one and only product is on the decline.  As we approach a post-pandemic situation, Moderna already has started to feel the impact.  Does today's drop in vaccine sales mean it's too late to buy Moderna stock?, Headline: Up 40% in 1 Day, Is Novavax Stock a Buy Now?, source:Yahoo, summary: On May 9, Novavax (NASDAQ: NVAX) shareholders got a much-needed reprieve from the stock's downward trajectory over the last year.  Novavax's decline is a regrettable one.  Its coronavirus vaccine candidate ran into regulatory issues during clinical development, and arrived on the market much later than those of competitors like Pfizer and Moderna., Headline: An Intrinsic Calculation For Moderna, Inc. (NASDAQ:MRNA) Suggests It's 46% Undervalued, source:Yahoo, summary: Key Insights The projected fair value for Moderna is US$241 based on 2 Stage Free Cash Flow to Equity Moderna is..., Headline: Moderna Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.74% higher to $130.26 Monday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: Universal flu vaccine based on mRNA tech to be tested by National Institutes of Health, source:CNBC, summary: Scientists hope the vaccine will protect against a variety of flu strains and provide long-term immunity so people do not have to receive a shot every year.  ",MRNA
220,2023-05-16,"Headline: Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry, source:Yahoo, summary: Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's MIMiC™ platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications., Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 3.95% to $125.11 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Could Latecomer Moderna Match Big Pharma Rivals in RSV?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) started its billion-dollar story with the coronavirus vaccine.  The company plans to submit its candidate for use in older adults to regulators soon and aims for a 2024 launch.  The U.S. Food and Drug Administration (FDA) recently approved GSK's vaccine -- the first RSV vaccine to ever win a nod.",MRNA
221,2023-05-17,"Headline: Ready to Buy the Dip? This Biotech Stock Is a Smart Buy, source:Yahoo, summary: Moderna (NASDAQ: MRNA) saw its shares jump in 2021 and 2022 on the back of strong sales of its COVID-19 vaccine Spikevax.  Spikevax helped prove to the world the effectiveness of messenger RNA (mRNA) technology.  The company advanced three COVID-19 vaccines from phase 1 to commercial status in a year., Headline: Moderna Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.37% higher to $125.57 Wednesday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: This Fund Owns SpaceX, Moderna, and ByteDance. Buy It at a Discount., source:MarketWatch, summary: The world’s largest closed-end fund, Scottish Mortgage Investment Trust, is now trading at a 23% discount to its net asset value. Top holdings include...",MRNA
222,2023-05-18,"Headline: Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons, source:PR Newswire, summary: No summary, Headline: Here’s Why You Should Hold Moderna (MRNA), source:Yahoo, summary: Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell […], Headline: 3 Magnificent Growth Stocks to Buy to Help Build a Millionaire Portfolio, source:Yahoo, summary: It's never too early to start building a portfolio that may eventually make you a millionaire.  Today, many growth stocks are suffering, but in some cases, prospects over time remain bright.  Amazon (NASDAQ: AMZN) was on an earnings roll, delivering gains in net income year after year -- until last year, when the company swung to a loss for the first time since 2014., Headline: Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%, source:Yahoo, summary: Moderna (NASDAQ: MRNA) surprised investors last quarter when it didn't incur a loss despite a significant drop in sales.  For the first three months of 2023, Moderna's revenue totaled just under $1.9 billion, which is just a fraction of the $6.1 billion it reported in the same period last year.  Meanwhile, its operating expenses, totaling $2.2 billion, rose by more than 21%., Headline: Pfizer: Ridiculous Selloff To A 2-Year Low, source:SeekingAlpha, summary: Pfizer hits a two-year low on COVID vaccines revenue pessimism, but valuation is attractive as sellers rushed out. Click here to read more on PFE stock., Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. sank 0.19% to $125.33 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: CureVac`s Lawsuit against Pfizer, BioNTech Picks Up Steam, source:TipRanks, summary: No summary, Headline: Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference, source:Seeking Alpha, summary: No summary",MRNA
223,2023-05-19,"Headline: Phase 1/2 Interim Data on Moderna`s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting, source:Accesswire, summary: No summary, Headline: Moderna reports interim data from Phase 1/2 trial of mRNA-3927, source:Thefly.com, summary: No summary, Headline: Moderna shares Phase 1/2 data for mRNA therapy targeted at rare metabolic disorder, source:Seeking Alpha, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Geo Capital Gestora de Recursos Ltd Buys 4, Sells 1 in 1st Quarter, source:GuruFocus, summary: No summary, Headline: Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting, source:Yahoo, summary: Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), presented at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting., Headline: Biotech Stocks Are Already Risky -- Now There Are 3 New Headwinds to Face in 2023, source:Yahoo, summary: Biotech investors love to take on oodles of risk in hopes of getting an outsized reward when one of their bets finally pays off.  While NHPs account for only 0.5% of the animal models used in biomedicine, biotechs and other researchers in the U.S. have faced a shortage of NHPs since at least 2019., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.73% higher to $126.24 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...",MRNA
224,2023-05-20,"Headline: Should Investors Worry About Moderna Inc`s Insider Sells?, source:GuruFocus, summary: No summary, Headline: CureVac’s Lawsuit against Pfizer, BioNTech Picks Up Steam, source:TipRanks, summary: No summary",MRNA
225,2023-05-21,"Headline: This Insider Just Sold Shares of Moderna Inc, source:GuruFocus, summary: No summary, Headline: Billions of dollars at stake as FDA shortcut allows half-proven drugs - report, source:Seeking Alpha, summary: No summary, Headline: Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today, source:Benzinga, summary: No summary",MRNA
226,2023-05-22,"Headline: Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich … or Broke., source:Yahoo, summary: These biotech stocks are swinging for the fences. They may hit homers, they may strike out. But you’ll definitely want to watch them. Biotech stocks have been a high risk, high reward proposition in recent years. Many biotech companies soared high during the pandemic only to crash hard in its aftermath. We now search through the wreckage to see which will soar again, and which are best left for dead. For an investor who wants stability and low risk, there are plenty of big biotech stocks out the, Headline: Here’s what Pfizer and Moderna say is next for their Covid vaccines, source:CNBC, summary: Pfizer and Moderna are ushering in a new era for their Covid shots that aims to simplify what people need to do to coexist with the virus. , Headline: Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy, source:Yahoo, summary: Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits., Headline: Moderna Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.40% higher to $126.74 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: BioNTech: Able To Tap Into High Medical Need PD-L1 Refractory NSCLC Market, source:SeekingAlpha, summary: BioNTech SE has initiation of a phase 3 study using BNT316 as a monotherapy for PD-1/PD-L1 refractory non-small cell lung cancer. Click here to read more., Headline: Debt Ceiling Concerns Nudge Stocks Lower And Treasury Yields Higher; Technical Analyst Predicts Uptrend To Continue, source:Benzinga, summary: No summary, Headline: COVID vaccine stocks light up amid fears of new infections in China, source:Seeking Alpha, summary: No summary, Headline: Healthcare Stocks Thrive on Fresh Round of COVID-19 in China, source:TipRanks, summary: No summary",MRNA
227,2023-05-23,"Headline: China's new Covid surge could result in 65M infections a week, Bloomberg says, source:Thefly.com, summary: No summary, Headline: Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare, source:Thefly.com, summary: No summary, Headline: Why did Moderna stock jump today? Renewed COVID fears, source:Seeking Alpha, summary: No summary, Headline: 6 Stocks With Heavy Call Flow: ENPH, META, MRNA, MSFT, NVDA, QCOM, source:Fintel, summary: nan, Headline: Early notable gainers among liquid option names on May 23rd, source:Thefly.com, summary: No summary, Headline: 3 Stocks You'll Be Glad You Bought at These Prices, source:Yahoo, summary: The good news is you really don't have to -- and you still can win in the stock market.  The success of Moderna's (NASDAQ: MRNA) blockbuster coronavirus vaccine helped the stock soar earlier in the pandemic.  Here's why they shouldn't: The vaccine represents just the beginning of Moderna's growth story., Headline: Moderna call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: Is Trending Stock Moderna, Inc. (MRNA) a Buy Now?, source:Yahoo, summary: No summary, Headline: Is Moderna Stock a Buy Now?, source:Yahoo, summary: Biotech giant Moderna (NASDAQ: MRNA) made a name for itself in the past couple of years as it developed and marketed one of the most successful coronavirus vaccines.  Demand for coronavirus vaccines has started to fall, affecting Moderna's revenue.  Is Moderna's stock worth considering, especially at current levels?, Headline: Seres Q1 Earnings: Major News For Investors, source:SeekingAlpha, summary: The latest reporting from Seres Therapeutics resolves many of the issues that have caused the stock price to fall. Click here to read an analysis of MCRB., Headline: Moderna Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. advanced 8.69% to $137.75 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Report of new COVID wave in China pushes shares of vaccine makers higher, source:CNBC, summary: Dr. Kavita Patel, fmr. White House health policy director, joins 'Fast Money' to discuss the latest reports of a possible uptick of COVID cases in China, the immunity situation in the country, and the impact an outbreak could have on U.S. companies., Headline: CNBC Daily Open: A debt ceiling deal won’t solve everything, source:CNBC, summary: The only story to be made of yesterday’s market moves is that, well, there wasn’t one.  Markets are still in reactive mode, not a sustained rally., Headline: GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results, source:Benzinga, summary: No summary, Headline: CNBC Daily Open: A debt ceiling deal won't fix everything, source:CNBC, summary: The only story to be made of yesterday’s market moves is that, well, there wasn’t one.  Markets are still in reactive mode, not a sustained rally., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",MRNA
228,2023-05-24,"Headline: Stocks making the biggest moves premarket: Moderna, Kohl's, Intuit, Analog Devices & more, source:CNBC, summary: These are the stocks posting the largest moves in premarket trading. , Headline: Unusually active option classes on open May 24th, source:Thefly.com, summary: No summary, Headline: Looking At Moderna's Recent Unusual Options Activity, source:Benzinga, summary: No summary, Headline: As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction, source:Benzinga, summary: No summary, Headline: Stocks making the biggest moves midday: Abercrombie & Fitch, Palo Alto Networks, Moderna and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Moderna: Don't Try To Catch The Falling Knives, source:SeekingAlpha, summary: Moderna investors have endured a lot of pain this year as the company struggles to live with life after COVID. Click here to read my analysis of MRNA stock., Headline: Moderna shares react to Covid resurgence news in China, source:Yahoo, summary: Yahoo Finance Live discusses a drop in shares of Moderna after a report of a resurgence of Covid in China., Headline: Novavax: Sell The Covid Rips, source:SeekingAlpha, summary: Novavax stock continues to rally on positive Covid news, but the vaccine demand continues to trend lower. Click for our outlook on NVAX stock., Headline: Moderna Spikes Amid Covid Fears, but Is It Just a False Positive?, source:Yahoo, summary: The Moving Average Convergence Divergence (MACD) oscillator is below the zero line telling us that MRNA lacks trend strength.  In this daily Point and Figure chart of MRNA, below, I can see a potential upside price target in the $179 area.  This weekly Point and Figure chart of MRNA, below, shows us the same $179 price target as the daily chart above., Headline: Vertex: CF Focus, Potential To Alter Acute Pain Treatment Market Landscape, source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated data readout from a phase 3 program could be released by the 1st half of 2024. Find out why VRTX stock is a Strong Buy., Headline: Durham firm inks billion-dollar deal with Novo Nordisk to discover new treatments, source:Yahoo, summary: A life sciences company in Durham has secured a major partnership to discover new gene therapy treatments., Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $14,364.00K, source:Fintel, summary: nan, Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $18,396.00K, source:Fintel, summary: nan, Headline: 7 Stocks That Even Company Insiders are Selling, source:Yahoo, summary: Insider buying, or the legal, reported purchase of shares in a company by its C-suite/board members/large shareholders, is considered a bullish signal. However, does that mean it is best to sell/avoid stocks insiders are selling? Put simply, it depends. Heavy insider selling, or even a lack of insider buying, can sometimes be a sign that those most “in the know” at a company are not very confident in its future prospects. Then again, much like with “outsider” investors, lack of confidence isn’t, Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary, Headline: Noteworthy Thursday Option Activity: MRNA, AAPL, ANET, source:Stock Options Channel, summary: No summary",MRNA
229,2023-05-25,"Headline: BioNTech readying next COVID shot in line WHO guidance, source:Seeking Alpha, summary: No summary, Headline: BioNTech readying next COVID shot in line with WHO guidance, source:Seeking Alpha, summary: No summary, Headline: Interesting MRNA Put And Call Options For July 7th, source:Stock Options Channel, summary: No summary, Headline: 7 Top Stock Tips for June 2023, source:InvestorPlace, summary: No summary, Headline: Financial Literacy for All Welcomes American Express, Dow Jones, and Moderna to its Mission of Advancing Financial Literacy, source:Business Wire, summary: No summary, Headline: Possible Bearish Signals With Moderna Insiders Disposing Stock \, source:Yahoo, summary: The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past..., Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: Baillie Gifford Dumps Salesforce, Loads Up on AMD, source:GuruFocus, summary: No summary",MRNA
230,2023-05-26,"Headline: Moderna Inc CEO Stephane Bancel Sells 80,000 Shares, source:GuruFocus, summary: No summary, Headline: Biggest gainers, decliners since the pandemic among Mass. public companies, source:Yahoo, summary: Three years since the pandemic upended the economy, here are the Massachusetts public companies that made it through in the best — and worst — shape., Headline: Moderna registers biotech firm in Shanghai, local media reports, source:Reuters, summary: Moderna has registered a biotech firm in China's financial hub Shanghai with capital of $100 million, according to Chinese data providers including company database Qichacha., Headline: Moderna registers biotech unit in China with $100M investment, source:Seeking Alpha, summary: No summary, Headline: Moderna says looking for opportunities in China after registering legal entity, source:Yahoo, summary: BEIJING (Reuters) -Vaccine maker Moderna Inc said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy.  The U.S. biotech firm registered a unit called Moderna (China) Biotech Ltd in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha.  ""We are exploring opportunities to engage in the market and bring the power of Moderna's mRNA platform to the people of China,"" a company spokesperson said in response to a query from Reuters., Headline: UPDATE 1-Moderna says looking for opportunities in China after registering legal entity, source:Yahoo, summary: U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy.  The U.S. pharmaceutical and biotech firm registered a unit called Moderna (China) Biotech Limited in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha.  ""We are exploring opportunities to engage in the market and bring the power of Moderna’s mRNA platform to the people of China,"" a spokesperson said in response to a query from Reuters., Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: Health authorities to target next COVID shot to new strain, WSJ says, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 0.18% to $126.24 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Next Covid Boosters to Target New Strain, source:Yahoo, summary: Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S., Headline: Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines, source:Reuters, summary: Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc and Moderna Inc in Delaware federal court, again claiming that the companies' COVID-19 vaccines infringe its patents.",MRNA
231,2023-05-27,"Headline: Moderna Inc CEO Stephane Bancel Sells 80,000 Shares, source:GuruFocus, summary: No summary",MRNA
232,2023-05-29,"Headline: Looking At Moderna's Recent Unusual Options Activity, source:Benzinga, summary: No summary, Headline: Oppenheimer biotech analyst to hold a reception, source:Thefly.com, summary: No summary",MRNA
233,2023-05-30,"Headline: If You Invested $2,500 in Moderna in 2019, This Is How Much You Would Have Today, source:Yahoo, summary: You'd have a lot more money, but only if you resisted the temptation to take the initial profits., Headline: Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago, IL., Headline: Moderna, Inc. (NASDAQ:MRNA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?, source:Yahoo, summary: With its stock down 8.4% over the past week, it is easy to disregard Moderna (NASDAQ:MRNA). However, a closer look at..., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 2.10% to $128.89 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Cramer says the money's in tech this year, tread carefully when it comes to any other sector, source:CNBC, summary: If you stray from tech this year, you might lose, CNBC's Jim Cramer told investors on Tuesday., Headline: Do You Really Want AI To Pick Your Stocks?, source:TalkMarkets, summary: No summary, Headline: Carisma Therapeutics Shines on New Cancer Treatment, source:TipRanks, summary: No summary",MRNA
234,2023-05-31,"Headline: Carisma Therapeutics assumed at Buy from Hold at Jefferies, source:Thefly.com, summary: No summary, Headline: Carisma spikes as Jefferies issues Buy citing lead asset, source:Seeking Alpha, summary: No summary, Headline: 2 Healthcare AI Stocks to Buy on the Dip, source:Yahoo, summary: Artificial intelligence (AI) could change the way we treat and prevent illnesses, which makes it a highly valuable opportunity for companies.  In fact, the global AI healthcare market is set to reach more than $100 billion later this decade, a Markets and Markets report shows.  Two perfect examples are biotech Moderna (NASDAQ: MRNA) and medical device giant Medtronic (NYSE: MDT)., Headline: Vaccine Fatigue Can Give Your Portfolio a Booster, source:Yahoo, summary: Moderna Pfizer  and its partner  BioNTech  are among the biggest losers in the healthcare sector this year, dropping more than 25% each.  The declines have been driven by a sense that, as the Covid-19 emergency enters the rearview mirror, demand for boosters will continue to wane.  Just last week, the European Commission cut the number of vaccines it is purchasing from Pfizer and BioNTech., Headline: 3 Innovative Growth Stocks to Buy for Next-Gen Profits, source:Yahoo, summary: In a globally synchronized world, there are big opportunities across sectors. This has intensified competition as companies look to grab a share of the pie. It eventually boils down to the survival of the fittest. In the context of corporations, the innovation factor determines the “fittest.” Therefore, this column focuses on innovative growth stocks for future profits. It goes without saying that the basic screening criteria are to investigate companies with high investment in research and deve, Headline: Heard on the Street: Investors Are Too Bearish on Vaccine-Makers, source:Yahoo, summary: OVER $300 BILLION That's how much has been wiped off the combined market value of [Moderna](https://www.wsj.com/market-data/quotes/MRNA), [Pfizer](https://www.wsj.com/market-data/quotes/PFE) and [BioNTech](https://www., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. sank 0.92% to $127.71 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...",MRNA
235,2023-06-01,"Headline: MRNA July 14th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: COVID Concerns Are Rising in China Again: Will This Send Moderna's Stock Soaring?, source:Yahoo, summary: The number of people with COVID-19 has been rising rapidly in China in recent weeks, and there are concerns that the government in Beijing could consider reviving its strict lockdown policies again.  COVID-19 cases have been surging in China, largely due to the spread of the omicron XBB variants.  In February, the Centers for Disease Control and Prevention pointed to early study results showing that for the  bivalent vaccine boosters created to target omicron variants, ""[vaccine effectiveness] was generally similar against BA.5-related infections [original omicron] and XBB/XBB.1.5-related infections."", Headline: Moderna Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.63% higher to $128.52 Thursday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: Moderna to Present at Upcoming Conferences in June 2023, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:, Headline: Catalyst Watch: Apple's WWDC event, OPEC fallout and REITs on display, source:Seeking Alpha, summary: No summary, Headline: Johnson & Johnson COVID vaccine authorization revoked by FDA, source:Seeking Alpha, summary: No summary, Headline: Moderna Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: No summary",MRNA
236,2023-06-02,"Headline: Oppenheimer biotech analyst to hold a reception, source:Thefly.com, summary: No summary, Headline: Better Healthcare AI Stock: Moderna vs. Doximity, source:Yahoo, summary: The AI in healthcare market is expected to top $100 billion by the end of the decade, and some companies are already leveraging this technology to advance their work.  Two great examples are Moderna (NASDAQ: MRNA) and Doximity (NYSE: DOCS).  Moderna isn't a novice when it comes to AI., Headline: Moderna Inc. stock underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Moderna Inc. advanced 1.55% to $130.51 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: 10 Stocks Jim Cramer and Hedge Funds Have In Common, source:Yahoo, summary: In this article, we will be taking a look at 10 stocks Jim Cramer and hedge funds have in common. To see more of these stocks, you can go directly to see 5 Stocks Jim Cramer and Hedge Funds Have In Common. “If You Use NVIDIA’s Chips, You Can Speak In The Vernacular Of ChatGPT” […]",MRNA
237,2023-06-03,"Headline: As the market starts to cool down, Cramer says don't be afraid to stay bullish , source:CNBC, summary: nan, Headline: Recent uptick might appease Moderna, Inc. (NASDAQ:MRNA) institutional owners after losing 4.8% over the past year, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Moderna implies that they have significant influence over the...",MRNA
238,2023-06-04,"Headline: Looking At Moderna's Recent Unusual Options Activity, source:Benzinga, summary: No summary",MRNA
239,2023-06-05,"Headline: Moderna, Merck announce DMFS results from Phase 2b study, source:Thefly.com, summary: No summary, Headline: 2 Blue-Chip REITs At Big Discounts, source:SeekingAlpha, summary: Real estate is the worst-performing sector of the stock market over the last year as the market has shunned REITs. Click here for our exclusive top 2 REIT picks., Headline: Moderna/ Merck cancer shot with Keytruda cut melanoma spread, source:Seeking Alpha, summary: No summary, Headline: Early notable gainers among liquid option names on June 5th, source:Thefly.com, summary: No summary, Headline: Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading, source:CNBC, summary: Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society., Headline: Moderna and Merck reveal new data on individualized cancer treatment, source:MarketWatch, summary: No summary, Headline: Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA,, Headline: Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data, source:Reuters, summary: Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday., Headline: Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock, source:Yahoo, summary: No summary, Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 1.23% to $128.90 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite..., Headline: Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced distant metastasis-free survival (DMFS) results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940) plus Keytruda for resected high-risk melanoma. The candidate is an investigational individualized neoantigen therapy. The companies recently announced the first presentation of the study's primary endpoint, recurrence-free survival, from the Phase 2 KEYNOTE-942/mRNA-4157-P201 trial in April 2023 at the American, Headline: Moderna, Inc. (MRNA) ASCO Investor Event Conference (Transcript), source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) ASCO Investor Event Conference Call June 5, 2023 7:00 PM ETCompany ParticipantsLavina Talukdar - Senior Vice President and Head of Investor..., Headline: UPDATE 1-Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data, source:Yahoo, summary: Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid-stage trial, the companies reported on Monday.  With this and earlier data, Moderna is considering seeking faster approval from regulators for the treatment, the company told investors after having presented the results at the American Society of Clinical Oncology meeting in Chicago.  ""Some of the residual uncertainty seems to be going away on that potential (option),"" said Moderna President Stephen Hoge., Headline: $100 Invested In This Stock 5 Years Ago Would Be Worth $700 Today, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: No summary",MRNA
240,2023-06-06,"Headline: Narrow market proving a headwind for mutual funds, opportunity for hedge funds, source:Seeking Alpha, summary: No summary, Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Seagen (SGEN) and Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants, source:Benzinga, summary: No summary, Headline: SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories, source:Benzinga, summary: No summary, Headline: 3 Biotech Stocks to Sell in June Before They Crash and Burn, source:Yahoo, summary: The biotechnology sector has seen better days. From the heady days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both demand and sales decline. This means there’s more than a couple biotech stocks to sell. The iShares US Pharmaceuticals ETF (NYSEARCA:IHE) that tracks the industry is down 10% over the last 12 months and major players such as Pfizer (NYSE:PFE) have seen their share price decline 25% so far in 2023. The, Headline: Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading, source:Yahoo, summary: Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients., Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slid 1.55% to $126.90 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Moderna, Pfizer hit with new patent lawsuits over COVID vaccines, source:Reuters, summary: Biotech firm Promosome LLC sued Moderna, Pfizer and BioNTech in federal court in San Diego, California, on Tuesday, accusing their COVID-19 vaccines of infringing a patent related to messenger RNA technology.",MRNA
241,2023-06-07,"Headline: SVB Securities Keeps Their Sell Rating on Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Pfizer, Moderna face new patent lawsuits over COVID vaccine tech, source:Seeking Alpha, summary: No summary, Headline: Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech, source:Benzinga, summary: No summary, Headline: ChatGPT's Parent Has No IPO Plans, CNN CEO Chris Licht Out, Kim Kardashian's Bid To Dismiss EthereumMax Lawsuit Rejected: Today's Top Stories, source:Benzinga, summary: No summary, Headline: Those who invested in Moderna (NASDAQ:MRNA) three years ago are up 118%, source:Yahoo, summary: While Moderna, Inc. ( NASDAQ:MRNA ) shareholders are probably generally happy, the stock hasn't had particularly good..., Headline: Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech, source:Yahoo, summary: Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by Promosome accusing their COVID-19 vaccines of infringing a patent related to messenger RNA (mRNA) technology. The small biotechnology firm claims that its scientists, including Nobel laureate Gerald Edelman, who died in 2014, Vincent Mauro, and two colleagues from The Scripps Research Institute, developed a method used in the COVID-19 vaccines. The lawsuit claims that one of the scientist, Headline: As AI advances in healthcare, industry players wrestle with its risks, source:MarketWatch, summary: Accuracy of health information, privacy and equity are among executives’ key concerns as health AI rapidly evolves., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.02% to $125.61 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Moderna Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.02% to $125.61 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",MRNA
242,2023-06-08,"Headline: SVB Securities bullish on CureVac, initiates with an Outperform, source:Thefly.com, summary: No summary, Headline: Interesting MRNA Put And Call Options For July 28th, source:Stock Options Channel, summary: No summary, Headline: Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Jefferies Global Healthcare Conference June 8, 2023 10:30 AM ETCompany ParticipantsStephen Hoge - PresidentConference Call ParticipantsMichael Yee -..., Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. sank 0.53% to $124.94 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?, source:Yahoo, summary: Shares of e-commerce company Etsy (NASDAQ: ETSY) have dropped more than 20% so far this year.  First, Etsy has managed to keep the gains it made over the past few years.  The company's total gross merchandise sales (GMS) soared more than 200% in the first quarter compared to the same quarter four years ago., Headline: Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $124.94, marking a -0.53% move from the previous day.",MRNA
243,2023-06-09,"Headline: Moderna Inc CEO Stephane Bancel Sells 80,000 Shares, source:GuruFocus, summary: No summary, Headline: S&P 500 Bull Market Kicks Off, But The Dominance Of 7 Stocks Leaves S&P 493 In The Dust, source:Benzinga, summary: No summary, Headline: 13 Best Future Stocks for the Long-Term, source:Yahoo, summary: In this piece, we will take a look at the 13 best future stocks for the long-term. For more stocks, head on over to 5 Best Future Stocks for the Long-Term. Investing these days is a ride not for the faint hearted. Within a couple of years, stocks that were once thought to be immune […], Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 1.34% to $123.26 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: 10 Quantum Computing Stocks Billionaires Are Loading Up On, source:Yahoo, summary: In this article, we will take a look at the 10 quantum computing stocks billionaires are purchasing. If you want to skip our detailed analysis of the industry and its growth prospects, go to the 5 Quantum Computing Stocks Billionaires Are Loading Up On. As reported in one of our articles earlier, the size of the […]",MRNA
244,2023-06-10,"Headline: Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now?, source:Yahoo, summary: Cancer vaccines have been around a long time, but they usually don't produce such compelling results.",MRNA
245,2023-06-12,"Headline: The First Vaccines for RSV Are Coming Soon. What to Know., source:Yahoo, summary: The U.S. is on the brink of rolling out a number of shots designed to prevent RSV in young children and in older adults., Headline: 3 Top AI Stocks to Buy Hand Over Fist, source:Yahoo, summary: Looking to invest in Artificial Intelligence (AI)?  You may immediately think of tech companies.  Today, let's take a look at an e-commerce player and two healthcare companies that have been using AI for a while., Headline: Moderna's Weakness Is Your Opportunity, source:SeekingAlpha, summary: Moderna is expected to have negative profits in 2023, impacting the company's strong net-cash position. Click for our view of MRNA stock prospects., Headline: Updated Covid vaccines need to target XBB omicron variants this fall, FDA staff says , source:CNBC, summary: Vaccine manufacturers Pfizer, Moderna and Novavax will be expected to update their shots according to the strain the FDA selects for the fall. , Headline: Moderna: Likely To Drop Further (Technical Analysis), source:SeekingAlpha, summary: Moderna faces significant bearish pressure on its shares despite promising clinical trial results for its cancer vaccine. Read my technical analysis of MRNA here., Headline: Get Out Now! 3 Value Stocks That Are Poised to Plunge., source:Yahoo, summary: With the stock market rising quickly, many companies have become expensive. Understandably, investors are considering value stocks as an alternative to frothy growth picks. But not all cheap equities are created equal. In fact, in the case of these three overvalued value stocks to sell, the apparent discount is an illusion. That’s because these firms will likely see their profits and cash flows decline over time. It’s a good sign when a company is quite profitable historically. But that’s not en, Headline: Moderna Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.21% higher to $123.52 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...",MRNA
246,2023-06-13,"Headline: Moderna Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: No summary, Headline: Moderna (MRNA) Gets a Hold from Bank of America Securities, source:TipRanks, summary: No summary, Headline: 7 Stocks to Sell in June Before They Crash and Burn, source:Yahoo, summary: As we pass the halfway mark of 2023, it’s time to consider which stocks to sell in June. If investors continue to have trouble understanding whether the markets are due for another correction soon it’s for good reason. June tends to be a historically tough month for markets. That’s a negative. Yet, a potential Fed pivot and the recent artificial intelligence boom both provide reasons for optimism. Then again, AI could be a bubble in itself. It has fueled the upward movement of tech giants which, Headline: Vast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David Ricks, source:CNBC, summary: Eli Lilly CEO David Ricks joins CNBC's Bertha Coombs and 'The Exchange' live from the World Medical Innovation Forum to discuss Eli Lilly's alzheimer's treatment, concerns over coverage reimbursement schemes, and upcoming drug price negotiations., Headline: Pfizer: Deeper Value Found Amidst Diversified Pipelines, source:SeekingAlpha, summary: Pfizer presents a buying opportunity as value has deepened following weak price action due to post-pandemic revenue concerns. Read why PFE stock is a Buy., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.61% to $127.98 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Tracking Philippe Laffont's Coatue Management Portfolio - Q1 2023 Update, source:SeekingAlpha, summary: Philippe Laffontâs 13F portfolio value increased from $8.92B to $15.04B this quarter. Read more on the portfolio and its holdings here.",MRNA
247,2023-06-14,"Headline: Covid vaccine maker Novavax sees a pathway to survival – but it won’t be easy , source:CNBC, summary: Cash-strapped Covid vaccine Novavax still faces a nunber of challenges, chiefly competing with Pfizer and Moderna in the U.S. commercial market this fall. , Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.51% to $126.05 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed at $126.05 in the latest trading session, marking a -1.51% move from the prior day., Headline: Moderna, Inc. (MRNA) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 7:40 PM ETCompany ParticipantsJamey Mock - CFOLavina Talukdar - Head of IRConference..., Headline: Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?, source:Yahoo, summary: Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term., Headline: FDA advisors back updating COVID shots to monovalent XBB-lineage, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: No summary",MRNA
248,2023-06-15,"Headline: The FDA Is Prepping for Fall Covid Boosters. The Next Step Is Today., source:Yahoo, summary: The agency's vaccines advisors will meet Thursday to settle on a design for this year’s updated Covid-19 vaccine., Headline: FDA advisors recommend that new Covid vaccines target an omicron XBB variant this fall , source:CNBC, summary: The FDA advisory panel's recommendation is a win for Covid vaccine makers Pfizer, Moderna and Novavax, which will race to deliver updated shots for the fall. , Headline: FDA advisers endorse updating COVID vaccines to target latest omicron strain, source:MarketWatch, summary: The COVID-19 vaccines are on track for a big recipe change this fall., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 3.12% to $129.98 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: FDA panel recommends updated COVID-19 vaccines targeting XBB.1.5 subvariant, source:Thefly.com, summary: No summary, Headline: Noteworthy Friday Option Activity: MRNA, MSFT, COST, source:Stock Options Channel, summary: No summary, Headline: FDA advises COVID vaccine makers to produce updated shots against XBB1.5, source:Seeking Alpha, summary: No summary",MRNA
249,2023-06-16,"Headline: Exit Strategy: Get Out of These 3 Poor-Performing Stocks Now, source:InvestorPlace, summary: No summary, Headline: FDA advisors raise doubts about seasonal updates to Covid vaccines as with flu shots, source:CNBC, summary: The panel's concerns push back against the FDA's proposed shift to annual Covid shots — an approach that vaccine makers like Pfizer are already preparing for. , Headline: Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know, source:Yahoo, summary: No summary, Headline: FDA recommends that updated Covid shots target omicron subvariant XBB.1.5 this fall , source:CNBC, summary: The FDA's decision is a win for vaccine makers Pfizer, Moderna and Novavax, which have all been developing versions of their Covid shots to target XBB.1.5., Headline: Pfizer, Moderna, and Novavax Gear Up for XBB.1.5 Strain Targeted Vaccines as FDA AdCom Unanimously Support, source:Yahoo, summary: Thursday, the FDA's Vaccines and Related Biological Products Advisory Committee all 21 members voted ""Yes,"" recommending that updated monovalent COVID shots in the fall and winter targeting the XBB variants, which are now the dominant strains of the SARS-CoV-2 virus in the world. The agency dropped the original coronavirus strain (Wuhan strain) from the formulation. Since earlier this year, the XBB lineage has dominated infections across the United States and the world, starting with XBB.1.5 and, Headline: FDA Panel Endorses Updating COVID Jab to Target XBB Strain, source:Yahoo, summary: An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus., Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. dropped 0.96% to $128.73 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $128.73, moving -0.96% from the previous trading session., Headline: How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities, source:TalkMarkets, summary: No summary",MRNA
250,2023-06-18,"Headline: Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 48% Discount?, source:Yahoo, summary: Key Insights The projected fair value for Moderna is US$247 based on 2 Stage Free Cash Flow to Equity Current share..., Headline: How to Retire Rich: Biotech Stocks Edition, source:Yahoo, summary: Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement, Headline: 7 Value Stocks to Dump Before They Decline Even Further, source:Yahoo, summary: The key to making profits in the markets has been to buy large-cap growth stocks, and sell value stocks. At least, that’s what it seems like, when you take into account that the surge of the S&P 500 index year-to-date is largely attributable to big gains among big tech stocks. Although not for certain, this trend could continue in the near-term. Ongoing economic issues like high inflation, high interest rates, and slowing economic growth are keeping value stocks at depressed prices. Meanwhile, s",MRNA
251,2023-06-19,"Headline: Why Peter Hotez says he won’t debate RFK Jr. after weekend of Rogan, Musk taunts, source:MarketWatch, summary: No summary, Headline: Civitas and Mueller Can Boast High Profit, Low Debt, source:GuruFocus, summary: No summary",MRNA
252,2023-06-20,"Headline: 5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies, source:Benzinga, summary: No summary, Headline: Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start, source:CNBC, summary: The FDA's strain selection puts Pfizer, Moderna and Novavax on track to deliver updated coronavirus shots in time for the fall. , Headline: What Do Bears Know About Novavax That Bulls Don't?, source:Yahoo, summary: Novavax (NASDAQ: NVAX) soared early in the coronavirus vaccine race.  Novavax launched a vaccine -- but about a year after rivals Pfizer and Moderna, so it lost out on lots of the initial early pandemic revenue.  Novavax is on track to provide an updated vaccine this fall., Headline: Alexandria Research completes sale of five facilities, reiterates 2023 guidance, source:Seeking Alpha, summary: No summary, Headline: Sanders launches Senate probe into Amazon's safety practices and asks workers to share stories, source:Associated Press, The, summary: No summary, Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 3.50% to $124.23 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: 20 Worst Performing S&P 500 Stocks in 2023, source:Yahoo, summary: In this article, we discuss 20 worst performing S&P 500 stocks in 2023. If you want to skip our detailed analysis of the stock market outlook, skip over to 5 Worst Performing S&P 500 Stocks in 2023. Wall Street analysts are still largely split when it comes to their forecasts for the S&P 500 index, […], Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",MRNA
253,2023-06-21,"Headline: GSK’s RSV Vaccine Could Be Effective for Longer. What That Means., source:MarketWatch, summary: The drugmaker says its RSV shot prevents disease for 18 months., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 2.54% to $121.07 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: If You Invested $100 In This Stock 5 Years Ago, You Would Have $600 Today, source:Benzinga, summary: No summary, Headline: Moderna files for FDA authorization for updated COVID-19 vaccine, source:Thefly.com, summary: No summary",MRNA
254,2023-06-22,"Headline: Moderna files application with FDA for updated COVID shot, source:Seeking Alpha, summary: No summary, Headline: Moderna Seeks FDA Nod For Updated COVID-19 Vaccine To Tackle Dominant Strain: The Hill, source:Benzinga, summary: No summary, Headline: Interesting MRNA Put And Call Options For August 4th, source:Stock Options Channel, summary: No summary, Headline: CDC Advisors Offer Lukewarm Endorsement of GSK, Pfizer RSV Vaccines. What to Know., source:MarketWatch, summary: A key committee backed a policy saying adults 65 and older ""may receive"" the shots, rather than one saying the injections ""are recommended."", Headline: Moderna Unusual Options Activity For June 22, source:Benzinga, summary: No summary, Headline: Moderna files for FDA approval of updated Covid vaccine for fall , source:CNBC, summary: Moderna said the submission is based on the FDA's recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5. , Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 0.49% to $120.48 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Biotech ETFs in Focus on Covid Vaccines' Fall Rollout, source:Yahoo, summary: The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs., Headline: Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has completed submission of a regulatory application to the U.S., Headline: UPDATE 2-Moderna seeks US FDA authorization for updated COVID vaccine, source:Yahoo, summary: Moderna said on Thursday it has completed a submission to the U.S. Food and Drug Administration seeking authorization for its updated COVID-19 vaccine to target the XBB.1.5 subvariant.  The submission from the company follows the FDA's advice last week to manufacturers that are updating their COVID-19 vaccines to develop monovalent shots to target XBB.1.5.  Monovalent, or single-target, vaccines would be a change from the most recent bivalent COVID boosters that targeted both the original and Omicron strains of the coronavirus., Headline: Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $120.48, marking a -0.49% move from the previous day., Headline: Smith & Wesson Brands, CarMax And 3 Stocks To Watch Heading Into Friday, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: No summary, Headline: 6 Director Elections In 2023 That Were Surprisingly Close, source:TalkMarkets, summary: No summary",MRNA
255,2023-06-23,"Headline: Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine, source:Yahoo, summary: Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same., Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.64% to $118.50 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...",MRNA
256,2023-06-24,"Headline: Wall Street Says This Beaten-Down Stock May Climb Nearly 78%. Is That Too Optimistic?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) once delivered rapid multibagger returns -- and was the stock everyone wanted to own.  The coronavirus vaccine maker rose by more than 400% in 2020 and soared even more in the first half of 2021.  Wall Street analysts, as a group, are a lot more optimistic about its prospects., Headline: 10 Personalized Medicine Stocks Billionaires Are Loading Up On, source:Yahoo, summary: In this article, we will take a look at the 10 personalized medicine stocks billionaires are purchasing. If you want to skip our detailed analysis of the industry and its growth prospects, go to the 5 Personalized Medicine Stocks Billionaires Are Loading Up On. According to Allied Market Research, the global personalized medicine industry is set […]",MRNA
257,2023-06-25,"Headline: Analysts Reconsider MRNA Stock, Share Prices Improve, source:TipRanks, summary: No summary, Headline: Moderna Stock Price Forecast: UBS Sees A 60% Upside, source:TalkMarkets, summary: No summary, Headline: Noteworthy Monday Option Activity: MRNA, AMZN, ENPH, source:Stock Options Channel, summary: No summary, Headline: Steve Weiss Once Predicted Moderna Stock Would Rise 500% And Trade Like Amazon: Now He's Selling As The CEO Dumps Shares, source:Benzinga, summary: No summary, Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: No summary",MRNA
258,2023-06-26,"Headline: Moderna upgraded to Buy from Neutral at UBS, source:Thefly.com, summary: No summary, Headline: UBS upgrades Moderna to buy while cutting price target, source:MarketWatch, summary: UBS upgraded its rating on vaccine maker Moderna to buy from neutral on valuation grounds, but cut its price target to $191 from $221. “We acknowledge the..., Headline: Moderna raised to Buy at UBS on underappreciated pipeline, source:Seeking Alpha, summary: No summary, Headline: GLOBAL BROKER RATINGS: UBS likes Moderna; Goldman Sachs cuts Tesla, source:Alliance News, summary: No summary, Headline: Amazon, Marriott And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: Monday’s Top Analyst Upgrades and Downgrades: Accenture, Moderna, Tesla, Under Armour, Wayfair, Welltower and More, source:247WallSt, summary: No summary, Headline: Stocks making the biggest premarket moves: Tesla, Moderna, Alphabet, PacWest and more, source:CNBC, summary: These are the stocks posting the largest moves in the premarket., Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Tesla, Alphabet fall premarket; Moderna, Lucid Group rise, source:Yahoo, summary: Investing.com -- Stocks in focus in premarket trade on Monday, June 26th. Please refresh for updates., Headline: Alphabet downgraded, Moderna upgraded: Wall Street's top analyst calls, source:Thefly.com, summary: No summary, Headline: Moderna Pipeline For Any Vaccine Beyond Covid Is 'Underappreciated,' Analyst Says, source:Benzinga, summary: No summary, Headline: Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023, source:Benzinga, summary: No summary, Headline: Analyst Ratings for Moderna, source:Benzinga, summary: No summary, Headline: Tracking Lone Pine Capital Portfolio - Q1 2023 Update, source:SeekingAlpha, summary: Lone Pine Capital's 13F portfolio value increased from $10.48B to $10.80B in Q1 2023, with the number of holdings decreasing from 30 to 29. Read more here., Headline: Stocks making the biggest moves midday: Pfizer, Lucid, WSFS Financial and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics, source:Benzinga, summary: No summary, Headline: IN THE KNOW: UBS sees success for Moderna ahead as Covid unwinds, source:Alliance News, summary: No summary, Headline: Moderna Stock Is a Buy. The Pipeline Is Underappreciated, Says Analyst., source:Yahoo, summary: UBS analyst Eliana Merle upgraded Moderna stock to Buy from Neutral, but trimmed the price target. The Covid and RSV businesses alone are worth $123 a share, she says., Headline: Moderna stock up after UBS upgrade, source:Yahoo, summary: Moderna shares are up after the stock receives an upgrade from UBS. Yahoo Finance Live breaks down the company's stock movement., Headline: NEW YORK MARKET CLOSE: Stocks stutter as Russian drama plays out, source:Alliance News, summary: No summary, Headline: UBS Upgrades Moderna (MRNA), source:Fintel, summary: nan, Headline: UPDATE 1-Biogen shareholders back Susan Langer as director, source:Yahoo, summary: Biogen shareholders elected former company executive Susan Langer as a director on Monday, weeks after her romantic partner, Alex Denner, vacated the seat and the board nominated her to replace him.  Langer, 32, had served in various roles at the biotech company from 2013 to 2019.  Denner was a hedge fund manager, who had been a Biogen director since 2009 and headed the company's nominating and governance committee., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 1.61% to $120.41 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite..., Headline: Pfizer and Moderna: The Vaccine Boom is Over, and Shares are Plunging, source:TipRanks, summary: No summary",MRNA
259,2023-06-27,"Headline: How to Invest $10,000 -- No Matter What the Market is Doing, source:Yahoo, summary: One of the biggest questions on investors' minds these days is this: Have we reached a new bull market?  The good news is you don't have to invest for a bear market or a bull market.  A good example is coronavirus vaccine maker Moderna (NASDAQ: MRNA)., Headline: Moderna Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.22% higher to $120.67 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Moderna Unusual Options Activity, source:Benzinga, summary: No summary, Headline: REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug, source:TipRanks, summary: No summary, Headline: Moderna Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: No summary",MRNA
260,2023-06-28,"Headline: Citi screens for most crowded short stocks with new model, source:Seeking Alpha, summary: No summary, Headline: 3 Pharma Stocks That Have Big Investors Running for the Exit, source:Yahoo, summary: Pharmaceutical stocks are trailing the market this year. So far in 2023, the Dow Jones U.S. Select Pharmaceuticals Index is down 5.4% while all three major indices are positive on the year. The declining investor interest in pharma stocks is a sharp reversal from the pandemic when the shares of many leading drugmakers were sitting at all-time highs. As Covid-19 slid into our collective rearview mirror, pharma stocks have declined sharply. Companies with multiple best-selling medications and stro, Headline: Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rallied 1.93% to $123.00 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Moderna (MRNA) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed at $123 in the latest trading session, marking a +1.93% move from the prior day., Headline: Moderna says updated COVID vaccine will be ready for the fall, source:Seeking Alpha, summary: No summary, Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary",MRNA
261,2023-06-29,"Headline: Goldman adds 39 new stocks to its Sharpe Ratio basket with megacaps absent, source:Seeking Alpha, summary: No summary, Headline: Moderna and 7 More Stocks That Can Beat Big Tech in the Second Half, source:MarketWatch, summary: Big Tech is having its best start to the year ever. But a different group may thrive in the second half., Headline: Moderna and 7 More Stocks That Can Beat Apple in Second Half, source:Yahoo, summary: Big Tech is having its best start to the year ever. But a different group of stocks may thrive in the second half., Headline: MRNA August 11th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: 8 Beaten Up Stocks to Buy for Second-Half Turnarounds, source:Yahoo, summary: Big Tech is having its best start to the year ever. But a different group may thrive in the second half., Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: Moderna initiates rolling NDS to Health Canada for updated COVID-19 vaccine, source:Thefly.com, summary: No summary, Headline: Moderna Files Submission to Health Canada for Updated Covid-19 Vaccine, source:Finnhub, summary: By Stephen Nakrosis 


  Moderna on Thursday said it submitted a rolling new drug submission to Health Canada for an updated Covid-19 vaccine. 

  Moderna previously submitted its updated its monovalent Covid-19 vaccine, Spikevax XBB.1.5, to the U.S. F..., Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 0.72% to $122.11 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE, source:Yahoo, summary: Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada for its updated monovalent COVID-19 vaccine, SPIKEVAX® XBB.1.5 (mRNA-1273.815) targeting the omicron subvariant XBB.1.5 of SARS-CoV-2. This follows Moderna's submission to the U.S. Food and Drug Administration for authorization., Headline: Moderna Billionaire Set to Score 3,000% Gain on Tiny Biotech, source:Yahoo, summary: (Bloomberg) -- Noubar Afeyan became a billionaire backing Moderna Inc., the dark horse biotech firm that became a household name due to its lifesaving Covid vaccine. He just added to his fortune after another one of his long-shot bets quintupled in value.Most Read from BloombergSwitzerland Blocks Sale of Leopard 1 Tanks Bound for UkraineA $100 Billion Wealth Migration Tilts US Economy’s Center of Gravity SouthPutin Claims He’s Back in Control. Russia’s Elite Isn’t SureSupreme Court Rejects Use o",MRNA
262,2023-06-30,"Headline: Declining Stock and Solid Fundamentals: Is The Market Wrong About Moderna, Inc. (NASDAQ:MRNA)?, source:Yahoo, summary: With its stock down 20% over the past three months, it is easy to disregard Moderna (NASDAQ:MRNA). However, stock..., Headline: Medicare revises guidance on drug price negotiations amid lawsuits, source:Seeking Alpha, summary: No summary, Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 0.50% to $121.50 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...",MRNA
263,2023-07-02,"Headline: 3 stocks that could still light up 2023 just like July 4 fireworks, source:Yahoo, summary: The stock market's strong year has essentially been driven by less than 20 stocks. But could the second half of the year see some surprise winners that have under-performed thus far?, Headline: Moderna files for European authorization of updated COVID vaccine, source:Finnhub, summary: U.S. biotech firm Moderna
said on Monday it had submitted a regulatory application to the
European Medicines Agency  seeking authorization for its
updated COVID-19 vaccine to target the XBB.1.5...",MRNA
264,2023-07-03,"Headline: Moderna Seeks European Nod For Updated COVID-19 Vaccine Shot To Tackle New Dominant Strain, source:Benzinga, summary: No summary, Headline: Moderna submits regulatory application to EMA for updated COVID-19 vaccine, source:Thefly.com, summary: No summary, Headline: Moderna submits EMA regulatory filing for updated Covid-19 vaccine, source:Alliance News, summary: No summary, Headline: CarMax, Walmart And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: Moderna applies for EU approval of updated COVID-19 vaccine, source:Seeking Alpha, summary: No summary, Headline: Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine, source:Accesswire, summary: No summary, Headline: Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab, source:Yahoo, summary: Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.",MRNA
265,2023-07-04,"Headline: Moderna’s stock pops as company wins China business and seeks regulatory nods for RSV vaccine, source:MarketWatch, summary: No summary, Headline: Dow ends down over 100 points after Fed minutes show almost all policy makers expect additional rate increases, source:MarketWatch, summary: No summary",MRNA
266,2023-07-05,"Headline: Moderna Set to Invest $1 Billion in China, Yicai Reports, source:Yahoo, summary: (Bloomberg) -- Moderna Inc. is set to announce its first investment in China as early as Wednesday as heightened geopolitical tensions puts the spotlight on the Asian nation’s efforts to rebuild ties with foreign firms.Most Read from BloombergUS Stocks Mixed as Tech Giants Hold Onto Gains: Markets WrapEarth Keeps Breaking Temperature Records Due to Global WarmingXi’s Metal Curbs Risk Backfiring as G-7 Seeks China AlternativeLazard Fires Senior Banker for Inappropriate Behavior at PartyChina Rest, Headline: Dow remains lower, Nasdaq wavers after Fed minutes show almost all policy makers expect additional rate increases, source:MarketWatch, summary: U.S. stocks remain lower on Wednesday, after minutes of the Fed's last policy meeting show almost all participants expect additional interest-rate increases., Headline: Moderna provides update on regulatory submissions for mRNA-1345, source:Thefly.com, summary: No summary, Headline: Moderna signs deal in China to develop mRNA medicines - Reuters, source:Seeking Alpha, summary: No summary, Headline: Rivian, Moderna and Wolf stocks rise, UPS and Generac shares fall, and other stocks the move, source:MarketWatch, summary: Rivian's stock climbed Wednesday after Amazon said it had rolled out the first delivery vans from the electric-vehicle maker. UPS, Microsoft shares were also..., Headline: Moderna files global marketing submissions for RSV shot, source:Seeking Alpha, summary: No summary, Headline: Moderna starts application process for approval of RSV vaccine, source:Finnhub, summary: Moderna Inc said on
Wednesday it had started the application process for approval of
its respiratory syncytial virus  vaccine with various
regulators, including those in the United States and..., Headline: Moderna starts application process for RSV vaccine approval in older adults, source:Finnhub, summary: Moderna Inc said on
Wednesday it had started the application process for its
respiratory syncytial virus  vaccine, seeking approval to
be used in older adults, with various regulators, including..., Headline: Yicai says Moderna set to invest $1B in China, Bloomberg reports, source:Thefly.com, summary: No summary, Headline: Moderna, Inc., source:Finnhub, summary: Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus  Vaccine, MRNA-1345
Moderna has submitted marketing authorization applications for the investigational RSV vaccine,..., Headline: Moderna submits global regulatory submission for respiratory vaccine, source:Finnhub, summary: Moderna Inc on Wednesday said it submitted a marketing authorisation application for the investigational respiratory syncytial virus vaccine mRNA-1345, with the European Medicines Agency, Swissmedic,..., Headline: Moderna to invest $1 billion in China to develop mRNA medicines - reports, source:Yahoo, summary: Investing.com -- Shares in Moderna (NASDAQ:MRNA) moved higher on Wednesday after media reports said that the drugmaker had signed a memorandum of understanding and a land collaboration agreement with China to research and develop messenger RNA medicines in the country., Headline: Unusually active option classes on open July 5th, source:Thefly.com, summary: No summary, Headline: Early notable gainers among liquid option names on July 5th, source:Thefly.com, summary: No summary, Headline: Moderna strikes deal to develop mRNA drugs in China , source:CNBC, summary: The deal is the biotech company's first agreement with China after the Asian nation repeatedly refused to accept mRNA vaccines from U.S.-based manufacturers. , Headline: Moderna says it has signed deal in China with view to research and make mRNA medicines, source:Yahoo, summary: Vaccine maker Moderna Inc said on Wednesday it had signed a memorandum of understanding and a land collaboration agreement to work towards opportunities for it to research, develop and manufacture mRNA medicines in China.  Chinese media outlet Yicai reported on Tuesday that Moderna was set to make its first investment in China that could be worth around $1 billion, and that Chief Executive Officer Stéphane Bancel is in Shanghai., Headline: Is Moderna Heading for a Critical Moment?, source:Yahoo, summary: Moderna (NASDAQ: MRNA) has generated billions of dollars in sales and profit from its coronavirus vaccine.  This doesn't mean the revenue opportunity is over, though.  Let's take a closer look at exactly how important this moment will be for Moderna., Headline: MRNA Stock Jumps as It Progresses with RSV Vaccine Application, source:TipRanks, summary: No summary, Headline: UPDATE 1-Moderna agrees deal in China with view to  developing mRNA medicines, source:Yahoo, summary: Vaccine maker Moderna Inc said on Wednesday it had signed a memorandum of understanding and a land collaboration agreement to work towards opportunities for it to research, develop and manufacture mRNA medicines in China.  Chinese media outlet Yicai reported on Tuesday that Moderna was set to make its first investment in China that could be worth around $1 billion, and that Chief Executive Officer Stéphane Bancel was visiting Shanghai.  Moderna said in May it was looking for opportunities in China after registering a legal entity in the world's second-largest economy., Headline: Moderna stock pops after company makes regulatory submissions in U.S., Europe, Switzerland and Australia for its RSV vaccine, source:MarketWatch, summary: No summary, Headline: EXCLUSIVE: Top 10 Most-Searched Tickers On Benzinga Pro In Q2 — Tesla, Nvidia, C3.ai, Meta Platforms, Microsoft And More, source:Benzinga, summary: No summary, Headline: Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older., Headline: Moderna Makes Regulatory Submissions for RSV Vaccine Candidate >MRNA, source:MarketWatch, summary: By Colin Kellaher Moderna on Wednesday said it has launched efforts to win approval in the U.S., Europe and Australia for its mRNA-1345 investigational..., Headline: UPDATE 2-Moderna starts application process for RSV vaccine for older adults, source:Yahoo, summary: Moderna Inc said on Wednesday it had started the application process to get an approval for its respiratory syncytial virus (RSV) vaccine in older adults with regulators in the United States, Australia and Europe.  It is aiming to be the third vaccine maker to get an approval in the country after GSK and Pfizer Inc.  Moderna has also submitted applications to the European, Swiss and Australian regulators, the company said., Headline: US biotech Moderna strikes deal to develop mRNA drugs in China, source:Yahoo, summary: US drugmaker Moderna has struck a deal to make messenger RNA drugs for use in China, despite the tensions between Washington and Beijing.  The biotech said on Wednesday that it had reached an agreement with authorities in Beijing to research, develop and manufacture drugs that would “not be exported”.  Drugmakers remain interested in expanding in China, which faces an ageing population, higher rates of chronic diseases and health concerns stemming from an increasingly westernised diet., Headline: Moderna seeks regulatory approval of RSV vaccine for people 60 and older, source:Finnhub, summary: Moderna has submitted its RSV vaccine for people 60 and older regulatory approval in the United States and elsewhere in the world, the company said.
We are proud to announce these filings for the use..., Headline: Moderna Strikes mRNA Drug Pact With Chinese Authorities: Report, source:Benzinga, summary: No summary, Headline: US STOCKS-Wall Street set to open lower, all eyes on Fed minutes, source:Yahoo, summary: Wall Street futures fell on Wednesday as investors awaited minutes of the Federal Reserve's June meeting for clues on the central bank's monetary policy path, while Sino-U.S. tensions and weak economic data from Beijing dented sentiment.  Rate-sensitive megacap companies such as Microsoft and Alphabet slid 0.9% and 0.6%, respectively, in premarket trading., Headline: Stocks making the biggest moves midday: Meta Platforms, Coinbase, UPS, General Motors & more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: AstraZeneca, Moderna Stocks Rise, source:Yahoo, summary: Two large drugmakers are advancing in early trading Wednesday. + AstraZeneca's New-York listed ADR rose 2.6% shortly after the open; shares in the drugmaker sold off Monday after it reported mixed results in a trial for an experimental cancer drug., Headline: Trending : Moderna Makes RSV Vaccine Submissions, Plans to Develop mRNA Meds in China, source:Finnhub, summary: 14:03 ET -- Moderna is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The Cambridge, Mass.-based vaccine maker plans to..., Headline: Moderna Stock Is Surging on Deal to Make Vaccines in China, source:Yahoo, summary: Drugmaker Moderna reached an agreement to produce mRNA vaccines in China. One report noted the company could invest up to $1 billion in the country., Headline: Moderna Initiates Regulatory Application Process Seeking Approval For Its RSV Vaccine In Older Adults, source:Yahoo, summary: Moderna Inc (NASDAQ: MRNA) provided an update on regulatory submissions for the mRNA-1345 vaccine to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease in adults aged 60 years or older. mRNA-1345 is an investigational RSV vaccine with a single mRNA sequence encoding for a stabilized prefusion F glycoprotein. The vaccine uses the same lipid nanoparticles as in the Moderna COVID-19 vaccines. The company has submitted marketing authorization applications, Headline: Moderna stock surges on China expansion deal, source:Yahoo, summary: Moderna shares are surging after the company announced a new expansion deal to develop and manufacture mRNA medicines in China. Yahoo Finance's Rachelle Akuffo breaks down the deal., Headline: Stock market today: Dow slips as Fed minutes show more hikes ahead; Meta jumps, source:Yahoo, summary: By Yasin Ebrahim, Headline: Three-Stock Lunch: UPS, Moderna and Coinbase, source:CNBC, summary: Michael Landsberg, Landsberg Bennett Private Wealth Management CIO, joins 'Power Lunch' to discuss Landsberg's thoughts on three stocks: UPS, Moderna, and Coinbase., Headline: Markets Fall at Midday Ahead of the Release of the Fed's Latest Meeting Minutes, source:Yahoo, summary: U.S. equities declined at midday on Wednesday, July 5, 2023, ahead of the release of meeting minutes from the Fed's June policy meeting., Headline: NEW YORK MARKET CLOSE: Fed eyes more rate hikes keeping Dow in check, source:Alliance News, summary: No summary, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rallied 1.49% to $123.54 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: US STOCKS-Wall Street dips on jitters ahead of Fed minutes, source:Yahoo, summary: Wall Street's main indexes fell on Wednesday ahead of the Federal Reserve's June meeting minutes, while weak U.S. and China economic data as well as rising Sino-U.S. tensions dented investor sentiment.  May U.S. factory orders rose less than expected, according to a Commerce Department report, fanning fears of a slowdown due to high interest rates after data on Monday showed manufacturing slumped further last month., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 1.49% to $123.54 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Cramer examines the worst performers from the first half of 2023, explains why the market seems narrow, source:CNBC, summary: CNBC's Jim Cramer told investors on Wednesday that if they're waiting for the market to broaden for a rally, they might be waiting forever., Headline: Shanghai Authorities Signed MoU With Moderna On Wednesday - Government Statement, source:Finnhub, summary: Shanghai City Government:
              * SHANGHAI AUTHORITIES SIGNED MOU WITH MODERNA ON
WEDNESDAY - GOVERNMENT STATEMENT
              Source text
Further company coverage:

            ..., Headline: Moderna Shares Advance After Striking mRNA Drug Development Deal With China, source:Yahoo, summary: Moderna shares rose 1.5% on Wednesday after signing an agreement with China to research, develop, and make mRNA treatments there., Headline: Moderna (MRNA) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed the most recent trading day at $123.54, moving +1.49% from the previous trading session., Headline: 3 Value Stocks to Consider Selling Before They Do Your Portfolio In, source:Yahoo, summary: Selling value stocks is vital for investors who prioritize safeguarding their portfolios. Within portfolio management, it becomes imperative to identify the opportune moment to divest from value stocks that fail to deliver anticipated returns. Although it may appear counter-intuitive to relinquish these previously promising investments, it is essential to acknowledge that their present state of overvaluation has eroded their value proposition. The allure of undervalued stocks lies in the potenti, Headline: Moderna To Develop mRNA Vaccines in China, source:Yahoo, summary: The US and China may be taking jabs at one another over trade and other stuff, but that isn't stopping Beijing from inviting an American company..., Headline: Moderna (NYSE:MRNA) Chooses to Cater to Chinese Consumers, source:TipRanks, summary: No summary, Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary",MRNA
267,2023-07-06,"Headline: Dow ends nearly 370 points lower as jobs data triggers jump in bond yields, source:MarketWatch, summary: U.S. stocks end lower Thursday after a report from ADP showed the private sector created nearly half a million new jobs in June., Headline: Keurig Dr Pepper’s stock climbs on upgrade, Exxon shares slip after update, and other stocks on the move, source:MarketWatch, summary: Meta Platforms, Exxon Mobil and Spirit Airlines shares are all on the move., Headline: Video: S&P 500 Movers: MRNA, KDP, source:Market News Video, summary: No summary, Headline: With 66% ownership of the shares, Moderna, Inc. (NASDAQ:MRNA) is heavily dominated by institutional owners, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Moderna's stock price might be vulnerable to their..., Headline: Stocks making the biggest moves midday: JetBlue, Affirm, Genius Sports, Sweetgreen and more, source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: A Big Test Is Looming for Pfizer, Moderna, and Novavax, source:Yahoo, summary: Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Novavax (NASDAQ: NVAX) were all popular stocks to own when demand for COVID vaccines was strong.  Demand for vaccines is still there, but whether it's enough for these companies to hit their forecasts this year is questionable., Headline: Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY, source:Yahoo, summary: Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector., Headline: Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine, source:Yahoo, summary: Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above., Headline: Novo Nordisk spent $11 million on Ozempic promotion, source:Yahoo, summary: Novo Nordisk spent $11 million on food and travel for doctors to promote weight loss and type 2 diabetes drug Ozempic. Yahoo Finance Healthcare Reporter Anjalee Khemlani discusses Novo Nordisk's lobbying, as well as Moderna's deal with China., Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 4.25% to $118.29 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Moderna: Potential To Get Second Product To Market, source:SeekingAlpha, summary: Moderna has submitted multiple regulatory submission of mRNA-1345 and more regulatory submissions are expected in coming months. Click here for more on MRNA stock., Headline: Wait Before Buying Moderna Stock, Says Bear Signal, source:Yahoo, summary: MRNA's 60-day moving average has stymied the equity in the past, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",MRNA
268,2023-07-07,"Headline: Company News for Jul 7, 2023, source:Yahoo, summary: Companies in The News Are: JBLU, AAL, F, MRNA, GENI., Headline: Novavax's (NVAX) COVID Jab Gets Full Approval in Europe, source:Yahoo, summary: Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe., Headline: Moderna Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.49% higher to $118.87 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration, source:TalkMarkets, summary: No summary",MRNA
269,2023-07-09,"Headline: Week In Review: Billion Dollar Deals - Moderna's Shanghai Investment And F-Star's Takeda Collaboration, source:SeekingAlpha, summary: Moderna signed a deal to set up operations in Shanghai that will develop and make mRNA products specifically for the Chinaâs market. Click here to read more., Headline: Are We Heading for a Recession? Here's What Investors Should Do., source:Yahoo, summary: Are we heading for a recession?  Meanwhile, the economy has shown a certain degree of resilience -- and some economists say a recession could happen later or not at all.  Should you go for growth stocks that tend to outperform in strong economies?, Headline: Goldman Sachs sees rays of hope in underperforming health sector, source:Seeking Alpha, summary: No summary",MRNA
270,2023-07-10,"Headline: Evelo spikes on $25.5M private placement, source:Seeking Alpha, summary: No summary, Headline: Tesla, Netflix And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: RBC Capital Sticks to Its Buy Rating for Moderna (MRNA), source:TipRanks, summary: No summary, Headline: The Perfect 10 Portfolio Is Ready to Roll, source:GuruFocus, summary: No summary, Headline: Novavax stock spikes 20% after company snags $350 million from Canada for unused Covid shots, source:CNBC, summary: Canada's Covid shot settlement is a sign of hope for investors after Novavax raised doubts about its ability to stay in business earlier this year. , Headline: Moderna Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rose 3.55% to $123.09 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...",MRNA
271,2023-07-11,"Headline: EXCLUSIVE: The 20 Most-Searched For Tickers On Benzinga Pro From The First Six Months Of 2023, source:Benzinga, summary: No summary, Headline: Prime Day for Stocks? Disney, Moderna and 13 More That Look Like Bargains., source:Yahoo, summary: Amazon Prime shopping days are here, and everyone loves good deals, Barron's looked for some in the stock market, and found 15 stocks primed to go higher., Headline: Morgan Stanley Maintains Moderna (MRNA) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 0.78% to $122.13 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: We've only seen the beginning of Moderna's story, says Goldman Sachs' Salveen Richter, source:CNBC, summary: Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Closing Bell Overtime' to discuss the biotech sector and how investors should play in the space., Headline: Get another COVID-19 booster in the fall, Canada's immunization panel recommends, source:Finnhub, summary: OTTAWA — Canadians should get another COVID-19 vaccine booster in the fall if it's been at least six months since their last dose or COVID-19 infection, the National Advisory Committee on..., Headline: Prime Day for the Stock Market? Disney, Moderna, and 13 More That Look Like Bargains., source:Yahoo, summary: Amazon Prime shopping days are here, and everyone loves good deals, Barron's looked for some in the stock market, and found 15 stocks primed to go higher., Headline: S&P 500 Q2 2023 Earnings Preview: A Repeat Performance?, source:SeekingAlpha, summary: Over the last three months, Q2 EPS estimate declined from $54.24 to $52.81 per share, resulting in analysts downgrading y/y growth expectations by 2.5 ppt heading into earnings season.",MRNA
272,2023-07-12,"Headline: 3 Things About Vertex Pharmaceuticals That Smart Investors Know, source:Yahoo, summary: Vertex Pharmaceuticals' (NASDAQ: VRTX) stock has climbed nearly 20% so far this year, and for good reason.  The biotech company completed a regulatory submission for what may become its next blockbuster product.  Vertex and partner CRISPR Therapeutics hope to launch exa-cel, a gene-editing treatment for blood disorders, as soon as next year., Headline: Check Out What Whales Are Doing With MRNA, source:Benzinga, summary: No summary, Headline: Nvidia invests $50 million in biotech company Recursion for AI drug discovery , source:CNBC, summary: Nvidia is investing in Recursion, which uses AI models to identify new therapies and offers those models to its partners, including Roche and Bayer., Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rallied 3.10% to $125.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: 2Q23 Earnings: Where Street Estimates Are Too Low And Who Should Beat, source:SeekingAlpha, summary: Street Earnings are lower than Core Earnings for 146 companies in the S&P 500, representing 28% of the market cap of the S&P 500., Headline: 2-year Treasury yield continues to slide after cool June CPI figure, source:CNBC, summary: U.S. Treasury yields were mostly lower on Thursday after June's inflation print came in cooler than expected.",MRNA
273,2023-07-13,"Headline: Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m., Headline: 7 Biotech Stocks to Sell in July, source:Yahoo, summary: Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category. For one, while biotechs are some of the riskier stocks out there, that doesn’t mean all of them offer the possibility of outsized rewards. Plenty of names in this category have massive downside risk, while at the same time offering questionable upside potential. Other biotechs may have tremendous upsid, Headline: Moderna: Buy While It's Cheap (Rating Upgrade), source:SeekingAlpha, summary: Moderna is on track to achieve about $2B of its FY23 $5B COVID vaccine revenue target in H1 but may fall short unless sales momentum improves in H2. Learn more about MRNA here., Headline: Did Nvidia Make Recursion Pharmaceuticals (RXRX) Stock the Next AI Play?, source:InvestorPlace, summary: No summary, Headline: Biden administration asks Pfizer, Moderna and Novavax for 'reasonable' prices on updated Covid vaccines, source:CNBC, summary: Pfizer, Moderna and Novavax have not disclosed the exact pricing of their new vaccines, which will target the circulating omicron subvariant XBB.1.5. , Headline: Biden administration to provide free Covid vaccines to uninsured Americans this fall through end of 2024, source:CNBC, summary: The HHS program aims to maintain broad access to Covid shots and treatments after the federal government shifts those products to the commercial market. , Headline: Moderna Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.55% higher to $126.61 Thursday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: 15 Deadliest Cancers in the U.S., source:Yahoo, summary: In this article, we will discuss the 15 deadliest cancers in the U.S. To skip our detailed analysis and recent updates regarding cancer research and the oncology market, go directly to the 5 Deadliest Cancers in the U.S. Cancer stands as a pervasive, highly destructive, and agonizing disease, with a significant global impact. Cancer, also […], Headline: Moderna (MRNA) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $126.62, marking a +0.56% move from the previous day., Headline: Moderna initiated with a Reduce at HSBC, source:Thefly.com, summary: No summary",MRNA
274,2023-07-14,"Headline: Treasury yields moderate after two-day slide on light inflation data, source:CNBC, summary: U.S. Treasury yields climbed on Friday, reversing some of the sharp declines seen in the last two sessions on the back of cooler-than-expected inflation prints., Headline: MODERNA TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS ON THURSDAY, AUGUST 3, 2023, source:Finnhub, summary: CAMBRIDGE - Moderna, Inc. , a biotechnology company pioneering messenger RNA  therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on..., Headline: Video: Nasdaq 100 Movers: MRNA, TEAM, source:Market News Video, summary: No summary, Headline: Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 4.15% to $121.35 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: HSBC Initiates Coverage of Moderna (MRNA) with Reduce Recommendation, source:Fintel, summary: nan",MRNA
275,2023-07-16,"Headline: Buy/Sell: Wall Street's top 10 stock calls this week, source:Thefly.com, summary: No summary, Headline: Those who invested in Moderna (NASDAQ:MRNA) three years ago are up 28%, source:Yahoo, summary: While Moderna, Inc. ( NASDAQ:MRNA ) shareholders are probably generally happy, the stock hasn't had particularly good...",MRNA
276,2023-07-17,"Headline: If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,600 Today, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. advanced 1.03% to $122.60 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Moderna president Hoge sells 15,000 common shares, source:Thefly.com, summary: No summary",MRNA
277,2023-07-18,"Headline: Moderna Co-Founder’s Firm Bought Up This Embattled Biotech Stock, source:Yahoo, summary: Flagship Pioneering, an investment vehicle helmed by Noubar Afeyan, a co-founder of Moderna and its chairman, bought $12.5 million of shares of biotech Evelo., Headline: Pfizer and Flagship Pioneering to invest $100 million to develop treatments for unmet medical needs, source:MarketWatch, summary: Pfizer Inc. and Flagship Pioneering said Tuesday they are investing a total of $100 million upfront to explore opportunities to develop 10 single-asset..., Headline: How Is The Market Feeling About Moderna?, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.01% higher to $122.61 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Check Out What Whales Are Doing With MRNA, source:Benzinga, summary: No summary",MRNA
278,2023-07-19,"Headline: 5 Beaten-Down Healthcare Stocks With Potential for a Rebound, source:Yahoo, summary: Investors have fled healthcare stocks this year, ducking out of a trade that seemed a smart defensive play last year, as market conditions have changed., Headline: Coinbase Global, Moderna And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: ClearBridge Select Strategy Q2 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge Select Strategy performed in line with its benchmark during the second quarter of 2023. Click here to read the full fund letter., Headline: Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030, source:Yahoo, summary: When you think of biotech giants, you may think of Amgen or Biogen. These companies have brought significant treatments to market over time -- and have generated billions of dollars in earnings, too. Most investors would be happy to find the next company set to follow in their footsteps., Headline: 3 Healthcare Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry.  Let's look at three healthcare stocks that are leaders or innovators in their respective niches and could provide excellent returns in the next 10 years: Vertex Pharmaceuticals (NASDAQ: VRTX), Moderna (NASDAQ: MRNA), and Gilead Sciences (NASDAQ: GILD).  Vertex Pharmaceuticals has soundly beaten the market in the past 10 years, and the company is in an excellent position to do so in the next decade., Headline: Uber and Snowflake Make Morningstar List of Undervalued Growth Stocks, source:Yahoo, summary: Growth stocks have surged 33% so far this year, and some have more room for gains, according to Morningstar.",MRNA
279,2023-07-20,"Headline: Moderna Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slipped 0.32% to $124.77 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Tesla Q2 Earnings Confirm Our Thesis, It Is One Of The Most Overvalued Stocks, source:SeekingAlpha, summary: Tesla stock is overvalued and should be closer to $26 per share. Learn why TSLA's fundamentals are disconnected from reality., Headline: Moderna (MRNA) Stock Moves -0.32%: What You Should Know, source:Yahoo, summary: Moderna (MRNA) closed at $124.77 in the latest trading session, marking a -0.32% move from the prior day., Headline: Obey the Sell Signals: 3 Blue-Chip Stocks to Let Go, source:Yahoo, summary: FOMO is carrying the day, week and month on Wall Street. And the rally is starting to spread beyond the tech sector. This means some blue-chip stocks are beginning to catch a bid. That’s encouraging news. However, while this rally may have legs, there are still some blue-chip stocks to avoid. Blue-chip stocks are sought after for their financial stability. These companies tend to stack quarter after quarter of solid revenue and earnings. And many pay dividends, which adds to their appeal. But no",MRNA
280,2023-07-21,"Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 1.33% to $126.43 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",MRNA
281,2023-07-22,"Headline: Moderna director sells $1.88M in common stock, source:Thefly.com, summary: No summary",MRNA
282,2023-07-23,"Headline: Fentanyl Crisis In US: Biden Administration Contemplates Easing Sanctions on China's Forensic Institute, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: No summary",MRNA
283,2023-07-24,"Headline: Moderna Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: No summary, Headline: Moderna initiated with a Market Perform at William Blair, source:Thefly.com, summary: No summary, Headline: Moderna price target lowered to $165 from $175 at TD Cowen, source:Thefly.com, summary: No summary, Headline: Tesla downgraded, Netflix upgraded: Wall Street's top analyst calls, source:Thefly.com, summary: No summary, Headline: Cathie Wood's Ark Invest Makes Major Moves In This Warren Buffett-Backed EV Company, Moderna, source:Benzinga, summary: No summary, Headline: Cathie Wood's Ark Buy More Moderna Shares As It Trims Stake In This Warren Buffett-Backed EV Maker, source:Benzinga, summary: No summary, Headline: Moderna Is Fairly Valued, Balancing Declining COVID-19 Base Business with Promising Future Pipeline: Analyst, source:Benzinga, summary: No summary, Headline: Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition, source:Benzinga, summary: No summary, Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?, source:Yahoo, summary: Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs., Headline: The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023, source:Yahoo, summary: Growth investors are frequently looking for biotech stocks to buy. So what exactly is a biotech stock? It’s a company that’s somehow involved in the creation of innovative drugs. This can be through research, development, or production. This sector saw a huge pandemic-related boost when the mRNA technology that many of them specialize in was thrust into the spotlight. The biotech industry is underpinned by some pretty undeniable growth trends. First and foremost is the aging global population. A, Headline: William Blair to hold a webinar on initiation of coverage, source:Thefly.com, summary: No summary",MRNA
284,2023-07-25,"Headline: TD Cowen Maintains Moderna (MRNA) Outperform Recommendation, source:Fintel, summary: nan, Headline: William Blair Initiates Coverage of Moderna (MRNA) with Market Perform Recommendation, source:Fintel, summary: nan, Headline: Pfizer and Moderna’s parent are investing $100 million in a new partnership to find the next big drug, source:Yahoo, summary: ""What we are doing now, I don’t think anyone has done so far,"" Pfizer CEO Albert Bourla says., Headline: Moderna Unusual Options Activity For July 25, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 0.93% to $121.87 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Notable Wednesday Option Activity: MRNA, ANET, GS, source:Stock Options Channel, summary: No summary, Headline: Moderna On Cathie Wood's Radar Ahead Of Q2 Results: Ark Boosts Stake In COVID-19 Vaccine Maker By $12M This Week, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",MRNA
285,2023-07-26,"Headline: Merck, Moderna initiate Phase 3 study of V940 in combination with Keytruda, source:Thefly.com, summary: No summary, Headline: Merck and Moderna launch late-stage trial of V940 with Keytruda as treatment for high-risk melanoma, source:MarketWatch, summary: Merck & Co. and Moderna Inc. said Wednesday they have launched a Phase 3 trial of Moderna’s V940 in combination with Merck’s Keytruda as a treatment for..., Headline: Moderna, Merck begin phase 3 trial on mRNA melanoma combo treatment, source:Seeking Alpha, summary: No summary, Headline: Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma, source:Yahoo, summary: RAHWAY, N.J. & CAMBRIDGE, Mass., July 26, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in, Headline: CORRECTED-UPDATE 2-Moderna/Merck begins late-stage study of skin cancer vaccine combination, source:Yahoo, summary: Moderna said on Wednesday it has begun enrolling patients in a late-stage study evaluating its and partner Merck's personalised mRNA-based skin cancer vaccine in combination with the drugmaker's blockbuster therapy Keytruda.  Data from a mid-stage study had shown that the combination cut the risk of recurrence or death of melanoma, the most deadly form of skin cancer, by 44% when compared with Keytruda alone.  The companies would now test if the combination would be effective in cutting the risk of disease recurrence in a larger trial of about 1,089 patients., Headline: Individualized Cancer Treatment: Merck/Moderna's Personalized Skin Cancer Therapy Enters Late-Stage Of Development, source:Benzinga, summary: No summary, Headline: Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings, source:Yahoo, summary: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates., Headline: UPDATE 3-Moderna/Merck begins late-stage study of skin cancer vaccine combination, source:Yahoo, summary: Moderna and its partner Merck said on Wednesday that they had begun enrolling patients in a late-stage study testing their personalized mRNA-based skin cancer vaccine in combination with the immunotherapy Keytruda.  Data from a mid-stage study in 157 patients had shown that the vaccine combination cut the risk of recurrence or death by 44% in patients with melanoma, the most deadly form of skin cancer, when compared with Keytruda alone.  The companies are testing the vaccine in melanoma patients whose tumors were surgically removed before being treated with either the drug-vaccine combination or Keytruda alone., Headline: Moderna Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slipped 1.00% to $120.65 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Report: Moderna inks large sublease in Seattle, source:Yahoo, summary: Around 70 Seattle LinkedIn users list Moderna as their employer, and Moderna's website lists 46 open positions here., Headline: Moderna (MRNA) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Moderna (MRNA) closed at $120.65, marking a -1% move from the previous day., Headline: $1000 Invested In This Stock 5 Years Ago Would Be Worth $6,400 Today, source:Benzinga, summary: No summary",MRNA
286,2023-07-27,"Headline: BioNTech And Moderna: Fallen Angels Of The COVID Era Are Buys Ahead Of Earnings, source:SeekingAlpha, summary: BioNTech and Moderna will always be compared due to the phenomenal success of their COVID vaccines. Click here to see our take on BNTX stock now., Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 1.77% to $118.51 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Cathie Wood Is Buying Up Shares of This Beaten-Down Biotech. Should You?, source:Yahoo, summary: Cathie Wood is known for betting on innovative companies, with the idea that they'll deliver game-changing results over the long term.  The founder of ARK Invest loves these players' exciting products or product candidates and their potential for earnings and share performance down the road.  In the investor's latest shopping spree, she snapped up more than 98,800 shares of Moderna (NASDAQ: MRNA) over a two-day period., Headline: Earnings week ahead: Amazon, Apple, Pfizer, Starbucks, Uber and more, source:Seeking Alpha, summary: No summary",MRNA
287,2023-07-28,"Headline: 20 Countries With Highest Rates of Cancer, source:Yahoo, summary: In this article, we’ll take a detailed look at the 20 countries with the highest rates of cancer. For a quick overview of the top five countries, read our article 5 Countries With Highest Rates of Cancer. Cancer, a pervasive and devastating disease, leaves a profound global impact. Also known as malignant tumors or neoplasms, […], Headline: Moderna director sells $1.81M in common stock, source:Thefly.com, summary: No summary, Headline: Earnings This Week: Apple, Amazon And AMD, source:TalkMarkets, summary: No summary, Headline: William Blair to hold a webinar on initiation of coverage, source:Thefly.com, summary: No summary, Headline: Worried about Lyme disease? CDC warns that 450,000 people may have been infected by a tick-related meat allergy., source:MarketWatch, summary: No summary, Headline: Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III, source:Yahoo, summary: AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results., Headline: Moderna Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.13% higher to $118.66 Friday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: As COVID-19 Cases Spike This Summer, Healthcare Experts See It As Recurring Theme And Recommend These Measures, source:Benzinga, summary: No summary",MRNA
288,2023-07-29,"Headline: What is alpha-gal syndrome? CDC warns 450,000 people may have had this tick-related meat allergy., source:MarketWatch, summary: No summary, Headline: RSV treatment market to surge past $9B by 2029, source:Seeking Alpha, summary: No summary",MRNA
289,2023-07-30,"Headline: 7 Stocks to Buy Before They Surpass 2021 Highs, source:InvestorPlace, summary: No summary",MRNA
290,2023-07-31,"Headline: 7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick, source:InvestorPlace, summary: No summary, Headline: Accenture, Hewlett Packard Enterprise And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: 5 things to know before the stock market opens Monday, source:CNBC, summary: Here are the most important news items that investors need to start their trading day., Headline: Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda, source:Benzinga, summary: No summary, Headline: Tracking Baillie Gifford's 13F Portfolio - Q2 2023 Update, source:SeekingAlpha, summary: Baillie Gifford's 13F portfolio value increased from ~$111B to ~$118B this quarter. Top three holdings make up ~17% of the portfolio. Click here to read more., Headline: Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?, source:Yahoo, summary: Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings., Headline: Moderna Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. dropped 0.84% to $117.66 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Stocks That Hit 52-Week Lows On Tuesday, source:Benzinga, summary: No summary, Headline: 3 Health Care Stocks That Fit Ben Graham's Lost Formula, source:GuruFocus, summary: No summary, Headline: 15 Worst Performing NASDAQ Stocks In 2023, source:Yahoo, summary: In this article, we discuss 15 worst performing NASDAQ stocks in 2023. If you want to skip our detailed discussion on the stock market performance this year, head directly to 5 Worst Performing NASDAQ Stocks In 2023. The tech rally so far in 2023 has fueled the momentum of the NASDAQ 100 Index, as it […]",MRNA
291,2023-08-01,"Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary, Headline: Merck Earnings Top Expectations. More M&A Could Be Next., source:MarketWatch, summary: CFO Caroline Litchfield said sales of the company’s cancer treatments and vaccines were growing and more M&A could be on the horizon., Headline: 3 Cheap Healthcare Stocks That Smart Investors Will Snap Up Now, source:InvestorPlace, summary: No summary, Headline: Daiichi COVID vaccine endorsed in Japan; Shionogi’s shot declined, source:Seeking Alpha, summary: No summary, Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 3.16% to $113.94 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: 3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now, source:InvestorPlace, summary: No summary, Headline: Notable Wednesday Option Activity: MRNA, CNNE, NVCR, source:Stock Options Channel, summary: No summary",MRNA
292,2023-08-02,"Headline: Moderna Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary, Headline: Check Out What Whales Are Doing With MRNA, source:Benzinga, summary: No summary, Headline: GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine, source:CNBC, summary: Both RSV vaccines were approved by the U.S. Food and Drug Administration for use in adults 60 and above., Headline: Moderna's COVID-19 vaccine proves safest, most effective for older adults, study says, source:Finnhub, summary: In examining real-world data on the long-term health of elderly patients who received the COVID-19 vaccine, researchers at Brown University and Boston-based Hebrew SeniorLife determined that the..., Headline: Can Moderna spring a surprise for Q2 2023 despite falling vaccine demand, source:Seeking Alpha, summary: No summary, Headline: Possible Bearish Signals With Moderna Insiders Disposing Stock, source:Yahoo, summary: The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past..., Headline: Moderna's COVID-19 vaccine safest, most effective for older adults, study says, source:Finnhub, summary: In examining real-world data on the long-term health of elderly patients who received the COVID-19 vaccine, researchers at Brown University and Boston-based Hebrew SeniorLife determined that the..., Headline: Should You Buy Moderna (MRNA) Ahead of Earnings?, source:Yahoo, summary: Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season., Headline: Moderna Raises Hope, Concern, With Update on Sales of Covid-19 Vaccine, source:MarketWatch, summary: The company offered a mixed report about sales of the shots, the only product it has on the market., Headline: NEW YORK MARKET CLOSE: Fitch downgrade sparks retreat on Wall Street, source:Alliance News, summary: No summary, Headline: Stock futures are little changed Wednesday night after U.S. downgrade spurs a selloff: Live updates, source:CNBC, summary: Fitch’s recent downgrade of the United States’ long-term rating dragged down investors’ spirits – as well as the major averages., Headline: GLOBAL BRIEFING: China's services see strong growth in July, source:Alliance News, summary: No summary, Headline: U.S. stocks edge lower after biggest drop in 3 months, source:MarketWatch, summary: No summary, Headline: What You Missed On Wall Street On Thursday, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary, Headline: Baillie Gifford Acquires Significant Stake in Sweetgreen Inc, source:GuruFocus, summary: No summary, Headline: Baillie Gifford Reduces Stake in SiteOne Landscape Supply Inc, source:GuruFocus, summary: No summary, Headline: Baillie Gifford Reduces Stake in Upwork Inc, source:GuruFocus, summary: No summary",MRNA
293,2023-08-03,"Headline: Apple among BofA picks for options opportunity on earnings surprise, source:Seeking Alpha, summary: No summary, Headline: Baillie Gifford Boosts Stake in Sweetgreen Inc, source:GuruFocus, summary: No summary, Headline: Moderna beats Q2 top and bottom line estimates; updates FY23 outlook, source:Seeking Alpha, summary: No summary, Headline: Moderna (MRNA) Gets a Hold from Bank of America Securities, source:TipRanks, summary: No summary, Headline: U.S. stocks fall for third day as bond yields surge, source:MarketWatch, summary: U.S. stocks end lower Thursday as a global bond market selloff sent yields higher., Headline: US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month, source:Benzinga, summary: No summary, Headline: Moderna raises COVID vaccine sales outlook despite 94% Q2 drop, source:Seeking Alpha, summary: No summary, Headline: Moderna's stock jumps 5% premarket after narrower-than-expected loss and revenue beat, source:MarketWatch, summary: No summary, Headline: Moderna shares rise on better Covid vaccine outlook despite sharp drop in sales, source:CNBC, summary: Moderna and its rivals Pfizer and Novavax have all seen a steep drop in sales of Covid vaccines and treatments as the world moves on from the pandemic.  , Headline: Moderna’s stock jumps 5% premarket after narrower-than-expected loss and revenue beat, source:MarketWatch, summary: No summary, Headline: U.S. stock futures point to third straight drop to kick off August, source:MarketWatch, summary: No summary, Headline: Moderna revenue beats estimates despite COVID vaccine sales slump, source:Yahoo, summary: Investing.com -- Moderna (NASDAQ:MRNA) has reported better-than-expected revenue in the second quarter despite falling steeply due to weaker post-pandemic demand for its COVID-19 vaccine., Headline: 5 things to know before the stock market opens Thursday, source:CNBC, summary: Here are the most important news items that investors need to start their trading day., Headline: Moderna (NASDAQ:MRNA) Expects Upbeat COVID-19 Vaccine Sales for 2023; Late Stage Pipeline Impresses, source:TipRanks, summary: No summary, Headline: Moderna downgraded to Hold from Buy at Deutsche Bank, source:Thefly.com, summary: No summary, Headline: Stocks making the biggest moves premarket: Qualcomm, Moderna, PayPal and more, source:CNBC, summary: These are the stocks posting the largest moves in premarket trading., Headline: Moderna, Inc. 2023 Q2 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Moderna, Inc., Headline: Deutsche downgrades Moderna to Hold on low revenue visibility, source:Thefly.com, summary: No summary, Headline: U.S. stocks headed for 3rd straight drop as jobs report, earnings from Apple, Amazon loom, source:MarketWatch, summary: No summary, Headline: TOP NEWS: Moderna turns to loss amid fewer Covid-related sales, source:Alliance News, summary: No summary, Headline: Moderna downgraded at Deutsche Bank on outlook, source:Seeking Alpha, summary: No summary, Headline: Moderna : 2Q 2023 Earnings Call Presentation, source:Finnhub, summary: Second Quarter 2023 Financial Results
        
        
          August 3, 2023
        
      
      
        
          © 2023 Moderna, Inc. All rights reserved.
       ..., Headline: Moderna Lifts 2023 COVID-19 Vaccine Sales Outlook, Despite Over 90% Fall In Q2 Sales, source:Benzinga, summary: No summary, Headline: First Week of January 2025 Options Trading For Moderna (MRNA), source:Stock Options Channel, summary: No summary, Headline: Moderna reports Q2 EPS ($3.62), consensus ($3.92), source:Thefly.com, summary: No summary, Headline: Moderna sees 2023 COVID-19 vaccine sales of $6B-$8B, source:Thefly.com, summary: No summary, Headline: Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the second quarter of 2023., Headline: Moderna sees up to $8 bln in 2023 COVID vaccine sales on private market hopes, source:Yahoo, summary: Moderna Inc on Thursday raised its annual forecast for COVID-19 vaccine sales to up to $8 billion on hopes of a boost in the fall season as sales move to a private market in the United States from government contracts., Headline: Moderna sees up to $4 billion in 2023 sales from private market for COVID shots, source:Yahoo, summary: (Reuters) -Moderna Inc on Thursday forecast as much as $4 billion in revenue from its COVID-19 vaccine when sales shift to a private market from government contracts this year, and said it expects demand to grow further in 2024 and match the market for flu shots.  The vaccine maker anticipates $4 billion in sales to governments this year, and between $2 and $4 billion in a private market for the shot in the United States and other countries.  It had previously expected sales of $5 billion from government contracts., Headline: UPDATE 4-Moderna sees up to $4 billion in 2023 sales from private market for COVID shots, source:Yahoo, summary: Moderna Inc on Thursday forecast as much as $4 billion in revenue from its COVID-19 vaccine when sales shift to a private market from government contracts this year, and said it expects demand to grow further in 2024 and match the market for flu shots.  The vaccine maker anticipates $4 billion in sales to governments this year, and between $2 and $4 billion in a private market for the shot in the United States and other countries.  It had previously expected sales of $5 billion from government contracts., Headline: Nasdaq turns positive, U.S. stocks pare losses after productivity report, source:MarketWatch, summary: No summary, Headline: Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential, source:GuruFocus, summary: No summary, Headline: Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates, source:Yahoo, summary: Moderna (MRNA) delivered earnings and revenue surprises of 5.73% and 18.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Stocks edge higher as S&P 500 consolidates after biggest drop in 3 months, source:MarketWatch, summary: No summary, Headline: US STOCKS-Wall St set to open lower as Treasury yields hit nine-month high, source:Yahoo, summary: Most megacap growth and technology stocks including Apple , Alphabet and Microsoft slipped between 0.3% and 0.7% in premarket trading, as yields on the 10-year note rose to a nine-month high.  The yield on the 10-year benchmark note rose 1.2 basis points to 4.158% after the jobless claims data.  ""I would take that (jobless claims) data as a non-event, it is right on target,"" said Andre Bakhos, managing member at Ingenium Analytics., Headline: Midday movers: Qualcomm, PayPal, DoorDash, Moderna and more, source:Yahoo, summary: Investing.com -- U.S. stocks were rebounding on Thursday, with investors getting set for earnings reports from tech giants Apple (NASDAQ:AAPL) and Amazon (NASDAQ:AMZN)., Headline: Moderna, Inc. (MRNA) Q2 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Q2 2023 Results Earnings Conference Call August 3, 2023 8:00 AM ETCompany ParticipantsLavina Talukdar - Head, Investor RelationsStÃ©phane Bancel - Chief..., Headline: Moderna ups forecast for fall Covid vaccines, but there's one question mark, source:Yahoo, summary: With the fall launch of its updated Covid-19 vaccine likely weeks away, Moderna Inc. is forecasting sales of $6 to $8 billion, up from the $5 billion it previously forecast. But there's one major unknown for the Cambridge biotech., Headline: Moderna shares up after hiking forecast on Covid-19 vaccine, source:Yahoo, summary: Moderna stock is on the rise after the company hikes its full-year forecast on its Covid-19 vaccine. Yahoo Finance Live's Julie Hyman breaks down the story., Headline: Moderna Raises Hope, Concern, With Update on Sales of Covid-19 Vaccine, source:Yahoo, summary: The vaccine maker  Moderna  offered a mixed report about sales of its Covid-19 vaccine, leaving uncertainty about the main issue affecting its near-term prospects.  Moderna  (ticker: MRNA) raised its projection for Covid-19 vaccine sales this year, saying it now expects full-year sales of between $6 billion and $8 billion, up from its previous forecast of at least $5 billion.  At the same time, however, the company said that $1 billion of Covid-19 vaccines originally intended to be delivered in 2023 under advance-purchase agreements had been deferred until 2024., Headline: US STOCKS-Wall St slides on rising bond yields, mixed earnings, source:Yahoo, summary: Wall Street's main indexes slipped on Thursday as a jump in bonds yields, a mixed bag of corporate earnings and a slew of economic data pointing to stubborn inflation kept investors on edge.  Market participants have been keeping a close watch on data as they fear the Federal Reserve may stick to its rate hike path if it fails to bring inflation within its targeted range.  Another report showed the U.S. services sector slowed in July, but businesses faced higher prices for inputs as demand continued to hold up, suggesting a long and slow road to low inflation., Headline: Moderna (MRNA) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's second-quarter 2023 financial results and business updates.  On today's call are Stéphane Bancel, our chief executive officer; Stephen Hoge, our president; Arpa Garay, our chief commercial officer; and Jamie Mock, our chief financial officer., Headline: Trending : Moderna Posts Loss as Vaccine Sales Decline, source:Finnhub, summary: 1458 ET -- Moderna is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The company reported a $1.38 billion quarterly loss...., Headline: Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View, source:Yahoo, summary: Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season., Headline: US STOCKS-S&P 500, Dow slip in volatile session as yields rise, earnings disappoint, source:Yahoo, summary: The Dow and the S&P 500 slipped in choppy trading on Thursday as a jump in bonds yields, downbeat corporate earnings and a slew of economic data pointing to stubborn inflation kept investors on edge.  Market participants have been keeping a close watch on data as they fear the Federal Reserve may stick to its rate-hike path if it fails to bring inflation within its targeted range., Headline: NEW YORK MARKET CLOSE: Rising yields and looming jobs report limit Dow, source:Alliance News, summary: No summary, Headline: Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work., source:Yahoo, summary: The biggest names in Covid are updating their vaccines for a fall campaign, but that might not bolster Pfizer stock and Moderna stock., Headline: Health Care Down Slightly After Moderna, Merck KGaA Earnings -- Health Care Roundup, source:MarketWatch, summary: Health-care companies fell slightly after mixed earnings reports. Moderna shares were more or less flat after the biotech concern, which developed one of the..., Headline: Moderna (MRNA) Price Target Decreased by 5.49% to 206.23, source:Fintel, summary: nan, Headline: Moderna's Game Over? Not Quite, As Company Boosts Its 2023 Outlook, source:Yahoo, summary: Moderna raised its outlook for the year on Thursday, predicting $6 billion to $8 billion in Covid vaccine sales. MRNA stock edged down., Headline: Deutsche Bank Downgrades Moderna (MRNA), source:Fintel, summary: nan, Headline: Stocks That Hit 52-Week Lows On Friday, source:Benzinga, summary: No summary, Headline: Q2 2023 Moderna Inc Earnings Call, source:Yahoo, summary: Q2 2023 Moderna Inc Earnings Call, Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: No summary, Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary",MRNA
294,2023-08-04,"Headline: Moderna downgraded to Market Perform from Outperform at TD Cowen, source:Thefly.com, summary: No summary, Headline: 4 big analyst cuts: Etsy slashed to market perform, Moderna downgraded twice, source:Yahoo, summary: ""We are late on this one. You live and you learn. We were hoping that Q3 GMS guidance and management commentary could draw a line in the sand on the business returning to growth, but it wasn't quite as reassuring."", Headline: Moderna price target lowered to $150 from $175 at BofA, source:Thefly.com, summary: No summary, Headline: Moderna price target lowered to $175 from $275 at Jefferies, source:Thefly.com, summary: No summary, Headline: Friday’s Top Upgrades and Downgrades: DXC Technology, Etsy, Moderna, PagSeguro Digital, Qualcomm, Roku, Ross Stores, Royal Caribbean Cruises, Southwest Airlines, Spirit AeroSystems, StoneCo, Wayfair, source:247WallSt, summary: No summary, Headline: Friday’s Top Wall Street Analyst Upgrades and Downgrades: Etsy, Moderna, Qualcomm, Roku, Ross Stores, Royal Caribbean, Southwest Airlines, Wayfair and More, source:247WallSt, summary: No summary, Headline: Moderna under pressure as TD Cowen becomes latest to downgrade, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: What To Do After July's Job Report, source:SeekingAlpha, summary: Employment increased by 187,000 in July, led by healthcare, social assistance, financial activities, and wholesale trade. Read what the latest jobs report means for markets., Headline: Apple downgraded, Amazon upgraded: Wall Street's top analyst calls, source:Yahoo, summary: Apple downgraded, Amazon upgraded: Wall Street's top analyst calls, Headline: TD Cowen Downgrades Moderna (MRNA), source:Fintel, summary: nan, Headline: Moderna (MRNA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates, source:Yahoo, summary: While the top- and bottom-line numbers for Moderna (MRNA) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values., Headline: RBC Capital Maintains Moderna (MRNA) Outperform Recommendation, source:Fintel, summary: nan, Headline: B of A Securities Maintains Moderna (MRNA) Neutral Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Maintains Moderna (MRNA) Equal-Weight Recommendation, source:Fintel, summary: nan",MRNA
295,2023-08-05,"Headline: Moderna, Inc. (NASDAQ:MRNA) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA) Q2 2023 Earnings Call Transcript August 3, 2023 Moderna, Inc. misses on earnings expectations. Reported EPS is $-3.62 EPS, expectations were $3.84. Operator: Good day and thank you for standing by. Welcome to Moderna Second Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ […], Headline: 10 Oversold Blue Chip Stocks To Buy, source:Yahoo, summary: In this article, we will be taking a look at 10 oversold blue chip stocks to buy. To skip our detailed analysis of current market conditions, you can go directly to see the 5 Oversold Blue Chip Stocks To Buy. The markets have been full of surprises so far this year. With rampant inflation and […]",MRNA
296,2023-08-06,"Headline: Why did Moderna stock go down today? Bearish views pile up, source:Seeking Alpha, summary: No summary, Headline: Moderna Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: No summary",MRNA
297,2023-08-07,"Headline: BioNTech Stock Was a Covid Darling. Now It’s Paying the Price., source:MarketWatch, summary: Sales drop by more than expected in the second quarter, but BioNTech says its new 'variant-adapted Covid-19 vaccine' is still on track., Headline: Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), SAGE Therapeutics (SAGE), source:TipRanks, summary: No summary, Headline: Monday’s Top Wall Street Analyst Upgrades and Downgrades: Amazon, Apple, Block, Coinbase, Datadog, Fortinet, Gilead Sciences, Moderna, Nvidia, PayPal, Petrobras and More, source:247WallSt, summary: No summary, Headline: Video: Nasdaq 100 Movers: MRNA, BKNG, source:Market News Video, summary: No summary, Headline: Stocks making the biggest moves midday: Tesla, Berkshire Hathaway, PayPal, Cinemark and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Can Novavax beat in Q2 amid pressure on COVID vaccine sales, source:Seeking Alpha, summary: No summary, Headline: Stocks Rebound, Value Makes Comeback, Treasury Yields  Resume Climb: What's Driving Markets Monday?, source:Benzinga, summary: No summary, Headline: Is Moderna (MRNA) a Potential Value Trap? A Deep Dive into the Financials, source:Yahoo, summary: Assessing Moderna's Stock Value Amidst Market Fluctuations, Headline: People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared Holz, source:CNBC, summary: Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk Eli Lilly earnings, obesity drug demand and more., Headline: Moderna Weakens With No Bottom in Sight, source:Yahoo, summary: Vaccine maker Moderna has slumped to a new 52-week low Monday. Let's check out the trends and conditions of the charts and indicators. In the daily bar chart of MRNA, below, I can see a weak setup. The shares have been in a downward trend since December., Headline: Moderna Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: No summary",MRNA
298,2023-08-08,"Headline: 15 Worst Performing Biotech Stocks in 2023, source:Yahoo, summary: In this article, we discuss 15 worst performing biotech stocks in 2023. If you want to skip our detailed discussion about the biotech industry, head directly to 5 Worst Performing Biotech Stocks in 2023. The biotech industry was the center of global attention during the pandemic. With accelerated efforts to come up with vaccinations to […], Headline: Institutional owners may consider drastic measures as Moderna, Inc.'s (NASDAQ:MRNA) recent US$6.3b drop adds to long-term losses, source:Yahoo, summary: Key Insights Significantly high institutional ownership implies Moderna's stock price is sensitive to their trading..., Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",MRNA
299,2023-08-09,"Headline: Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease, source:PR Newswire, summary: No summary, Headline: The 3 Best Healthcare Stocks to Buy in August, source:InvestorPlace, summary: No summary, Headline: WHO names newly dominant EG.5 strain as COVID 'variant of interest', source:Seeking Alpha, summary: No summary, Headline: Unusual Put Option Trade in Moderna (MRNA)  Worth $9,868.50K, source:Fintel, summary: nan, Headline: 3 Healthcare Stocks to Sell in August Before They Crash and Burn, source:Yahoo, summary: Healthcare continues to lag in the broader market. Year to date, the Standards and Practices (S&P) 500 Health Care index is down 2% versus a 17% gain in the benchmark S&P 500 index. The declines among healthcare stocks are broad-based, with health insurers, pharmaceutical companies and device manufacturers all trailing the stock market. Fears of a recession and a presidential election cycle kicking into gear help to account for the declines. Spending on non-urgent medical procedures tends to tap, Headline: WHO names Eris a COVID variant of interest. Here’s what you need to know., source:MarketWatch, summary: No summary, Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary",MRNA
300,2023-08-10,"Headline: Warning: MRNA is at high risk of performing badly, source:Seeking Alpha, summary: No summary, Headline: Moderna Falling As Vaccine Hesitancy Rises, source:SeekingAlpha, summary: Moderna's stock has dropped further as revenues plunge with faltering Covid-19 vaccine sales. Read more here., Headline: Vertex: Continued Advances In Cystic Fibrosis Market With Expansion Plans, source:SeekingAlpha, summary: Vertex Pharmaceuticals is performing well in cystic fibrosis market with its drug Trikafta, leading to 2023 guidance increase. Find out why VRTX stock is a Strong Buy., Headline: The Moderna COVID-19 vaccine was the ultimate home run for this biotech venture firm. It’s a tough act to follow, source:Yahoo, summary: Unorthodox, brash, and sometimes controversial, Flagship Pioneering is looking for its next blockbuster., Headline: Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare, source:InvestorPlace, summary: No summary, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",MRNA
301,2023-08-11,"Headline: Meet Eris, The COVID Variant Behind A Summer Resurgence In Cases: 3 Drugmakers Prep Fall Booster Shots, source:Benzinga, summary: No summary, Headline: WHO names Eris a coronavirus variant of interest. Here’s what you need to know., source:MarketWatch, summary: No summary, Headline: Covid Vaccine Revenues Are Caving. New Boosters May Not Help., source:Yahoo, summary: Moderna and Pfizer expected strong demand for the latest Covid shots. Now they're walking back those projections., Headline: 3 Pharma Stocks to Sell in August Before They Crash and Burn, source:Yahoo, summary: With pharmaceutical companies, it’s all about the pipeline of new medications. Drugmakers, and their pharma stocks, are judged based on sales of current medications and potential sales of future prescriptions. Analysts and investors alike are always on the lookout for the next blockbuster drug. This helps to explain why the stocks of pharmaceutical companies with weight-loss medications in their pipeline have gone through the roof this year. Wall Street sees weight loss drugs as the next frontie",MRNA
302,2023-08-12,"Headline: Moderna, Inc.'s (NASDAQ:MRNA) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?, source:Yahoo, summary: It is hard to get excited after looking at Moderna's (NASDAQ:MRNA) recent performance, when its stock has declined 22...",MRNA
303,2023-08-13,"Headline: Inside COVID-19 vaccine makers: Hope vs hype, source:Seeking Alpha, summary: No summary, Headline: New Covid Strain Arrives as Vaccine Makers Gear Up, source:MarketWatch, summary: Pfizer, Moderna, and Novavax are getting ready to roll out updated Covid-19 vaccines that will target recent strains, though not specifically the most..., Headline: 15 Worst Performing Healthcare Stocks in 2023, source:Yahoo, summary: In this article, we discuss 15 worst performing healthcare stocks in 2023. If you want to skip our detailed discussion about the healthcare industry, head directly to 5 Worst Performing Healthcare Stocks in 2023. In 2021, healthcare spending in the United States accounted for over 18.3% of its GDP and the national healthcare expenditure came […], Headline: Moderna Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: No summary",MRNA
304,2023-08-14,"Headline: Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines, source:PR Newswire, summary: No summary, Headline: $1000 Invested In This Stock 5 Years Ago Would Be Worth $5,300 Today, source:Benzinga, summary: No summary, Headline: UMass Chan Medical School to begin enrolling study on CMV transmission, source:Thefly.com, summary: No summary, Headline: New Covid vaccines are on the way as 'Eris' variant rises, source:Yahoo, summary: A new COVID vaccine is due out next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from ""Eris"", a variant of the Omicron form of the coronavirus, rise around the country.  Some public health experts hope that Americans will welcome the new shot as they would a flu jab.  In the fall of 2022, by which time most people had either had the COVID virus or the vaccine, fewer than 50 million people got the shots., Headline: China Looks to Attract Foreign Investment as Its Economy Struggles, source:Yahoo, summary: (Bloomberg) -- China’s latest attempt to reverse the nation’s foreign investment slump includes pledges to offer overseas firms better tax treatment and make it easier for them to obtain visas, as officials try to allay fears about doing business in the world’s second-largest economy. Most Read from BloombergOutsider Milei Upends Argentina’s Election With Primary WinAmerica’s Fastest Growing City Is Embracing ‘Yellowstone’ ManiaZuckerberg Says ‘Time to Move On’ From Musk Cage FightRuble Sinks to, Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: UMass Chan Medical School announces enrollment in study to examine impact of cytomegalovirus (CMV) transmission in early education settings, source:Yahoo, summary: UMass Chan Medical School today announced it will begin enrolling participants at group child care and early childhood education settings in Worcester and Cambridge to examine the impact of cytomegalovirus (CMV) transmission. The study is a collaboration with Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA)-based therapeutics and vaccines, which is currently researching a vaccine for CMV., Headline: Moderna Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary, Headline: As the new Eris Covid variant spreads across the world, here’s what we know so far, source:CNBC, summary: EG.5 or ""Eris,"" now the dominant variant in the United States, is currently thought to have the same risk level as existing variants. ",MRNA
305,2023-08-15,"Headline: Your Mid-August Market Update: Selling And Scanning, source:TalkMarkets, summary: No summary, Headline: Alltrna Expands Leadership Team with Appointments of Chief Scientific Officer and Chief Technology Officer, source:PR Newswire, summary: No summary, Headline: Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?, source:Yahoo, summary: With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years., Headline: Outlook For Healthcare Sector As Obesity Drugs Gain Popularity, source:SeekingAlpha, summary: Risk-on sentiment and end of pandemic boom have weighed on healthcare. Health insurers and medical device firms have held up better. Growing opportunity in obesity treatments., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",MRNA
306,2023-08-16,"Headline: Cheaper Alternatives of Weight-Loss Drugs? Chinese Pharma Companies Are Working On a Local Version, source:Benzinga, summary: No summary, Headline: S&P 500 2023 Q2 Earnings Review: Revenues Miss Analyst Expectations, source:Seeking Alpha, summary: No summary, Headline: Piper Sandler's Craig Johnson breaks down the technicals of NVDA, ANF, MRNA & MSFT, source:CNBC, summary: Craig Johnson, Piper Sandler, joins 'Power Lunch' to discuss technical support for Nvidia, Abercrombie & Fitch, Moderna and Microsoft., Headline: Stocks Waver Amid Rising Treasury Yields; Oil Leads, Bitcoin Dips: Thursday's Market Movers, source:Benzinga, summary: No summary, Headline: MRNA Stock Alert: Why Is Moderna Up 7% Today?, source:InvestorPlace, summary: No summary, Headline: Moderna Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary, Headline: Moderna says updated COVID vaccine effective against widely circulating Eris variant, source:MarketWatch, summary: No summary",MRNA
307,2023-08-17,"Headline: Moderna hires former former UK government health official, source:Seeking Alpha, summary: No summary, Headline: Moderna updated COVID-19 vaccine effective against Eris, Fornax variants, source:Seeking Alpha, summary: No summary, Headline: Moderna hires former UK government health official, source:Seeking Alpha, summary: No summary, Headline: Why did BioNTech stock go up today? Rising COVID rates, source:Seeking Alpha, summary: No summary, Headline: Early notable gainers among liquid option names on August 17th, source:Thefly.com, summary: No summary, Headline: Moderna call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: Moderna's (NASDAQ:MRNA) investors will be pleased with their notable 46% return over the last three years, source:Yahoo, summary: It hasn't been the best quarter for Moderna, Inc. ( NASDAQ:MRNA ) shareholders, since the share price has fallen 22% in..., Headline: Moderna says new Covid vaccine was effective against Eris variant in early trial , source:CNBC, summary: Moderna's vaccine and new shots from Pfizer and Novavax are slated to roll out within weeks, pending potential approvals from the Food and Drug Administration. , Headline: Jonathan Van-Tam takes role at vaccine maker Moderna, source:Yahoo, summary: Sir Jonathan Van-Tam, who became a prominent figure in the UK government’s pandemic response, has taken a role as senior medical consultant at Covid vaccine maker Moderna.  The UK’s former deputy chief medical officer, who gained celebrity status among the British public during the pandemic and was affectionately known as “JVT”, took up the role as part-time adviser to Moderna in May, according to official filings.  As part of his duties during the pandemic, Van-Tam was a member of the Vaccine Taskforce, which the government said made decisions on “all vaccine supply contracts and major investments in manufacturing and clinical opportunities”., Headline: Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants, source:Yahoo, summary: Moderna, Inc. (NASDAQ:MRNA) today announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies against EG.5 and FL.1.5.1 variants., Headline: Ross Stores, Applied Materials, Moderna: After-hour movers, source:Yahoo, summary: Yahoo Finance Live's Seana Smith takes a look at the stock action surrounding Ross Stores (ROST) and semiconductor company Applied Materials (AMAT) after both companies reported earnings beats, as well as Moderna (MRNA) shares after publishing positive trial results for its updated COVID vaccine., Headline: Moderna's updated COVID vaccine effective against 'Eris' variant in humans, source:Yahoo, summary: Moderna said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the ""Eris"" and ""Fornax"" subvariants in humans.  The company expects the updated shot to be available, pending approval from health regulators in the United States, Europe and elsewhere, in the coming weeks for the fall vaccination season.  Moderna and other COVID-19 vaccine makers Novavax, Pfizer and German partner BioNTech SE have created versions of their shots aimed at the XBB.1.5 subvariant., Headline: Jonathan Van-Tam joins Covid vaccine maker Moderna, source:Yahoo, summary: One of the architects of Britain’s pandemic response has taken a role advising Covid vaccine maker Moderna., Headline: Friday Sector Laggards: Healthcare, Financial, source:Market News Video, summary: No summary, Headline: Moderna’s (NASDAQ:MRNA) Updated COVID Vaccine Effective Against Eris Variant, source:TipRanks, summary: No summary, Headline: As COVID hospitalizations rise, Pfizer and Moderna say updated shots show promise against Eris variant, source:MarketWatch, summary: No summary, Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: No summary",MRNA
308,2023-08-18,"Headline: Moderna president Hoge sells 15,000 common shares, source:Thefly.com, summary: No summary, Headline: Jerome Dodson's Parnassus Value Equity Fund Commentary, source:GuruFocus, summary: No summary, Headline: Parnassus Comments on Moderna, source:GuruFocus, summary: No summary, Headline: Moderna, Pfizer's Updated COVID Shot Shows Effectiveness Against 'Eris' Variant In Early Human, Preclinical Studies, source:Benzinga, summary: No summary, Headline: Diluting worker pledges leaves Labour open to fire from all sides, source:Yahoo, summary: Risks of the party’s strategy heighten as officials enjoy less freedom to tailor messages to certain audiences, Headline: SpaceX On Par With Intel, Disney; US Weight Loss Drugs Pricier; Moderna, Pfizer's Shot Effective Against New Variant: Today's Top Stories, source:Benzinga, summary: No summary, Headline: New Covid vaccines from Pfizer, Moderna and Novavax will likely protect against Eris variant, source:CNBC, summary: The drugmakers designed their updated coronavirus shots to target the omicron subvariant XBB.1.5, which is slowly declining nationwide. , Headline: 5 Things to Know Before Markets Open, source:Yahoo, summary: Applied Materials shares climb after boosting its forecast on rising demand for AI computing and internet-connected devices, while ADRs of Chinese EV maker XPeng slide after a decline in deliveries. Here’s what investors need to know today., Headline: 2 Biotech Stocks That Could Make You Richer, source:Yahoo, summary: Neither is performing particularly well this year compared to the broader market, but don't let that chase you away., Headline: Covid Vaccine Rally Dashed As Pfizer, Moderna Give Back Gains On Eris' Advance, source:Yahoo, summary: Pfizer stock and Moderna stock dipped Friday — giving back some of their late Thursday gains on an upswing related to their updated Covid shots., Headline: Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant, source:Yahoo, summary: Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study., Headline: Buy Moderna and BioNTech Stock. Both Pharmas Have Strong Drug Pipelines and Plenty of Cash., source:Yahoo, summary: Moderna and BioNTech are no longer minting money from Covid vaccines. But both have strong drug pipelines and plenty of cash., Headline: BUZZ Investing: A Shift In Market Leadership, source:SeekingAlpha, summary: 7 tech stocks accounted for almost 75% of the S&P 500's year-to-date gains, marking the technical start of a new bull market, even as investors raised concerns about narrow market breadth.",MRNA
309,2023-08-19,"Headline: EXPLAINER-Eris, BA.2.86: Do I need to worry about COVID again?, source:Yahoo, summary: The World Health Organization and the U.S. Centers for Disease Control and Prevention are tracking a new, highly mutated lineage of the virus that causes COVID-19.  Six cases in four countries have been detected since late July.  Scientists are keeping an eye on the new lineage, named BA.2.86, because it has 36 mutations that distinguish it from the currently-dominant XBB.1.5 variant.",MRNA
310,2023-08-20,"Headline: RSV vaccine sales for elderly expected to top $10B by 2030 in G7 nations, source:Seeking Alpha, summary: No summary, Headline: ‘Programmable Planet’ Review: Biology’s Big Bonus, source:Yahoo, summary: The idea of using life to improve life, the guiding principle of bioengineering, is yielding exciting results., Headline: Biden administration to urge Americans get new COVID-19 boosters, source:Yahoo, summary: The Biden administration plans to urge all Americans to get a booster shot for the coronavirus this autumn to counter a new wave of infections, a White House official said on Sunday.  The official said that while the Centers for Disease Control and Prevention are reporting an increase in infections and hospital admissions from the virus, overall levels remain low.  On Thursday, Moderna said initial data showed its updated COVID-19 vaccine is effective against the ""Eris"" and ""Fornax"" subvariants in humans., Headline: Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session, source:Benzinga, summary: No summary, Headline: Crude Oil Falls; Nikola Shares Plummet, source:Benzinga, summary: No summary",MRNA
311,2023-08-21,"Headline: Moderna: Buy Before The Fall Covid-19 Wave, source:SeekingAlpha, summary: Moderna's COVID-19 vaccine was found to be over 95% effective at preventing illness, hospitalizations, and deaths. Find out why MRNA stock is a buy., Headline: Moderna signs cancer vaccine deal with China-based CARsgen, source:Seeking Alpha, summary: No summary, Headline: Will The Bears Deliver The Knockout? Prepare For The Upcoming Week With Mando Trading!, source:Benzinga, summary: No summary, Headline: CureVac price target lowered to $8 from $10 at BofA, source:Thefly.com, summary: No summary, Headline: Early notable gainers among liquid option names on August 21st, source:Thefly.com, summary: No summary, Headline: Nvidia, Zoom, Moderna, Baidu, Tesla: Why These Five Stocks Are Drawing Investors' Attention Today, source:Benzinga, summary: No summary, Headline: Moderna call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: Moderna short-sellers lose $119m in 24 hours amid new Covid vaccine success, source:DowJones, summary: On 17 August, Moderna shares jumped by more than 7%, Headline: Moderna, BioNTech And Other Big Stocks Moving Higher On Monday, source:Benzinga, summary: No summary, Headline: Dow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike Higher, source:Benzinga, summary: No summary, Headline: US Stocks Mixed, Treasury Yields Soar To More Than A Decade High: What's Driving Markets Monday?, source:Benzinga, summary: No summary, Headline: Covid vaccine stocks jump as new variants emerge ahead of fall shot rollout, source:CNBC, summary: Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall. , Headline: Vaccine makers light up as COVID hospitalizations rise, source:Seeking Alpha, summary: No summary, Headline: 11 Most Profitable Biotech Stocks Today, source:Yahoo, summary: In this piece, we will take a look at the 11 most profitable biotechnology stocks to buy today. If you want to skip our introduction to the biotechnology industry and want to take a look at the top five stocks in this list, then head on over to 5 Most Profitable Biotech Stocks Today. Biotechnology […], Headline: Moderna Stock Rises Ahead of Fall Covid-19 Booster Campaign, source:Yahoo, summary: It has been a tough year for the stock prices of Covid-19 vaccine makers, but today is a different story. Moderna shares are up 7% Monday, after a Biden administration official urged Americans to get booster shots for the disease this fall., Headline: NEW YORK MARKET CLOSE: Tech rebounds led by Nvidia but blue-chips flag, source:Alliance News, summary: No summary, Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. rose 9.31% to $111.08 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite..., Headline: Markets Mixed in Midday Trading as Tech Stocks Surge, source:Yahoo, summary: U.S. equity markets were mixed in midday trading on Monday, Aug. 21, 2023 as tech stocks surged and Treasury yields rose., Headline: S&P 500: Cybersecurity Giant Soars On Earnings; Tesla, Nvidia Are Big Winners, source:Yahoo, summary: Palo Alto surged Monday after earnings, leading the S&P 500. Megacaps Tesla and NVDA were big winners too, with Nvidia earnings looming., Headline: Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market, source:Yahoo, summary: Moderna stock surged Monday after the biotech company inked a deal with China's Carsgen to study a new cancer vaccine regimen., Headline: Moderna, Pfizer stocks rise amid new Covid variants, source:Yahoo, summary: Covid vaccine maker stocks including Moderna (MRNA), Pfizer (PFE), and BioNTech (BNTX), rose as concerns grow about new Covid variants., Headline: Shares of Moderna and Other COVID-19 Vaccine Makers Surge Amid Booster Push as Cases Rise, source:Yahoo, summary: Shares of COVID-19 vaccine makers including Moderna and Novavax surged on Monday after a report that the Biden administration plans to urge Americans to get booster shots for the fall, as new subvariants emerge and cases rise., Headline: Why Moderna, BioNTech SE, and Novavax Surged Today, source:Yahoo, summary: The companies have developed vaccines for the current dominant strain of COVID, and the Biden administration is getting behind a new booster campaign., Headline: S&P 500 Gains and Losses Today: Tech Stocks Lead Index Higher, source:Yahoo, summary: The S&P 500 posted a 0.7% gain to start the trading week on Monday, Aug. 21, 2023, boosted by strong performance from technology stocks., Headline: Novavax (NASDAQ:NVAX) Surges Following Success Against Eris, Omicron, source:TipRanks, summary: No summary, Headline: Novavax (NASDAQ:NVAX) Surges Following Success Against COVID-19 Variants, source:TipRanks, summary: No summary",MRNA
312,2023-08-22,"Headline: Lions Gate brings back mask mandate as COVID cases resurge in LA, source:Seeking Alpha, summary: No summary, Headline: Tuesday Talk: Monday Rebound, source:TalkMarkets, summary: No summary, Headline: CARsgen Announced 2023 Interim Results, source:PR Newswire, summary: No summary, Headline: Novavax says updated COVID vaccine effective against Eris, other new variants, source:MarketWatch, summary: Novavax Inc. said Tuesday that its updated COVID-19 vaccine has shown promise against newer strains of the virus. In small animal and non-human primate..., Headline: Novavax (NVAX) Stock Is Getting Ready to Rally Again, source:InvestorPlace, summary: No summary, Headline: Unusually active option classes on open August 22nd, source:Thefly.com, summary: No summary, Headline: Early notable gainers among liquid option names on August 22nd, source:Thefly.com, summary: No summary, Headline: Novavax shares surge after drugmaker says new Covid vaccine was effective against Eris variant, source:CNBC, summary: Novavax's vaccine and new shots from Pfizer and Moderna are expected to roll out in the U.S. within weeks, pending potential approvals from the FDA. , Headline: Check Out What Whales Are Doing With MRNA, source:Benzinga, summary: No summary, Headline: U.S. Govt to Urge Citizens to Get New COVID-19 Shots, source:Yahoo, summary: Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall., Headline: Moderna Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Moderna Inc. rallied 4.65% to $116.24 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Markets Mixed Midday as Bank Stocks Face Pressure After Downgrades, source:Yahoo, summary: U.S. equity markets were mixed in midday trading on Tuesday, Aug. 22, 2023 as bank stocks lost ground after S&P downgraded several U.S. banks., Headline: Covid Hospitalizations Jump. So Could Vaccine Demand., source:Yahoo, summary: Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing. And investors are turning bullish., Headline: Covid-19 Hospitalizations Jump. So Could Vaccine Demand., source:Yahoo, summary: Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing. And investors are turning bullish., Headline: S&P 500 Gains and Losses Today: Banking Stocks Lose Ground After S&P Downgrades, source:Yahoo, summary: The S&P 500 dipped 0.3% on Tuesday, Aug. 22, 2023, dragged down by weakness in the banking sector following S&P's downgrade of several lenders.",MRNA
313,2023-08-23,"Headline: The Zacks Analyst Blog Highlights Moderna, BioNTech, Novavax and Pfizer, source:Yahoo, summary: Moderna, BioNTech, Novavax and Pfizer are included in this Analyst Blog., Headline: When can I get a Covid booster? Here's what to know about fall vaccines, source:Yahoo, summary: This fall marks the first time that vaccines will be available to fight the triple threat of Covid-19, flu and respiratory syncytial virus, or RSV. Some Massachusetts scientists are at the center of the upcoming vaccine campaigns. Here's what to expect this fall., Headline: CARsgen Announced 2023 Interim Results, source:Finnhub, summary: SHANGHAI - CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim..., Headline: New COVID variant can cause infection in those previously vaccinated - CDC, source:Seeking Alpha, summary: No summary, Headline: Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant, source:Yahoo, summary: In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant., Headline: Moderna Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Moderna Inc. slumped 0.67% to $115.46 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Is Moderna Stock A Buy As Covid Hospitalizations — And Its Shares — Rise?, source:Yahoo, summary: Is Moderna stock a buy as Covid hospitalizations rise, possibly boosting vaccine demand? Is MRNA stock a buy right now?",MRNA
314,2023-08-24,"Headline: The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collab, source:Yahoo, summary: A Watertown biotech trimmed its pipeline again, setting aside all of its experimental drugs except one. It's the second time the company has cut programs this year. Plus other life sciences news you may have missed., Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary, Headline: Moderna Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. shed 2.43% to $112.65 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Covid Boosters Will Come Later Than Last Year, Despite Rising Hospitalizations, source:Yahoo, summary: The variant that the updated vaccines were designed to target has already all-but-disappeared from the U.S., and new ones have emerged., Headline: CDC advisors to meet Sept. 12 to discuss new COVID shots, source:Seeking Alpha, summary: No summary",MRNA
315,2023-08-25,"Headline: Alnylam intends to appeal ruling on two patents asserted against Moderna, source:Thefly.com, summary: No summary, Headline: The Nvidia Distraction Is Over. Jackson Hole, Powell, Bonds Take Center Stage., source:MarketWatch, summary: Hawaiian Electric suspends dividend as troubles build, fast-fashion rivals Shein and Forever 21 team up, and other news to start your day., Headline: 7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole, source:Yahoo, summary: Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product. But there are also plenty of pitfalls that make such investments a risk. Biotech stocks represent companies that develop products and technology involving genetics and molecular biology. Some of them develop new drugs, therapies and medical treatments. Others develop genetically modified organisms to improve crop yield or the nutritional content of food.Investo, Headline: Moderna Unusual Options Activity, source:Benzinga, summary: No summary, Headline: Moderna Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Moderna Inc. slumped 0.64% to $111.93 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Alnylam to appeal ruling on patents related to Moderna's COVID vaccines, source:Finnhub, summary: Alnylam Pharmaceuticals saidon Friday it plans to appeal a ruling by the U.S. District Courtfor the District of Delaware on two patents asserted againstModerna for the latter's COVID-19 vaccine..., Headline: UPDATE 1-Alnylam to appeal ruling on patents related to Moderna's COVID vaccines, source:Yahoo, summary: Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine Spikevax.  Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA.  The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year.",MRNA
316,2023-08-26,"Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Spotify, Headline: Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca, source:TalkMarkets, summary: No summary",MRNA
317,2023-08-27,"Headline: Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca, source:SeekingAlpha, summary: WIR China and Poland partner to create a new drug distribution network. Click here to read more about the past week's new deals, financings, and approvals. , Headline: 18 Best 52-Week Low Stocks To Buy Now, source:Yahoo, summary: In this article, we will take a look at the 18 best 52-week low stocks to buy now. To see more such companies, go directly to 5 Best 52-Week Low Stocks To Buy Now. US stock markets are jittery after Fed Chair Jerome Powell made it clear that inflation is still high and needs further […], Headline: Alnylam appealing patent ruling in case against Moderna, source:Seeking Alpha, summary: No summary",MRNA
318,2023-08-28,"Headline: Hedge and mutual funds rotate from tech; see the stocks they love and shun, source:Seeking Alpha, summary: No summary, Headline: Ross Stores, Vertex Pharmaceuticals And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: More Trouble Ahead For Bulls? Prepare For The Busy Upcoming Week With Mando Trading!, source:Benzinga, summary: No summary, Headline: Early notable gainers among liquid option names on August 28th, source:Thefly.com, summary: No summary, Headline: COVID is evolving quickly in white-tailed deer, study finds, source:MarketWatch, summary: No summary, Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary",MRNA
319,2023-08-29,"Headline: Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings, source:Benzinga, summary: No summary, Headline: Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner, source:PR Newswire, summary: No summary, Headline: Want to diversify your stock-market investments away from top-heavy indexes? Here’s another easy way., source:MarketWatch, summary: The Invesco S&P 500 GARP ETF selects rapidly growing companies that are trading at lower valuations than the tech highfliers that dominate the stock market., Headline: Invaio achieves first registration for citrus greening solution featuring Trecise™ technology, source:Yahoo, summary: Invaio Sciences, a bio platform company accelerating the leap to nature-positive agriculture, today announced that its Citrus Health solution to suppress citrus greening in oranges received approval from the Florida Department of Agriculture and Community Services (FDACS) under section 24(c) of the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA)., Headline: 5 Things to Know About the New ‘Pirola’ Variant of Covid, source:Yahoo, summary: Scientists still don’t know how widespread or infectious the BA. 2.86 variant is, or if it causes different or more serious symptoms than other Covid-19 strains.",MRNA
320,2023-08-30,"Headline: CapitalGainsReport : Top Corona Stocks Watchlist (AXLA, BIXT, TOMDF, NVAX, MRNA), source:Finnhub, summary: Covid infections are on the rise. Hospitalizations are at 15,000 in the United States and rising on a week to week basis. It's up over double the low 6,300 cases set in June. To make matters worse..., Headline: Moderna to Host Investor Event - R&D Day and Business Updates, source:Yahoo, summary: Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m., Headline: Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases, source:SeekingAlpha, summary: Moderna and Pfizer/BioNTech earned more than $110 billion from their COVID vaccines. Read how patent infringement cases could impact their respective businesses., Headline: Moderna Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Moderna Inc. inched 0.54% higher to $116.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the...",MRNA
321,2023-08-31,"Headline: MODERNA TO HOST INVESTOR EVENT, R&D DAY AND BUSINESS UPDATES, source:Finnhub, summary: CAMBRIDGE - Moderna, Inc. today announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023.The event will include presentations..., Headline: Moderna Unusual Options Activity For August 31, source:Benzinga, summary: No summary, Headline: Pfizer (PFE) & BioNTech Get CHMP Nod for Updated Covid-19 Jab, source:Yahoo, summary: Pfizer (PFE) and partner BioNTech receive a positive recommendation from the CHMP for its Omicron XBB.1.5-adapted Covid-19 vaccine., Headline: Moderna Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. shed 3.04% to $113.07 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...",MRNA
322,2023-09-01,"Headline: Catalent Stock Soars on Agreement With Activist Investor Elliott Management, source:MarketWatch, summary: Battered drug manufacturer agrees to add directors and engage in a strategic review. Wall Street takes a wait-and-see-attitude., Headline: Moderna Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Moderna Inc. slid 0.45% to $112.56 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",MRNA
